{"PMC7165758": [["RESPIRATORY ILLNESS IN ATHLETESAlthough athletes have a similar distribution of URTI episodes to the general population,9the association with seasonal variation does not always hold true for the competitive athlete, with the influence of training and competition schedules masking seasonal differences.", [["URTI", "DISEASE", 80, 84], ["RESPIRATORY ILLNESS", "PROBLEM", 0, 19], ["URTI episodes", "PROBLEM", 80, 93], ["seasonal variation", "PROBLEM", 142, 160], ["competition schedules", "TREATMENT", 251, 272], ["ILLNESS", "OBSERVATION", 12, 19], ["similar", "OBSERVATION_MODIFIER", 56, 63], ["distribution", "OBSERVATION_MODIFIER", 64, 76], ["URTI episodes", "OBSERVATION", 80, 93]]], ["However, a recent 4\u2010year prospective study identified a higher incidence of URS in elite swimmers during winter.16A small proportion (5\u20137%) of athletes experience recurrent episodes of URS at significantly higher rates than the incidence in the general population.9,25In these athletes the URS can be associated with fatigue and poor performance.12,26,27Increased risk of URS is more likely during periods of intense training10,16and competition,3in swimmers,16,25whereas in other sports such as distance runners they appear more frequently after a competition.28Studies of illness\u2010prone athletes indicate higher susceptibility to URS following increases in training load.10,16,23,27However, a study of distance runners showed no clear association of training mileage, intensity or load with the incidence of respiratory illness.17Although fitter adults are less likely to experience URS than sedentary individuals,29this paradigm does not hold true for elite athletes who experience recurrent URS.26,27There appears to be a threshold of training load that puts athletes at increased risk of URS.", [["respiratory", "ANATOMY", 809, 820], ["fatigue", "DISEASE", 317, 324], ["respiratory illness", "DISEASE", 809, 828], ["prospective study", "TEST", 25, 42], ["recurrent episodes of URS", "PROBLEM", 163, 188], ["fatigue", "PROBLEM", 317, 324], ["poor performance", "PROBLEM", 329, 345], ["Increased risk of URS", "PROBLEM", 354, 375], ["illness\u2010prone athletes", "PROBLEM", 574, 596], ["higher susceptibility to URS", "PROBLEM", 606, 634], ["a study of distance runners", "TEST", 692, 719], ["respiratory illness", "PROBLEM", 809, 828], ["recurrent URS", "PROBLEM", 984, 997], ["training load", "TREATMENT", 1038, 1051], ["URS", "PROBLEM", 1092, 1095], ["small", "OBSERVATION_MODIFIER", 116, 121], ["more likely", "UNCERTAINTY", 379, 390], ["higher susceptibility", "OBSERVATION_MODIFIER", 606, 627], ["no", "UNCERTAINTY", 727, 729], ["respiratory illness", "OBSERVATION", 809, 828], ["appears to be", "UNCERTAINTY", 1009, 1022]]], ["Longitudinal studies have identified the impacts of intense training over both short (months)30,31,32,33and long (years)16periods (Table 2).RESPIRATORY INFLAMMATIONThe known causes of inflammation in the respiratory tract in athletes include immune activation in response to local infections, allergic responses to inhaled allergens, asthma and trauma to the respiratory epithelium predominantly disruption of mucosal membrane integrity.", [["respiratory tract", "ANATOMY", 204, 221], ["respiratory epithelium", "ANATOMY", 359, 381], ["mucosal membrane", "ANATOMY", 410, 426], ["inflammation", "DISEASE", 184, 196], ["respiratory tract", "DISEASE", 204, 221], ["infections", "DISEASE", 281, 291], ["allergic", "DISEASE", 293, 301], ["asthma", "DISEASE", 334, 340], ["trauma", "DISEASE", 345, 351], ["respiratory tract", "ORGANISM_SUBDIVISION", 204, 221], ["respiratory epithelium", "TISSUE", 359, 381], ["mucosal membrane", "MULTI-TISSUE_STRUCTURE", 410, 426], ["Longitudinal studies", "TEST", 0, 20], ["intense training", "TREATMENT", 52, 68], ["RESPIRATORY INFLAMMATION", "PROBLEM", 140, 164], ["inflammation in the respiratory tract", "PROBLEM", 184, 221], ["immune activation", "PROBLEM", 242, 259], ["local infections", "PROBLEM", 275, 291], ["allergic responses", "PROBLEM", 293, 311], ["inhaled allergens", "PROBLEM", 315, 332], ["asthma", "PROBLEM", 334, 340], ["trauma", "PROBLEM", 345, 351], ["the respiratory epithelium", "PROBLEM", 355, 381], ["mucosal membrane integrity", "PROBLEM", 410, 436], ["intense", "OBSERVATION_MODIFIER", 52, 59], ["INFLAMMATION", "OBSERVATION", 152, 164], ["inflammation", "OBSERVATION", 184, 196], ["respiratory tract", "ANATOMY", 204, 221], ["immune activation", "OBSERVATION", 242, 259], ["local", "OBSERVATION_MODIFIER", 275, 280], ["infections", "OBSERVATION", 281, 291], ["asthma", "OBSERVATION", 334, 340], ["respiratory epithelium", "ANATOMY", 359, 381], ["predominantly", "OBSERVATION_MODIFIER", 382, 395], ["disruption", "OBSERVATION", 396, 406], ["mucosal membrane integrity", "OBSERVATION", 410, 436]]], ["An athlete typically presents with common symptomology, and the associated inflammation may be difficult to differentiate without physician assessment and supportive pathology evidence or other clinical investigations.12,14Despite a combination of clinical and laboratory investigations a substantial proportion of presentations are classified as \u2018unidentified\u2019 aetiology.RESPIRATORY INFLAMMATIONThere is good evidence for the impact of inhaled allergens in susceptible athletes.34,35,36Several clinical studies have identified a prevalence of 20\u201340% for aeroallergen sensitivity in athletes12,14resulting in allergic rhinoconjunctivitis.", [["inflammation", "DISEASE", 75, 87], ["aeroallergen", "CHEMICAL", 555, 567], ["allergic rhinoconjunctivitis", "DISEASE", 609, 637], ["common symptomology", "PROBLEM", 35, 54], ["the associated inflammation", "PROBLEM", 60, 87], ["physician assessment", "TEST", 130, 150], ["supportive pathology", "TEST", 155, 175], ["other clinical investigations", "TEST", 188, 217], ["laboratory investigations", "TEST", 261, 286], ["inhaled allergens", "PROBLEM", 437, 454], ["Several clinical studies", "TEST", 487, 511], ["aeroallergen sensitivity", "TEST", 555, 579], ["allergic rhinoconjunctivitis", "PROBLEM", 609, 637], ["athlete", "OBSERVATION", 3, 10], ["inflammation", "OBSERVATION", 75, 87], ["good", "OBSERVATION_MODIFIER", 405, 409], ["allergic rhinoconjunctivitis", "OBSERVATION", 609, 637]]], ["Two studies of Olympic athletes35,36identified a 40\u201350% prevalence of allergic rhinoconjunctivitis confirmed by a positive skin\u2010prick test to at least one aeroallergen, with 29\u201334% positive for seasonal aeroallergens (mainly pollens).", [["allergic rhinoconjunctivitis", "DISEASE", 70, 98], ["pollens", "ORGANISM_SUBDIVISION", 225, 232], ["Olympic athletes", "TEST", 15, 31], ["allergic rhinoconjunctivitis", "PROBLEM", 70, 98], ["a positive skin\u2010prick test", "PROBLEM", 112, 138], ["seasonal aeroallergens", "PROBLEM", 194, 216], ["allergic rhinoconjunctivitis", "OBSERVATION", 70, 98], ["aeroallergens", "OBSERVATION", 203, 216]]], ["A study of French commandos undertaking intense training identified that 40% of illnesses were associated with rhinopharyngitis23.", [["A study", "TEST", 0, 7], ["intense training", "TREATMENT", 40, 56], ["illnesses", "PROBLEM", 80, 89], ["rhinopharyngitis23", "PROBLEM", 111, 129]]], ["Allergy as a cause for URS is often overlooked and was under\u2010diagnosed in 39% of athletes with confirmed IgE antibodies to areoallergens.14Treatment of airway allergic conditions with topical medications can benefit athletes with a history of URS (Table 2).37,38", [["airway", "ANATOMY", 152, 158], ["Allergy", "DISEASE", 0, 7], ["airway allergic", "DISEASE", 152, 167], ["IgE antibodies", "GENE_OR_GENE_PRODUCT", 105, 119], ["airway", "MULTI-TISSUE_STRUCTURE", 152, 158], ["IgE antibodies", "PROTEIN", 105, 119], ["URS", "PROBLEM", 23, 26], ["IgE antibodies to areoallergens", "PROBLEM", 105, 136], ["airway allergic conditions", "PROBLEM", 152, 178], ["topical medications", "TREATMENT", 184, 203], ["airway", "ANATOMY", 152, 158], ["allergic", "OBSERVATION", 159, 167]]]], "PMC7348110": [["COVID-19 has evoked a widespread and worldwide threat to health due to vulnerability to the virus or difficulty coping with it.", [["COVID-19", "CHEMICAL", 0, 8], ["the virus", "PROBLEM", 88, 97], ["widespread", "OBSERVATION_MODIFIER", 22, 32]]], ["Research concerning risk perception and mental health in cases of emerging infectious disease is still relatively limited.", [["infectious disease", "DISEASE", 75, 93], ["emerging infectious disease", "PROBLEM", 66, 93], ["infectious", "OBSERVATION", 75, 85]]], ["Although perceived risk is not the same as actual risk in most cases, perceived risk still leads to negative emotions and mental health outcomes, such as anxiety and depression [5, 6].", [["anxiety", "DISEASE", 154, 161], ["depression", "DISEASE", 166, 176], ["mental health outcomes", "PROBLEM", 122, 144], ["anxiety", "PROBLEM", 154, 161], ["depression", "PROBLEM", 166, 176]]], ["It is urgent to investigate the influence of risk perception on negative emotion and public mental health during the COVID-19 pandemic.Altruism and mental health ::: IntroductionAs an important concept in social psychology, altruism is highly valued for its profound importance to human evolution and the development of human civilization [7].", [["Altruism", "DISEASE", 135, 143], ["human", "ORGANISM", 281, 286], ["human", "ORGANISM", 320, 325], ["human", "SPECIES", 281, 286], ["human", "SPECIES", 320, 325], ["human", "SPECIES", 281, 286], ["human", "SPECIES", 320, 325], ["the COVID", "TEST", 113, 122], ["pandemic", "PROBLEM", 126, 134]]], ["Altruism was first defined by Comte as \u201can unselfish regard for the welfare of others\u201d [8], and it comprises the following two core concepts: empathy (altruistic attitude) and prosocial behaviour (altruistic behaviour).", [["Altruism", "DISEASE", 0, 8]]], ["Altruistic behaviour is associated with reduced aggression, better physical and mental health, longevity, and improved well-being [10\u201312].", [["aggression", "DISEASE", 48, 58], ["reduced aggression", "PROBLEM", 40, 58]]], ["The physiological advantages model claims that altruistic emotions gain dominance over anxiety and fear and reduce the stress caused by the fight-fight response in the face of perceived danger.", [["anxiety", "DISEASE", 87, 94], ["anxiety", "PROBLEM", 87, 94], ["the stress", "PROBLEM", 115, 125]]], ["The positive emotion model explains that the positive emotions (such as kindness, compassion, and other-regarding love) induced by altruism enhance health by displacing negative emotions [11].", [["the positive emotions", "PROBLEM", 41, 62], ["positive emotion", "OBSERVATION", 4, 20]]], ["The incentive factors of altruism, such as enhanced self-efficacy as an agentic mechanism and increased social worth as a communal mechanism, also provide possible explanations for engagement in altruistic activities [15].", [["an agentic mechanism", "TREATMENT", 69, 89]]], ["Nonetheless, few studies have explored the psychological outcomes of altruists with empathy when altruistic behaviours cannot be performed under specific circumstances.", [["few studies", "TEST", 13, 24]]], ["The outbreak of COVID-19 represents a context in which most people in China self-isolated at home under the policy of social distancing.", [["COVID-19", "CHEMICAL", 16, 24], ["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66]]], ["Most altruists could only remain at home and access COVID-19-related information on social media instead of performing direct altruistic behaviours during the pandemic.", [["social media", "TREATMENT", 84, 96]]], ["A neglected possibility is that altruism may not serve as a protective mental health factor against the threat of COVID-19 during the self-isolation period.", [["COVID-19", "CHEMICAL", 114, 122], ["COVID", "TEST", 114, 119]]], ["We predict that compared to individuals with low altruism, those with high altruism may feel more anxious due to their empathy towards infected patients and more depressed due to their helplessness towards others.", [["depressed", "DISEASE", 162, 171], ["helplessness", "DISEASE", 185, 197], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["more anxious", "PROBLEM", 93, 105]]], ["However, to the best of our knowledge, previous research has provided no guidance regarding altruists\u2019 psychological responses in such a situation.Mechanism underlying the effect of altruism on mental health ::: IntroductionThere is no consensus among researchers regarding the mechanisms underlying the association between altruism and mental health.", [["no", "UNCERTAINTY", 233, 235]]], ["Theoretical works have suggested that altruism affects mental health through increased positive mood or decreased negative mood.", [["decreased negative mood", "DISEASE", 104, 127], ["increased positive mood", "PROBLEM", 77, 100], ["decreased negative mood", "PROBLEM", 104, 127]]], ["Some studies have proposed that altruism accelerates elevated positive mood [17, 18], whereas other studies have argued that altruism buffers against negative mood [19].", [["elevated positive mood", "DISEASE", 53, 75], ["Some studies", "TEST", 0, 12], ["altruism accelerates elevated positive mood", "PROBLEM", 32, 75], ["other studies", "TEST", 94, 107]]], ["The outbreak of COVID-19 provides a natural research context to explore this controversy.", [["COVID-19", "CHEMICAL", 16, 24], ["COVID", "TREATMENT", 16, 21]]], ["As noted above, we expect that people with high altruism may have had more negative mental health outcomes (anxiety and depressive symptoms) during the self-isolation period, which could verify the mediating role of positive or negative affect.Aims of this study ::: IntroductionThis article focuses on health psychology to formulate a theoretical model of psychological responses to the COVID-19 threat.", [["anxiety", "DISEASE", 108, 115], ["depressive symptoms", "DISEASE", 120, 139], ["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37], ["anxiety", "PROBLEM", 108, 115], ["depressive symptoms", "PROBLEM", 120, 139], ["this study", "TEST", 252, 262], ["the COVID", "TEST", 384, 393], ["positive", "OBSERVATION", 216, 224], ["negative", "OBSERVATION", 228, 236]]], ["First, we examine the effect of individual perceived risk on public mental health outcomes, including anxiety and depressive symptoms.", [["anxiety", "DISEASE", 102, 109], ["depressive symptoms", "DISEASE", 114, 133], ["anxiety", "PROBLEM", 102, 109], ["depressive symptoms", "PROBLEM", 114, 133]]], ["Second, we attempt to extend the understanding of altruistic norms from a different perspective by examining the effect of altruism on emotional outcomes while focusing on conditions under which altruistic behaviour cannot occur.", [["emotional outcomes", "TREATMENT", 135, 153]]], ["In brief, by combining the above corollaries, we hypothesize the following: (1) perceived risk will directly predict mental health (including anxiety and depressive symptoms); (2) perceived risk will predict negative affect, and the effect of perception on negative affect will be moderated by altruism; and (3) negative affect will mediate the effect of perceived risk on mental health (including anxiety and depressive symptoms).Participants and sampling ::: MethodsThis study adopted a cross-sectional design and was conducted during the outbreak of COVID-19 (February 8\u201328, 2020).", [["anxiety", "DISEASE", 142, 149], ["depressive symptoms", "DISEASE", 154, 173], ["anxiety", "DISEASE", 398, 405], ["depressive symptoms", "DISEASE", 410, 429], ["Participants", "SPECIES", 431, 443], ["anxiety", "PROBLEM", 142, 149], ["depressive symptoms", "PROBLEM", 154, 173], ["mental health", "PROBLEM", 373, 386], ["anxiety", "PROBLEM", 398, 405], ["depressive symptoms", "PROBLEM", 410, 429], ["Methods", "TREATMENT", 461, 468], ["This study", "TEST", 468, 478], ["COVID", "TEST", 553, 558]]], ["Simple cluster sampling was used to construct the sample.", [["Simple cluster sampling", "PROBLEM", 0, 23], ["the sample", "TEST", 46, 56]]], ["University students from a Beijing university were recruited to complete an online questionnaire while they self-isolated at home under the government policy of social distancing and school closure.", [["school closure", "TREATMENT", 183, 197]]], ["The students were from cities and towns located in different areas of China and were not only from Beijing; thus, the results yielded from this sample may be generalizable to a larger population of students in different areas throughout the country during this specific period.", [["larger", "OBSERVATION_MODIFIER", 177, 183], ["population", "OBSERVATION_MODIFIER", 184, 194]]], ["Participants who met the following criteria were included: (1) Chinese students; (2) students who were able to understand Chinese; and (3) students who were not diagnosed with COVID-19 and whose family members had not been diagnosed.Ethical approval and consent ::: MethodsThe participants were informed about the purpose and procedures of this study via an online WeChat notification before the investigation.", [["participants", "ORGANISM", 277, 289], ["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 277, 289], ["Methods", "TREATMENT", 266, 273], ["this study", "TEST", 340, 350], ["the investigation", "TEST", 392, 409]]], ["Online informed written consent was obtained from all participants at the beginning of the questionnaire.", [["participants", "SPECIES", 54, 66]]], ["The research protocol was approved by the Research Ethics Review Committee of Beijing Normal University, China.Perceived risk of COVID-19 ::: Measures ::: MethodsIndividual perceived risk was assessed by three items.", [["COVID-19", "CHEMICAL", 129, 137]]], ["Two items were related to perceived vulnerability to COVID-19 (i.e., \u201cHow likely do you think it is that you will be infected with COVID-19?\u201d and \u201cHow likely do you think it is that your family members/relatives/friends will be infected with COVID-19?\u201d) and were rated on an 11-point scale from 0 to 100%.", [["COVID", "TEST", 53, 58]]], ["The participants were given five choices (1 = within 1 month; 2 = 2\u20133 months; 3 = 4\u20136 months; 4 = 7\u201312 months; 5 = more than 1 year).", [["participants", "ORGANISM", 4, 16], ["participants", "SPECIES", 4, 16]]], ["The responses to these items formed the composite score of perceived risk (\u03b1 = .70), with higher scores indicating a greater perceived risk.Altruism ::: Measures ::: MethodsThe Self-Report Altruism Scale (SRA scale) was adapted from the scale designed by Rushton, Chrisjohn and Fekken, and it includes 20 items concerning altruistic behaviours (e.g., \u201cI have helped push a stranger\u2019s car out of the snow\u201d and \u201cI have helped an acquaintance to move households\u201d) [20].", [["Altruism Scale (SRA scale", "TREATMENT", 189, 214]]], ["The Chinese version of the SRA scale (C-SRA scale) has been validated (Cronbach\u2019s \u03b1 = .86) [21].", [["the SRA scale", "TREATMENT", 23, 36], ["C-SRA scale", "TREATMENT", 38, 49], ["Cronbach", "TEST", 71, 79]]], ["The participants clicked the option that best conformed to their past acts on a 5-point scale (1 = never; 2 = once, 3 = more than once; 4 = often; 5 = very often).", [["participants", "SPECIES", 4, 16]]], ["We calculated a composite altruism composite score (\u03b1 = .89), with higher scores indicating higher altruism.Positive and negative affect ::: Measures ::: MethodsThe Positive and Negative Affect Scale (PANAS) consisting of 20 items was used to measure emotional outcomes [22].", [["Methods", "TEST", 154, 161], ["negative affect", "OBSERVATION_MODIFIER", 121, 136], ["Positive", "OBSERVATION", 165, 173]]], ["The PANAS comprises two scales, i.e., a 10-item positive affect scale (e.g., enthusiastic, excited, and inspired) and a 10-item negative affect scale (e.g., afraid, upset, and distressed).", [["PANAS", "DNA", 4, 9], ["two", "OBSERVATION_MODIFIER", 20, 23], ["scales", "OBSERVATION_MODIFIER", 24, 30]]], ["Previous studies have regarded positive and negative affect as two dominant and relatively independent dimensions rather than two poles on the same continuous scale [22, 23].", [["Previous studies", "TEST", 0, 16], ["negative", "OBSERVATION", 44, 52], ["dominant", "OBSERVATION_MODIFIER", 67, 75], ["relatively", "OBSERVATION_MODIFIER", 80, 90], ["independent dimensions", "OBSERVATION_MODIFIER", 91, 113]]], ["For each item, the participants were asked to indicate the extent to which they had felt the corresponding emotion in the past 2 weeks on a 5-point scale (1 = very slightly or not at all; 2 = a little, 3 = moderately; 4 = quite a bit; 5 = extremely).", [["participants", "SPECIES", 19, 31]]], ["Composite positive (\u03b1 = .92) and negative (\u03b1 = .94) affect scores were calculated separately, with higher scores indicating higher positive or negative emotions.Mental health ::: Measures ::: MethodsAnxiety and depression are the two most common indicators used to assess mental health in the general population and clinical practice [24, 25].", [["depression", "DISEASE", 211, 221], ["affect scores", "TEST", 52, 65], ["higher positive or negative emotions", "PROBLEM", 124, 160], ["MethodsAnxiety", "TREATMENT", 192, 206], ["depression", "PROBLEM", 211, 221], ["negative emotions", "OBSERVATION", 143, 160]]], ["Anxiety and depression diagnoses frequently tend to co-occur, and their symptoms are highly correlated [26].", [["Anxiety", "DISEASE", 0, 7], ["depression", "DISEASE", 12, 22], ["Anxiety", "PROBLEM", 0, 7], ["depression diagnoses", "PROBLEM", 12, 32], ["their symptoms", "PROBLEM", 66, 80]]], ["Thus, the latent variable \u201cmental health\u201d was constructed as an outcome variable based on anxiety and depressive symptoms in this study.", [["anxiety", "DISEASE", 90, 97], ["depressive symptoms", "DISEASE", 102, 121], ["anxiety", "PROBLEM", 90, 97], ["depressive symptoms", "PROBLEM", 102, 121], ["this study", "TEST", 125, 135], ["latent", "OBSERVATION_MODIFIER", 10, 16], ["variable", "OBSERVATION_MODIFIER", 17, 25]]], ["The 7-item Generalized Anxiety Disorder Scale (GAD-7), which is a self-report screening scale, was used to assess anxiety symptoms [27].", [["Anxiety Disorder", "DISEASE", 23, 39], ["anxiety", "DISEASE", 114, 121], ["Generalized Anxiety Disorder", "PROBLEM", 11, 39], ["GAD", "TEST", 47, 50], ["anxiety symptoms", "PROBLEM", 114, 130]]], ["The Chinese version of the GAD-7 has been validated and shown great reliability (Cronbach\u2019s \u03b1 = 0.89) [28].", [["GAD", "PROTEIN", 27, 30]]], ["The participants were asked to indicate the frequency of the occurrence of anxiety symptoms over the past 2 weeks on a 4-point Likert scale (0 = not at all; 1 = several days, 2 = more than half the days; 3 = nearly every day).", [["anxiety", "DISEASE", 75, 82], ["participants", "SPECIES", 4, 16], ["anxiety symptoms", "PROBLEM", 75, 91]]], ["A composite anxiety score was created (\u03b1 = .92), with higher scores indicating anxiety symptoms of greater severity.", [["anxiety", "DISEASE", 12, 19], ["anxiety", "DISEASE", 79, 86], ["A composite anxiety score", "TEST", 0, 25], ["higher scores", "PROBLEM", 54, 67], ["anxiety symptoms", "PROBLEM", 79, 95], ["greater severity", "PROBLEM", 99, 115], ["greater severity", "OBSERVATION_MODIFIER", 99, 115]]], ["Anxiety symptoms were identified based on a cut-off score of 5 in this study [27].", [["Anxiety", "DISEASE", 0, 7], ["Anxiety symptoms", "PROBLEM", 0, 16], ["a cut-off score", "TEST", 42, 57], ["this study", "TEST", 66, 76]]], ["Similar to anxiety symptoms, depressive symptoms were measured through the self-report 9-item Patient Health Questionnaire (PHQ-9) [29], which has been verified in China (Cronbach\u2019s \u03b1 = 0.86) [30].", [["anxiety", "DISEASE", 11, 18], ["depressive symptoms", "DISEASE", 29, 48], ["Patient", "SPECIES", 94, 101], ["anxiety symptoms", "PROBLEM", 11, 27], ["depressive symptoms", "PROBLEM", 29, 48], ["PHQ", "TEST", 124, 127]]], ["Each item assesses the frequency of the occurrence of depressive symptoms over the past 2 weeks on a 4-point scale from 0 (not at all) to 3 (nearly every day).", [["depressive symptoms", "DISEASE", 54, 73], ["depressive symptoms", "PROBLEM", 54, 73], ["a 4-point scale", "TREATMENT", 99, 114]]], ["We computed the composite depression score (\u03b1 = .89).", [["depression", "DISEASE", 26, 36], ["the composite depression score", "PROBLEM", 12, 42]]], ["Higher scores indicated more severe depressive symptoms.", [["depressive symptoms", "DISEASE", 36, 55], ["Higher scores", "PROBLEM", 0, 13], ["more severe depressive symptoms", "PROBLEM", 24, 55], ["severe", "OBSERVATION_MODIFIER", 29, 35]]], ["The cut-off score for depressive symptoms was 5 in our study [29].Data analysis ::: MethodsWe used the Shapiro-Wilk test to examine the normality of the continuous variables.", [["depressive symptoms", "DISEASE", 22, 41], ["depressive symptoms", "PROBLEM", 22, 41], ["our study", "TEST", 51, 60], ["Data analysis", "TEST", 66, 79], ["the Shapiro-Wilk test", "TEST", 99, 120]]], ["We found that all continuous variables were not normally distributed.", [["not", "UNCERTAINTY", 44, 47], ["normally", "OBSERVATION_MODIFIER", 48, 56], ["distributed", "OBSERVATION_MODIFIER", 57, 68]]], ["Comparisons of the demographic characteristics between the participants with and without anxiety symptoms and between those with and without depressive symptoms were conducted.", [["anxiety", "DISEASE", 89, 96], ["depressive symptoms", "DISEASE", 141, 160], ["participants", "SPECIES", 59, 71], ["anxiety symptoms", "PROBLEM", 89, 105], ["depressive symptoms", "PROBLEM", 141, 160]]], ["A Mann-Whitney U test was performed for the age comparisons, and a chi-square test was performed for the sex and ethnic comparisons.", [["U test", "TEST", 15, 21], ["a chi-square test", "TEST", 65, 82]]], ["Spearman correlations between the continuous variables measured above were calculated due to their non-normal distributions All above analyses were performed using IBM SPSS Statistics software version 23.0.", [["Spearman correlations", "TEST", 0, 21], ["All above analyses", "TEST", 124, 142]]], ["In addition, the hypothesized moderating and mediating effects were examined by structural equation modelling (SEM) using Mplus software version 8.0.", [["Mplus software version", "TEST", 122, 144]]], ["The goodness of fit was assessed by computing the comparative fit index (CFI), Tucker-Lewis index (TLI), root mean square error of approximation (RMSEA) and standardized root mean residual (SRMR) [31].", [["root", "ANATOMY", 170, 174], ["CFI", "TEST", 73, 76], ["Tucker", "TEST", 79, 85], ["standardized root mean residual (SRMR)", "PROBLEM", 157, 195], ["root", "OBSERVATION_MODIFIER", 105, 109], ["root", "OBSERVATION_MODIFIER", 170, 174]]], ["The acceptable levels of the goodness-of-fit model parameters are CFI > .90, TFI > .90, RMSEA < 08, and SRMR < .08 [32].", [["the goodness", "TEST", 25, 37], ["CFI", "TEST", 66, 69], ["TFI", "TEST", 77, 80], ["RMSEA", "TEST", 88, 93], ["SRMR", "TEST", 104, 108]]], ["Moreover, to test the statistical significance of the moderating and mediating effects, we conducted bias-corrected bootstrap tests with 95% confidence intervals.", [["bias", "TEST", 101, 105], ["bootstrap tests", "TEST", 116, 131]]], ["The significance value was set at .05 in this study.Background characteristics and covariates ::: ResultsIn total, 1493 questionnaires were distributed, and 1346 participants completed the survey.", [["participants", "SPECIES", 162, 174], ["The significance value", "TEST", 0, 22], ["this study", "TEST", 41, 51]]], ["The response rate was 90.15%.", [["The response rate", "TEST", 0, 17]]], ["The final sample comprised 1346 participants with the following characteristics: mean age = 19.76 \u00b1 2.23 years; 364 (27.0%) males (Mage = 19.69 \u00b1 2.30 years) and 982 (73.0%) females (Mage = 19.79 \u00b1 2.21 years); 1143 (84.9%) of Han nationality (Mage = 19.81 \u00b1 2.32 years) and 203 (15.1%) belonging to other ethnic groups (Mage = 19.48 \u00b1 1.66 years).", [["participants", "SPECIES", 32, 44], ["Mage", "TEST", 131, 135], ["Mage", "TEST", 183, 187], ["Han nationality", "TEST", 227, 242], ["Mage", "TEST", 244, 248], ["Mage", "TEST", 321, 325]]], ["Table 1 shows the summary statistics of the participants\u2019 background characteristics.", [["participants", "SPECIES", 44, 56]]]], "PMC2851619": [], "349c195b0c1171bc3a35e14a070c36c72a86751a": [["IntroductionThe Swine Flu (officially called the H1N1 Flu) first infected people in the United States in April (Center for Disease Control and Prevention, 2009) .", [["Flu", "CHEMICAL", 22, 25], ["Flu", "CHEMICAL", 54, 57], ["Swine Flu", "ORGANISM", 16, 25], ["H1N1 Flu", "ORGANISM", 49, 57], ["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80], ["Disease Control", "TREATMENT", 123, 138]]], ["By June 2009, the Swine Flu became a pandemic (World Health Organization, 2009 ).", [["Flu", "CHEMICAL", 24, 27]]], ["Similar to traditional, seasonal strains of influenza, Swine Flu is very contagious, and can spread through coughing, sneezing, or touching (Center for Disease Control and Prevention, 2009) .", [["influenza", "DISEASE", 44, 53], ["Flu", "CHEMICAL", 61, 64], ["coughing", "DISEASE", 108, 116], ["sneezing", "DISEASE", 118, 126], ["Swine Flu", "ORGANISM", 55, 64], ["Swine", "SPECIES", 55, 60], ["Swine Flu", "SPECIES", 55, 64], ["influenza", "PROBLEM", 44, 53], ["coughing", "PROBLEM", 108, 116], ["sneezing", "PROBLEM", 118, 126], ["Disease Control", "TREATMENT", 152, 167], ["influenza", "OBSERVATION", 44, 53]]], ["Although the Swine Flu does not significantly differ in symptomology compared to the traditional, seasonal flu, it garnered much attention in the media and became a significant health concern for many during the 2009 Swine Flu pandemic.", [["Flu", "CHEMICAL", 223, 226], ["Swine Flu", "ORGANISM", 13, 22], ["significant", "OBSERVATION_MODIFIER", 165, 176]]], ["It is possible that some individuals have significantly greater fears related to being infected by Swine Flu.IntroductionThe 2009 Swine Flu pandemic provided researchers with an opportunity to examine relationships between pandemic fears and health anxiety.", [["Flu", "CHEMICAL", 105, 108], ["pandemic fears", "DISEASE", 223, 237], ["anxiety", "DISEASE", 249, 256], ["Swine Flu", "ORGANISM", 99, 108], ["some individuals", "PROBLEM", 20, 36], ["health anxiety", "PROBLEM", 242, 256], ["infected", "OBSERVATION", 87, 95]]], ["Other recent pandemics showed that anxiety was elevated among individuals living in urban areas associated with the outbreak.", [["anxiety", "DISEASE", 35, 42], ["Other recent pandemics", "PROBLEM", 0, 22], ["anxiety", "PROBLEM", 35, 42]]], ["For example, during the outbreak of Severe Acute Respiratory Syndrome (SARS), which had primary outbreaks in Hong Kong and Toronto, it was shown that there was high anxiety regarding the risk of illness in general population of Hong Kong (Cheng & Cheung, 2005 ) and for individuals who attending a conference in Toronto (Stinson, McCartney, Leung, & Katz, 2004) .", [["Acute Respiratory Syndrome", "DISEASE", 43, 69], ["SARS", "DISEASE", 71, 75], ["anxiety", "DISEASE", 165, 172], ["illness", "DISEASE", 195, 202], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 36, 76], ["Severe Acute Respiratory Syndrome", "PROBLEM", 36, 69], ["high anxiety", "PROBLEM", 160, 172], ["Severe", "OBSERVATION_MODIFIER", 36, 42], ["Acute", "OBSERVATION_MODIFIER", 43, 48], ["Respiratory Syndrome", "OBSERVATION", 49, 69]]], ["The incidence of psychiatric disturbance following the SARS outbreak was limited primarily to those with prior psychiatric histories (Lancee, Maunder, & Goldbloom, 2008) .", [["psychiatric disturbance", "DISEASE", 17, 40], ["SARS", "DISEASE", 55, 59], ["psychiatric", "DISEASE", 111, 122], ["psychiatric disturbance", "PROBLEM", 17, 40], ["the SARS outbreak", "PROBLEM", 51, 68]]], ["Collectively, these studies show that widely publicized pandemics are associated with increased anxiety and potentially exacerbations of psychiatric disturbance.", [["pandemics", "DISEASE", 56, 65], ["anxiety", "DISEASE", 96, 103], ["psychiatric disturbance", "DISEASE", 137, 160], ["these studies", "TEST", 14, 27], ["increased anxiety", "PROBLEM", 86, 103], ["psychiatric disturbance", "PROBLEM", 137, 160], ["widely", "OBSERVATION_MODIFIER", 38, 44], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["anxiety", "OBSERVATION", 96, 103]]], ["In the case of psychiatric disturbance, obsessive-compulsive disorder (OCD) is an especially important condition that may be influenced by pandemic outbreaks.", [["psychiatric disturbance", "DISEASE", 15, 38], ["obsessive-compulsive disorder", "DISEASE", 40, 69], ["OCD", "DISEASE", 71, 74], ["psychiatric disturbance", "PROBLEM", 15, 38], ["obsessive-compulsive disorder", "PROBLEM", 40, 69], ["OCD", "PROBLEM", 71, 74]]], ["Those already suffering from symptoms of anxiety may be at greater risk of Swine Flu fears, and may also be more susceptible to taking excessive measures to reduce the likelihood of contracting Swine Flu.", [["anxiety", "DISEASE", 41, 48], ["Flu", "CHEMICAL", 200, 203], ["symptoms", "PROBLEM", 29, 37], ["anxiety", "PROBLEM", 41, 48], ["Swine Flu fears", "PROBLEM", 75, 90], ["excessive measures", "TREATMENT", 135, 153], ["contracting Swine Flu", "PROBLEM", 182, 203], ["contracting Swine Flu", "OBSERVATION", 182, 203]]], ["Additionally, given the common symptoms of contamination fears in individuals suffering from OCD (American Psychiatric Association, 2000; Ball, Baer, & Otto, 1996) , it is possible that individuals with obsessive-compulsive (OC) symptoms or OC beliefs are more likely to fear exposure to Swine Flu, along with taking excessive measures to prevent contracting this illness.", [["contamination fears", "DISEASE", 43, 62], ["OCD", "DISEASE", 93, 96], ["obsessive-compulsive", "DISEASE", 203, 223], ["OC", "CHEMICAL", 225, 227], ["OC", "CHEMICAL", 241, 243], ["Flu", "CHEMICAL", 294, 297], ["the common symptoms", "PROBLEM", 20, 39], ["obsessive-compulsive (OC) symptoms", "PROBLEM", 203, 237], ["OC beliefs", "PROBLEM", 241, 251], ["Swine Flu", "PROBLEM", 288, 297], ["excessive measures", "TREATMENT", 317, 335], ["this illness", "PROBLEM", 359, 371]]], ["Understanding these relationships could benefit clinicians in developing treatment plans for clients with significant pandemic fears, or anticipate the primary concerns of clients at risk for these fears when there are outbreaks presented in media reports of flu or other viral infections.Health-related anxietyFear of Swine Flu or other illnesses can be considered a specific type of anxiety called health-related anxiety.", [["flu", "DISEASE", 259, 262], ["viral infections", "DISEASE", 272, 288], ["Flu", "CHEMICAL", 325, 328], ["anxiety", "DISEASE", 385, 392], ["anxiety", "DISEASE", 415, 422], ["treatment plans", "TREATMENT", 73, 88], ["significant pandemic fears", "PROBLEM", 106, 132], ["outbreaks", "PROBLEM", 219, 228], ["flu", "PROBLEM", 259, 262], ["other viral infections", "PROBLEM", 266, 288], ["Swine Flu", "PROBLEM", 319, 328], ["anxiety", "PROBLEM", 385, 392], ["anxiety", "PROBLEM", 415, 422], ["viral", "OBSERVATION_MODIFIER", 272, 277], ["infections", "OBSERVATION", 278, 288]]], ["Taylor and Asmundson (2004) describe health anxiety as a useful function for humans to react to physical ailments with a certain level of concern.", [["anxiety", "DISEASE", 44, 51], ["humans", "ORGANISM", 77, 83], ["humans", "SPECIES", 77, 83], ["humans", "SPECIES", 77, 83], ["anxiety", "PROBLEM", 44, 51]]], ["This normal level of anxiety often causes us to take the necessary measures to prevent and alleviate illness.", [["anxiety", "DISEASE", 21, 28], ["illness", "DISEASE", 101, 108], ["anxiety", "PROBLEM", 21, 28], ["the necessary measures", "TREATMENT", 53, 75], ["alleviate illness", "PROBLEM", 91, 108]]], ["Health anxiety becomes problematic when the anxiety is chronic and excessive, or when the anxiety is significantly greater than the severity of the healthrelated threat (Taylor, McKay, & Abramowitz, 2012) .", [["anxiety", "DISEASE", 7, 14], ["anxiety", "DISEASE", 44, 51], ["anxiety", "DISEASE", 90, 97], ["Health anxiety", "PROBLEM", 0, 14], ["the anxiety", "PROBLEM", 40, 51], ["the anxiety", "PROBLEM", 86, 97], ["chronic", "OBSERVATION_MODIFIER", 55, 62]]], ["This kind of anxiety can be disabling, and is a common symptom in myriad psychological disorders, such as hypochondriasis, OCD, panic disorder, and specific phobias (Taylor et al., 2012) .Health-related anxietyPersons suffering from excessive health anxiety often seek reassurance that they are not ill, but the relief experienced from reassurance seeking generally does not last long and can actually increase long-term severity of health anxiety (Taylor & Asmundson, 2004) .", [["anxiety", "DISEASE", 13, 20], ["psychological disorders", "DISEASE", 73, 96], ["hypochondriasis", "DISEASE", 106, 121], ["OCD", "DISEASE", 123, 126], ["panic disorder", "DISEASE", 128, 142], ["phobias", "DISEASE", 157, 164], ["anxiety", "DISEASE", 203, 210], ["excessive health anxiety", "DISEASE", 233, 257], ["anxiety", "DISEASE", 440, 447], ["Persons", "ORGANISM", 210, 217], ["Persons", "SPECIES", 210, 217], ["anxiety", "PROBLEM", 13, 20], ["a common symptom", "PROBLEM", 46, 62], ["myriad psychological disorders", "PROBLEM", 66, 96], ["hypochondriasis", "PROBLEM", 106, 121], ["OCD", "PROBLEM", 123, 126], ["panic disorder", "PROBLEM", 128, 142], ["specific phobias", "PROBLEM", 148, 164], ["anxiety", "PROBLEM", 203, 210], ["excessive health anxiety", "PROBLEM", 233, 257]]], ["Excessive health anxiety is also often accompanied by excessive checking in many aspects, including bodily checking and checking medical sources about diseases.Health-related anxietyDue to preoccupations with health concerns and physical symptoms, it follows that health-related anxiety is commonly experienced in individuals suffering from symptoms of anxiety disorders such as OCD and panic disorder, where individuals often interpret benign physical symptoms (particularly anxiety-related arousal) as harmful (called anxiety sensitivity; Taylor et al., 2007) .", [["anxiety", "DISEASE", 17, 24], ["anxiety", "DISEASE", 279, 286], ["anxiety disorders", "DISEASE", 353, 370], ["OCD", "DISEASE", 379, 382], ["panic disorder", "DISEASE", 387, 401], ["anxiety", "DISEASE", 476, 483], ["anxiety", "DISEASE", 520, 527], ["Excessive health anxiety", "PROBLEM", 0, 24], ["bodily checking", "TEST", 100, 115], ["diseases", "PROBLEM", 151, 159], ["physical symptoms", "PROBLEM", 229, 246], ["anxiety", "PROBLEM", 279, 286], ["symptoms", "PROBLEM", 341, 349], ["anxiety disorders", "PROBLEM", 353, 370], ["OCD", "PROBLEM", 379, 382], ["panic disorder", "PROBLEM", 387, 401], ["benign physical symptoms", "PROBLEM", 437, 461], ["anxiety", "PROBLEM", 476, 483]]], ["Additionally, a common OC belief includes overestimation of threat.", [["OC", "CHEMICAL", 23, 25]]], ["In contamination-based OCD, this overestimation of threat may include health anxiety-based symptoms such as obsessions with becoming ill or contaminating others (Cisler, Brady, Olatunji, & Lohr, 2010) .", [["OCD", "DISEASE", 23, 26], ["anxiety", "DISEASE", 77, 84], ["obsessions", "DISEASE", 108, 118], ["ill", "DISEASE", 133, 136], ["health anxiety", "PROBLEM", 70, 84], ["based symptoms", "PROBLEM", 85, 99], ["obsessions", "PROBLEM", 108, 118]]], ["It is important to note that OC beliefs are not specific to OCD and are often experienced by individuals suffering from other anxiety disorders as well (Tolin, Worhunsky, & Maltby, 2006) .", [["OC", "CHEMICAL", 29, 31], ["OCD", "DISEASE", 60, 63], ["anxiety disorders", "DISEASE", 126, 143], ["other anxiety disorders", "PROBLEM", 120, 143]]], ["Finally, those who are more likely to experience disgust may also endorse a greater number of pandemic-related fears.", [["pandemic", "DISEASE", 94, 102], ["disgust", "PROBLEM", 49, 56], ["greater", "OBSERVATION_MODIFIER", 76, 83], ["number", "OBSERVATION_MODIFIER", 84, 90], ["pandemic", "OBSERVATION", 94, 102]]], ["Disgust sensitivity is seen in anxiety disorders such as OCD and certain phobias, and has been shown to play a critical role in those suffering from OCD, especially when symptoms are contamination-based (Thorpe, Patel, & Simonds, 2003) .Previous research on Swine Flu attitudes and behaviorsA telephone survey study in the UK examined how perceptions of Swine Flu affected behaviors taken to reduce Swine Flu (Rubin, Amlot, Page, & Wessely, 2009 ).", [["anxiety disorders", "DISEASE", 31, 48], ["OCD", "DISEASE", 57, 60], ["phobias", "DISEASE", 73, 80], ["OCD", "DISEASE", 149, 152], ["Flu", "CHEMICAL", 360, 363], ["Flu", "CHEMICAL", 405, 408], ["Swine", "SPECIES", 258, 263], ["Disgust sensitivity", "TEST", 0, 19], ["anxiety disorders", "PROBLEM", 31, 48], ["OCD", "PROBLEM", 57, 60], ["certain phobias", "PROBLEM", 65, 80], ["OCD", "PROBLEM", 149, 152], ["symptoms", "PROBLEM", 170, 178], ["A telephone survey study", "TEST", 291, 315], ["Swine Flu affected behaviors", "PROBLEM", 354, 382]]], ["Participants in this study were asked questions about specific behaviors they had engaged in over the previous few days relating to fear of Swine Flu.", [["Flu", "CHEMICAL", 146, 149], ["Participants", "SPECIES", 0, 12], ["this study", "TEST", 16, 26], ["Swine Flu", "PROBLEM", 140, 149]]], ["The researchers found that individuals with higher levels of anxiety about Swine Flu were significantly more likely to carry out avoidance behaviors recommended by the government than those who did not have high levels of anxiety (Rubin, Amlot, Page, & Wessely, 2009 ).", [["anxiety", "DISEASE", 61, 68], ["anxiety", "DISEASE", 222, 229], ["anxiety", "PROBLEM", 61, 68], ["Swine Flu", "PROBLEM", 75, 84], ["anxiety", "PROBLEM", 222, 229]]], ["Goodwin, Haque, Neto, and Myers (2009) conducted an internet and paper-based survey in Malaysia and Europe, which examined ''attitudinal and behavioral responses'' related to the Swine Flu pandemic.", [["the Swine Flu pandemic", "PROBLEM", 175, 197]]], ["In terms of anxiety regarding Swine Flu infection, about half of the participants reported being at least ''somewhat concerned'' by catching Swine Flu, and this percentage was significantly higher in the Malaysian sample (71% indicated they were at least ''somewhat concerned'') (Goodwin et al., 2009) .", [["anxiety", "DISEASE", 12, 19], ["Flu infection", "DISEASE", 36, 49], ["participants", "ORGANISM", 69, 81], ["participants", "SPECIES", 69, 81], ["anxiety", "PROBLEM", 12, 19], ["Swine Flu infection", "PROBLEM", 30, 49], ["infection", "OBSERVATION", 40, 49]]], ["Interestingly, the researchers found that while participants in the European sample were more likely to discuss their fears with their friends when compared to the Malaysian sample, Malaysian participants were more likely to contemplate behavioral changes (i.e., not using public transportation, and purchasing masks and other goods in preparation of an outbreak) (Goodwin et al., 2009) .", [["participants", "SPECIES", 48, 60], ["participants", "SPECIES", 192, 204], ["behavioral changes", "PROBLEM", 237, 255]]], ["These findings, plus the higher level of overall anxiety in the Malaysian population, shed light on some potential cultural differences when examining Swine Flu fears.", [["anxiety", "DISEASE", 49, 56], ["overall anxiety", "PROBLEM", 41, 56], ["overall", "OBSERVATION_MODIFIER", 41, 48], ["anxiety", "OBSERVATION", 49, 56]]], ["This could be based on multiple factors, such as access to health care, access to information regarding Swine Flu, and cultural differences about emotional expression to friends and family.Previous research on Swine Flu attitudes and behaviorsAnother study used a cross-sectional survey to ascertain the beliefs and attitudes of Australians about the Swine Flu during the WHO Phase 5 (Pandemic H1N1, 2009; Seale et al., 2009) .", [["Flu", "CHEMICAL", 357, 360], ["Australians", "ORGANISM", 329, 340], ["Swine", "SPECIES", 210, 215], ["Another study", "TEST", 243, 256], ["a cross-sectional survey", "TEST", 262, 286]]], ["While this study did not directly examine the relationship between anxiety and Swine Flu, it did find that almost half of the participants felt they did not have enough information regarding the pandemic, and only 33% of the participants felt that being infected by Swine Flu would affect their lives ''very seriously'' (Seale et al., 2009) .", [["anxiety", "DISEASE", 67, 74], ["Flu", "CHEMICAL", 272, 275], ["participants", "ORGANISM", 126, 138], ["participants", "ORGANISM", 225, 237], ["participants", "SPECIES", 126, 138], ["participants", "SPECIES", 225, 237], ["this study", "TEST", 6, 16], ["anxiety", "PROBLEM", 67, 74]]], ["Perhaps, there is a relationship between media exposure and perceived threat of Swine Flu, considering many participants in this study felt under-informed.", [["Flu", "CHEMICAL", 86, 89], ["participants", "SPECIES", 108, 120], ["this study", "TEST", 124, 134], ["Swine", "OBSERVATION_MODIFIER", 80, 85], ["Flu", "OBSERVATION", 86, 89]]], ["While the effects of media exposure on Swine Flu anxiety are beyond the scope of this paper, it is an important point to consider in future studies of epidemic attitudes and behaviors.", [["anxiety", "DISEASE", 49, 56], ["Swine", "SPECIES", 39, 44], ["media exposure", "PROBLEM", 21, 35], ["Swine Flu anxiety", "PROBLEM", 39, 56]]], ["While the research above describes different factors that may affect attitudes toward Swine Flu, none of these studies have directly examined the effect of psychological symptoms on Swine Flu attitudes.", [["these studies", "TEST", 105, 118], ["psychological symptoms", "PROBLEM", 156, 178]]], ["A 2011 study examined the relationship between Swine Flu fears and various symptoms related to health anxiety, including contamination fears, panic symptoms, and disgust in an undergraduate sample (Wheaton, Abramowitz, Berman, Fabricant, & Olatunji, 2012) .", [["Flu fears", "DISEASE", 53, 62], ["anxiety", "DISEASE", 102, 109], ["contamination fears", "DISEASE", 121, 140], ["panic symptoms", "DISEASE", 142, 156], ["A 2011 study", "TEST", 0, 12], ["Swine Flu fears", "PROBLEM", 47, 62], ["various symptoms", "PROBLEM", 67, 83], ["health anxiety", "PROBLEM", 95, 109], ["contamination fears", "PROBLEM", 121, 140], ["panic symptoms", "PROBLEM", 142, 156], ["disgust", "PROBLEM", 162, 169]]], ["Using regression analyses, Wheaton, Abramowitz, Berman, Fabricant, & Olatunji (2012) found that health-related anxiety, disgust sensitivity, and contamination fears all significantly predicted Swine Flu fears.", [["anxiety", "DISEASE", 111, 118], ["regression analyses", "TEST", 6, 25], ["anxiety", "PROBLEM", 111, 118], ["disgust sensitivity", "PROBLEM", 120, 139], ["contamination fears", "PROBLEM", 145, 164]]], ["This study was the first to demonstrate a relationship between various symptoms of anxiety and fears related to Swine Flu.Previous research on Swine Flu attitudes and behaviorsThese studies highlight how epidemics can impact an individual's mental and emotional state.", [["anxiety", "DISEASE", 83, 90], ["Flu", "CHEMICAL", 118, 121], ["Swine", "SPECIES", 143, 148], ["This study", "TEST", 0, 10], ["various symptoms", "PROBLEM", 63, 79], ["anxiety", "PROBLEM", 83, 90], ["Swine Flu", "PROBLEM", 112, 121], ["These studies", "TEST", 176, 189]]], ["The current study aims to build on the literature discussed above by examining how previous anxiety and other factors contribute to pandemic anxiety.Previous research on Swine Flu attitudes and behaviorsThe aims of the current study are to investigate the relationship between symptoms of various anxiety problems (e.g., panic, obsessive-compulsive disorder) and fear of contracting Swine Flu.", [["anxiety", "DISEASE", 92, 99], ["anxiety", "DISEASE", 141, 148], ["anxiety problems", "DISEASE", 297, 313], ["panic", "DISEASE", 321, 326], ["obsessive-compulsive disorder", "DISEASE", 328, 357], ["Flu", "CHEMICAL", 389, 392], ["Swine", "SPECIES", 170, 175], ["The current study", "TEST", 0, 17], ["previous anxiety", "PROBLEM", 83, 99], ["pandemic anxiety", "PROBLEM", 132, 148], ["the current study", "TEST", 215, 232], ["symptoms", "PROBLEM", 277, 285], ["various anxiety problems", "PROBLEM", 289, 313], ["panic", "PROBLEM", 321, 326], ["obsessive-compulsive disorder", "PROBLEM", 328, 357], ["contracting Swine Flu", "PROBLEM", 371, 392]]], ["Measuring these relationships will help clarify the role of anxiety in pandemic fears, which could be useful information for clinicians treating patients with such fears.Previous research on Swine Flu attitudes and behaviorsBased on the findings from Wheaton, Abramowitz, Berman, Fabricant, & Olatunji (2012) , the current study examined the mediating effects of various symptoms of anxiety between OC symptoms and OC beliefs and Swine Flu fears and behaviors.", [["anxiety", "DISEASE", 60, 67], ["anxiety", "DISEASE", 383, 390], ["OC", "CHEMICAL", 399, 401], ["OC", "CHEMICAL", 415, 417], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["Swine", "SPECIES", 191, 196], ["anxiety", "PROBLEM", 60, 67], ["Abramowitz", "TEST", 260, 270], ["the current study", "TEST", 311, 328], ["various symptoms", "PROBLEM", 363, 379], ["anxiety", "PROBLEM", 383, 390], ["OC symptoms", "PROBLEM", 399, 410], ["OC beliefs", "PROBLEM", 415, 425], ["Swine Flu fears", "PROBLEM", 430, 445]]], ["Mediation analyses allow for identification of possible causal pathways (MacKinnon, 2008) unexamined in the prior report.", [["Mediation analyses", "TEST", 0, 18]]], ["It is expected, based on the literature reviewed here, that OC symptoms and beliefs are intermediate causal factors between anxiety symptoms and the experience of Swine Flu fears.", [["OC", "CHEMICAL", 60, 62], ["anxiety", "DISEASE", 124, 131], ["OC symptoms", "PROBLEM", 60, 71], ["anxiety symptoms", "PROBLEM", 124, 140], ["Swine Flu fears", "PROBLEM", 163, 178]]], ["First, it was hypothesized that both OC beliefs and OC symptoms will significantly predict levels of Swine Flu fears and behaviors.", [["OC", "CHEMICAL", 37, 39], ["OC", "CHEMICAL", 52, 54], ["OC symptoms", "PROBLEM", 52, 63], ["Swine Flu fears", "PROBLEM", 101, 116]]], ["Then, it was hypothesized that measures that target symptoms of panic and disgust, will significantly mediate the relationship between both OC symptoms and OC beliefs, and Swine Flu fears and behaviors.Participants and procedureParticipants consisted of undergraduate students at Fordham University and the University of North Carolina (N \u00bc393), primarily in Introductory Psychology courses.", [["panic", "DISEASE", 64, 69], ["OC", "CHEMICAL", 140, 142], ["OC", "CHEMICAL", 156, 158], ["Participants", "SPECIES", 202, 214], ["target symptoms", "PROBLEM", 45, 60], ["panic", "PROBLEM", 64, 69], ["disgust", "PROBLEM", 74, 81], ["both OC symptoms", "PROBLEM", 135, 151]]], ["The sample from Fordham University included 208 participants, while the sample from University of North Carolina included 185 participants.", [["participants", "SPECIES", 48, 60], ["participants", "SPECIES", 126, 138], ["The sample", "TEST", 0, 10]]], ["Data collected from the University of North Carolina sample were also used for analysis in Wheaton, Abramowitz, Berman, Fabricant, & Olatunji (2012) .", [["analysis", "TEST", 79, 87]]], ["The sample consisted of 267 females (68%) and 126 males (32%).", [["The sample", "TEST", 0, 10]]], ["The mean age of participants was 20.13 years old.", [["participants", "ORGANISM", 16, 28], ["participants", "SPECIES", 16, 28]]], ["A majority of participants identified as Caucasian (N \u00bc269; 68%), 52 identified as Hispanic (13%), 29 identified as Asian (7%), 24 identified as African American (6%), and 19 participants identified as ''Other'' (5%).", [["participants", "ORGANISM", 14, 26], ["participants", "SPECIES", 14, 26], ["participants", "SPECIES", 175, 187]]], ["Participants completed a computer-administered online questionnaire.", [["Participants", "SPECIES", 0, 12]]], ["After reading and signing an informed consent form, participants answered a series of questionnaires measuring attitudes and behaviors related to Swine Flu, anxiety symptoms, and media exposure.", [["Flu", "CHEMICAL", 152, 155], ["anxiety", "DISEASE", 157, 164], ["participants", "SPECIES", 52, 64], ["Swine Flu", "PROBLEM", 146, 155], ["anxiety symptoms", "PROBLEM", 157, 173]]], ["Upon completing the survey, participants submitted their responses, which could only be viewed by the principal investigator or faculty sponsor.", [["participants", "SPECIES", 28, 40]]], ["Participants received compensation in the form of required research credits for their courses.", [["Participants", "SPECIES", 0, 12], ["compensation", "TREATMENT", 22, 34], ["research credits", "TREATMENT", 59, 75]]], ["During this time frame there continued to be substantial reports regarding Swine Flu in the region around one data collection site (Fordham University, located in New York City).Participants and procedureWhile the current study uses part of its sample from that of Wheaton, Abramowitz, Berman, Fabricant, & Olatunji (2012) , it extends this research by including comprehensive mediation analyses that more thoroughly examine the relationships between Swine Flu fears and anxiety symptoms.", [["Flu", "CHEMICAL", 81, 84], ["Flu fears", "DISEASE", 457, 466], ["anxiety", "DISEASE", 471, 478], ["Participants", "SPECIES", 178, 190], ["Swine Flu in the region", "PROBLEM", 75, 98], ["the current study", "TEST", 210, 227], ["anxiety symptoms", "PROBLEM", 471, 487], ["Flu", "OBSERVATION", 81, 84]]], ["Specifically, we employed path analysis to evaluate mediation models using the recommendations from MacKinnon (2008).", [["path analysis", "TEST", 26, 39]]], ["Therefore, all subscales of the OBQ, OCI-R and ASI-3 were evaluated in the mediation model tests using LISREL.Participants and procedureThe first step of data analysis included running a series of linear regressions to find the relationships between OC beliefs and symptoms and Swine Flu fears and behaviors.", [["OC", "CHEMICAL", 250, 252], ["ASI-3", "GENE_OR_GENE_PRODUCT", 47, 52], ["OCI", "DNA", 37, 40], ["Participants", "SPECIES", 110, 122], ["the OBQ", "TEST", 28, 35], ["OCI", "TEST", 37, 40], ["ASI", "TEST", 47, 50], ["procedure", "TREATMENT", 127, 136], ["data analysis", "TEST", 154, 167], ["linear regressions", "PROBLEM", 197, 215], ["symptoms", "PROBLEM", 265, 273], ["Swine Flu fears", "PROBLEM", 278, 293]]], ["Mediation models were then examined using the Sobel test (Baron & Kenny, 1986) .", [["the Sobel test", "TEST", 42, 56]]], ["Using structural equation modeling, full path models using manifest scale variables were also run, and best fitting models were determined using goodness-of-fit indices, including the Tucker Lewis Index (TLI), the Comparative Fit Index (CFI), Akaike Information Criterion (AIC), and Bayesian Information Criterion (BIC).", [["manifest scale variables", "TEST", 59, 83], ["goodness", "TEST", 145, 153], ["fit indices", "TEST", 157, 168]]], ["This was done to more fully examine the mediating relationship between anxiety and disgust sensitivity on Swine Flu fear and obsessive compulsive symptoms and beliefs (MacKinnon, 2008).MeasuresThe following measures were used in this study.", [["anxiety", "DISEASE", 71, 78], ["obsessive compulsive symptoms", "DISEASE", 125, 154], ["Swine", "SPECIES", 106, 111], ["anxiety", "PROBLEM", 71, 78], ["disgust sensitivity", "PROBLEM", 83, 102], ["Swine Flu fear", "PROBLEM", 106, 120], ["obsessive compulsive symptoms", "PROBLEM", 125, 154], ["this study", "TEST", 229, 239]]], ["Obsessive-Compulsive Inventory-Revised (OCI-R; Foa et al., 2002) .", [["Obsessive", "PROBLEM", 0, 9], ["Compulsive Inventory", "TEST", 10, 30]]], ["The OCI-R is an 18-item, self-report inventory developed from the earlier 42-item Obsessive-Compulsive Inventory (Foa, Kozak, Salkovskis, Coles, & Amir, 1998) .", [["OCI-R", "GENE_OR_GENE_PRODUCT", 4, 9], ["OCI", "DNA", 4, 7], ["The OCI", "TEST", 0, 7]]], ["Each item describes a symptom commonly associated with obsessive-compulsive disorder.", [["obsessive-compulsive disorder", "DISEASE", 55, 84], ["a symptom", "PROBLEM", 20, 29], ["obsessive-compulsive disorder", "PROBLEM", 55, 84], ["compulsive disorder", "OBSERVATION", 65, 84]]], ["The measure utilizes a 5-point scale, with participants rating from 0 to 4 the degree to which each item has caused distress in the last month.", [["participants", "SPECIES", 43, 55], ["a 5-point scale", "TREATMENT", 21, 36], ["distress", "PROBLEM", 116, 124], ["distress", "OBSERVATION", 116, 124]]], ["Higher scores indicate greater levels of distress due to symptoms.", [["Higher scores", "PROBLEM", 0, 13], ["distress", "PROBLEM", 41, 49], ["symptoms", "PROBLEM", 57, 65], ["greater", "OBSERVATION_MODIFIER", 23, 30]]], ["The total score, ranging from 0 to 72, is then divided into subscales to reflect the severity of symptoms in the following six dimensions of OCD: washing, checking, ordering, obsessing, hoarding, and neutralizing (Abramowitz & Deacon, 2006) .", [["OCD", "DISEASE", 141, 144], ["hoarding", "DISEASE", 186, 194], ["The total score", "TEST", 0, 15], ["the severity of symptoms", "PROBLEM", 81, 105], ["hoarding", "PROBLEM", 186, 194]]], ["The OCI-R demonstrates good internal consistency and test-retest reliability, along with strong convergent validity.MeasuresAnxiety Sensitivity Index-3 (ASI-3; Taylor et al., 2007) .", [["OCI-R", "GENE_OR_GENE_PRODUCT", 4, 9], ["OCI", "DNA", 4, 7], ["The OCI", "TEST", 0, 7], ["test", "TEST", 53, 57], ["retest reliability", "TEST", 58, 76], ["Sensitivity Index", "TEST", 132, 149], ["ASI", "TEST", 153, 156]]], ["The ASI-3 is an 18-item, self-report inventory measuring fear of arousal-related sensations (Taylor et al., 2007) .", [["ASI-3", "DNA", 4, 9], ["The ASI", "TEST", 0, 7], ["arousal", "PROBLEM", 65, 72], ["related sensations", "PROBLEM", 73, 91]]], ["The measure utilizes a 5-point scale, with participants rating from 0 to 4 the degree to which they agree with certain statements about their anxiety sensitivity.", [["anxiety", "DISEASE", 142, 149], ["participants", "SPECIES", 43, 55], ["a 5-point scale", "TREATMENT", 21, 36], ["their anxiety sensitivity", "PROBLEM", 136, 161]]], ["Taylor et al. (2007) developed the ASI-3 on a non-clinical sample of 2,361 U.S. and Canadian participants.", [["participants", "SPECIES", 93, 105], ["the ASI", "TEST", 31, 38]]], ["Research concluded that the ASI-3 has sufficient convergent and discriminant validity for this measure by comparing the ASI-3 to the 36-item, ASI-R, and the original, 16-item ASI.", [["ASI-3", "DNA", 28, 33], ["the ASI", "TEST", 24, 31], ["the ASI", "TEST", 116, 123], ["ASI", "TEST", 142, 145]]], ["The study also confirms strong construct validity for the ASI-3 (Taylor et al., 2007) .MeasuresSwine Flu Inventory.", [["The study", "TEST", 0, 9], ["the ASI", "TEST", 54, 61], ["Flu Inventory", "OBSERVATION", 101, 114]]], ["The Swine Flu Inventory is an 11-item, self-report, inventory examining attitudes and behaviors associated with fears of Swine Flu and measures taken to prevent getting Swine Flu.", [["Flu", "CHEMICAL", 127, 130], ["Flu", "CHEMICAL", 175, 178], ["Swine Flu", "TREATMENT", 121, 130]]], ["Participants rate their attitudes about Swine Flu on a 5-point scale from 1 to 5 for the first ten items.", [["Participants", "SPECIES", 0, 12], ["a 5-point scale", "TREATMENT", 53, 68]]], ["For item 11, participants use an 11-point scale describing how much they engage in certain behaviors because of Swine Flu.", [["Flu", "CHEMICAL", 118, 121], ["participants", "SPECIES", 13, 25], ["an 11-point scale", "TREATMENT", 30, 47]]], ["For the first two questions of the questionnaire, participants indicate whether or not they have ever had Swine Flu and whether or not they know somebody close to them who has had Swine Flu.", [["Flu", "CHEMICAL", 186, 189], ["participants", "SPECIES", 50, 62]]], ["In the present sample, the scale had high internal consistency, with a\u00bc 0.85.MeasuresObsessional Beliefs Questionnaire-44 (OBQ-44; Obsessive Compulsive Cognitions Working Group, 2001).", [["Obsessive Compulsive Cognitions", "DISEASE", 131, 162], ["the scale", "TEST", 23, 32], ["MeasuresObsessional Beliefs", "TEST", 77, 104], ["Questionnaire", "TEST", 105, 118], ["OBQ", "TEST", 123, 126]]], ["The OBQ-44 is a 44-item, self-report inventory developed from the earlier 87-item obsessive beliefs questionnaire (OBQ).", [["The OBQ", "TEST", 0, 7]]], ["Each item describes beliefs related to obsessive-compulsive symptoms.", [["obsessive-compulsive symptoms", "DISEASE", 39, 68], ["obsessive-compulsive symptoms", "PROBLEM", 39, 68]]], ["Participants rate how much they agree with certain obsessive beliefs on a 7-point scale from 1 to 7.", [["Participants", "SPECIES", 0, 12], ["a 7-point scale", "TREATMENT", 72, 87]]], ["Woods, Tolin, and Abramowitz (2004) concluded that the OBQ-44 loads best on to four factors, including one large factor and three smaller factors.", [["OBQ-44", "CHEMICAL", 55, 61], ["OBQ-44", "CHEMICAL", 55, 61]]], ["The large factor is called ''OBQ general'' because it involves general symptoms that may involve other anxiety disorders and are not necessarily specific to OCD.", [["anxiety disorders", "DISEASE", 103, 120], ["OCD", "DISEASE", 157, 160], ["general symptoms", "PROBLEM", 63, 79], ["other anxiety disorders", "PROBLEM", 97, 120], ["large", "OBSERVATION_MODIFIER", 4, 9]]], ["The three smaller factors are thought, perfectionism, and responsibility (Woods et al., 2004) .", [["perfectionism", "PROBLEM", 39, 52], ["smaller", "OBSERVATION_MODIFIER", 10, 17]]], ["The OBQ-44 has high internal consistency, and high convergent validity along with good criterion validity and test-retest reliability.MeasuresDisgust Scale-Revised (DS-R; Olatunji et al., 2007) .", [["The OBQ", "TEST", 0, 7], ["high internal consistency", "PROBLEM", 15, 40], ["test", "TEST", 110, 114], ["Scale", "TEST", 150, 155]]], ["The DS-R is a 27-item questionnaire developed from the full, 42-item Disgust Scale (DS; Haidt, McCauley, & Rozin, 1994) .", [["The DS", "TEST", 0, 6], ["DS", "TEST", 84, 86]]], ["Those completing the measure rate on a likert scale from 0 to 4 the extent to which they find a particular stimulus or situation disgusting.", [["a likert scale", "TEST", 37, 51]]], ["Three subscales of the DS-R include core disgust, animal remainder disgust, and contamination disgust.", [["contamination disgust", "DISEASE", 80, 101], ["the DS", "TEST", 19, 25], ["core disgust", "PROBLEM", 36, 48], ["animal remainder disgust", "PROBLEM", 50, 74], ["contamination disgust", "PROBLEM", 80, 101], ["contamination disgust", "OBSERVATION", 80, 101]]], ["The DS-R has demonstrated good internal consistency and good convergent and discriminant validity.Path models and mediating factors between the OBQ-44 and Swine Flu InventoryFirst a simple linear regression was performed to determine whether OC beliefs predicted Swine Flu fears and behaviors.", [["OC", "CHEMICAL", 242, 244], ["The DS", "TEST", 0, 6], ["Path models", "TEST", 98, 109], ["the OBQ", "TEST", 140, 147], ["a simple linear regression", "PROBLEM", 180, 206], ["good", "OBSERVATION", 26, 30]]], ["It was found that the OBQ-44 significantly predicted scores on the Swine Flu Inventory (b\u00bc.124, se \u00bc.033, t(393)\u00bc3.713 po.0005).", [["OBQ-44", "CHEMICAL", 22, 28], ["the OBQ", "TEST", 18, 25], ["the Swine Flu Inventory", "TEST", 63, 86]]], ["To determine mediation effects between OC beliefs and Swine Flu fears and behaviors, Sobel tests of mediation were performed.", [["OC", "CHEMICAL", 39, 41], ["OC beliefs", "TREATMENT", 39, 49], ["Swine Flu fears", "PROBLEM", 54, 69], ["Sobel tests of mediation", "TEST", 85, 109]]], ["The OBQ-44 was used as the IV in this mediation model, and the ASI-3 and DS-R were entered as separate MVs to compare their effects on the relationship between the OBQ-44 and the Swine Flu Inventory.", [["OBQ-44", "CHEMICAL", 4, 10], ["DS-R", "GENE_OR_GENE_PRODUCT", 73, 77], ["The OBQ", "TEST", 0, 7], ["the IV", "TREATMENT", 23, 29], ["the ASI", "TEST", 59, 66], ["DS", "TEST", 73, 75], ["the OBQ", "TEST", 160, 167], ["Swine", "OBSERVATION_MODIFIER", 179, 184], ["Flu", "OBSERVATION", 185, 188]]], ["The mediation models indicated that the DS-R was the most significant mediating factor between the OBQ-44 and the Swine Flu Inventory (z\u00bc \u00c03.36, po.001).", [["DS-R", "GENE_OR_GENE_PRODUCT", 40, 44], ["the DS", "TEST", 36, 42], ["the OBQ", "TEST", 95, 102], ["the Swine Flu Inventory", "TEST", 110, 133]]], ["Although linear regression analysis indicated that the OBQ-44 did not significantly predict scores on the DS-R (b\u00bc .065, se\u00bc .041, t(393) \u00bc1.609, p \u00bc.108).", [["linear regression analysis", "TEST", 9, 35], ["the OBQ", "TEST", 51, 58], ["the DS", "TEST", 102, 108], ["b\u00bc", "TEST", 112, 114], ["se\u00bc", "TEST", 121, 124], ["t", "TEST", 131, 132]]], ["A significant relationship was found with the DS-R predicting scores on the Swine Flu Inventory (b \u00bc \u00c0.232, se\u00bc.041) while controlling for the OBQ-44 (t(393)\u00bc \u00c05.589, po.0005).", [["OBQ-44", "CHEMICAL", 143, 149], ["the DS", "TEST", 42, 48], ["the OBQ", "TEST", 139, 146], ["significant", "OBSERVATION_MODIFIER", 2, 13]]], ["The ASI-3 did not significantly mediate the relationship between the OBQ-44 and Swine Flu Inventory (z\u00bc \u00c01.01, p\u00bc.317).", [["ASI-3", "DNA", 4, 9], ["The ASI", "TEST", 0, 7], ["the OBQ", "TEST", 65, 72]]], ["Although the OBQ-44 was a significant predictor of the ASI-3 (b \u00bc.146, se\u00bc.013, t(393) \u00bc11.070, po.0005), the ASI-3 did not significantly predict scores of the Swine Flu Inventory (b \u00bc \u00c0.137, se\u00bc.131, t(393) \u00bc \u00c01.044, p \u00bc.297) while controlling for the OBQ-44.", [["OBQ-44", "CHEMICAL", 13, 19], ["OBQ-44", "GENE_OR_GENE_PRODUCT", 13, 19], ["OBQ", "DNA", 13, 16], ["ASI-3", "DNA", 55, 60], ["ASI-3", "DNA", 110, 115], ["the OBQ", "TEST", 9, 16], ["the ASI", "TEST", 51, 58], ["the ASI", "TEST", 106, 113], ["se\u00bc", "TEST", 192, 195], ["t", "TEST", 201, 202], ["p", "TEST", 218, 219], ["the OBQ", "TEST", 249, 256]]], ["Table 1 outlines the beta coefficients for mediators between the OBQ-44 and the Swine Flu Inventory.Path models and mediating factors between the OBQ-44 and Swine Flu InventoryUsing structural equation modeling, these relationships were further examined.", [["beta", "GENE_OR_GENE_PRODUCT", 21, 25], ["the OBQ", "TEST", 61, 68], ["Path models", "TEST", 100, 111], ["mediating factors", "PROBLEM", 116, 133], ["the OBQ", "TEST", 142, 149]]], ["A full path model with the DS-R as a mediator produced a TLI and CFI of 1.00.", [["the DS", "TEST", 23, 29], ["CFI", "TEST", 65, 68]]], ["The AIC in this model was 10,430.953, and the BIC was 10,458.252.", [["The AIC", "TEST", 0, 7], ["AIC", "OBSERVATION", 4, 7]]], ["The AIC and BIC are relative measures of goodness-of-fit, and therefore compared against other models tests.", [["other models tests", "TEST", 89, 107]]], ["Accordingly, no AIC or BIC index is considered in isolation, but instead in relation to other models tested (i.e., Moses & Holland, 2010; Richards, Whittingham, & Stephens, 2011) .", [["AIC", "PROBLEM", 16, 19], ["BIC index", "TEST", 23, 32], ["no", "UNCERTAINTY", 13, 15]]], ["Fig. 1a and b shows the path models used for mediators between the OBQ-44 and Swine Flu Inventory.", [["the path models", "TEST", 20, 35], ["the OBQ", "TEST", 63, 70]]], ["When the ASI-3 was entered into the path model in place of the DS-R, the TLI and CFI were again 1.00.", [["ASI-3", "DNA", 9, 14], ["CFI", "DNA", 81, 84], ["CFI", "TEST", 81, 84], ["TLI", "ANATOMY", 73, 76]]], ["The AIC was 9747.336, and the BIC was 9774.712, indicating that this model was stronger than the model with the DS-R as the mediator.", [["DS-R", "GENE_OR_GENE_PRODUCT", 112, 116], ["The AIC", "TEST", 0, 7], ["the BIC", "TEST", 26, 33], ["the DS", "TEST", 108, 114]]], ["Based on these analyses, and using the established standard whereby the lower AIC and BIC values indicate models with better fit, we would conclude that the models with the DS-R as a mediator had the best fit (Wicherts & Dolan, 2004) .Path models and mediating factors between the OBQ-44 and Swine Flu InventoryAll other subscales of the OBQ and OCI-R were associated with poor model fit when used in the mediation tests.", [["DS-R", "GENE_OR_GENE_PRODUCT", 173, 177], ["OCI-R", "GENE_OR_GENE_PRODUCT", 346, 351], ["OBQ", "DNA", 338, 341], ["OCI", "DNA", 346, 349], ["these analyses", "TEST", 9, 23], ["mediating factors", "PROBLEM", 251, 268], ["the OBQ", "TEST", 277, 284], ["the OBQ", "TEST", 334, 341], ["poor model fit", "PROBLEM", 373, 387], ["the mediation tests", "TEST", 401, 420], ["OCI", "ANATOMY", 346, 349]]], ["Only the total score of the ASI-3 was associated with good model fit in the test of mediation.", [["ASI-3", "DNA", 28, 33], ["the ASI", "TEST", 24, 31]]], ["None of the subscales had adequate model fit.Path models and mediating factors between the OCI-R and Swine Flu InventoryTo determine if OC symptoms significantly predicted Swine Flu fears and behaviors, a simple linear regression was performed.", [["OC", "CHEMICAL", 136, 138], ["mediating factors", "PROBLEM", 61, 78], ["the OCI", "TEST", 87, 94], ["Swine Flu Inventory", "TREATMENT", 101, 120], ["OC symptoms", "PROBLEM", 136, 147], ["Swine Flu fears and behaviors", "PROBLEM", 172, 201], ["a simple linear regression", "PROBLEM", 203, 229], ["model fit", "OBSERVATION", 35, 44]]], ["This regression indicated that the OCI-R significantly predicted scores on the Swine Flu inventory (b \u00bc.752, se\u00bc .108, t(393)\u00bc6.956, po.0005).Path models and mediating factors between the OCI-R and Swine Flu InventoryTo examine mediator models for OC symptoms and Swine Flu fears and behaviors, the OCI was used as the IV.", [["OC", "CHEMICAL", 248, 250], ["OCI-R", "GENE_OR_GENE_PRODUCT", 35, 40], ["OCI", "DNA", 35, 38], ["the OCI", "TEST", 31, 38], ["the Swine Flu inventory", "TEST", 75, 98], ["se\u00bc", "TEST", 109, 112], ["Path models", "TEST", 142, 153], ["mediating factors", "PROBLEM", 158, 175], ["the OCI", "TEST", 184, 191], ["OC symptoms", "PROBLEM", 248, 259], ["Swine Flu fears", "PROBLEM", 264, 279], ["the IV", "TREATMENT", 315, 321]]], ["The ASI-3 and DS-R still served as the MVs, and the Swine Flu Inventory still served as the DV.", [["ASI-3 and DS-R", "DNA", 4, 18], ["The ASI", "TEST", 0, 7], ["DS", "TEST", 14, 16], ["the MVs", "PROBLEM", 35, 42], ["the Swine Flu Inventory", "TEST", 48, 71], ["MVs", "OBSERVATION", 39, 42]]], ["The ASI-3 was the most significant mediator between the OCI-R and Swine Flu Inventory (z\u00bc \u00c02.17, p\u00bc.030).", [["ASI-3", "GENE_OR_GENE_PRODUCT", 4, 9], ["ASI-3", "DNA", 4, 9], ["The ASI", "TEST", 0, 7], ["OCI", "ANATOMY", 56, 59]]], ["In this model, the OCI-R significantly predicted scores in the ASI-3 (b \u00bc.456, se\u00bc.046, t(393)\u00bc9.871, po.0005).", [["OCI-R", "GENE_OR_GENE_PRODUCT", 19, 24], ["OCI", "DNA", 19, 22], ["ASI-3", "DNA", 63, 68], ["the OCI", "TEST", 15, 22], ["the ASI", "TEST", 59, 66]]], ["The ASI-3 also significantly predicted scores in the Swine Flu Inventory when controlling for the OCI-R (b\u00bc \u00c0.268, se\u00bc.118, t(393)\u00bc \u00c02.283, p\u00bc.023).Path models and mediating factors between the OCI-R and Swine Flu InventoryAs seen with the OBQ-44, the DS-R also significantly mediated the relationship between the OCI-R and Swine Flu Inventory (z \u00bc \u00c03.56, p o.001).", [["OCI-R", "GENE_OR_GENE_PRODUCT", 98, 103], ["DS-R", "GENE_OR_GENE_PRODUCT", 252, 256], ["ASI-3", "DNA", 4, 9], ["OCI", "DNA", 98, 101], ["The ASI", "TEST", 0, 7], ["significantly predicted scores", "PROBLEM", 15, 45], ["the OCI", "TEST", 94, 101], ["b\u00bc", "TEST", 105, 107], ["Path models", "PROBLEM", 148, 159], ["mediating factors", "PROBLEM", 164, 181], ["the OCI", "TEST", 190, 197], ["the OBQ", "TEST", 236, 243], ["the DS", "TEST", 248, 254], ["the OCI", "TEST", 310, 317], ["OCI", "ANATOMY", 194, 197], ["Flu", "OBSERVATION", 210, 213], ["OCI", "ANATOMY", 314, 317], ["R", "ANATOMY_MODIFIER", 318, 319], ["Flu", "OBSERVATION", 330, 333]]], ["The OCI-R did not significantly predict scores on the DS-R (b \u00bc \u00c0.146, se \u00bc.138, t(393) \u00bc \u00c01.058, p\u00bc.291).", [["OCI", "DNA", 4, 7], ["The OCI", "TEST", 0, 7], ["the DS", "TEST", 50, 56]]], ["When controlling for the OCI-R, the DS-R significantly predicted scores on the Swine Flu Inventory (b \u00bc \u00c0.205, se \u00bc.039, t(393) \u00bc \u00c05.319, p o.0005).", [["OCI", "DNA", 25, 28], ["the OCI", "TEST", 21, 28], ["the DS", "TEST", 32, 38], ["t", "TEST", 121, 122]]], ["Table 2 displays the beta coefficients for mediators between the OCI-R and the Swine Flu Inventory, along with the Sobel test z-scores and significance.Path models and mediating factors between the OCI-R and Swine Flu InventoryFor the path models including the OCI-R, DS-R, and Swine Flu inventory, a TLI and CFI of 1.00 was found.", [["beta", "GENE_OR_GENE_PRODUCT", 21, 25], ["OCI", "PROTEIN", 65, 68], ["the OCI", "TEST", 61, 68], ["the Sobel test z-scores", "TEST", 111, 134], ["Path models", "TEST", 152, 163], ["mediating factors", "PROBLEM", 168, 185], ["the OCI", "TEST", 194, 201], ["the path models", "TEST", 231, 246], ["the OCI", "TEST", 257, 264], ["DS", "TEST", 268, 270], ["a TLI", "TEST", 299, 304], ["CFI", "TEST", 309, 312], ["OCI", "ANATOMY", 261, 264], ["TLI", "ANATOMY", 301, 304]]], ["The AIC in this model was 10,063.628, and the BIC was 10,091.337.", [["The AIC", "TEST", 0, 7], ["AIC", "OBSERVATION", 4, 7]]], ["When the ASI-3 replaced the DS-R in the path model, the TLI and CFI were still 1.00, but the AIC dropped to 9338.985, and the BIC dropped to 9366.766.", [["DS-R", "GENE_OR_GENE_PRODUCT", 28, 32], ["ASI-3", "DNA", 9, 14], ["DS-R", "DNA", 28, 32], ["CFI", "DNA", 64, 67], ["the ASI", "TEST", 5, 12], ["the DS", "TEST", 24, 30], ["the TLI", "TEST", 52, 59], ["CFI", "TEST", 64, 67], ["the AIC", "TEST", 89, 96], ["the BIC", "TEST", 122, 129], ["TLI", "ANATOMY", 56, 59]]], ["Given that the model including the OCI-R, ASI-3, and Swine Flu Inventory produced the lowest AIC and BIC values, this indicates that this path model produced the best fit (see Fig. 2a and b) .DiscussionHealth anxiety is a commonly occurring feature in anxiety disorders, including OCD, panic disorder, and phobias (Taylor & Asmundson, 2004) .", [["anxiety", "DISEASE", 209, 216], ["anxiety disorders", "DISEASE", 252, 269], ["OCD", "DISEASE", 281, 284], ["panic disorder", "DISEASE", 286, 300], ["phobias", "DISEASE", 306, 313], ["the OCI", "TEST", 31, 38], ["ASI", "TEST", 42, 45], ["Swine Flu Inventory", "TEST", 53, 72], ["BIC values", "TEST", 101, 111], ["anxiety", "PROBLEM", 209, 216], ["anxiety disorders", "PROBLEM", 252, 269], ["OCD", "PROBLEM", 281, 284], ["panic disorder", "PROBLEM", 286, 300], ["phobias", "PROBLEM", 306, 313]]], ["This study examined an anxiety mediation model that accounted for obsessive compulsive beliefs and symptoms, and anxiety sensitivity, in the prediction of pandemic fears and associated behaviors, Given that there was a recent pandemic outbreak, Swine Flu, this was used as a context for evaluating extreme health anxiety.", [["anxiety", "DISEASE", 23, 30], ["obsessive compulsive beliefs", "DISEASE", 66, 94], ["anxiety", "DISEASE", 113, 120], ["pandemic fears", "DISEASE", 155, 169], ["Flu", "CHEMICAL", 251, 254], ["anxiety", "DISEASE", 313, 320], ["This study", "TEST", 0, 10], ["an anxiety mediation model", "PROBLEM", 20, 46], ["obsessive compulsive beliefs", "PROBLEM", 66, 94], ["symptoms", "PROBLEM", 99, 107], ["anxiety sensitivity", "PROBLEM", 113, 132], ["pandemic fears", "PROBLEM", 155, 169], ["a recent pandemic outbreak", "PROBLEM", 217, 243], ["extreme health anxiety", "PROBLEM", 298, 320]]], ["Understanding these relationships would benefit clinicians treating individuals suffering from symptoms of health anxiety, as they may be able to determine who is at higher risk for fears surrounding future pandemics.", [["anxiety", "DISEASE", 114, 121], ["symptoms", "PROBLEM", 95, 103], ["health anxiety", "PROBLEM", 107, 121]]], ["Recent research from other pandemic outbreaks (i.e., SARS) shows that individuals exposed to information regarding these outbreaks experience higher anxiety (Cheng & Cheung, 2005) and, among at risk populations, there is a risk of exacerbation of preexisting psychiatric disturbance (Lancee et al., 2008) .", [["SARS", "DISEASE", 53, 57], ["anxiety", "DISEASE", 149, 156], ["psychiatric disturbance", "DISEASE", 259, 282], ["higher anxiety", "PROBLEM", 142, 156], ["preexisting psychiatric disturbance", "PROBLEM", 247, 282]]], ["Although limited research exists regarding the specific relationship between health anxiety and pandemic fears, this study supports that these relationships may, in fact, exist, and that individuals suffering from OC symptoms or beliefs may be at higher risk for pandemic fears, especially if they suffer from anxiety related to health concerns.DiscussionBased on the findings of this study, it appears that various symptoms of disorders related to health anxiety are significantly related to Swine Flu fears and behaviors.", [["anxiety", "DISEASE", 84, 91], ["OC", "CHEMICAL", 214, 216], ["anxiety", "DISEASE", 310, 317], ["anxiety", "DISEASE", 456, 463], ["health anxiety and pandemic fears", "PROBLEM", 77, 110], ["this study", "TEST", 112, 122], ["OC symptoms", "PROBLEM", 214, 225], ["pandemic fears", "PROBLEM", 263, 277], ["anxiety", "PROBLEM", 310, 317], ["this study", "TEST", 380, 390], ["various symptoms of disorders", "PROBLEM", 408, 437], ["health anxiety", "PROBLEM", 449, 463], ["Swine Flu fears", "PROBLEM", 493, 508]]], ["Consistent with the first hypothesis both OC beliefs and OC symptoms significantly predicted Swine Flu fears and behaviors.", [["OC", "CHEMICAL", 42, 44], ["OC", "CHEMICAL", 57, 59], ["OC symptoms", "PROBLEM", 57, 68]]], ["This is not surprising given the common symptoms of contamination fears found in OCD and ritualistic behavior to quell these fears.", [["OCD", "DISEASE", 81, 84], ["the common symptoms", "PROBLEM", 29, 48], ["contamination fears", "PROBLEM", 52, 71], ["OCD", "PROBLEM", 81, 84], ["ritualistic behavior", "PROBLEM", 89, 109], ["contamination", "OBSERVATION", 52, 65]]], ["Further, this hypothesis is in line with OC beliefs regarding overestimation of threat that is postulated to exist among individuals with contamination fears (Cisler et al., 2010) .DiscussionIt was also found that, while both OC beliefs and symptoms were significantly mediated by disgust sensitivity, only OC beliefs were significantly mediated by anxiety sensitivity.", [["OC", "CHEMICAL", 41, 43], ["contamination fears", "DISEASE", 138, 157], ["OC", "CHEMICAL", 226, 228], ["OC", "CHEMICAL", 307, 309], ["anxiety", "DISEASE", 349, 356], ["symptoms", "PROBLEM", 241, 249], ["disgust sensitivity", "TEST", 281, 300], ["anxiety sensitivity", "PROBLEM", 349, 368]]], ["This is not consistent with the study's second hypothesis, which predicted that of anxiety would significantly mediate OC symptoms and beliefs and Swine Flu fears and behaviors.", [["anxiety", "DISEASE", 83, 90], ["OC", "CHEMICAL", 119, 121], ["the study", "TEST", 28, 37], ["anxiety", "PROBLEM", 83, 90], ["significantly mediate OC symptoms", "PROBLEM", 97, 130], ["Swine Flu fears and behaviors", "PROBLEM", 147, 176], ["not consistent with", "UNCERTAINTY", 8, 27]]], ["This finding indicates that internal monitoring of physical reactions may not be as closely related to pandemic fears in individuals containing OC beliefs as opposed to actual OC symptoms.", [["OC", "CHEMICAL", 144, 146], ["OC", "CHEMICAL", 176, 178], ["physical reactions", "PROBLEM", 51, 69], ["actual OC symptoms", "PROBLEM", 169, 187], ["internal", "OBSERVATION_MODIFIER", 28, 36]]], ["However, our findings show that anxiety sensitivity plays an intermediary role between obsessive-compulsive beliefs and Swine Flu fears.", [["anxiety", "DISEASE", 32, 39], ["obsessive-compulsive beliefs", "DISEASE", 87, 115], ["anxiety sensitivity", "PROBLEM", 32, 51], ["Swine Flu fears", "PROBLEM", 120, 135]]], ["This finding builds upon the prior research by Wheaton, Abramowitz, Berman, Fabricant, & Olatunji (2012) , which relied on a regression model to evaluate simultaneous effects in predicting Swine Flu fears.", [["Swine Flu", "SPECIES", 189, 198], ["a regression model", "TREATMENT", 123, 141], ["simultaneous effects", "PROBLEM", 154, 174]]], ["However, mediation models allow for causal sequencing of variables (MacKinnon, 2008) , Future research should evaluate multiple mediators (i.e., both anxiety and disgust sensitivity multiple mediator variables (MacKinnon, Fairchild, & Fritz, 2007) , which based on the parameter estimates obtained would have required approximately triple the sample size reported here .", [["anxiety", "DISEASE", 150, 157], ["both anxiety", "PROBLEM", 145, 157], ["disgust sensitivity", "TEST", 162, 181]]], ["The results from the path models also indicate that the ASI-3 was a stronger mediator than the DS-R.", [["the path models", "TEST", 17, 32], ["the ASI", "TEST", 52, 59], ["R.", "ANATOMY", 98, 100]]], ["The best fitting model included the ASI-3 mediating the relationship between the OCI-R and the Swine Flu Inventory.", [["ASI-3", "DNA", 36, 41], ["the ASI", "TEST", 32, 39], ["OCI", "ANATOMY", 81, 84], ["Swine", "ANATOMY", 95, 100], ["Flu", "OBSERVATION", 101, 104]]], ["The path models indicate that individuals suffering from OC symptoms and beliefs are at higher risk for having anxiety centered around ongoing pandemics if they also experience anxiety sensitivity, which are closely related to panic symptoms.", [["OC", "CHEMICAL", 57, 59], ["anxiety", "DISEASE", 111, 118], ["anxiety", "DISEASE", 177, 184], ["panic", "DISEASE", 227, 232], ["OC symptoms", "PROBLEM", 57, 68], ["anxiety", "PROBLEM", 111, 118], ["anxiety sensitivity", "PROBLEM", 177, 196], ["panic symptoms", "PROBLEM", 227, 241]]], ["The results of this study support past research that indicates overlap between health anxiety and OCD (Fallon et al., 1991; Hollander, 1993; Deacon & Abramowitz, 2008) .", [["anxiety", "DISEASE", 86, 93], ["OCD", "DISEASE", 98, 101], ["this study", "TEST", 15, 25]]], ["Results from this study also support past survey data examining anxiety and Swine Flu, such as the research conducted by Rubin, Amlot, Page, & Wessely, 2009 .", [["anxiety", "DISEASE", 64, 71], ["this study", "TEST", 13, 23], ["past survey data", "TEST", 37, 53], ["anxiety", "PROBLEM", 64, 71], ["Swine Flu", "PROBLEM", 76, 85]]], ["As discussed earlier, Rubin, Amlot, Page, & Wessely, 2009 also found that higher levels of anxiety significantly predicted avoidance and safety behavior related to Swine Flu.DiscussionWhen examining both the path models and the Sobel tests of mediation, the only model that was significant using both analyses was the ASI-3 mediating the relationship between the OCI-R and the Swine Flu Inventory.", [["anxiety", "DISEASE", 91, 98], ["Flu", "CHEMICAL", 170, 173], ["anxiety", "PROBLEM", 91, 98], ["the Sobel tests", "TEST", 224, 239], ["OCI", "ANATOMY", 363, 366], ["Swine", "ANATOMY", 377, 382], ["Flu", "OBSERVATION", 383, 386]]], ["These findings suggest that experiencing OC symptoms may more strongly predict pandemic fears than holding OC beliefs, which as stated earlier, are not specific to OCD (Taylor et al., 2007; Tolin et al., 2006) .DiscussionThe results of this study can significantly impact treatment decisions, particularly in settings with clients at risk for experiencing anxiety.", [["OC", "CHEMICAL", 41, 43], ["OC", "CHEMICAL", 107, 109], ["OCD", "DISEASE", 164, 167], ["anxiety", "DISEASE", 356, 363], ["OC symptoms", "PROBLEM", 41, 52], ["this study", "TEST", 236, 246], ["treatment decisions", "TREATMENT", 272, 291], ["anxiety", "PROBLEM", 356, 363]]], ["Understanding the role of health anxiety in pandemic fears can help clinicians develop treatment plans for patients in light of future pandemics given that preexisting obsessive compulsive symptoms and beliefs will likely influence pandemic health related fears.", [["anxiety", "DISEASE", 33, 40], ["obsessive compulsive symptoms", "DISEASE", 168, 197], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["treatment plans", "TREATMENT", 87, 102], ["preexisting obsessive compulsive symptoms", "PROBLEM", 156, 197]]], ["Given the relationships found between Swine Flu fears and health anxiety symptoms, a person who is treated for health anxiety before a pandemic outbreak would experience less anxiety surrounding the pandemic compared to an individual with untreated health anxiety.Limitations and future directionsWhile the current study provides useful information regarding health anxiety and pandemic fears, there are several limitations to consider in order to improve future research in this area.", [["Swine Flu fears", "DISEASE", 38, 53], ["anxiety", "DISEASE", 65, 72], ["anxiety", "DISEASE", 118, 125], ["anxiety", "DISEASE", 175, 182], ["anxiety", "DISEASE", 256, 263], ["anxiety", "DISEASE", 366, 373], ["person", "SPECIES", 85, 91], ["health anxiety symptoms", "PROBLEM", 58, 81], ["health anxiety", "PROBLEM", 111, 125], ["a pandemic outbreak", "PROBLEM", 133, 152], ["less anxiety", "PROBLEM", 170, 182], ["untreated health anxiety", "PROBLEM", 239, 263], ["the current study", "TEST", 303, 320], ["health anxiety and pandemic fears", "PROBLEM", 359, 392]]], ["Over this time, two flu seasons occurred, when individuals are more likely to contract Swine Flu.", [["Flu", "CHEMICAL", 93, 96], ["two flu seasons", "PROBLEM", 16, 31]]], ["The datacollecting period also included long stretches of time outside of flu season, when it is less likely for individuals to contract Swine Flu.", [["Flu", "CHEMICAL", 143, 146]]], ["Therefore, it is possible that more Swine Flu fears and behaviors were reported when the threat of the flu was more immediate.", [["flu", "DISEASE", 103, 106], ["more Swine Flu fears", "PROBLEM", 31, 51], ["the flu", "PROBLEM", 99, 106], ["flu", "OBSERVATION", 103, 106]]], ["Researchers may examine future health threats and determine the historical effect of when the data were collected.", [["the data", "TEST", 90, 98]]], ["In this case, future research may compare Swine Flu anxiety during flu season to Swine Flu anxiety out of flu season.", [["anxiety", "DISEASE", 52, 59], ["anxiety", "DISEASE", 91, 98], ["Swine Flu anxiety", "PROBLEM", 42, 59]]], ["However, given the results of this study that an increase in symptoms of anxiety appear to predict an increase in Swine Flu fears, it would still be expected that this would be the case outside of flu season.", [["anxiety", "DISEASE", 73, 80], ["this study", "TEST", 30, 40], ["symptoms", "PROBLEM", 61, 69], ["anxiety", "PROBLEM", 73, 80], ["an increase in Swine Flu fears", "PROBLEM", 99, 129], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["increase", "OBSERVATION_MODIFIER", 102, 110]]], ["Further, during both flu seasons of data collection, there was regular reporting of Swine Flu in the media, including public health initiatives for receiving vaccines as well as reports on limitations in the efficacy of the vaccines.Limitations and future directionsFuture areas of research with pandemic fears and health anxiety may also include examining other mediation models.", [["Flu", "CHEMICAL", 90, 93], ["anxiety", "DISEASE", 322, 329], ["data collection", "TEST", 36, 51], ["vaccines", "TREATMENT", 158, 166], ["the vaccines", "TREATMENT", 220, 232], ["pandemic fears", "PROBLEM", 296, 310], ["health anxiety", "PROBLEM", 315, 329]]], ["For example, while the ASI-3 is a general measure of threat appraisals associated with panic, panic disorder is heterogeneous in terms of symptom presentation.", [["panic", "DISEASE", 87, 92], ["panic disorder", "DISEASE", 94, 108], ["ASI-3", "GENE_OR_GENE_PRODUCT", 23, 28], ["ASI-3", "DNA", 23, 28], ["panic, panic disorder", "PROBLEM", 87, 108], ["symptom presentation", "PROBLEM", 138, 158], ["heterogeneous", "OBSERVATION_MODIFIER", 112, 125]]], ["Future mediation analyses might investigate these relationships by examining different subtypes of panic disorder, which include respiratory, nocturnal, nonfearful, cognitive, and vestibular (Kirchanski, Phil, Craske, Epstein, & Wittchen, 2009 .", [["respiratory", "ANATOMY", 129, 140], ["panic disorder", "DISEASE", 99, 113], ["respiratory, nocturnal, nonfearful, cognitive, and vestibular", "DISEASE", 129, 190], ["Future mediation analyses", "TEST", 0, 25], ["panic disorder", "PROBLEM", 99, 113], ["respiratory, nocturnal, nonfearful, cognitive, and vestibular (Kirchanski", "PROBLEM", 129, 202], ["vestibular", "ANATOMY", 180, 190]]], ["Although cognitive behavioral therapy (CBT) is an empiricallybased treatment for health anxiety (Barsky & Ahern, 2004; Taylor et al., 2012) .", [["anxiety", "DISEASE", 88, 95], ["cognitive behavioral therapy", "TREATMENT", 9, 37], ["an empiricallybased treatment", "TREATMENT", 47, 76], ["health anxiety", "PROBLEM", 81, 95]]], ["Wheaton, Abramowitz, Berman, Fabricant, & Olatunji (2012) note that exposure to media related to a pandemic may inhibit treatment effectiveness.", [["pandemic", "DISEASE", 99, 107], ["treatment effectiveness", "TREATMENT", 120, 143]]], ["In this vein, while the data collection extended past the primary pandemic period, this extended period was only at the New York site, where pandemic fears were especially pronounced given the severity of the outbreak in that region.Limitations and future directionsFinally, it may also be useful to replicate and extend the current study using different, future pandemic.", [["vein", "ANATOMY", 8, 12], ["vein", "MULTI-TISSUE_STRUCTURE", 8, 12], ["pandemic fears", "PROBLEM", 141, 155], ["the outbreak in that region", "PROBLEM", 205, 232], ["the current study", "TEST", 321, 338], ["vein", "ANATOMY", 8, 12], ["severity", "OBSERVATION_MODIFIER", 193, 201], ["outbreak", "OBSERVATION", 209, 217]]], ["One specific hypothesis that should be investigated is the degree that treatment for health anxiety may serve as a protective factor in warding off future health anxiety should another pandemic arises.", [["anxiety", "DISEASE", 92, 99], ["anxiety", "DISEASE", 162, 169], ["health anxiety", "PROBLEM", 85, 99]]], ["This would provide a basis for the importance of focusing on health anxiety in clients with a wide range of anxiety disorders, and the need to treat symptoms and beliefs associated with OCD in order to alleviate likely future severe and potentially disabling health anxiety.", [["anxiety", "DISEASE", 68, 75], ["anxiety disorders", "DISEASE", 108, 125], ["OCD", "DISEASE", 186, 189], ["anxiety", "DISEASE", 266, 273], ["anxiety disorders", "PROBLEM", 108, 125], ["symptoms", "PROBLEM", 149, 157], ["OCD", "PROBLEM", 186, 189], ["future severe and potentially disabling health anxiety", "PROBLEM", 219, 273]]]], "PMC7254534": [["The changes occurring in an organization\u2019s environment are characterized by speed and direction which are often difficult to anticipate [3].", [["The changes", "PROBLEM", 0, 11]]], ["In addition, the environment\u2019s pace of change is higher that the organization\u2019s [4], and the speed is further increased by factors like the digital transformation of the society [5] and emerging technologies and strategies [3].", [["higher", "OBSERVATION_MODIFIER", 49, 55], ["increased", "OBSERVATION_MODIFIER", 110, 119]]], ["The concepts of change and strategy are not only linked to each other, but also to the concept of capability [6].IntroductionThe notion of capability bears significance because it depicts an organizational viewpoint that encompasses several notions significant to organizational change.", [["organizational change", "OBSERVATION", 264, 285]]], ["For example, goal, decision, context, process and service [7, 8] have been used, especially in the management literature, not only to describe an organization\u2019s value-generating elements, but have also been used as the core concepts of Enterprise Modeling (EM) approaches [8, 9].IntroductionEM, as a discipline, captures relevant knowledge and provides motivation and input for designing Information Systems (IS) to support the organization [10].", [["IntroductionEM", "TREATMENT", 279, 293]]], ["ISs are significant for every organization since they help in simplifying the organization\u2019s activities and processes and have gradually become integrated with almost every aspect of the business [11], to the level where business and IT have been \u201cfused\u201d into one [5].", [["ISs", "PROBLEM", 0, 3]]], ["Due to a high rate of change in modern enterprises, the maintenance of models that are sufficiently capturing the architecture from the perspective of involved stakeholders does not seem to be feasible.", [["a high rate of change", "PROBLEM", 7, 28], ["modern enterprises", "TREATMENT", 32, 50]]], ["One of the main challenges for EM is how to capture the motion of an organization, that is, its current and desired affairs [5].", [["main", "OBSERVATION_MODIFIER", 11, 15]]], ["Capability modeling, as a specialization of EM, also needs to tackle this challenge.", [["this challenge", "TREATMENT", 69, 83]]], ["This can be achieved by optimizing existing approaches or developing specific modeling approaches for depicting capability change.IntroductionThe objective of this study is to propose a meta-model for depicting capability change.", [["this study", "TEST", 159, 169], ["a meta-model", "TREATMENT", 184, 196]]], ["It belongs to a research project that aims to provide methodological and tool support for organizations that are undergoing changes or need to.", [["methodological and tool support", "TREATMENT", 54, 85], ["organizations", "TREATMENT", 90, 103]]], ["Following the exploration of the field [14], the elicitation of requirements for the artifact [15], and the introduction of a typology for changing capabilities [16], the present study belongs to the project step that concerns the initial development of a meta-model.", [["the exploration", "TEST", 10, 25], ["the artifact", "TEST", 81, 93], ["the present study", "TEST", 167, 184]]], ["This is a design artifact that will serve as a basis for a capability modeling method.", [["a design artifact", "PROBLEM", 8, 25]]], ["Section 2 provides a brief presentation of the background and research related to this study.", [["this study", "TEST", 82, 92]]], ["Section 3 describes the methods employed in this study.", [["this study", "TEST", 44, 54]]], ["Section 5 presents an example application of the meta-model on a case study.", [["a case study", "TEST", 63, 75]]], ["Section 6 discusses the meta-model and its application.", [["the meta-model", "TREATMENT", 20, 34]]], ["Section 7 provides concluding remarks.Organizational Change ::: Background and Related ResearchOrganizations are social goal-directed systems which maintain boundaries that reflect their goals [3].", [["Background and Related ResearchOrganizations", "TREATMENT", 64, 108]]], ["There are several terms describing the phenomenon with different terms, for example change, transformation, adaptation [3].", [["several", "OBSERVATION_MODIFIER", 10, 17]]], ["The terms business, organization and enterprise are often used interchangeably as well, however, there are also cases where they are distinguished, like for example [1], where an enterprise is defined as a collection of organizations that share a common set of goals.Organizational Change ::: Background and Related ResearchRegarding the drivers of organizational change, there are several perspectives and associated theories.", [["organizational change", "PROBLEM", 349, 370], ["organizational change", "OBSERVATION", 349, 370]]], ["One of the main perspectives is based on the assumption of human rationality and utility maximization, which results in assuming that entire organizations are rationally adapting to the environment [3].", [["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["main", "OBSERVATION_MODIFIER", 11, 15]]], ["These theories that consider the environment as the factor setting the point of time and the direction of change are called deterministic, in comparison to the voluntaristic theories that build on the importance of the consideration of strategic choice.", [["strategic choice", "TREATMENT", 236, 252]]], ["This perspective emphasizes on strategic choice of the organization\u2019s decision-makers and their role in shaping the organization [3].Organizational Change ::: Background and Related ResearchHowever, there are also theories that reconcile these perspectives to facilitate understanding of change as a combination of environmental and managerial forces taking also organizational inertia into consideration.", [["environmental and managerial forces", "TREATMENT", 315, 350]]], ["Including the negative aspect of change is in line with our earlier work [16].Organizational Change ::: Background and Related ResearchA noteworthy point is that the diverse drivers of change do not provide any indication between causes and consequences.", [["negative aspect", "OBSERVATION_MODIFIER", 14, 29]]], ["Any organization or its part can benefit from the application of EM.Enterprise Modeling ::: Background and Related ResearchAn enterprise model can help people in an organization to develop a deeper understanding of the system, in other words, how their work gets integrated in a bigger picture and, additionally, models can enable the users\u2019 understanding of the supporting information systems and its interplay with organizational action patterns [19].Enterprise Modeling ::: Background and Related ResearchFurthermore, since the meta-models specify modeling languages, they are valuable to (i) modelers, who are interested in understanding and applying the language, (ii) researchers, who have interest in evaluating and adapting a language, for example to a domain-specific version, and (iii) tool vendors, who have interest in developing tool for the language [20].Capability Modeling ::: Capabilities ::: Background and Related ResearchThe capability modeling approaches that exist in the literature have been identified and their meta-models have been explored in our earlier work.", [["people", "ORGANISM", 152, 158], ["people", "SPECIES", 152, 158]]], ["The change functions of the framework are observation, decision and delivery of capability change.", [["delivery of capability change", "TREATMENT", 68, 97]]], ["It has been identified that the majority of the meta-models include concepts that address at least partially, all the above mentioned functions and have a scope combining business and IT.", [["majority", "OBSERVATION_MODIFIER", 32, 40]]], ["A set of change related-concepts has been elicited for inclusion in a capability change meta-model, so as to facilitate the development of a method.Capability Modeling ::: Capabilities ::: Background and Related ResearchRegarding the modeling of capabilities, [23] have suggested three strategies within the Capability-Driven Development (CDD) method.", [["a method", "TREATMENT", 139, 147]]], ["All three strategies consist of three steps, which are (i) Capability design, (ii) Capability evaluation, and (iii) Development of Capability delivery application.", [["Capability evaluation", "TEST", 83, 104], ["Capability delivery application", "TREATMENT", 131, 162]]], ["The second step concerns the evaluation of the design from both business and technical perspectives before the implementation of the capability.", [["the evaluation", "TEST", 25, 39]]], ["The third step involves packaging the indicators for monitoring and the algorithms for run-time adjustments as a support application.", [["monitoring", "TEST", 53, 63], ["the algorithms", "TEST", 68, 82], ["run-time adjustments", "TREATMENT", 87, 107], ["a support application", "TREATMENT", 111, 132]]], ["It concerns the design of the capability using as a starting point: (i) goals, (ii) processes, or (iii) concepts [23].Design Science ::: MethodologyThe DSR project to which this study belongs follows the guidelines of [13].", [["this study", "TEST", 173, 183]]], ["According to this framework, a DSR project consists of five activities, namely (i) problem explication, (ii) outline artifact and define requirements, (iii) design and develop artifact, (iv) demonstrate artifact, and (v) evaluate artifact.", [["outline artifact and define requirements", "PROBLEM", 109, 149], ["artifact", "PROBLEM", 176, 184], ["artifact", "PROBLEM", 203, 211], ["artifact", "PROBLEM", 230, 238], ["artifact", "OBSERVATION", 203, 211]]], ["The present study belongs to the third step which, creates an artefact fulfilling the requirements elicited during the previous activity, since it presents the first stage of the development of a method artifact, the creation of a meta-model.", [["The present study", "TEST", 0, 17], ["an artefact fulfilling the requirements", "PROBLEM", 59, 98], ["a method artifact", "PROBLEM", 194, 211], ["a meta-model", "TREATMENT", 229, 241], ["artefact", "OBSERVATION", 62, 70], ["artifact", "OBSERVATION", 203, 211]]], ["The process is iterative and incremental, which means that several rounds of development are needed to reach a final version of the artifact.Meta-model Development ::: MethodologyA meta-model is a part of a modeling language which consists of (i) notation, which is its graphical representation, (ii) syntax, that is the available language concepts, and (iii) semantics, the meaning of the language concepts [24].", [["artifact", "OBSERVATION", 132, 140]]], ["Different meta-model specification techniques result to different meta-model types, i.e. slicing, referencing, generic, notation-aware, matrix and tabular meta-models.", [["matrix", "CELLULAR_COMPONENT", 136, 142]]], ["In this study, the notation aspect is not being addressed.Meta-model Development ::: MethodologyRegarding the syntax of the developed meta-model itself, the principles of the Unified Modeling Language (UML) [25] have been followed.", [["this study", "TEST", 3, 13]]], ["The common element types that existing in meta-models are (i) First Class concepts (classes), (ii) Relationships (of classes), (iii) attributes, (iv) inheritance and (v) others [26].", [["common element", "OBSERVATION_MODIFIER", 4, 18], ["types", "OBSERVATION_MODIFIER", 19, 24]]], ["In our earlier work, a plethora of existing capability modeling approaches has been explored and 64 meta-models have been identified and analyzed in terms of their inclusion of concepts relevant to change [14].", [["meta-models", "TREATMENT", 100, 111]]], ["A framework has been used that identified the main functions of a capability oriented adaptive system.", [["main", "OBSERVATION_MODIFIER", 46, 50]]], ["The three functions are observation, decision and delivery, which reflect capturing information from the organizational internal and external environment, deciding on a change based on analyzing the observed conditions and applying criteria based on intention elements and finally, delivering the change in the capability\u2019s configuration, taking into consideration the interrelation of existing capabilities.", [["delivery", "TREATMENT", 50, 58]]], ["In this way, the adaptive characteristics of capability meta-models that have been explored in the literature, have been analyzed to identify the concepts that may be useful to include in a meta-model aiming to capture changing capabilities.", [["a meta-model aiming", "TREATMENT", 188, 207]]], ["Furthermore, the literature review, combined with a case study involving inter-organizational capabilities have resulted in a set of goals [15] for the meta-model under development.", [["a case study", "TEST", 50, 62], ["the meta-model", "TREATMENT", 148, 162]]], ["These goals are:To manage capability changeTo observe business contextTo support decision on capability changeTo manage capability deliveryTo identify decision criteriaTo identify capability alternativesTo analyze observed context dataTo ensure that decision complies with intentionsTo elicit internal and external business contextTo manage transition deliveryTo manage capability architectureTo observe external business contextTo observe internal business contextTo monitor political, economic, social, technological and legal contextTo measure relevant propertiesTo establish KPIsTo manage introduction of a new capabilityTo manage retirement of a new capabilityTo manage modification of a new capabilityTo manage capability configurationTo allocate resources to capabilityTo specify capability ownershipTo specify resource ownershipTo manage internal resourcesTo identify external resourcesTo identify outsourced tasksTo support defining organizational boundariesTo identify collaborating organization", [["KPIs", "DNA", 579, 583], ["capability delivery", "TREATMENT", 120, 139], ["context data", "TEST", 223, 235], ["transition delivery", "TREATMENT", 341, 360], ["a new capability", "TREATMENT", 609, 625], ["a new capability", "PROBLEM", 649, 665], ["a new capability", "PROBLEM", 691, 707], ["internal resources", "TREATMENT", 846, 864], ["external resources", "TREATMENT", 876, 894], ["new", "OBSERVATION_MODIFIER", 693, 696], ["capability", "OBSERVATION_MODIFIER", 697, 707]]]], "12b030be66b617bec99c12d770c89cb59c3773a9": [["IntroductionAvian coronavirus infectious bronchitis virus (IBV) causes a highly contagious upper respiratory tract disease in chickens.", [["upper respiratory tract", "ANATOMY", 91, 114], ["coronavirus infectious bronchitis virus", "DISEASE", 18, 57], ["upper respiratory tract disease", "DISEASE", 91, 122], ["IntroductionAvian coronavirus infectious bronchitis virus", "ORGANISM", 0, 57], ["IBV", "ORGANISM", 59, 62], ["upper", "ORGANISM_SUBDIVISION", 91, 96], ["respiratory tract", "ORGANISM_SUBDIVISION", 97, 114], ["chickens", "ORGANISM", 126, 134], ["coronavirus infectious bronchitis virus", "SPECIES", 18, 57], ["chickens", "SPECIES", 126, 134], ["IntroductionAvian coronavirus infectious bronchitis virus", "SPECIES", 0, 57], ["IBV", "SPECIES", 59, 62], ["chickens", "SPECIES", 126, 134], ["IntroductionAvian coronavirus infectious bronchitis virus", "PROBLEM", 0, 57], ["a highly contagious upper respiratory tract disease in chickens", "PROBLEM", 71, 134], ["coronavirus", "OBSERVATION_MODIFIER", 18, 29], ["infectious", "OBSERVATION", 30, 40], ["highly", "OBSERVATION_MODIFIER", 73, 79], ["contagious", "OBSERVATION_MODIFIER", 80, 90], ["upper", "ANATOMY_MODIFIER", 91, 96], ["respiratory tract", "ANATOMY", 97, 114]]], ["Live attenuated vaccines are used against the virus but the disease is difficult to control because cross-protection does not usually occur between different serotypes.", [["Live attenuated vaccines", "TREATMENT", 0, 24], ["the virus", "PROBLEM", 42, 51], ["the disease", "PROBLEM", 56, 67], ["disease", "OBSERVATION", 60, 67], ["serotypes", "OBSERVATION", 158, 167]]], ["The respiratory disease caused by this virus can be mild to moderate and can vary depending on the breed of chicken infected as well as the strain of the virus [1] .", [["respiratory", "ANATOMY", 4, 15], ["respiratory disease", "DISEASE", 4, 23], ["chicken", "ORGANISM", 108, 115], ["chicken", "SPECIES", 108, 115], ["chicken", "SPECIES", 108, 115], ["The respiratory disease", "PROBLEM", 0, 23], ["this virus", "PROBLEM", 34, 44], ["chicken infected", "PROBLEM", 108, 124], ["respiratory disease", "OBSERVATION", 4, 23], ["moderate", "OBSERVATION_MODIFIER", 60, 68]]], ["The virus is worldwide in distribution, and in addition to chickens, IBV has been isolated from peafowl (Galliformes) and other Electronic supplementary material The online version of this article (doi:10.1007/s11262-011-0668-7) contains supplementary material, which is available to authorized users. gamma-coronaviruses have been isolated from teal (Anas crecca), geese (Anserinae), pigeons (Columbiformes), and ducks (Anserfiformes) [2] .IntroductionCoronaviruses are enveloped viruses in the order Nidovirales and are classified based on genome organization and antigenic characteristics as alpha (previously group 1), beta (previously group 2), and gamma (previously group 3)-coronaviruses with the avian coronaviruses belonging to the gamma-coronaviruses.", [["chickens", "ORGANISM", 59, 67], ["IBV", "ORGANISM", 69, 72], ["gamma-coronaviruses", "ORGANISM", 302, 321], ["teal", "ORGANISM_SUBDIVISION", 346, 350], ["Anas crecca", "ORGANISM", 352, 363], ["geese", "ORGANISM_SUBDIVISION", 366, 371], ["pigeons", "ORGANISM", 385, 392], ["Columbiformes)", "ORGANISM", 394, 408], ["ducks", "ORGANISM", 414, 419], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 453, 466], ["alpha (previously group 1", "GENE_OR_GENE_PRODUCT", 595, 620], ["beta (previously group 2", "GENE_OR_GENE_PRODUCT", 623, 647], ["coronaviruses", "ORGANISM", 681, 694], ["avian coronaviruses", "ORGANISM", 704, 723], ["gamma-coronaviruses", "ORGANISM", 741, 760], ["beta", "PROTEIN", 623, 627], ["gamma", "PROTEIN", 654, 659], ["gamma-coronaviruses", "PROTEIN", 741, 760], ["chickens", "SPECIES", 59, 67], ["Anas crecca", "SPECIES", 352, 363], ["pigeons", "SPECIES", 385, 392], ["ducks", "SPECIES", 414, 419], ["avian", "SPECIES", 704, 709], ["chickens", "SPECIES", 59, 67], ["IBV", "SPECIES", 69, 72], ["Anas crecca", "SPECIES", 352, 363], ["The virus", "PROBLEM", 0, 9], ["IBV", "PROBLEM", 69, 72], ["gamma-coronaviruses", "PROBLEM", 302, 321], ["coronaviruses", "PROBLEM", 681, 694], ["the avian coronaviruses", "PROBLEM", 700, 723], ["virus", "OBSERVATION", 4, 9], ["worldwide", "OBSERVATION_MODIFIER", 13, 22], ["distribution", "OBSERVATION_MODIFIER", 26, 38], ["coronaviruses", "OBSERVATION", 308, 321], ["enveloped", "OBSERVATION_MODIFIER", 471, 480], ["viruses", "OBSERVATION", 481, 488], ["gamma", "ANATOMY", 654, 659], ["gamma", "ANATOMY", 741, 746]]], ["Subgroups within each group have been reported, and recently, comparative full-length genome analysis placed a novel coronavirus from a beluga whale in subgroup 3b and three new coronavirus isolates from passerine birds in subgroup 3c [3] .", [["coronavirus", "ORGANISM", 117, 128], ["coronavirus", "ORGANISM", 178, 189], ["coronavirus", "SPECIES", 117, 128], ["a novel coronavirus", "PROBLEM", 109, 128], ["three new coronavirus isolates", "TREATMENT", 168, 198]]], ["Infectious bronchitis virus and related isolates as well as turkey coronavirus (TCoV) are assigned to subgroup 3a.IntroductionCoronaviruses have a single-stranded positive-sense RNA genome ranging in size from 27 to 30 kb, with a 5 0 cap and a 3 0 poly-A tail.", [["Infectious bronchitis virus", "DISEASE", 0, 27], ["turkey coronavirus", "DISEASE", 60, 78], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["turkey coronavirus", "ORGANISM", 60, 78], ["TCoV", "CANCER", 80, 84], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 126, 139], ["Coronaviruses", "PROTEIN", 126, 139], ["5 0 cap", "DNA", 230, 237], ["3 0 poly-A tail", "DNA", 244, 259], ["turkey coronavirus", "SPECIES", 60, 78], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["turkey coronavirus", "SPECIES", 60, 78], ["TCoV", "SPECIES", 80, 84], ["Infectious bronchitis virus", "PROBLEM", 0, 27], ["related isolates", "PROBLEM", 32, 48], ["size", "OBSERVATION_MODIFIER", 200, 204], ["27 to 30 kb", "OBSERVATION_MODIFIER", 210, 221], ["tail", "ANATOMY", 255, 259]]], ["Transcription occurs through a leader-primed RNA synthesis mechanism that results for IBV in six 3 0 co-terminal subgenomic mRNA molecules.", [["3 0 co-terminal subgenomic mRNA molecules", "RNA", 97, 138], ["IBV", "SPECIES", 86, 89], ["IBV", "PROBLEM", 86, 89], ["terminal subgenomic mRNA molecules", "PROBLEM", 104, 138], ["subgenomic mRNA molecules", "OBSERVATION", 113, 138]]], ["Four structural proteins-spike (S), envelope (E), membrane (M), and nucleocapsid (N)-along with the viral RNA make up the enveloped virion.", [["membrane", "ANATOMY", 50, 58], ["virion", "ANATOMY", 132, 138], ["membrane", "CELLULAR_COMPONENT", 50, 58], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 68, 84], ["structural proteins", "PROTEIN", 5, 24], ["spike (S), envelope (E), membrane (M)", "PROTEIN", 25, 62], ["nucleocapsid (N)", "PROTEIN", 68, 84], ["viral RNA", "RNA", 100, 109], ["Four structural proteins", "TEST", 0, 24], ["spike", "PROBLEM", 25, 30], ["envelope (E), membrane (M), and nucleocapsid (N)", "PROBLEM", 36, 84], ["the viral RNA", "PROBLEM", 96, 109], ["spike", "OBSERVATION_MODIFIER", 25, 30]]], ["The N protein binds to the viral RNA forming the ribonucleoprotein (RNP) complex.", [["RNP", "CELLULAR_COMPONENT", 68, 71], ["N protein", "PROTEIN", 4, 13], ["viral RNA", "RNA", 27, 36], ["ribonucleoprotein (RNP) complex", "PROTEIN", 49, 80], ["The N protein binds", "TREATMENT", 0, 19], ["the viral RNA", "TREATMENT", 23, 36], ["viral RNA", "OBSERVATION", 27, 36], ["ribonucleoprotein", "OBSERVATION_MODIFIER", 49, 66]]], ["The E and the M protein are membrane bound proteins that play a role in virus assembly [4] .", [["membrane", "ANATOMY", 28, 36], ["membrane", "CELLULAR_COMPONENT", 28, 36], ["M protein", "PROTEIN", 14, 23], ["membrane bound proteins", "PROTEIN", 28, 51], ["membrane bound proteins", "PROBLEM", 28, 51]]], ["The S glycoprotein on the surface of the virus mediates attachment to the host cell, is responsible for fusion of the host cell membrane and viral envelope, and in IBV, it contains epitopes that define serotype and induce neutralizing antibodies [5] .", [["surface", "ANATOMY", 26, 33], ["cell", "ANATOMY", 79, 83], ["cell membrane", "ANATOMY", 123, 136], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 18], ["surface", "CELLULAR_COMPONENT", 26, 33], ["host cell", "CELL", 74, 83], ["cell membrane", "CELLULAR_COMPONENT", 123, 136], ["IBV", "ORGANISM", 164, 167], ["S glycoprotein", "PROTEIN", 4, 18], ["epitopes", "PROTEIN", 181, 189], ["neutralizing antibodies", "PROTEIN", 222, 245], ["IBV", "SPECIES", 164, 167], ["The S glycoprotein", "TREATMENT", 0, 18], ["fusion of the host cell membrane", "PROBLEM", 104, 136], ["viral envelope", "PROBLEM", 141, 155], ["IBV", "PROBLEM", 164, 167], ["epitopes", "PROBLEM", 181, 189], ["serotype and induce neutralizing antibodies", "PROBLEM", 202, 245], ["S glycoprotein", "OBSERVATION_MODIFIER", 4, 18], ["host cell", "OBSERVATION", 74, 83], ["host cell membrane", "OBSERVATION", 118, 136], ["viral envelope", "OBSERVATION", 141, 155]]], ["The S glycoprotein of IBV is post-translationally cleaved into S1 and S2 subunits, and the S1 subunit is reported to have three hypervariable regions [6] [7] [8] .", [["IBV", "ORGANISM", 22, 25], ["S1", "GENE_OR_GENE_PRODUCT", 63, 65], ["S2", "GENE_OR_GENE_PRODUCT", 70, 72], ["S glycoprotein", "PROTEIN", 4, 18], ["S1 and S2 subunits", "PROTEIN", 63, 81], ["S1 subunit", "PROTEIN", 91, 101], ["IBV", "SPECIES", 22, 25], ["The S glycoprotein of IBV", "TREATMENT", 0, 25]]], ["Mutations, insertions, deletions, and recombination in S contribute to the genetic diversity of IBV, which is recognized as different genetic or serologic types of the virus [5] .IntroductionTwo polyproteins 1a and 1ab account for approximately two-thirds of the viral genome-coding region and make up the replication transcription complex (RTC).", [["IBV", "ORGANISM", 96, 99], ["1a", "GENE_OR_GENE_PRODUCT", 208, 210], ["1", "GENE_OR_GENE_PRODUCT", 215, 216], ["polyproteins 1a and 1ab", "DNA", 195, 218], ["viral genome", "DNA", 263, 275], ["replication transcription complex", "PROTEIN", 306, 339], ["RTC", "PROTEIN", 341, 344], ["IBV", "SPECIES", 96, 99], ["Mutations, insertions, deletions", "PROBLEM", 0, 32], ["IBV", "PROBLEM", 96, 99], ["the virus", "PROBLEM", 164, 173], ["Two polyproteins 1a", "TREATMENT", 191, 210], ["IBV", "OBSERVATION", 96, 99], ["viral genome", "OBSERVATION", 263, 275]]], ["The polyprotein 1ab is translated through a-1 frame-shift translation mechanism that occurs approximately 20-40% of the time [9] .", [["1ab", "GENE_OR_GENE_PRODUCT", 16, 19], ["polyprotein 1ab", "PROTEIN", 4, 19], ["The polyprotein 1ab", "TREATMENT", 0, 19]]], ["The IBV 1a and 1ab polyproteins are post-translationally cleaved into 15 nonstructural proteins (nsps), nsps 2 through 16 by a papain-like protease (PLP) and the main protease (Mpro), also referred to as the 3C-like protease [10] .", [["IBV 1a", "ORGANISM", 4, 10], ["1", "GENE_OR_GENE_PRODUCT", 15, 16], ["nsps", "GENE_OR_GENE_PRODUCT", 97, 101], ["nsps 2", "GENE_OR_GENE_PRODUCT", 104, 110], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 127, 147], ["PLP", "GENE_OR_GENE_PRODUCT", 149, 152], ["Mpro", "GENE_OR_GENE_PRODUCT", 177, 181], ["IBV 1a and 1ab polyproteins", "DNA", 4, 31], ["15 nonstructural proteins", "PROTEIN", 70, 95], ["nsps", "PROTEIN", 97, 101], ["nsps 2 through 16", "PROTEIN", 104, 121], ["papain-like protease", "PROTEIN", 127, 147], ["PLP", "PROTEIN", 149, 152], ["protease", "PROTEIN", 167, 175], ["Mpro", "PROTEIN", 177, 181], ["3C-like protease", "PROTEIN", 208, 224], ["IBV", "SPECIES", 4, 7], ["The IBV 1a", "TREATMENT", 0, 10], ["1ab polyproteins", "TREATMENT", 15, 31], ["nsps", "TEST", 104, 108], ["a papain", "TREATMENT", 125, 133], ["protease (PLP", "TREATMENT", 139, 152], ["the main protease", "TREATMENT", 158, 175], ["the 3C-like protease", "TREATMENT", 204, 224]]], ["IBV does not have an nsp 1 equivalent found in some other coronaviruses.", [["IBV", "ORGANISM", 0, 3], ["nsp 1", "GENE_OR_GENE_PRODUCT", 21, 26], ["coronaviruses", "ORGANISM", 58, 71], ["IBV", "SPECIES", 0, 3], ["IBV", "PROBLEM", 0, 3], ["an nsp", "PROBLEM", 18, 24], ["some other coronaviruses", "PROBLEM", 47, 71], ["coronaviruses", "OBSERVATION", 58, 71]]], ["The PLP contained within nsp 3 is divided into PL1 and PL2 papain-like proteases.", [["PLP", "CHEMICAL", 4, 7], ["PLP", "GENE_OR_GENE_PRODUCT", 4, 7], ["nsp 3", "GENE_OR_GENE_PRODUCT", 25, 30], ["PL1", "GENE_OR_GENE_PRODUCT", 47, 50], ["PL2", "GENE_OR_GENE_PRODUCT", 55, 58], ["PLP", "PROTEIN", 4, 7], ["nsp 3", "PROTEIN", 25, 30], ["PL1", "PROTEIN", 47, 50], ["PL2 papain-like proteases", "PROTEIN", 55, 80], ["The PLP", "TEST", 0, 7], ["PL1", "TEST", 47, 50], ["PL2 papain", "TREATMENT", 55, 65]]], ["The PL1 protease, present in other coronaviruses, is truncated and nonfunctional in IBV, thus PL2 cleaves nsps 2, 3, and 4 [11] .", [["PL1 protease", "GENE_OR_GENE_PRODUCT", 4, 16], ["IBV", "ORGANISM", 84, 87], ["PL2", "GENE_OR_GENE_PRODUCT", 94, 97], ["nsps 2", "GENE_OR_GENE_PRODUCT", 106, 112], ["3", "GENE_OR_GENE_PRODUCT", 114, 115], ["PL1 protease", "PROTEIN", 4, 16], ["PL2", "PROTEIN", 94, 97], ["IBV", "SPECIES", 84, 87], ["The PL1 protease", "TREATMENT", 0, 16], ["PL2 cleaves nsps", "TEST", 94, 110], ["nonfunctional", "OBSERVATION", 67, 80]]], ["The Mpro contained within nsp 5 cleaves nsps 5 through 16 .", [["Mpro", "GENE_OR_GENE_PRODUCT", 4, 8], ["Mpro", "PROTEIN", 4, 8], ["nsp 5 cleaves nsps 5 through 16", "DNA", 26, 57]]], ["The biological characteristics of many nsps have been previously reported [9, 10, [12] [13] [14] [15] [16] [17] .", [["9, 10, [12] [13] [14] [15] [16] [17", "CHEMICAL", 75, 110], ["nsps", "GENE_OR_GENE_PRODUCT", 39, 43], ["[12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 82, 111], ["many nsps", "PROBLEM", 34, 43], ["many", "OBSERVATION_MODIFIER", 34, 38], ["nsps", "OBSERVATION", 39, 43]]], ["In addition to nsps 3 and 5, which contain proteases PL2 and Mpro, respectively, nsps 2, 4, and 6 contain hydrophobic residues predicted to play a role in anchoring the RTC to the Golgi.", [["Golgi", "ANATOMY", 180, 185], ["nsps 3", "GENE_OR_GENE_PRODUCT", 15, 21], ["5", "GENE_OR_GENE_PRODUCT", 26, 27], ["PL2", "GENE_OR_GENE_PRODUCT", 53, 56], ["Mpro", "GENE_OR_GENE_PRODUCT", 61, 65], ["nsps 2", "GENE_OR_GENE_PRODUCT", 81, 87], ["4", "GENE_OR_GENE_PRODUCT", 89, 90], ["6", "GENE_OR_GENE_PRODUCT", 96, 97], ["RTC", "GENE_OR_GENE_PRODUCT", 169, 172], ["Golgi", "CELLULAR_COMPONENT", 180, 185], ["nsps 3 and 5", "PROTEIN", 15, 27], ["proteases", "PROTEIN", 43, 52], ["PL2", "PROTEIN", 53, 56], ["Mpro", "PROTEIN", 61, 65], ["nsps 2, 4, and 6", "PROTEIN", 81, 97], ["hydrophobic residues", "PROTEIN", 106, 126], ["RTC", "PROTEIN", 169, 172], ["nsps", "TEST", 15, 19], ["Mpro", "TEST", 61, 65], ["nsps", "TEST", 81, 85], ["hydrophobic residues", "PROBLEM", 106, 126]]], ["Nonstructural proteins 7, 8, 9, and 10 are reported to have RNA-binding activity.", [["Nonstructural proteins 7", "GENE_OR_GENE_PRODUCT", 0, 24], ["8", "GENE_OR_GENE_PRODUCT", 26, 27], ["9", "GENE_OR_GENE_PRODUCT", 29, 30], ["10", "GENE_OR_GENE_PRODUCT", 36, 38], ["Nonstructural proteins 7, 8, 9, and 10", "PROTEIN", 0, 38], ["Nonstructural proteins", "TEST", 0, 22], ["RNA", "TEST", 60, 63], ["binding activity", "OBSERVATION", 64, 80]]], ["Nonstructural protein 11/12 is the RNA-dependent RNA-polymerase, nsp 13 is a RNA helicase, nsp 14 is an exoribonuclease, nsp 15 is an endoribonuclease, and nsp 16 is a methyltransferase.IntroductionAdaptation of IBV to different hosts has been associated with changes in the S glycoprotein, suggesting that spike plays a key role in pathogenicity [18, 19] .", [["Nonstructural protein 11/12", "GENE_OR_GENE_PRODUCT", 0, 27], ["nsp 13", "GENE_OR_GENE_PRODUCT", 65, 71], ["nsp 14", "GENE_OR_GENE_PRODUCT", 91, 97], ["nsp 15", "GENE_OR_GENE_PRODUCT", 121, 127], ["nsp 16", "GENE_OR_GENE_PRODUCT", 156, 162], ["IBV", "ORGANISM", 212, 215], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 275, 289], ["Nonstructural protein 11/12", "PROTEIN", 0, 27], ["RNA-dependent RNA-polymerase", "PROTEIN", 35, 63], ["nsp 13", "PROTEIN", 65, 71], ["RNA helicase", "PROTEIN", 77, 89], ["nsp 14", "PROTEIN", 91, 97], ["exoribonuclease", "PROTEIN", 104, 119], ["nsp 15", "PROTEIN", 121, 127], ["endoribonuclease", "PROTEIN", 134, 150], ["nsp 16", "PROTEIN", 156, 162], ["methyltransferase", "PROTEIN", 168, 185], ["S glycoprotein", "PROTEIN", 275, 289], ["IBV", "SPECIES", 212, 215], ["Nonstructural protein", "TEST", 0, 21], ["the RNA", "TEST", 31, 38], ["nsp", "TEST", 65, 68], ["IntroductionAdaptation", "TREATMENT", 186, 208], ["IBV", "TREATMENT", 212, 215], ["changes in the S glycoprotein", "PROBLEM", 260, 289], ["spike", "PROBLEM", 307, 312], ["endoribonuclease", "OBSERVATION", 134, 150]]], ["However, the ectodomain of the S glycoprotein from the Beaudette strain of IBV, an attenuated laboratory strain, was replaced with an S from a pathogenic strain (Mass 41 strain) of the same serotype.", [["S glycoprotein", "GENE_OR_GENE_PRODUCT", 31, 45], ["Beaudette strain", "ORGANISM", 55, 71], ["IBV", "ORGANISM", 75, 78], ["Mass 41 strain", "ORGANISM", 162, 176], ["ectodomain", "PROTEIN", 13, 23], ["S glycoprotein", "PROTEIN", 31, 45], ["IBV", "SPECIES", 75, 78], ["IBV", "PROBLEM", 75, 78], ["an attenuated laboratory strain", "PROBLEM", 80, 111], ["an S", "PROBLEM", 131, 135], ["a pathogenic strain (Mass 41 strain", "PROBLEM", 141, 176], ["the same serotype", "PROBLEM", 181, 198], ["attenuated", "OBSERVATION_MODIFIER", 83, 93], ["laboratory strain", "OBSERVATION", 94, 111]]], ["This chimeric virus was shown to induce an immune response but remained nonpathogenic in chickens, indicating that the S glycoprotein is not solely responsible for pathogenicity of IBV [2, 20] .", [["chickens", "ORGANISM", 89, 97], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 119, 133], ["IBV", "ORGANISM", 181, 184], ["S glycoprotein", "PROTEIN", 119, 133], ["chickens", "SPECIES", 89, 97], ["chickens", "SPECIES", 89, 97], ["IBV", "SPECIES", 181, 184], ["This chimeric virus", "PROBLEM", 0, 19], ["nonpathogenic", "PROBLEM", 72, 85], ["the S glycoprotein", "PROBLEM", 115, 133], ["IBV", "PROBLEM", 181, 184], ["nonpathogenic", "OBSERVATION_MODIFIER", 72, 85]]], ["In another study, a chimeric IBV was created with the replicase genes 1a and 1ab from the attenuated Beaudette strain, and all of the structural genes from the pathogenic Mass 41 strain including the S gene.", [["IBV", "ORGANISM", 29, 32], ["1", "GENE_OR_GENE_PRODUCT", 77, 78], ["Beaudette strain", "ORGANISM", 101, 117], ["Mass 41 strain", "ORGANISM", 171, 185], ["replicase genes 1a and 1ab", "DNA", 54, 80], ["structural genes", "DNA", 134, 150], ["S gene", "DNA", 200, 206], ["IBV", "SPECIES", 29, 32], ["another study", "TEST", 3, 16], ["a chimeric IBV", "TREATMENT", 18, 32], ["the attenuated Beaudette strain", "PROBLEM", 86, 117], ["the pathogenic Mass", "PROBLEM", 156, 175], ["pathogenic", "OBSERVATION_MODIFIER", 160, 170], ["Mass", "OBSERVATION", 171, 175]]], ["This chimeric virus was not pathogenic in chickens, indicating that the replicase proteins also appear to be determinants of IBV pathotype [2, 21] .", [["chimeric virus", "ORGANISM", 5, 19], ["chickens", "ORGANISM", 42, 50], ["IBV", "ORGANISM", 125, 128], ["replicase proteins", "PROTEIN", 72, 90], ["chickens", "SPECIES", 42, 50], ["chickens", "SPECIES", 42, 50], ["IBV", "SPECIES", 125, 128], ["This chimeric virus", "PROBLEM", 0, 19], ["pathogenic", "PROBLEM", 28, 38], ["the replicase proteins", "PROBLEM", 68, 90], ["IBV pathotype", "PROBLEM", 125, 138], ["not", "UNCERTAINTY", 24, 27], ["pathogenic", "OBSERVATION_MODIFIER", 28, 38]]], ["Genetic differences reported in 1a and S between virulent and avirulent strains of IBV also led others to suggest that the replicase proteins, in addition to S, are involved in the pathotype of the virus [22] .IntroductionTo examine the sequence changes in individual genes associated with attenuation of IBV for chickens, we sequenced and compared the full-length consensus genomes of pathogenic IBV viruses and egg-passaged attenuated (for chickens) viruses from three different serotypes.", [["IBV", "ORGANISM", 83, 86], ["IBV", "ORGANISM", 305, 308], ["chickens", "ORGANISM", 313, 321], ["IBV viruses", "ORGANISM", 397, 408], ["egg", "ORGANISM", 413, 416], ["chickens", "ORGANISM", 442, 450], ["replicase proteins", "PROTEIN", 123, 141], ["S", "PROTEIN", 158, 159], ["full-length consensus genomes", "DNA", 353, 382], ["chickens", "SPECIES", 313, 321], ["chickens", "SPECIES", 442, 450], ["IBV", "SPECIES", 83, 86], ["IBV", "SPECIES", 305, 308], ["chickens", "SPECIES", 313, 321], ["IBV viruses", "SPECIES", 397, 408], ["chickens", "SPECIES", 442, 450], ["Genetic differences", "PROBLEM", 0, 19], ["virulent", "PROBLEM", 49, 57], ["IBV", "PROBLEM", 83, 86], ["the replicase proteins", "PROBLEM", 119, 141], ["the sequence changes", "PROBLEM", 233, 253], ["IBV", "TREATMENT", 305, 308], ["chickens", "PROBLEM", 313, 321], ["pathogenic IBV viruses", "PROBLEM", 386, 408], ["chickens) viruses", "PROBLEM", 442, 459], ["pathogenic IBV viruses", "OBSERVATION", 386, 408]]], ["We also examined the replication of pathogenic and attenuated viruses in embryonated eggs and in chickens to determine whether there are differences in growth rate between the pathotypes.VirusesPathogenic and attenuated (for chickens) IBV strains from three different serotypes were used in this study.", [["eggs", "ANATOMY", 85, 89], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 85, 89], ["chickens", "ORGANISM", 97, 105], ["chickens", "ORGANISM", 225, 233], ["IBV", "ORGANISM", 235, 238], ["chickens", "SPECIES", 97, 105], ["chickens", "SPECIES", 225, 233], ["chickens", "SPECIES", 97, 105], ["chickens", "SPECIES", 225, 233], ["IBV", "SPECIES", 235, 238], ["pathogenic and attenuated viruses in embryonated eggs", "PROBLEM", 36, 89], ["VirusesPathogenic", "PROBLEM", 187, 204], ["attenuated", "PROBLEM", 209, 219], ["chickens) IBV strains", "PROBLEM", 225, 246], ["three different serotypes", "TREATMENT", 252, 277], ["this study", "TEST", 291, 301], ["pathogenic", "OBSERVATION_MODIFIER", 36, 46], ["attenuated", "OBSERVATION_MODIFIER", 51, 61], ["viruses", "OBSERVATION", 62, 69], ["attenuated", "OBSERVATION_MODIFIER", 209, 219], ["different", "OBSERVATION_MODIFIER", 258, 267], ["serotypes", "OBSERVATION", 268, 277]]], ["The pathogenic Arkansas-Delmarva Poultry Industry Ark/Ark-DPI/81 and the Massachusetts strain Mass/Mass41/41 were obtained from Dr. J. Gelb, Jr. (University of Delaware, Newark, DE).", [["Arkansas-Delmarva Poultry Industry Ark/Ark-DPI/81", "SPECIES", 15, 64], ["DPI", "TEST", 58, 61], ["the Massachusetts strain Mass", "TEST", 69, 98], ["pathogenic", "OBSERVATION_MODIFIER", 4, 14], ["Arkansas", "OBSERVATION_MODIFIER", 15, 23], ["Mass", "OBSERVATION", 94, 98]]], ["The pathogenic Georgia 98 virus, GA98/CWL0470/98 virus, was isolated in our laboratory in 1998 [23] .", [["Georgia 98 virus", "ORGANISM", 15, 31], ["GA98/CWL0470/98 virus", "ORGANISM", 33, 54], ["Georgia 98 virus", "SPECIES", 15, 31], ["GA98/CWL0470/98 virus", "SPECIES", 33, 54], ["The pathogenic Georgia", "TEST", 0, 22], ["GA98", "TEST", 33, 37], ["virus", "PROBLEM", 49, 54]]], ["The pathogenic viruses were propagated in 10-day-old embryonated chicken eggs (Ark/Ark-DPI/81 pass 6, Mass/Mass41/41 pass 8, and GA98/CWL0470/98 pass 8) as previously described [24] .VirusesThe attenuated viruses of the same strain and serotype were obtained from Intervet and were designated Ark-attenuated (Mildvac-Ark), Mass41-attenuated (Mildvac-H), and GA98attenuated (Mildvac-Ga-98).VirusesWhole-genome nucleotide and deduced amino acid sequence analysis Viral RNA extraction, RT-PCR, library construction, and sequencing were conducted as previously described [25] .", [["eggs", "ANATOMY", 73, 77], ["Mildvac-Ga-98", "CHEMICAL", 374, 387], ["nucleotide", "CHEMICAL", 409, 419], ["amino acid", "CHEMICAL", 432, 442], ["nucleotide", "CHEMICAL", 409, 419], ["amino acid", "CHEMICAL", 432, 442], ["chicken", "ORGANISM", 65, 72], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 73, 77], ["Mass41", "SIMPLE_CHEMICAL", 323, 329], ["Mildvac-H", "CELL", 342, 351], ["amino acid", "AMINO_ACID", 432, 442], ["VirusesWhole-genome nucleotide", "DNA", 389, 419], ["chicken", "SPECIES", 65, 72], ["chicken", "SPECIES", 65, 72], ["Mildvac-Ga-98", "SPECIES", 374, 387], ["The pathogenic viruses", "PROBLEM", 0, 22], ["old embryonated chicken eggs", "PROBLEM", 49, 77], ["Mass", "TEST", 102, 106], ["Viruses", "PROBLEM", 183, 190], ["serotype", "PROBLEM", 236, 244], ["Mildvac", "TEST", 309, 316], ["Mass41", "TEST", 323, 329], ["GA98attenuated", "TEST", 358, 372], ["Mildvac", "TEST", 374, 381], ["Ga", "TEST", 382, 384], ["VirusesWhole", "TEST", 389, 401], ["genome nucleotide", "TEST", 402, 419], ["deduced amino acid sequence analysis", "TEST", 424, 460], ["Viral RNA extraction", "TREATMENT", 461, 481], ["RT-PCR", "TEST", 483, 489], ["library construction", "TREATMENT", 491, 511], ["pathogenic", "OBSERVATION_MODIFIER", 4, 14], ["viruses", "OBSERVATION", 15, 22], ["attenuated", "OBSERVATION_MODIFIER", 194, 204], ["viruses", "OBSERVATION", 205, 212]]], ["Briefly, the viruses were filtered through a 0.8-lm filter then through a 0.22-lm filter (Millipore, Billerica, MA) prior to RNA extraction.", [["a 0.8-lm filter", "TREATMENT", 43, 58], ["a 0.22-lm filter (Millipore, Billerica, MA", "TREATMENT", 72, 114], ["RNA extraction", "TREATMENT", 125, 139]]], ["Viral RNA was purified using the high pure RNA isolation kit according to the manufacturer's recommendation (Roche Diagnostic Corporation, Foster City, CA) and re-suspended in DEPC-treated water.", [["DEPC", "CHEMICAL", 176, 180], ["DEPC", "CHEMICAL", 176, 180], ["Viral", "ORGANISM", 0, 5], ["DEPC", "SIMPLE_CHEMICAL", 176, 180], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["the high pure RNA isolation kit", "TREATMENT", 29, 60]]], ["Reverse transcription (RT) and polymerase chain reaction (PCR) amplification were performed with the Takara RNA LA PCR kit (Takara Bio Inc., Otsu, Shiga, Japan) using a random primer and an amplification primer in a strand displacement amplification reaction following the manufacture's protocol.", [["amplification primer", "DNA", 190, 210], ["Reverse transcription", "TREATMENT", 0, 21], ["polymerase chain reaction", "PROBLEM", 31, 56], ["PCR", "TEST", 58, 61], ["a random primer", "TREATMENT", 167, 182], ["an amplification primer", "TREATMENT", 187, 210], ["a strand displacement amplification reaction", "PROBLEM", 214, 258], ["the manufacture's protocol", "TREATMENT", 269, 295]]], ["The sequence of the random reverse transcription primer was 5 0 -AGC GGG GGT TGT CGA ATG TTT GAN NNN N-3 0 , and the amplification primer sequence, which is designed to anneal to the complement of the conserved region on the random primer, was 5 0 -AGC GGG GGT TGT CGA ATG TTT GA-3 0 .", [["random reverse transcription primer", "DNA", 20, 55], ["5 0 -AGC GGG GGT TGT CGA ATG TTT GAN NNN N-3 0", "DNA", 60, 106], ["amplification primer sequence", "DNA", 117, 146], ["conserved region", "DNA", 201, 217], ["5 0 -AGC GGG GGT TGT CGA ATG TTT GA-3 0", "DNA", 244, 283], ["the random reverse transcription primer", "TEST", 16, 55], ["AGC GGG", "TEST", 65, 72], ["GGT", "TEST", 73, 76], ["TGT", "TEST", 77, 80], ["ATG", "TEST", 85, 88], ["TTT GAN NNN N", "TEST", 89, 102], ["the amplification primer sequence", "TEST", 113, 146], ["AGC GGG", "TEST", 249, 256], ["GGT", "TEST", 257, 260], ["TGT", "TEST", 261, 264], ["ATG", "TEST", 269, 272], ["TTT GA", "TEST", 273, 279]]], ["Both primers were obtained from Integrated DNA Technologies, Inc. (Coralville, IA).", [["DNA", "CELLULAR_COMPONENT", 43, 46]]], ["For the RT reaction, a master mix was prepared, which included MgCl 2 (5 mM), 109 RNA PCR buffer (19) , dNTP mixture (1 mM), RNase inhibitor (1 units/ll), reverse transcriptase (0.25 units/ll), 5 0 degenerate primer (2.5 lM), and RNA (5.75 ll/reaction) then 10 ll per sample was aliquoted in a thermocycler tube.", [["sample", "ANATOMY", 268, 274], ["MgCl 2", "CHEMICAL", 63, 69], ["dNTP", "CHEMICAL", 104, 108], ["MgCl 2", "CHEMICAL", 63, 69], ["dNTP", "CHEMICAL", 104, 108], ["MgCl 2", "SIMPLE_CHEMICAL", 63, 69], ["dNTP", "SIMPLE_CHEMICAL", 104, 108], ["RNase", "GENE_OR_GENE_PRODUCT", 125, 130], ["tube", "TISSUE", 307, 311], ["RNase", "PROTEIN", 125, 130], ["reverse transcriptase", "PROTEIN", 155, 176], ["the RT reaction", "PROBLEM", 4, 19], ["MgCl", "TEST", 63, 67], ["RNA PCR buffer", "TREATMENT", 82, 96], ["dNTP mixture", "TREATMENT", 104, 116], ["RNase inhibitor", "TREATMENT", 125, 140], ["reverse transcriptase", "TREATMENT", 155, 176], ["RNA", "TEST", 230, 233], ["ll/reaction", "TEST", 240, 251], ["a thermocycler tube", "TREATMENT", 292, 311], ["thermocycler tube", "OBSERVATION", 294, 311]]], ["The reaction conditions for the RT reaction were 10 min at 30\u00b0C for the primer annealing then an hour at 50\u00b0C for extension followed by a five-minute incubation at 99\u00b0C for inactivation of the enzyme and a five-minute period at 5\u00b0C. A PCR master mix-which included at the final concentrations MgCl 2 (2.5 mM), 109 LA PCR Buffer (19) , sterilized distilled water (32.25 ll), Takara LA Taq (1.25U/50 ll), and 5 0 primer (0.2 lM)-was prepared and 10 ll of the RT reaction was added to 40 ll of the mix.", [["MgCl 2", "CHEMICAL", 293, 299], ["LA", "CHEMICAL", 314, 316], ["LA", "CHEMICAL", 381, 383], ["MgCl 2", "CHEMICAL", 293, 299], ["C", "GENE_OR_GENE_PRODUCT", 167, 168], ["enzyme", "PROTEIN", 193, 199], ["The reaction conditions", "PROBLEM", 0, 23], ["the RT reaction", "PROBLEM", 28, 43], ["the enzyme", "TEST", 189, 199], ["A PCR master mix", "TREATMENT", 233, 249], ["LA PCR Buffer", "TREATMENT", 314, 327], ["sterilized distilled water", "TREATMENT", 335, 361], ["Takara LA Taq", "TREATMENT", 374, 387], ["the RT reaction", "TREATMENT", 453, 468]]], ["The amplification reaction consisted of a 94\u00b0C step for 2 min followed by 30 cycles of 94\u00b0C for 30 s, 60\u00b0C for 30 s, and 72\u00b0C for 3 min.VirusesTen PCR were combined for each virus and purified using the QIAquick PCR purification kit (QIAGEN, Foster City, CA) and then run on a 1% agarose gel to visualize the amplified product.", [["VirusesTen", "GENE_OR_GENE_PRODUCT", 136, 146], ["agarose", "SIMPLE_CHEMICAL", 280, 287], ["VirusesTen PCR", "DNA", 136, 150], ["The amplification reaction", "PROBLEM", 0, 26], ["VirusesTen PCR", "TEST", 136, 150], ["each virus", "PROBLEM", 169, 179], ["the QIAquick PCR purification", "TREATMENT", 199, 228], ["a 1% agarose gel", "TREATMENT", 275, 291]]], ["The PCR products were size selected by cutting out amplicons between 500 and 1500 bp from the gel.", [["PCR products", "DNA", 4, 16], ["The PCR products", "TREATMENT", 0, 16], ["size", "OBSERVATION_MODIFIER", 22, 26]]], ["The amplicons were purified using the QIAquick (QIAGEN) gel purification kit.VirusesThe TOPO cloning kit (Invitrogen, Life Technologies, Carlsbad CA) was used to clone the PCR products into the pCR-XL-TOPO vector according to the manufacturer's recommendations.", [["TOPO", "GENE_OR_GENE_PRODUCT", 88, 92], ["Carlsbad CA", "GENE_OR_GENE_PRODUCT", 137, 148], ["TOPO", "GENE_OR_GENE_PRODUCT", 201, 205], ["PCR products", "DNA", 172, 184], ["pCR-XL-TOPO vector", "DNA", 194, 212], ["The amplicons", "TREATMENT", 0, 13], ["the QIAquick (QIAGEN) gel purification kit", "TREATMENT", 34, 76], ["The TOPO cloning kit (Invitrogen, Life Technologies", "TREATMENT", 84, 135], ["Carlsbad CA", "PROBLEM", 137, 148], ["the pCR", "TEST", 190, 197], ["TOPO vector", "TREATMENT", 201, 212]]], ["Then, One Shot TOPO Electrocompetent Escherichia coli cells (Invitrogen) were transformed using 30 ll of competent cells mixed with 2 ll of the ligation reaction and electroporated with settings at 20 kV and 200 X using a BioRad (BioRad Gene Pulser, Hercules, CA).", [["cells", "ANATOMY", 54, 59], ["cells", "ANATOMY", 115, 120], ["Escherichia coli cells", "CELL", 37, 59], ["Invitrogen", "ORGANISM", 61, 71], ["cells", "CELL", 115, 120], ["Escherichia coli cells", "CELL_LINE", 37, 59], ["competent cells", "CELL_TYPE", 105, 120], ["Escherichia coli", "SPECIES", 37, 53], ["Escherichia coli", "SPECIES", 37, 53], ["Escherichia coli cells", "PROBLEM", 37, 59], ["Invitrogen", "TEST", 61, 71], ["the ligation reaction", "TREATMENT", 140, 161], ["a BioRad", "TEST", 220, 228], ["Escherichia coli cells", "OBSERVATION", 37, 59], ["ligation", "OBSERVATION", 144, 152]]], ["The electroporated cells were incubated at 37\u00b0C in 480 ll of Super Optimal broth medium for 1 h on a rotary shaker.", [["cells", "ANATOMY", 19, 24], ["cells", "CELL", 19, 24], ["electroporated cells", "CELL_LINE", 4, 24], ["The electroporated cells", "TREATMENT", 0, 24], ["electroporated cells", "OBSERVATION", 4, 24]]], ["The cultures were mixed with 70% glycerol and frozen in -80\u00b0C until plated on Q-trays (Genetix, Boston, MA) containing liquid broth agar CAT#3002-032 (MP Biomedicals, LLC, Solon, Oh) with 50 lg/ml of kanamycin.", [["cultures", "ANATOMY", 4, 12], ["glycerol", "CHEMICAL", 33, 41], ["CAT#3002-032", "CHEMICAL", 137, 149], ["kanamycin", "CHEMICAL", 200, 209], ["glycerol", "CHEMICAL", 33, 41], ["kanamycin", "CHEMICAL", 200, 209], ["glycerol", "SIMPLE_CHEMICAL", 33, 41], ["kanamycin", "SIMPLE_CHEMICAL", 200, 209], ["The cultures", "TEST", 0, 12], ["70% glycerol", "TREATMENT", 29, 41], ["frozen", "TEST", 46, 52], ["liquid broth agar CAT#", "TREATMENT", 119, 141], ["kanamycin", "TREATMENT", 200, 209], ["LLC", "ANATOMY", 167, 170]]], ["The Q-trays were pre-warmed at 37\u00b0C before the entire culture (approximately 500 ll) was spread on the plates and incubated overnight at 37\u00b0C, then robotically picked with a Q-BOT (Genetix, Boston, MA).VirusesPlasmid DNA from the libraries of cloned cDNA fragments for each virus was isolated using an alkaline lysis method modified for the 96-well format, and incorporating both Hydra and Tomtek robots (http://www.intl-pag.org/ 11/abstracts/P2c_P116_XI.html).", [["VirusesPlasmid DNA", "CELLULAR_COMPONENT", 202, 220], ["VirusesPlasmid DNA", "DNA", 202, 220], ["cloned cDNA fragments", "DNA", 243, 264], ["The Q-trays", "TEST", 0, 11], ["the entire culture", "TEST", 43, 61], ["the plates", "TEST", 99, 109], ["VirusesPlasmid DNA", "PROBLEM", 202, 220], ["cloned cDNA fragments", "PROBLEM", 243, 264], ["each virus", "PROBLEM", 269, 279], ["an alkaline lysis method", "TREATMENT", 299, 323], ["both Hydra and Tomtek robots", "TREATMENT", 375, 403]]], ["Cycle sequencing reactions were performed using the BigDye TM Terminator \u00d2 Cycle Sequencing kit Version 3.1 (Applied Biosystems, Foster City, CA) and MJ Research (Watertown, MA) thermocyclers.", [["Cycle sequencing reactions", "TEST", 0, 26], ["the BigDye TM Terminator", "TREATMENT", 48, 72], ["Sequencing kit Version", "TEST", 81, 103], ["MJ Research (Watertown, MA) thermocyclers", "TREATMENT", 150, 191]]], ["Finished reactions were filtered through Sephadex filter plates into Perkin-Elmer MicroAmp Optical 96-well plates.", [["Sephadex filter plates", "TREATMENT", 41, 63]]], ["A 1/12-strength sequencing reaction on an ABI 3730 was used to sequence each clone from both the 5 0 and 3 0 ends.", [["5 0 and 3 0 ends", "DNA", 97, 113], ["an ABI", "TEST", 39, 45]]], ["Each viral genome was sequenced to approximately 109 coverage.", [["viral genome", "DNA", 5, 17], ["Each viral genome", "PROBLEM", 0, 17], ["viral genome", "OBSERVATION", 5, 17]]], ["The accuracy of the sequence was ensured by generating data in both the 5 0 and the 3 0 directions.VirusesGaps and areas with less than 29 coverage were identified and specific primers were synthesized (IDT) for RT-PCR amplification and sequencing of the ambiguous areas.", [["the sequence", "TEST", 16, 28], ["VirusesGaps", "TEST", 99, 110], ["specific primers", "TEST", 168, 184], ["RT-PCR amplification", "TREATMENT", 212, 232], ["areas", "OBSERVATION_MODIFIER", 115, 120]]], ["The RT-PCR was conducted as described above, and the reaction conditions were 42\u00b0C for 60 min, 95\u00b0C for 5 min, then 10 cycles of 94\u00b0C for 30 s, 50\u00b0C for 30 s, 68\u00b0C for 90 s, followed by 25 cycles of 94\u00b0C for 30 s, 50\u00b0C for 30 s, 68\u00b0C for 90 s ? 5 s/cycle added.", [["The RT-PCR", "TEST", 0, 10], ["the reaction conditions", "PROBLEM", 49, 72]]], ["The final elongation step was 68\u00b0C for 7 min, and then, the reaction was cooled to 4\u00b0C. The PCR products were sequenced in both directions using the ABI Prism BigDye Terminator v3.0 (Applied Biosystems, Foster City, CA) and the specific primers that were used for amplification at a concentration of 15 ng.", [["PCR products", "DNA", 92, 104], ["the reaction", "PROBLEM", 56, 68], ["The PCR products", "TREATMENT", 88, 104], ["the ABI Prism BigDye Terminator", "TREATMENT", 145, 176], ["the specific primers", "TREATMENT", 224, 244], ["elongation", "OBSERVATION_MODIFIER", 10, 20]]], ["The amount of cDNA added to the reaction ranged from 20 to 30 ng, and the sequencing reactions were analyzed on an ABI 3730 (Applied Biosystems).VirusesChromatogram files and trace data were read and assembled using SeqMan Pro, and genome annotation was conducted with SeqBuilder (DNASTAR, Inc., v.8.0.2, Madison, WI).", [["cDNA", "DNA", 14, 18], ["the reaction", "PROBLEM", 28, 40], ["the sequencing reactions", "PROBLEM", 70, 94], ["an ABI", "TEST", 112, 118], ["VirusesChromatogram files", "TEST", 145, 170], ["trace data", "TEST", 175, 185], ["genome annotation", "TEST", 232, 249], ["amount", "OBSERVATION_MODIFIER", 4, 10]]], ["Low-quality segments and vector sequence were trimmed from the ends of each sequence and removed from further analysis.", [["Low-quality segments", "DNA", 0, 20], ["vector sequence", "DNA", 25, 40], ["Low-quality segments and vector sequence", "PROBLEM", 0, 40], ["further analysis", "TEST", 102, 118], ["quality segments", "OBSERVATION_MODIFIER", 4, 20]]], ["Full-length genomes were uploaded to the National Center for Biotechnology Information (NCBI) open reading frame (ORF) finder (http://www.ncbi. nlm.nih.gov/gorf/) to identify ORFs.", [["National Center for Biotechnology Information (NCBI) open reading frame", "DNA", 41, 112], ["ORF", "DNA", 114, 117], ["ORFs", "DNA", 175, 179]]], ["Nucleotide and deduced amino acid alignments were generated using ClustalW, and phylogenetic trees with 1,000 bootstrap replicates were constructed in the MegAlign program (DNASTAR, Inc.).", [["Nucleotide", "CHEMICAL", 0, 10], ["amino acid", "CHEMICAL", 23, 33], ["amino acid", "CHEMICAL", 23, 33], ["amino acid", "AMINO_ACID", 23, 33], ["Nucleotide and deduced amino acid alignments", "TEST", 0, 44], ["ClustalW", "TREATMENT", 66, 74], ["amino acid alignments", "OBSERVATION", 23, 44]]], ["Hydrophilicity analysis using Hopp-Woods and Kyte-Doolittle were conducted with the Protean program (DNASTAR, Inc.).Pathogenicity testing in chickensThe viruses were titrated in 10 day of incubation embryonated eggs to obtain a 50% embryo infectious dose (EID 50 ) according to previously published procedures (24).", [["eggs", "ANATOMY", 211, 215], ["embryo", "ANATOMY", 232, 238], ["chickens", "ORGANISM", 141, 149], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 232, 238], ["chickens", "SPECIES", 141, 149], ["chickens", "SPECIES", 141, 149], ["Hydrophilicity analysis", "TEST", 0, 23], ["Hopp", "TEST", 30, 34], ["Pathogenicity testing", "TEST", 116, 137], ["The viruses", "PROBLEM", 149, 160], ["incubation embryonated eggs", "TREATMENT", 188, 215], ["a 50% embryo infectious dose", "TREATMENT", 226, 254], ["viruses", "OBSERVATION", 153, 160]]], ["Two-week-old chickens were given 1 9 10 4 EID 50 of virus in 100 ll of PBS equally divided intraocularly and intranasally.", [["intranasally", "ANATOMY", 109, 121], ["chickens", "ORGANISM", 13, 21], ["chickens", "SPECIES", 13, 21], ["chickens", "SPECIES", 13, 21], ["virus", "TREATMENT", 52, 57], ["PBS", "TREATMENT", 71, 74]]], ["Due to isolator availability, different numbers of birds were tested for each virus.", [["birds", "ORGANISM", 51, 56], ["each virus", "PROBLEM", 73, 83]]], ["Six birds were given Ark/ Ark-DPI/81, 20 birds were given Ark attenuated, 10 birds each were given Mass/Mass41/41, Mass attenuated, and GA98 attenuated, and 12 birds were given GA98/ CWL0470/98.", [["DPI", "CHEMICAL", 30, 33], ["GA98", "CHEMICAL", 177, 181], ["GA98", "CHEMICAL", 177, 181], ["birds", "ORGANISM", 4, 9], ["Ark", "GENE_OR_GENE_PRODUCT", 21, 24], ["birds", "ORGANISM", 41, 46], ["birds", "ORGANISM", 77, 82], ["birds", "ORGANISM", 160, 165], ["Ark attenuated", "PROBLEM", 58, 72], ["Mass", "PROBLEM", 99, 103], ["Mass attenuated", "PROBLEM", 115, 130], ["GA98", "TEST", 177, 181], ["Mass", "OBSERVATION", 115, 119]]], ["Each of the negative control groups consisted of 10 birds.", [["birds", "ORGANISM", 52, 57]]], ["Clinical signs and lesions were recorded, and tracheal swabs were collected and placed in 1 ml of ice-cold PBS (pH 7.4) at 5 days post-exposure [26] .", [["lesions", "ANATOMY", 19, 26], ["tracheal swabs", "ANATOMY", 46, 60], ["lesions", "PATHOLOGICAL_FORMATION", 19, 26], ["tracheal swabs", "MULTI-TISSUE_STRUCTURE", 46, 60], ["Clinical signs", "TEST", 0, 14], ["lesions", "PROBLEM", 19, 26], ["tracheal swabs", "TEST", 46, 60], ["ice-cold PBS", "TREATMENT", 98, 110], ["pH", "TEST", 112, 114], ["lesions", "OBSERVATION", 19, 26], ["tracheal", "ANATOMY", 46, 54]]], ["The presence of virus in the tracheal swab supernatant was determined by quantitative real-time RT-PCR [27] .", [["tracheal swab supernatant", "ANATOMY", 29, 54], ["tracheal swab", "ORGANISM_SUBSTANCE", 29, 42], ["virus", "PROBLEM", 16, 21], ["the tracheal swab", "TREATMENT", 25, 42], ["virus", "OBSERVATION", 16, 21], ["tracheal", "ANATOMY", 29, 37]]], ["Tracheas were collected in 10% neutral buffered formalin, routinely processed into paraffin, and 5-lm sections were cut for hematoxylin and eosin staining.", [["Tracheas", "ANATOMY", 0, 8], ["5-lm sections", "ANATOMY", 97, 110], ["formalin", "CHEMICAL", 48, 56], ["paraffin", "CHEMICAL", 83, 91], ["hematoxylin", "CHEMICAL", 124, 135], ["eosin", "CHEMICAL", 140, 145], ["Tracheas", "CELL", 0, 8], ["formalin", "SIMPLE_CHEMICAL", 48, 56], ["lm sections", "CANCER", 99, 110], ["hematoxylin", "SIMPLE_CHEMICAL", 124, 135], ["eosin", "SIMPLE_CHEMICAL", 140, 145], ["Tracheas", "TREATMENT", 0, 8], ["10% neutral buffered formalin", "TREATMENT", 27, 56], ["5-lm sections", "TREATMENT", 97, 110], ["hematoxylin", "TREATMENT", 124, 135]]], ["Epithelial hyperplasia, lymphocyte infiltration, and the severity of epithelial deciliation were scored for each trachea with 1 being normal and 4 being severe [28] .Virus replication in embryonated chicken eggs and chicksAs a measure of adaptation, we examined the growth of the Ark/Ark-DPI/81, Ark attenuated, Mass/Mass41/41 and Mass41-attenuated in embryonated eggs and chicks.", [["Epithelial hyperplasia", "ANATOMY", 0, 22], ["lymphocyte", "ANATOMY", 24, 34], ["epithelial", "ANATOMY", 69, 79], ["trachea", "ANATOMY", 113, 120], ["eggs", "ANATOMY", 207, 211], ["eggs", "ANATOMY", 364, 368], ["Epithelial hyperplasia", "DISEASE", 0, 22], ["Mass41", "CHEMICAL", 331, 337], ["Epithelial", "TISSUE", 0, 10], ["lymphocyte", "CELL", 24, 34], ["epithelial", "TISSUE", 69, 79], ["trachea", "ORGAN", 113, 120], ["Virus", "ORGANISM", 166, 171], ["chicken", "ORGANISM", 199, 206], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 207, 211], ["chicks", "ORGANISM", 216, 222], ["Ark", "GENE_OR_GENE_PRODUCT", 280, 283], ["Ark", "GENE_OR_GENE_PRODUCT", 296, 299], ["Mass41/41", "GENE_OR_GENE_PRODUCT", 317, 326], ["Mass41", "GENE_OR_GENE_PRODUCT", 331, 337], ["chicken", "SPECIES", 199, 206], ["chicks", "SPECIES", 216, 222], ["chicks", "SPECIES", 373, 379], ["chicken", "SPECIES", 199, 206], ["Epithelial hyperplasia", "PROBLEM", 0, 22], ["lymphocyte infiltration", "PROBLEM", 24, 47], ["epithelial deciliation", "PROBLEM", 69, 91], ["Virus replication", "TREATMENT", 166, 183], ["Mass", "TEST", 312, 316], ["Mass41/41", "TEST", 317, 326], ["Mass41", "TEST", 331, 337], ["embryonated eggs", "PROBLEM", 352, 368], ["chicks", "PROBLEM", 373, 379], ["hyperplasia", "OBSERVATION", 11, 22], ["lymphocyte infiltration", "OBSERVATION", 24, 47], ["severity", "OBSERVATION_MODIFIER", 57, 65], ["epithelial deciliation", "OBSERVATION", 69, 91], ["trachea", "ANATOMY", 113, 120], ["normal", "OBSERVATION", 134, 140], ["embryonated chicken eggs", "OBSERVATION", 187, 211], ["Mass", "OBSERVATION", 312, 316], ["embryonated eggs", "OBSERVATION", 352, 368], ["chicks", "OBSERVATION_MODIFIER", 373, 379]]], ["Because of limited isolator availability, we did not include the GA 98 viruses in this experiment.", [["the GA", "TEST", 61, 67]]], ["Virus growth in embryonated eggs was examined by inoculating 1 9 10 5 EID 50 of each virus into 30 eggs at 10 days of incubation via the chorioallantoic route.", [["eggs", "ANATOMY", 28, 32], ["eggs", "ANATOMY", 99, 103], ["chorioallantoic", "ANATOMY", 137, 152], ["Virus", "ORGANISM", 0, 5], ["chorioallantoic route", "MULTI-TISSUE_STRUCTURE", 137, 158], ["Virus growth in embryonated eggs", "PROBLEM", 0, 32], ["the chorioallantoic route", "TREATMENT", 133, 158]]], ["For each virus, allantoic fluid was harvested from five eggs at 12, 24, 36, 48, 72, and 96 h after inoculation.", [["allantoic fluid", "ANATOMY", 16, 31], ["eggs", "ANATOMY", 56, 60], ["allantoic fluid", "ORGANISM_SUBSTANCE", 16, 31], ["each virus", "PROBLEM", 4, 14], ["allantoic fluid", "TREATMENT", 16, 31], ["inoculation", "PROBLEM", 99, 110], ["virus", "OBSERVATION", 9, 14], ["allantoic", "OBSERVATION_MODIFIER", 16, 25], ["fluid", "OBSERVATION", 26, 31]]], ["The amount of virus present in fresh (not previously frozen) allantoic fluid was determined by quantitative real-time RT-PCR [27] .Virus replication in embryonated chicken eggs and chicksTo examine virus growth in chicks, 1 9 10 5 EID 50 of each virus was inoculated into 30 specific pathogen-free chicks at 1 day of age via the ocular/nasal route.", [["allantoic fluid", "ANATOMY", 61, 76], ["eggs", "ANATOMY", 172, 176], ["ocular", "ANATOMY", 329, 335], ["nasal", "ANATOMY", 336, 341], ["allantoic fluid", "ORGANISM_SUBSTANCE", 61, 76], ["Virus", "ORGANISM", 131, 136], ["chicken", "ORGANISM", 164, 171], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 172, 176], ["chicks", "ORGANISM", 181, 187], ["chicks", "ORGANISM", 298, 304], ["ocular", "ORGAN", 329, 335], ["chicken", "SPECIES", 164, 171], ["chicks", "SPECIES", 181, 187], ["chicks", "SPECIES", 214, 220], ["chicks", "SPECIES", 298, 304], ["chicken", "SPECIES", 164, 171], ["virus", "PROBLEM", 14, 19], ["allantoic fluid", "TEST", 61, 76], ["Virus replication", "TREATMENT", 131, 148], ["virus growth", "TEST", 198, 210], ["each virus", "PROBLEM", 241, 251], ["the ocular/nasal route", "TREATMENT", 325, 347], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["virus", "OBSERVATION", 14, 19], ["embryonated chicken eggs", "OBSERVATION", 152, 176], ["ocular", "ANATOMY", 329, 335], ["nasal", "ANATOMY", 336, 341]]], ["Tracheal swabs were collected from each of five birds at 12, 24, 36, 48, 72, and 96 h after inoculation and placed in 1 ml of ice-cold PBS (pH 7.4).", [["Tracheal swabs", "ANATOMY", 0, 14], ["Tracheal swabs", "MULTI-TISSUE_STRUCTURE", 0, 14], ["Tracheal swabs", "TEST", 0, 14], ["ice-cold PBS", "TREATMENT", 126, 138], ["pH", "TEST", 140, 142]]], ["Once the birds were swabbed, they were removed from the study.", [["birds", "ORGANISM", 9, 14], ["the study", "TEST", 52, 61]]], ["The amount of virus present in the fresh (not previously frozen) tracheal swab supernatant was determined by quantitative real-time RT-PCR [27] .GenBank accession numbersSequences generated in this study were submitted to GenBank and assigned the following accession numbers: Ark/Ark-DPI/81 (GQ504720); Ark-attenuated (GQ504721); GA98/CWL0470/98 (GQ504722); GA98-attenuated (GQ50 4723); Mass/Mass41/41 (GQ504724); and Mass41-attenuated (GQ504725).Full-length genome sequencing and analysisThe consensus sequence of the full-length genomes of Ark/ Ark-DPI/81, Ark-attenuated, GA98/CWL0470/98, GA98attenuated, Mass/Mass41/41, and Mass41-attenuated were sequenced, and the genome sizes were found to be 27,651 nt, 27,620 nt, 27,638 nt, 27,621 nt, 27,475 nt, and 27,451 nt, respectively.", [["tracheal swab supernatant", "ANATOMY", 65, 90], ["tracheal swab", "ORGANISM_SUBSTANCE", 65, 78], ["Ark", "GENE_OR_GENE_PRODUCT", 542, 545], ["Ark", "GENE_OR_GENE_PRODUCT", 547, 550], ["GA98", "GENE_OR_GENE_PRODUCT", 575, 579], ["CWL0470/98", "GENE_OR_GENE_PRODUCT", 580, 590], ["GA98attenuated", "GENE_OR_GENE_PRODUCT", 592, 606], ["Mass41/41", "GENE_OR_GENE_PRODUCT", 613, 622], ["Mass41", "GENE_OR_GENE_PRODUCT", 628, 634], ["Mass41", "DNA", 418, 424], ["consensus sequence", "DNA", 493, 511], ["full-length genomes", "DNA", 519, 538], ["GA98", "DNA", 575, 579], ["CWL0470/98", "DNA", 580, 590], ["Mass41/41", "DNA", 613, 622], ["Mass41", "DNA", 628, 634], ["virus", "PROBLEM", 14, 19], ["tracheal swab supernatant", "TEST", 65, 90], ["this study", "TEST", 193, 203], ["GA98", "TEST", 330, 334], ["GA98", "TEST", 358, 362], ["Mass", "TEST", 387, 391], ["Mass41", "TEST", 418, 424], ["analysis", "TEST", 481, 489], ["The consensus sequence", "TEST", 489, 511], ["Ark", "TEST", 542, 545], ["DPI", "TEST", 551, 554], ["Ark-attenuated", "TEST", 559, 573], ["GA98", "TEST", 575, 579], ["GA98attenuated", "TEST", 592, 606], ["Mass", "TEST", 608, 612], ["Mass41/41", "TEST", 613, 622], ["Mass41", "TEST", 628, 634], ["the genome sizes", "TEST", 666, 682], ["nt", "TEST", 707, 709], ["nt", "TEST", 718, 720], ["nt", "TEST", 729, 731], ["nt", "TEST", 740, 742], ["nt", "TEST", 751, 753], ["nt", "TEST", 766, 768], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["virus", "OBSERVATION", 14, 19], ["tracheal", "ANATOMY", 65, 73], ["Mass", "OBSERVATION", 387, 391], ["Mass", "OBSERVATION", 608, 612], ["sizes", "OBSERVATION_MODIFIER", 677, 682]]], ["The genome organization consisting of a 5 0 untranslated region (UTR), polyproteins 1a and 1ab, spike, 3a, 3b, envelope, membrane, 4b, 5a, 5b, nucleocapsid, and 3 0 UTR was the same for all six viruses (Table 1) .", [["membrane", "ANATOMY", 121, 129], ["polyproteins 1a", "GENE_OR_GENE_PRODUCT", 71, 86], ["1", "GENE_OR_GENE_PRODUCT", 91, 92], ["3b", "GENE_OR_GENE_PRODUCT", 107, 109], ["membrane", "CELLULAR_COMPONENT", 121, 129], ["4b", "GENE_OR_GENE_PRODUCT", 131, 133], ["5a", "GENE_OR_GENE_PRODUCT", 135, 137], ["5", "GENE_OR_GENE_PRODUCT", 139, 140], ["b", "GENE_OR_GENE_PRODUCT", 140, 141], ["nucleocapsid", "GENE_OR_GENE_PRODUCT", 143, 155], ["5 0 untranslated region", "DNA", 40, 63], ["UTR", "DNA", 65, 68], ["polyproteins 1a", "DNA", 71, 86], ["spike, 3a, 3b, envelope, membrane, 4b, 5a, 5b, nucleocapsid, and 3 0 UTR", "DNA", 96, 168], ["a 5 0 untranslated region (UTR)", "PROBLEM", 38, 69], ["polyproteins", "TEST", 71, 83], ["spike", "PROBLEM", 96, 101], ["nucleocapsid", "TEST", 143, 155], ["UTR", "TEST", 165, 168], ["genome organization", "OBSERVATION", 4, 23]]], ["Gene locations for the nsps in ORF 1a and 1ab are shown in Table 2 .", [["nsps", "GENE_OR_GENE_PRODUCT", 23, 27], ["ORF 1a", "GENE_OR_GENE_PRODUCT", 31, 37], ["nsps", "DNA", 23, 27], ["ORF 1a", "DNA", 31, 37], ["1ab", "DNA", 42, 45]]], ["The 4b protein, previously recognized in M41 [21] , is 94 amino acids long and located downstream from the membrane protein in all the viruses sequenced.", [["membrane", "ANATOMY", 107, 115], ["amino acids", "CHEMICAL", 58, 69], ["amino acids", "CHEMICAL", 58, 69], ["4b", "GENE_OR_GENE_PRODUCT", 4, 6], ["amino acids", "AMINO_ACID", 58, 69], ["membrane", "CELLULAR_COMPONENT", 107, 115], ["4b protein", "PROTEIN", 4, 14], ["membrane protein", "PROTEIN", 107, 123], ["The 4b protein", "TEST", 0, 14], ["amino acids", "TEST", 58, 69], ["the membrane protein", "TEST", 103, 123], ["membrane protein", "OBSERVATION", 107, 123], ["viruses", "OBSERVATION", 135, 142]]], ["A BLAST search was conducted, and we found the protein to have 96% sequence identity with the 4b protein from TCoV (TCoV, GenBank accession number EU022526.1).", [["TCoV", "GENE_OR_GENE_PRODUCT", 110, 114], ["4b protein", "PROTEIN", 94, 104], ["TCoV", "PROTEIN", 110, 114], ["TCoV", "PROTEIN", 116, 120], ["TCoV", "SPECIES", 110, 114], ["A BLAST search", "TEST", 0, 14], ["the protein", "TEST", 43, 54], ["the 4b protein", "TEST", 90, 104]]], ["In addition, a 6b protein downstream of the nucleocapsid protein was similar to the predicted 6b ORF reported for TCoV (GenBank accession number EU022526.1).", [["6b protein", "PROTEIN", 15, 25], ["nucleocapsid protein", "PROTEIN", 44, 64], ["6b ORF", "DNA", 94, 100], ["TCoV", "PROTEIN", 114, 118], ["a 6b protein downstream", "TEST", 13, 36], ["the nucleocapsid protein", "TEST", 40, 64]]], ["The 6b ORF was identified in the Ark and GA98 viruses but not in the Mass 41 viruses.Full-length genome sequencing and analysisAlignment and phylogenetic analysis of the full-length genomes show that Ark/Ark-DPI/81 has 99.1% sequence identity with Ark-attenuated, GA98/CWL0470/98 has 97.1% sequence identity with GA98-attenuated, and Mass/ Mass41/41 has 92.3% sequence similarity with Mass41attenuated (Fig. 1) .Full-length genome sequencing and analysisNucleotide and amino acid sequence differences were identified between each of the pathogenic and attenuated viruses (Table 3) .", [["DPI", "CHEMICAL", 208, 211], ["GA98", "CHEMICAL", 313, 317], ["amino acid", "CHEMICAL", 469, 479], ["amino acid", "CHEMICAL", 469, 479], ["6b", "GENE_OR_GENE_PRODUCT", 4, 6], ["Ark", "GENE_OR_GENE_PRODUCT", 33, 36], ["GA98 viruses", "ORGANISM", 41, 53], ["Mass 41 viruses", "ORGANISM", 69, 84], ["Ark", "GENE_OR_GENE_PRODUCT", 200, 203], ["Ark", "GENE_OR_GENE_PRODUCT", 204, 207], ["amino acid", "AMINO_ACID", 469, 479], ["6b ORF", "DNA", 4, 10], ["full-length genomes", "DNA", 170, 189], ["Ark/Ark-DPI/81", "DNA", 200, 214], ["GA98", "DNA", 264, 268], ["CWL0470/98", "DNA", 269, 279], ["GA98", "DNA", 313, 317], ["Mass41/41", "DNA", 340, 349], ["GA98 viruses", "SPECIES", 41, 53], ["Mass 41 viruses", "SPECIES", 69, 84], ["The 6b ORF", "TEST", 0, 10], ["the Mass 41 viruses", "PROBLEM", 65, 84], ["analysis", "TEST", 119, 127], ["Alignment", "TEST", 127, 136], ["phylogenetic analysis", "TEST", 141, 162], ["Ark/Ark", "TEST", 200, 207], ["sequence identity", "TEST", 225, 242], ["Ark-attenuated", "TEST", 248, 262], ["GA98", "TEST", 264, 268], ["sequence identity", "TEST", 290, 307], ["GA98", "TEST", 313, 317], ["Mass", "TEST", 334, 338], ["Mass41/41", "TEST", 340, 349], ["analysis", "TEST", 446, 454], ["Nucleotide and amino acid sequence differences", "TEST", 454, 500], ["the pathogenic and attenuated viruses", "PROBLEM", 533, 570], ["Mass", "OBSERVATION", 69, 73], ["viruses", "OBSERVATION", 77, 84], ["attenuated", "OBSERVATION_MODIFIER", 318, 328], ["Mass", "OBSERVATION", 334, 338], ["attenuated", "OBSERVATION_MODIFIER", 552, 562], ["viruses", "OBSERVATION", 563, 570]]], ["When the genome sequences are compared, there are 249 nucleotide (nt) changes resulting in 62 amino acid changes in the coding regions between the Ark viruses, 629 nt changes resulting in 268 amino acid changes between the GA98 viruses, and 1,805 nt changes resulting in 462 amino acid changes between the Mass 41 viruses (see Table 3 and Supplemental data Tables 5 and 6 ).Full-length genome sequencing and analysisThe size of the 5 0 UTR is 528 nt for all the viruses ( Table 1 ).", [["nucleotide", "CHEMICAL", 54, 64], ["amino acid", "CHEMICAL", 94, 104], ["amino acid", "CHEMICAL", 192, 202], ["amino acid", "CHEMICAL", 275, 285], ["nucleotide", "CHEMICAL", 54, 64], ["amino acid", "CHEMICAL", 94, 104], ["amino acid", "CHEMICAL", 192, 202], ["amino acid", "CHEMICAL", 275, 285], ["amino acid", "AMINO_ACID", 94, 104], ["amino acid", "AMINO_ACID", 192, 202], ["amino acid", "AMINO_ACID", 275, 285], ["genome sequences", "DNA", 9, 25], ["coding regions", "DNA", 120, 134], ["5 0 UTR", "DNA", 432, 439], ["Mass 41 viruses", "SPECIES", 306, 321], ["the genome sequences", "TEST", 5, 25], ["nucleotide (nt) changes", "PROBLEM", 54, 77], ["62 amino acid changes", "PROBLEM", 91, 112], ["268 amino acid changes", "PROBLEM", 188, 210], ["1,805 nt changes", "PROBLEM", 241, 257], ["amino acid changes", "PROBLEM", 275, 293], ["the Mass 41 viruses", "PROBLEM", 302, 321], ["analysis", "TEST", 408, 416], ["amino acid", "OBSERVATION", 94, 104], ["Ark viruses", "OBSERVATION", 147, 158], ["amino acid", "OBSERVATION", 192, 202], ["amino acid", "OBSERVATION", 275, 285], ["size", "OBSERVATION_MODIFIER", 420, 424], ["viruses", "OBSERVATION", 462, 469]]], ["The number of nt differences between the Ark viruses for the 5 0 UTR was 25 with a 95.6% identity.", [["5 0 UTR", "DNA", 61, 68], ["nt differences", "OBSERVATION_MODIFIER", 14, 28], ["viruses", "OBSERVATION", 45, 52]]], ["The GA98 viruses have 6 nt differences with 98.9% identity, and the Mass viruses have 12 nt differences with 98.3% identity in the 5 0 UTR ( Table 3 ).", [["GA98 viruses", "ORGANISM", 4, 16], ["5 0 UTR", "DNA", 131, 138], ["GA98 viruses", "SPECIES", 4, 16], ["The GA98 viruses", "TEST", 0, 16], ["the Mass viruses", "PROBLEM", 64, 80], ["Mass", "OBSERVATION", 68, 72]]], ["The leader junction sequence, nucleotides 57-64 (5 0 -CTTAACAA), were found to be identical for the Ark and Mass viruses, whereas the GA98/CWL0470/98 pathogenic virus leader junction sequence is 5 0 -CTCAACAA and the GA98 attenuated virus sequence is 5 0 -CTTTACAA.", [["nucleotides", "CHEMICAL", 30, 41], ["Ark", "GENE_OR_GENE_PRODUCT", 100, 103], ["GA98/CWL0470/98 pathogenic virus", "ORGANISM", 134, 166], ["leader junction sequence", "DNA", 4, 28], ["nucleotides 57-64", "DNA", 30, 47], ["GA98/CWL0470/98 pathogenic virus leader junction sequence", "DNA", 134, 191], ["GA98 attenuated virus sequence", "DNA", 217, 247], ["The leader junction sequence", "TEST", 0, 28], ["nucleotides", "TEST", 30, 41], ["the Ark", "PROBLEM", 96, 103], ["Mass viruses", "PROBLEM", 108, 120], ["the GA98", "TEST", 130, 138], ["the GA98 attenuated virus sequence", "PROBLEM", 213, 247], ["Mass viruses", "OBSERVATION", 108, 120]]], ["The transcriptional regulatory sequences (TRS) were identical in all of the viruses and were 5 0 -CTGAACAA-3 0 for mRNAs 2 and 3, and 5 0 -CTTAACAA-3 0 for mRNAs 4, 5, and 6.Full-length genome sequencing and analysisThe size of the 3 0 UTRs is 273 nt for Ark/Ark-DPI/81 pathogenic and Ark-attenuated, 276 nt for GA98/ CWL0470/98, 244 nt for GA98-attenuated, and 322 nt for Mass/Mass41/41, and Mass41-attenuated ( Table 1 ).", [["DPI", "CHEMICAL", 263, 266], ["3", "GENE_OR_GENE_PRODUCT", 127, 128], ["transcriptional regulatory sequences", "DNA", 4, 40], ["TRS", "DNA", 42, 45], ["CTTAACAA", "DNA", 139, 147], ["mRNAs 4, 5, and 6", "DNA", 156, 173], ["3 0 UTRs", "DNA", 232, 240], ["GA98", "DNA", 312, 316], ["CWL0470/98", "DNA", 318, 328], ["GA98", "DNA", 341, 345], ["The transcriptional regulatory sequences", "TEST", 0, 40], ["CTGAACAA", "TEST", 98, 106], ["mRNAs", "TEST", 115, 120], ["CTTAACAA", "TEST", 139, 147], ["mRNAs", "TEST", 156, 161], ["analysis", "TEST", 208, 216], ["Ark/Ark", "TEST", 255, 262], ["DPI", "TEST", 263, 266], ["pathogenic", "PROBLEM", 270, 280], ["Ark-attenuated", "TEST", 285, 299], ["nt", "TEST", 305, 307], ["GA98", "TEST", 312, 316], ["CWL0470/98", "TEST", 318, 328], ["nt", "TEST", 334, 336], ["GA98", "TEST", 341, 345], ["Mass", "TEST", 373, 377], ["Mass41/41", "TEST", 378, 387], ["Mass41", "TEST", 393, 399], ["viruses", "OBSERVATION", 76, 83], ["size", "OBSERVATION_MODIFIER", 220, 224], ["Mass", "OBSERVATION", 373, 377]]], ["The number of nt differences within the 3 0 UTRs for the Ark viruses is 6 with 98.5% identity.", [["3 0 UTRs", "DNA", 40, 48], ["the Ark viruses", "TEST", 53, 68], ["nt differences", "OBSERVATION_MODIFIER", 14, 28], ["viruses", "OBSERVATION", 61, 68]]], ["The GA98 viruses have 9 nt differences resulting in 97.1% identity, and the Mass viruses have 2 nt differences with 99.4% identity within the 3 0 UTRs ( Table 3) .", [["GA98 viruses", "ORGANISM", 4, 16], ["0 UTRs", "DNA", 144, 150], ["GA98 viruses", "SPECIES", 4, 16], ["The GA98 viruses", "TEST", 0, 16], ["9 nt differences", "PROBLEM", 22, 38], ["the Mass viruses", "PROBLEM", 72, 88], ["9 nt differences", "OBSERVATION_MODIFIER", 22, 38], ["Mass", "OBSERVATION", 76, 80]]], ["The 3 0 UTRs contain the S2M motif, which is 41 nt long with a sequence identity of 92.7% or higher between the six viruses.Protein alignments between pathotypesAnalysis of the locations and number of sequence differences between pathogenic and attenuated viruses of the same serotype for individual nsps in polyproteins 1a and 1a/b (Table 3) shows that nsp 3 has the highest number of amino acid differences among all the nsps.", [["amino acid", "CHEMICAL", 386, 396], ["amino acid", "CHEMICAL", 386, 396], ["S2M", "GENE_OR_GENE_PRODUCT", 25, 28], ["nsps", "GENE_OR_GENE_PRODUCT", 300, 304], ["Table 3", "GENE_OR_GENE_PRODUCT", 334, 341], ["nsp 3", "GENE_OR_GENE_PRODUCT", 354, 359], ["amino acid", "AMINO_ACID", 386, 396], ["3 0 UTRs", "DNA", 4, 12], ["S2M motif", "DNA", 25, 34], ["41 nt long", "DNA", 45, 55], ["nsps", "DNA", 300, 304], ["polyproteins 1a and 1a/b", "PROTEIN", 308, 332], ["nsp 3", "PROTEIN", 354, 359], ["the S2M motif", "TREATMENT", 21, 34], ["a sequence identity", "TEST", 61, 80], ["Protein alignments", "TEST", 124, 142], ["pathotypesAnalysis", "TEST", 151, 169], ["pathogenic", "PROBLEM", 230, 240], ["attenuated viruses", "PROBLEM", 245, 263], ["polyproteins", "TEST", 308, 320], ["amino acid differences", "PROBLEM", 386, 408], ["viruses", "OBSERVATION", 116, 123], ["attenuated", "OBSERVATION_MODIFIER", 245, 255], ["viruses", "OBSERVATION", 256, 263], ["amino acid", "OBSERVATION", 386, 396]]], ["In addition, nsp 3 has the greatest number of differences when coding regions across the entire genome are compared.", [["nsp 3", "GENE_OR_GENE_PRODUCT", 13, 18], ["nsp 3", "PROTEIN", 13, 18], ["greatest", "OBSERVATION_MODIFIER", 27, 35], ["number", "OBSERVATION_MODIFIER", 36, 42], ["entire", "OBSERVATION_MODIFIER", 89, 95], ["genome", "OBSERVATION", 96, 102]]], ["A schematic representation of nsp 3 and number of amino acid changes in each domain is presented in Fig. 2 .", [["amino acid", "CHEMICAL", 50, 60], ["amino acid", "CHEMICAL", 50, 60], ["nsp 3", "GENE_OR_GENE_PRODUCT", 30, 35], ["amino acid", "AMINO_ACID", 50, 60], ["nsp 3", "PROTEIN", 30, 35], ["nsp", "PROBLEM", 30, 33], ["amino acid changes", "PROBLEM", 50, 68], ["amino acid", "OBSERVATION", 50, 60]]], ["The nsp 3 ORF has 43.66% of all amino acid differences observed between Ark/Ark-DPI/81 and Ark-attenuated (including a ten amino acid deletion in the attenuated virus at positions 789-798), 34.75% of all amino acid differences observed between GA98/CWL0470/98 and GA98-attenuated (including an eight amino acid deletion in the pathogenic virus at positions 901-908 and a three amino acid deletion in the pathogenic virus at positions 950-952), and 37.08% of all amino acid differences observed between Mass/Mass41/41 and Mass-attenuated (including a ten amino acid deletion in the attenuated virus at positions 797-806).", [["amino acid", "CHEMICAL", 32, 42], ["DPI", "CHEMICAL", 80, 83], ["amino acid", "CHEMICAL", 123, 133], ["amino acid", "CHEMICAL", 204, 214], ["GA98", "CHEMICAL", 264, 268], ["amino acid", "CHEMICAL", 300, 310], ["amino acid", "CHEMICAL", 377, 387], ["amino acid", "CHEMICAL", 462, 472], ["amino acid", "CHEMICAL", 554, 564], ["amino acid", "CHEMICAL", 32, 42], ["amino acid", "CHEMICAL", 123, 133], ["amino acid", "CHEMICAL", 204, 214], ["amino acid", "CHEMICAL", 300, 310], ["amino acid", "CHEMICAL", 377, 387], ["amino acid", "CHEMICAL", 462, 472], ["amino acid", "CHEMICAL", 554, 564], ["nsp 3", "GENE_OR_GENE_PRODUCT", 4, 9], ["amino acid", "AMINO_ACID", 32, 42], ["amino acid", "AMINO_ACID", 204, 214], ["amino acid", "AMINO_ACID", 377, 387], ["amino acid", "AMINO_ACID", 462, 472], ["nsp 3 ORF", "DNA", 4, 13], ["GA98", "PROTEIN", 264, 268], ["The nsp 3 ORF", "TEST", 0, 13], ["all amino acid differences", "PROBLEM", 28, 54], ["Ark/Ark", "TEST", 72, 79], ["DPI", "TEST", 80, 83], ["Ark-attenuated", "PROBLEM", 91, 105], ["a ten amino acid deletion", "PROBLEM", 117, 142], ["the attenuated virus", "PROBLEM", 146, 166], ["all amino acid differences", "PROBLEM", 200, 226], ["GA98", "TEST", 244, 248], ["GA98", "TEST", 264, 268], ["an eight amino acid deletion", "PROBLEM", 291, 319], ["the pathogenic virus", "PROBLEM", 323, 343], ["a three amino acid deletion", "PROBLEM", 369, 396], ["the pathogenic virus", "PROBLEM", 400, 420], ["all amino acid differences", "PROBLEM", 458, 484], ["Mass", "TEST", 502, 506], ["Mass-attenuated", "PROBLEM", 521, 536], ["a ten amino acid deletion", "PROBLEM", 548, 573], ["the attenuated virus", "PROBLEM", 577, 597], ["amino acid", "OBSERVATION", 462, 472], ["Mass", "OBSERVATION", 502, 506]]], ["These changes represent 1.96, 5.18, and 11.06 differences per 100 amino acids within nsp 3 for Ark, GA98 and Mass 41, respectively.", [["amino acids", "CHEMICAL", 66, 77], ["amino acids", "CHEMICAL", 66, 77], ["amino acids", "AMINO_ACID", 66, 77], ["Ark", "GENE_OR_GENE_PRODUCT", 95, 98], ["amino acids", "TEST", 66, 77], ["nsp", "TEST", 85, 88], ["Ark", "TEST", 95, 98], ["GA98", "TEST", 100, 104], ["Mass", "TEST", 109, 113], ["Mass", "OBSERVATION", 109, 113]]], ["We also found a virus subpopulation within the Ark/Ark-DPI/81 strain, which had a ten amino acid deletion in nsp 3 at positions 789-798 similar to the Ark-attenuated virus.", [["DPI", "CHEMICAL", 55, 58], ["amino acid", "CHEMICAL", 86, 96], ["amino acid", "CHEMICAL", 86, 96], ["Ark", "GENE_OR_GENE_PRODUCT", 47, 50], ["Ark", "GENE_OR_GENE_PRODUCT", 51, 54], ["amino acid", "AMINO_ACID", 86, 96], ["nsp 3", "GENE_OR_GENE_PRODUCT", 109, 114], ["Ark-attenuated virus", "ORGANISM", 151, 171], ["nsp 3", "DNA", 109, 114], ["Ark-attenuated virus", "SPECIES", 151, 171], ["a virus subpopulation", "PROBLEM", 14, 35], ["DPI", "PROBLEM", 55, 58], ["81 strain", "PROBLEM", 59, 68], ["a ten amino acid deletion", "PROBLEM", 80, 105], ["the Ark-attenuated virus", "PROBLEM", 147, 171], ["virus subpopulation", "OBSERVATION", 16, 35], ["virus", "OBSERVATION", 166, 171]]], ["The catalytic triad of the PL2 protease, amino acids Cys623, Hys786, Asp802 [29] was conserved among all of the viruses, and a hydrophobicity plot of nsp 3 predicted fours transmembrane regions between amino acids 1,000 and 1,300 (data not shown).", [["amino acids Cys623", "CHEMICAL", 41, 59], ["Hys786", "CHEMICAL", 61, 67], ["amino acids", "CHEMICAL", 202, 213], ["amino acids", "CHEMICAL", 41, 52], ["Cys", "CHEMICAL", 53, 56], ["amino acids", "CHEMICAL", 202, 213], ["PL2", "GENE_OR_GENE_PRODUCT", 27, 30], ["amino acids", "AMINO_ACID", 41, 52], ["Cys623", "AMINO_ACID", 53, 59], ["Hys", "AMINO_ACID", 61, 64], ["786", "AMINO_ACID", 64, 67], ["nsp 3", "GENE_OR_GENE_PRODUCT", 150, 155], ["amino acids", "AMINO_ACID", 202, 213], ["PL2 protease", "PROTEIN", 27, 39], ["nsp 3", "PROTEIN", 150, 155], ["transmembrane regions", "PROTEIN", 172, 193], ["amino acids Cys", "TEST", 41, 56], ["Hys", "TEST", 61, 64], ["Asp802", "TEST", 69, 75], ["the viruses", "PROBLEM", 108, 119], ["a hydrophobicity plot", "TEST", 125, 146], ["nsp", "PROBLEM", 150, 153], ["amino acids", "TEST", 202, 213], ["viruses", "OBSERVATION", 112, 119]]], ["The fewest amino acid changes for the nsps between pathogenic and attenuated viruses within a serotype are found in nsps 7-10, which are the RNA-binding proteins.", [["amino acid", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 11, 21], ["amino acid", "AMINO_ACID", 11, 21], ["nsps", "GENE_OR_GENE_PRODUCT", 38, 42], ["nsps 7-10", "GENE_OR_GENE_PRODUCT", 116, 125], ["nsps", "PROTEIN", 38, 42], ["nsps 7-10", "DNA", 116, 125], ["RNA-binding proteins", "PROTEIN", 141, 161], ["The fewest amino acid changes", "TREATMENT", 0, 29], ["the nsps between pathogenic and attenuated viruses", "PROBLEM", 34, 84], ["a serotype", "PROBLEM", 92, 102], ["nsps", "TEST", 116, 120], ["fewest", "OBSERVATION_MODIFIER", 4, 10], ["amino acid", "OBSERVATION", 11, 21], ["attenuated", "OBSERVATION_MODIFIER", 66, 76], ["viruses", "OBSERVATION", 77, 84]]], ["The polyprotein 1ab-1 frame-shift slippery sequence (5 0 -UUUAAAC) is conserved among all six viruses but the location was found at nt 12,328 for Ark/Ark-DPI/81, nt 12,298 for Ark-attenuated, nt 12,321 for GA98/CWL0470/ 98, nt 12,360 for GA98-attenuated, nt 12,391 for Mass/ Mass41/41 and nt 12,327 for Mass41-attenuated.Protein alignments between pathotypesThe percent amino acid identity for the S glycoprotein is 97.8% for Ark viruses, 96.6% for GA98 viruses, and 97.2% for Mass 41 viruses (Fig. 3) .", [["Mass41", "CHEMICAL", 303, 309], ["amino acid", "CHEMICAL", 370, 380], ["amino acid", "CHEMICAL", 370, 380], ["1ab-1", "GENE_OR_GENE_PRODUCT", 16, 21], ["Ark", "GENE_OR_GENE_PRODUCT", 146, 149], ["amino acid", "AMINO_ACID", 370, 380], ["Ark viruses", "ORGANISM", 426, 437], ["Mass 41 viruses", "ORGANISM", 477, 492], ["polyprotein 1ab-1 frame-shift slippery sequence", "DNA", 4, 51], ["nt 12,328 for Ark/Ark-DPI/81", "DNA", 132, 160], ["nt 12,298", "DNA", 162, 171], ["Ark-attenuated, nt 12,321 for GA98/CWL0470/ 98", "DNA", 176, 222], ["nt 12,360 for GA98", "DNA", 224, 242], ["nt 12,391 for Mass/ Mass41/41 and nt 12,327 for Mass41", "DNA", 255, 309], ["S glycoprotein", "PROTEIN", 398, 412], ["Ark viruses", "SPECIES", 426, 437], ["GA98 viruses", "SPECIES", 449, 461], ["Mass 41 viruses", "SPECIES", 477, 492], ["The polyprotein 1ab", "TEST", 0, 19], ["nt", "TEST", 132, 134], ["Ark/Ark", "TEST", 146, 153], ["DPI", "TEST", 154, 157], ["nt", "TEST", 162, 164], ["Ark-attenuated", "PROBLEM", 176, 190], ["nt", "TEST", 192, 194], ["GA98", "TEST", 206, 210], ["nt", "TEST", 224, 226], ["GA98", "TEST", 238, 242], ["nt", "TEST", 255, 257], ["Mass", "PROBLEM", 269, 273], ["Mass41/41", "TEST", 275, 284], ["nt", "TEST", 289, 291], ["Mass41", "TEST", 303, 309], ["Protein alignments between pathotypes", "PROBLEM", 321, 358], ["The percent amino acid identity", "TEST", 358, 389], ["the S glycoprotein", "TEST", 394, 412], ["Ark viruses", "TEST", 426, 437], ["GA98 viruses", "TEST", 449, 461], ["Mass 41 viruses", "PROBLEM", 477, 492]]], ["The number of amino acid differences within the S glycoprotein between pathogenic and attenuated viruses are 7, 33, and 27 for Ark, GA98, and Mass 41, respectively ( Table 3 ).", [["amino acid", "CHEMICAL", 14, 24], ["amino acid", "CHEMICAL", 14, 24], ["amino acid", "AMINO_ACID", 14, 24], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 48, 62], ["S glycoprotein", "PROTEIN", 48, 62], ["amino acid differences", "PROBLEM", 14, 36], ["the S glycoprotein", "TEST", 44, 62], ["pathogenic and attenuated viruses", "PROBLEM", 71, 104], ["Ark", "TEST", 127, 130], ["GA98", "TEST", 132, 136], ["Mass", "TEST", 142, 146], ["number", "OBSERVATION_MODIFIER", 4, 10], ["amino acid", "OBSERVATION", 14, 24], ["S glycoprotein", "OBSERVATION_MODIFIER", 48, 62], ["attenuated", "OBSERVATION_MODIFIER", 86, 96], ["viruses", "OBSERVATION", 97, 104], ["Mass", "OBSERVATION", 142, 146]]], ["The S glycoprotein for the Ark viruses had 9.86% (0.60 differences/100 amino acids) of all amino acid differences, which is the third most variable ORF in the entire genome after nsp 3 and 12.", [["amino acids", "CHEMICAL", 71, 82], ["amino acid", "CHEMICAL", 91, 101], ["amino acids", "CHEMICAL", 71, 82], ["amino acid", "CHEMICAL", 91, 101], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 18], ["Ark viruses", "ORGANISM", 27, 38], ["amino acids", "AMINO_ACID", 71, 82], ["amino acid", "AMINO_ACID", 91, 101], ["nsp 3", "GENE_OR_GENE_PRODUCT", 179, 184], ["S glycoprotein", "PROTEIN", 4, 18], ["ORF", "DNA", 148, 151], ["nsp 3 and 12", "PROTEIN", 179, 191], ["the Ark viruses", "TEST", 23, 38], ["amino acids", "TEST", 71, 82], ["all amino acid differences", "PROBLEM", 87, 113], ["nsp", "TEST", 179, 182], ["amino acid", "OBSERVATION", 91, 101]]], ["For the GA98 viruses, the S glycoprotein has 13.36% (2.82 differences/100 amino acids) of all amino acid differences, which is the third most variable ORF in the entire genome after nsp 3 and ORF 6b.", [["amino acids", "CHEMICAL", 74, 85], ["amino acid", "CHEMICAL", 94, 104], ["amino acids", "CHEMICAL", 74, 85], ["amino acid", "CHEMICAL", 94, 104], ["GA98 viruses", "ORGANISM", 8, 20], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 26, 40], ["amino acids", "AMINO_ACID", 74, 85], ["amino acid", "AMINO_ACID", 94, 104], ["nsp 3", "GENE_OR_GENE_PRODUCT", 182, 187], ["ORF 6b", "GENE_OR_GENE_PRODUCT", 192, 198], ["S glycoprotein", "PROTEIN", 26, 40], ["ORF", "DNA", 151, 154], ["nsp 3", "DNA", 182, 187], ["ORF 6b", "DNA", 192, 198], ["GA98 viruses", "SPECIES", 8, 20], ["the GA98 viruses", "PROBLEM", 4, 20], ["the S glycoprotein", "TEST", 22, 40], ["amino acids", "TEST", 74, 85], ["all amino acid differences", "PROBLEM", 90, 116], ["nsp", "TEST", 182, 185], ["amino acid", "OBSERVATION", 94, 104]]], ["The S glycoprotein for the Mass 41 viruses has 5.77% of all amino acid differences (2.31 differences/100 amino acids), which was the fourth most variable ORF in the entire genome after nsp 3, 2, and 4.", [["amino acid", "CHEMICAL", 60, 70], ["amino acids", "CHEMICAL", 105, 116], ["amino acid", "CHEMICAL", 60, 70], ["amino acids", "CHEMICAL", 105, 116], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 18], ["Mass 41 viruses", "ORGANISM", 27, 42], ["amino acid", "AMINO_ACID", 60, 70], ["amino acids", "AMINO_ACID", 105, 116], ["nsp 3", "GENE_OR_GENE_PRODUCT", 185, 190], ["S glycoprotein", "PROTEIN", 4, 18], ["ORF", "DNA", 154, 157], ["nsp 3, 2, and 4", "PROTEIN", 185, 200], ["Mass 41 viruses", "SPECIES", 27, 42], ["The S glycoprotein", "TREATMENT", 0, 18], ["the Mass 41 viruses", "PROBLEM", 23, 42], ["all amino acid differences", "PROBLEM", 56, 82], ["amino acids", "TEST", 105, 116], ["nsp", "TEST", 185, 188]]], ["ORF 3b has the fewest number of differences with no differences observed between the Ark viruses, whereas the GA98 and Mass viruses each have one amino acid difference.", [["amino acid", "CHEMICAL", 146, 156], ["amino acid", "CHEMICAL", 146, 156], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 0, 6], ["Ark viruses", "ORGANISM", 85, 96], ["GA98", "GENE_OR_GENE_PRODUCT", 110, 114], ["Mass viruses", "ORGANISM", 119, 131], ["amino acid", "AMINO_ACID", 146, 156], ["ORF 3b", "DNA", 0, 6], ["the Ark viruses", "PROBLEM", 81, 96], ["Mass viruses", "PROBLEM", 119, 131], ["one amino acid difference", "PROBLEM", 142, 167], ["fewest", "OBSERVATION_MODIFIER", 15, 21], ["viruses", "OBSERVATION", 89, 96], ["Mass", "OBSERVATION", 119, 123], ["amino acid", "OBSERVATION", 146, 156]]], ["For ORF 4b, no amino acid differences are observed for the Ark viruses, 16 amino acid differences are observed between the GA98 viruses, and 17 amino acid differences are observed between the Mass 41 viruses.", [["amino acid", "CHEMICAL", 15, 25], ["amino acid", "CHEMICAL", 75, 85], ["amino acid", "CHEMICAL", 144, 154], ["amino acid", "CHEMICAL", 15, 25], ["amino acid", "CHEMICAL", 75, 85], ["amino acid", "CHEMICAL", 144, 154], ["amino acid", "AMINO_ACID", 15, 25], ["amino acid", "AMINO_ACID", 75, 85], ["amino acid", "AMINO_ACID", 144, 154], ["ORF 4b", "DNA", 4, 10], ["Mass 41 viruses", "SPECIES", 192, 207], ["ORF", "TEST", 4, 7], ["amino acid differences", "PROBLEM", 15, 37], ["the Ark viruses", "TEST", 55, 70], ["amino acid differences", "TEST", 75, 97], ["amino acid differences", "TEST", 144, 166], ["the Mass 41 viruses", "PROBLEM", 188, 207], ["Mass", "OBSERVATION", 192, 196], ["41 viruses", "OBSERVATION", 197, 207]]], ["The Ark virus 6b proteins have only one amino acid mutation and are 99.9% similar to each other, whereas the GA98 virus 6b proteins have 43 amino acid mutations, 3 amino acid deletions, and 1 substitution and are only 41.9% similar.", [["amino acid", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 140, 150], ["amino acid", "CHEMICAL", 164, 174], ["amino acid", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 140, 150], ["amino acid", "CHEMICAL", 164, 174], ["Ark virus 6", "ORGANISM", 4, 15], ["amino acid", "AMINO_ACID", 40, 50], ["GA98 virus 6b", "ORGANISM", 109, 122], ["amino acid", "AMINO_ACID", 140, 150], ["amino acid", "AMINO_ACID", 164, 174], ["Ark virus 6b proteins", "PROTEIN", 4, 25], ["GA98 virus 6b proteins", "PROTEIN", 109, 131], ["Ark virus", "SPECIES", 4, 13], ["GA98 virus", "SPECIES", 109, 119], ["The Ark virus", "TEST", 0, 13], ["one amino acid mutation", "TEST", 36, 59], ["the GA98 virus 6b proteins", "TEST", 105, 131], ["amino acid mutations", "TEST", 140, 160], ["amino acid deletions", "TEST", 164, 184]]], ["Because this protein has not been previously recognized in IBV, a nucleotide BLAST search rather than an amino acid search was conducted and showed that the GA98/CWL0470/98 virus has 98% identity with Mass H120 (FJ888351) and the GA98-attenuated virus has 98% identity with Ark-DPI (EU418976).", [["nucleotide", "CHEMICAL", 66, 76], ["amino acid", "CHEMICAL", 105, 115], ["Ark-DPI", "CHEMICAL", 274, 281], ["EU418976", "CHEMICAL", 283, 291], ["nucleotide", "CHEMICAL", 66, 76], ["amino acid", "CHEMICAL", 105, 115], ["EU418976", "CHEMICAL", 283, 291], ["IBV", "ORGANISM", 59, 62], ["amino acid", "AMINO_ACID", 105, 115], ["GA98/CWL0470/98 virus", "ORGANISM", 157, 178], ["GA98", "ORGANISM", 230, 234], ["Ark-DPI", "SIMPLE_CHEMICAL", 274, 281], ["GA98", "PROTEIN", 157, 161], ["IBV", "SPECIES", 59, 62], ["GA98/CWL0470/98 virus", "SPECIES", 157, 178], ["Mass H120", "SPECIES", 201, 210], ["a nucleotide BLAST search", "TEST", 64, 89], ["an amino acid search", "TEST", 102, 122], ["the GA98", "TEST", 153, 161], ["virus", "PROBLEM", 173, 178], ["Mass", "TEST", 201, 205], ["the GA98", "TEST", 226, 234], ["attenuated virus", "PROBLEM", 235, 251], ["Ark", "TEST", 274, 277], ["Mass", "OBSERVATION", 201, 205]]], ["To determine whether the GA98-attenuated virus 6b sequence was a subpopulation within the GA98/CWL0470/98 virus, two forward primers (GA98A #1 5 0 -TCACGCTCAAGTTCAAGACCTG-3 0 , and GA98A #3 5 0 -CAGCTTTAGGTGAGAATGAACT-3 0 ) and two reverse primers (GA98A #2 5 0 -TACGATAAAACAA ACTAATGAGAA-3 0 , and GA98A #4 5 0 -TTGATAGGAA AGCACAGAAATAG-3 0 ) specific for the GA98-attenuated 1MProtein alignments between pathotypesa Positions are based on 1ab from TCoV (accession number YP_001941164) and presented as the residue position with 1 being the methionine at the beginning of ORF 1a and 1ab followed by the single letter code for the amino acid at that position 6b sequence were used in combination in an RT-PCR assay, but no amplicons were observed.Pathogenicity testing in chicksThe data on pathogenicity of the viruses in 2-week-old SPF chicks are presented in Table 4 . a Birds were given 1 9 10 4 50% embryo infectious doses intraocularly/intranasally and examined for clinical signs, virus, and lesions at 5 days post-inoculation b Virus was detected in tracheal swabs by real-time RT-PCR as previously described Callison et al. [27] c Epithelial hyperplasia, lymphocyte infiltration, and the severity of epithelial deciliation were scored for each trachea with one being normal and four being severe d A representative control group from one of the experiments is presented.", [["embryo", "ANATOMY", 903, 909], ["intranasally", "ANATOMY", 941, 953], ["lesions", "ANATOMY", 998, 1005], ["tracheal swabs", "ANATOMY", 1057, 1071], ["Epithelial hyperplasia", "ANATOMY", 1139, 1161], ["lymphocyte", "ANATOMY", 1163, 1173], ["epithelial", "ANATOMY", 1208, 1218], ["trachea", "ANATOMY", 1252, 1259], ["GA98", "CHEMICAL", 25, 29], ["GA98", "CHEMICAL", 361, 365], ["TCoV", "CHEMICAL", 450, 454], ["methionine", "CHEMICAL", 542, 552], ["amino acid", "CHEMICAL", 631, 641], ["methionine", "CHEMICAL", 542, 552], ["amino acid", "CHEMICAL", 631, 641], ["GA98", "GENE_OR_GENE_PRODUCT", 25, 29], ["virus 6b", "ORGANISM", 41, 49], ["GA98/CWL0470/98 virus", "ORGANISM", 90, 111], ["GA98", "GENE_OR_GENE_PRODUCT", 361, 365], ["methionine", "SIMPLE_CHEMICAL", 542, 552], ["amino acid", "AMINO_ACID", 631, 641], ["chicks", "ORGANISM", 772, 778], ["SPF", "ORGANISM", 833, 836], ["chicks", "ORGANISM", 837, 843], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 903, 909], ["lesions", "PATHOLOGICAL_FORMATION", 998, 1005], ["Virus", "ORGANISM", 1035, 1040], ["tracheal swabs", "MULTI-TISSUE_STRUCTURE", 1057, 1071], ["lymphocyte", "CELL", 1163, 1173], ["epithelial", "TISSUE", 1208, 1218], ["trachea", "ORGAN", 1252, 1259], ["GA98-attenuated virus 6b sequence", "DNA", 25, 58], ["reverse primers", "DNA", 232, 247], ["TTGATAGGAA AGCACAGAAATAG", "DNA", 313, 337], ["GA98-attenuated 1MProtein alignments", "DNA", 361, 397], ["TCoV", "DNA", 450, 454], ["ORF 1a", "DNA", 573, 579], ["position 6b sequence", "DNA", 650, 670], ["GA98/CWL0470/98 virus", "SPECIES", 90, 111], ["the GA98", "TEST", 21, 29], ["attenuated virus 6b sequence", "PROBLEM", 30, 58], ["the GA98", "TEST", 86, 94], ["forward primers", "TEST", 117, 132], ["GA98A", "TEST", 134, 139], ["TCACGCTCAAGTTCAAGACCTG", "TEST", 148, 170], ["GA98A", "TEST", 181, 186], ["CAGCTTTAGGTGAGAATGAACT", "TEST", 195, 217], ["GA98A", "TEST", 249, 254], ["TACGATAAAACAA", "TEST", 263, 276], ["ACTAATGAGAA", "TEST", 277, 288], ["GA98A", "TEST", 299, 304], ["AGCACAGAAATAG", "TEST", 324, 337], ["the GA98", "TEST", 357, 365], ["the methionine", "TREATMENT", 538, 552], ["the amino acid", "TREATMENT", 627, 641], ["an RT-PCR assay", "TEST", 699, 714], ["amplicons", "PROBLEM", 723, 732], ["Pathogenicity testing", "TEST", 747, 768], ["The data", "TEST", 778, 786], ["the viruses", "PROBLEM", 807, 818], ["clinical signs", "PROBLEM", 971, 985], ["virus", "PROBLEM", 987, 992], ["lesions", "PROBLEM", 998, 1005], ["post-inoculation b Virus", "PROBLEM", 1016, 1040], ["tracheal swabs", "TEST", 1057, 1071], ["Epithelial hyperplasia", "PROBLEM", 1139, 1161], ["lymphocyte infiltration", "PROBLEM", 1163, 1186], ["epithelial deciliation", "PROBLEM", 1208, 1230], ["chicks", "OBSERVATION_MODIFIER", 772, 778], ["viruses", "OBSERVATION", 811, 818], ["lesions", "OBSERVATION", 998, 1005], ["tracheal", "ANATOMY", 1057, 1065], ["Epithelial", "ANATOMY", 1139, 1149], ["hyperplasia", "OBSERVATION", 1150, 1161], ["lymphocyte infiltration", "OBSERVATION", 1163, 1186], ["epithelial deciliation", "OBSERVATION", 1208, 1230], ["trachea", "ANATOMY", 1252, 1259], ["normal", "OBSERVATION", 1275, 1281]]], ["All of the data from the negative control groups were the same (Fig. 4a) .", [["the data", "TEST", 7, 15]]], ["The Ark-attenuated virus, which is adapted to embryonated eggs, only killed Chicks inoculated with virus at 1 day of age showed statistical differences (P B 0.1) in the amount of virus detected in the trachea between the Ark/Ark-DPI/81 and Ark-attenuated viruses at 24, 48, 72, and 96 h post-inoculation with the pathogenic Ark/Ark-DPI/81 having the higher amount of virus at each of the sample times (Fig. 4b) .", [["eggs", "ANATOMY", 58, 62], ["trachea", "ANATOMY", 201, 208], ["DPI", "CHEMICAL", 229, 232], ["DPI", "CHEMICAL", 332, 335], ["Ark-attenuated virus", "ORGANISM", 4, 24], ["Chicks", "ORGANISM", 76, 82], ["trachea", "ORGAN", 201, 208], ["Ark", "GENE_OR_GENE_PRODUCT", 221, 224], ["Ark-DPI/81", "ORGANISM", 225, 235], ["Ark-attenuated viruses", "ORGANISM", 240, 262], ["Ark-attenuated virus", "SPECIES", 4, 24], ["The Ark-attenuated virus", "PROBLEM", 0, 24], ["embryonated eggs", "PROBLEM", 46, 62], ["virus", "PROBLEM", 99, 104], ["statistical differences", "PROBLEM", 128, 151], ["virus", "PROBLEM", 179, 184], ["Ark-attenuated viruses", "PROBLEM", 240, 262], ["inoculation", "TEST", 292, 303], ["the pathogenic Ark", "TEST", 309, 327], ["Ark-DPI", "TEST", 328, 335], ["the higher amount of virus", "PROBLEM", 346, 372], ["virus", "OBSERVATION", 19, 24], ["virus", "OBSERVATION", 179, 184], ["trachea", "ANATOMY", 201, 208], ["virus", "OBSERVATION", 367, 372]]], ["Although not statistically different, the chicks given the pathogenic Ark/Ark-DPI/81 virus also had more virus detected in the trachea than the chicks given the Ark-attenuated virus at 12 and 36 h post-inoculation.DiscussionMany studies have examined sequence changes in the structural proteins of IBV and found that most of the changes associated with adaptation to a particular host or with a particular virus pathotype occur in the spike glycoprotein [18, 19, 30] .", [["trachea", "ANATOMY", 127, 134], ["DPI", "CHEMICAL", 78, 81], ["chicks", "ORGANISM", 42, 48], ["Ark/Ark-DPI/81 virus", "ORGANISM", 70, 90], ["trachea", "ORGAN", 127, 134], ["chicks", "ORGANISM", 144, 150], ["Ark-attenuated virus", "ORGANISM", 161, 181], ["IBV", "ORGANISM", 298, 301], ["structural proteins", "PROTEIN", 275, 294], ["spike glycoprotein", "PROTEIN", 435, 453], ["chicks", "SPECIES", 42, 48], ["chicks", "SPECIES", 144, 150], ["Ark/Ark-DPI/81 virus", "SPECIES", 70, 90], ["Ark-attenuated virus", "SPECIES", 161, 181], ["IBV", "SPECIES", 298, 301], ["the pathogenic Ark/Ark-DPI", "TEST", 55, 81], ["virus", "PROBLEM", 85, 90], ["more virus", "PROBLEM", 100, 110], ["the Ark-attenuated virus", "PROBLEM", 157, 181], ["IBV", "TREATMENT", 298, 301], ["the changes", "PROBLEM", 325, 336], ["a particular virus pathotype", "PROBLEM", 393, 421], ["not", "UNCERTAINTY", 9, 12], ["statistically different", "OBSERVATION_MODIFIER", 13, 36], ["virus", "OBSERVATION", 105, 110], ["trachea", "ANATOMY", 127, 134]]], ["But only a few studies have examined changes across the entire genome associated with biological characteristics of the virus [22, 31] .", [["a few studies", "TEST", 9, 22], ["the virus", "PROBLEM", 116, 125]]], ["Ammayappan et al. [22] found a total of 17 amino acid changes between the genomes of Ark DPI 11, a pathogenic virus and Ark DPI 101 an attenuated virus, with four amino changes in nsp 3 and six amino acid changes in the S1 glycoprotein.", [["amino acid", "CHEMICAL", 43, 53], ["DPI", "CHEMICAL", 89, 92], ["DPI", "CHEMICAL", 124, 127], ["amino acid", "CHEMICAL", 194, 204], ["amino acid", "CHEMICAL", 43, 53], ["amino", "CHEMICAL", 163, 168], ["amino acid", "CHEMICAL", 194, 204], ["amino acid", "AMINO_ACID", 43, 53], ["Ark DPI 11", "ORGANISM", 85, 95], ["nsp 3", "GENE_OR_GENE_PRODUCT", 180, 185], ["amino acid", "AMINO_ACID", 194, 204], ["S1 glycoprotein", "GENE_OR_GENE_PRODUCT", 220, 235], ["nsp 3", "PROTEIN", 180, 185], ["S1 glycoprotein", "PROTEIN", 220, 235], ["Ark DPI 101 an attenuated virus", "SPECIES", 120, 151], ["17 amino acid changes", "PROBLEM", 40, 61], ["Ark DPI", "TEST", 85, 92], ["a pathogenic virus", "PROBLEM", 97, 115], ["Ark DPI", "TEST", 120, 127], ["an attenuated virus", "PROBLEM", 132, 151], ["four amino changes in nsp", "PROBLEM", 158, 183], ["six amino acid changes in the S1 glycoprotein", "PROBLEM", 190, 235], ["S1 glycoprotein", "ANATOMY", 220, 235]]], ["Based on that data, it was suggested that changes in the replicase sequence in addition to structural proteins might play a role in pathogenicity.", [["replicase sequence", "DNA", 57, 75], ["structural proteins", "PROTEIN", 91, 110], ["the replicase sequence", "TEST", 53, 75], ["structural proteins", "PROBLEM", 91, 110]]], ["Fang et al. [31] found 53.06% of all amino acid substitutions across the entire genome were located in the spike glycoprotein following adaptation of an attenuated avian coronavirus to primate cells, suggesting that spike plays a role in host adaptation.DiscussionIn this study, we analyzed the consensus full-length genome for the pathogenic and attenuated viruses of three different IBV types and showed that within a virus type, 34.75 to 43.66% of all the amino acid changes between the pathotypes occurred in nsp 3, whereas changes in spike ranged from 5.8 to 13.4% of all changes.", [["cells", "ANATOMY", 193, 198], ["amino acid", "CHEMICAL", 37, 47], ["amino acid", "CHEMICAL", 459, 469], ["amino acid", "CHEMICAL", 37, 47], ["amino acid", "CHEMICAL", 459, 469], ["amino acid", "AMINO_ACID", 37, 47], ["avian coronavirus", "ORGANISM", 164, 181], ["primate", "ORGANISM", 185, 192], ["cells", "CELL", 193, 198], ["IBV", "ORGANISM", 385, 388], ["amino acid", "AMINO_ACID", 459, 469], ["nsp 3", "GENE_OR_GENE_PRODUCT", 513, 518], ["spike glycoprotein", "PROTEIN", 107, 125], ["primate cells", "CELL_TYPE", 185, 198], ["consensus full-length genome", "DNA", 295, 323], ["avian coronavirus", "SPECIES", 164, 181], ["avian coronavirus", "SPECIES", 164, 181], ["IBV", "SPECIES", 385, 388], ["all amino acid substitutions", "TREATMENT", 33, 61], ["an attenuated avian coronavirus", "TREATMENT", 150, 181], ["this study", "TEST", 267, 277], ["the pathogenic and attenuated viruses", "PROBLEM", 328, 365], ["a virus type", "TEST", 418, 430], ["the amino acid changes", "PROBLEM", 455, 477], ["the pathotypes", "PROBLEM", 486, 500], ["nsp", "TEST", 513, 516], ["spike", "TEST", 539, 544], ["attenuated", "OBSERVATION_MODIFIER", 347, 357], ["viruses", "OBSERVATION", 358, 365], ["amino acid", "OBSERVATION", 459, 469], ["spike", "OBSERVATION_MODIFIER", 539, 544]]], ["It should be noted, however, that spike had the highest number of differences between different serotypes of the virus, which is consistent with previous reports [5] [6] [7] [8] .", [["[5] [6] [7] [8]", "SIMPLE_CHEMICAL", 162, 177], ["spike", "PROBLEM", 34, 39], ["the virus", "PROBLEM", 109, 118], ["virus", "OBSERVATION", 113, 118], ["consistent with", "UNCERTAINTY", 129, 144]]], ["A high percentage of differences between pathogenic and attenuated viruses within a serotype in nsp 3 suggests this region plays a key role in pathogenicity.", [["nsp 3", "GENE_OR_GENE_PRODUCT", 96, 101], ["pathogenic and attenuated viruses", "PROBLEM", 41, 74], ["a serotype in nsp 3", "PROBLEM", 82, 101], ["high percentage", "OBSERVATION_MODIFIER", 2, 17], ["pathogenic", "OBSERVATION_MODIFIER", 41, 51], ["attenuated", "OBSERVATION_MODIFIER", 56, 66], ["viruses", "OBSERVATION", 67, 74], ["serotype", "OBSERVATION_MODIFIER", 84, 92], ["pathogenicity", "OBSERVATION", 143, 156]]], ["The nsp 3 is a complex protein with multiple domains making it an attractive target for antiviral drug design [9, 32] .", [["nsp 3", "GENE_OR_GENE_PRODUCT", 4, 9], ["nsp 3", "PROTEIN", 4, 9], ["complex protein", "PROTEIN", 15, 30], ["a complex protein", "PROBLEM", 13, 30], ["antiviral drug design", "TREATMENT", 88, 109]]], ["It is approximately 1,600 amino acid residues in length and consists of an acidic domain, an ADP-ribose 1 phosphatase, the PL2 protease (a deubiquitinating protease), Y and transmembrane domains.", [["amino acid", "CHEMICAL", 26, 36], ["ADP", "CHEMICAL", 93, 96], ["amino acid", "CHEMICAL", 26, 36], ["ADP", "CHEMICAL", 93, 96], ["ribose", "CHEMICAL", 97, 103], ["amino acid", "AMINO_ACID", 26, 36], ["ADP-ribose 1 phosphatase", "GENE_OR_GENE_PRODUCT", 93, 117], ["PL2 protease", "GENE_OR_GENE_PRODUCT", 123, 135], ["acidic domain", "PROTEIN", 75, 88], ["ADP-ribose 1 phosphatase", "PROTEIN", 93, 117], ["PL2 protease", "PROTEIN", 123, 135], ["deubiquitinating protease), Y and transmembrane domains", "PROTEIN", 139, 194], ["amino acid residues in length", "PROBLEM", 26, 55], ["an acidic domain", "TEST", 72, 88], ["an ADP-ribose 1 phosphatase", "TEST", 90, 117], ["the PL2 protease", "TREATMENT", 119, 135], ["a deubiquitinating protease)", "TREATMENT", 137, 165], ["Y and transmembrane domains", "TREATMENT", 167, 194], ["acid residues", "OBSERVATION", 32, 45]]], ["The acidic domain is of unknown function, however; there is some evidence that it possesses nucleic acid binding activity because it is consistently co-purified with singlestranded RNA [33] .", [["nucleic acid", "CHEMICAL", 92, 104], ["acidic domain", "PROTEIN", 4, 17], ["nucleic acid binding activity", "PROBLEM", 92, 121], ["acidic domain", "OBSERVATION", 4, 17], ["unknown function", "OBSERVATION_MODIFIER", 24, 40]]], ["Previous studies with other organisms indicate that electrostatic interactions from this type of domain play a key role in ligand binding [34] .", [["Previous studies", "TEST", 0, 16], ["other organisms", "PROBLEM", 22, 37], ["electrostatic interactions", "PROBLEM", 52, 78], ["electrostatic interactions", "OBSERVATION", 52, 78]]], ["Influenza A viruses also contain a polymerase acidic protein (PA) that is required for the transcription and replication activity of the viral polymerase [34] .", [["Influenza A viruses", "ORGANISM", 0, 19], ["polymerase acidic protein", "GENE_OR_GENE_PRODUCT", 35, 60], ["PA", "GENE_OR_GENE_PRODUCT", 62, 64], ["polymerase acidic protein", "PROTEIN", 35, 60], ["PA", "PROTEIN", 62, 64], ["viral polymerase", "PROTEIN", 137, 153], ["Influenza A viruses", "SPECIES", 0, 19], ["Influenza A viruses", "PROBLEM", 0, 19], ["the transcription", "TREATMENT", 87, 104], ["the viral polymerase", "TEST", 133, 153]]], ["Differences between pathogenic and attenuated IBV strains within a serotype, including deletions in Ark and Mass41 viruses, were in and around the acidic domain within nsp 3 (Fig. 2) .", [["IBV strains", "ORGANISM", 46, 57], ["Ark", "GENE_OR_GENE_PRODUCT", 100, 103], ["Mass41", "GENE_OR_GENE_PRODUCT", 108, 114], ["nsp 3", "GENE_OR_GENE_PRODUCT", 168, 173], ["acidic domain", "PROTEIN", 147, 160], ["nsp 3", "PROTEIN", 168, 173], ["IBV", "SPECIES", 46, 49], ["pathogenic", "PROBLEM", 20, 30], ["attenuated IBV strains", "PROBLEM", 35, 57], ["a serotype", "PROBLEM", 65, 75], ["deletions in Ark and Mass41 viruses", "PROBLEM", 87, 122], ["attenuated", "OBSERVATION_MODIFIER", 35, 45], ["IBV strains", "OBSERVATION", 46, 57]]], ["Thus, it is likely that the acidic domain plays a role in attenuation in chickens but the exact function(s) of the amino acids in this domain is unclear.", [["amino acids", "CHEMICAL", 115, 126], ["amino acids", "CHEMICAL", 115, 126], ["chickens", "ORGANISM", 73, 81], ["amino acids", "AMINO_ACID", 115, 126], ["acidic domain", "PROTEIN", 28, 41], ["chickens", "SPECIES", 73, 81], ["chickens", "SPECIES", 73, 81], ["the acidic domain", "PROBLEM", 24, 41], ["the amino acids", "TEST", 111, 126], ["is likely", "UNCERTAINTY", 9, 18], ["attenuation", "OBSERVATION_MODIFIER", 58, 69]]], ["It was interesting that we observed an eight and a three amino acid deletion in the pathogenic virus GA98/CWL0470/98 at positions 901-908 and 950-952, respectively, compared to the GA98-attenuated virus.", [["amino acid", "CHEMICAL", 57, 67], ["amino acid", "CHEMICAL", 57, 67], ["amino acid", "AMINO_ACID", 57, 67], ["GA98-attenuated virus", "ORGANISM", 181, 202], ["a three amino acid deletion", "PROBLEM", 49, 76], ["attenuated virus", "PROBLEM", 186, 202], ["acid deletion", "OBSERVATION", 63, 76], ["pathogenic virus", "OBSERVATION", 84, 100]]], ["Since sequence insertions are not likely to occur during the attenuation process, the GA98-attenuated virus possibly represents a minor undetected subpopulation in the pathogenic virus, which was selected by passage in embryonated eggs.DiscussionThe ADP-ribose-1 phosphatase domain within nsp 3 is relatively conserved between the pathogenic and attenuated strains.", [["eggs", "ANATOMY", 231, 235], ["GA98", "CHEMICAL", 86, 90], ["ADP", "CHEMICAL", 250, 253], ["ADP", "CHEMICAL", 250, 253], ["ribose", "CHEMICAL", 254, 260], ["GA98", "GENE_OR_GENE_PRODUCT", 86, 90], ["ADP-ribose-1 phosphatase", "GENE_OR_GENE_PRODUCT", 250, 274], ["nsp 3", "GENE_OR_GENE_PRODUCT", 289, 294], ["ADP-ribose-1 phosphatase domain", "PROTEIN", 250, 281], ["nsp 3", "PROTEIN", 289, 294], ["the attenuation process", "PROBLEM", 57, 80], ["the GA98-attenuated virus", "PROBLEM", 82, 107], ["a minor undetected subpopulation in the pathogenic virus", "PROBLEM", 128, 184], ["The ADP-ribose-1 phosphatase domain", "TEST", 246, 281], ["the pathogenic and attenuated strains", "PROBLEM", 327, 364], ["not likely", "UNCERTAINTY", 30, 40], ["attenuated", "OBSERVATION_MODIFIER", 91, 101], ["virus", "OBSERVATION", 102, 107], ["possibly represents", "UNCERTAINTY", 108, 127], ["minor", "OBSERVATION_MODIFIER", 130, 135], ["undetected", "OBSERVATION_MODIFIER", 136, 146], ["subpopulation", "OBSERVATION", 147, 160], ["pathogenic virus", "OBSERVATION", 168, 184], ["attenuated strains", "OBSERVATION", 346, 364]]], ["This domain has been shown in the Beaudette laboratory attenuated strain of IBV not to function as an ADP-ribose binding protein [35] .", [["ADP", "CHEMICAL", 102, 105], ["ADP", "CHEMICAL", 102, 105], ["ribose", "CHEMICAL", 106, 112], ["IBV", "ORGANISM", 76, 79], ["ADP-ribose binding protein", "GENE_OR_GENE_PRODUCT", 102, 128], ["ADP-ribose binding protein", "PROTEIN", 102, 128], ["IBV", "SPECIES", 76, 79], ["IBV", "PROBLEM", 76, 79], ["an ADP-ribose binding protein", "TEST", 99, 128]]], ["However, the triple glycine sequence that forms part of the ADP-ribose binding site (Gly47-Gly48-Gly49), which was not conserved in Beaudette, is conserved in all of the viruses sequenced herein [35] .", [["glycine", "CHEMICAL", 20, 27], ["ADP", "CHEMICAL", 60, 63], ["ribose", "CHEMICAL", 64, 70], ["glycine", "CHEMICAL", 20, 27], ["ADP", "CHEMICAL", 60, 63], ["ribose", "CHEMICAL", 64, 70], ["ADP", "SIMPLE_CHEMICAL", 60, 63], ["Gly47-Gly48-Gly49", "GENE_OR_GENE_PRODUCT", 85, 102], ["ADP-ribose binding site", "PROTEIN", 60, 83], ["the triple glycine sequence", "TEST", 9, 36], ["the ADP-ribose binding site", "PROBLEM", 56, 83]]], ["This suggests that the ADP-ribose-1 protein may be functional in the pathogenic and attenuated IBV viruses and is consistent with the results of the Mass 41-X domain as reported by Xu et al. [14] .", [["ADP", "CHEMICAL", 23, 26], ["ADP", "CHEMICAL", 23, 26], ["ribose", "CHEMICAL", 27, 33], ["ADP-ribose-1", "GENE_OR_GENE_PRODUCT", 23, 35], ["IBV viruses", "ORGANISM", 95, 106], ["ADP-ribose-1 protein", "PROTEIN", 23, 43], ["Mass 41-X domain", "PROTEIN", 149, 165], ["IBV viruses", "SPECIES", 95, 106], ["the ADP-ribose-1 protein", "TEST", 19, 43], ["the pathogenic and attenuated IBV viruses", "PROBLEM", 65, 106], ["the Mass", "PROBLEM", 145, 153], ["attenuated", "OBSERVATION_MODIFIER", 84, 94], ["IBV viruses", "OBSERVATION", 95, 106], ["consistent with", "UNCERTAINTY", 114, 129], ["Mass", "OBSERVATION", 149, 153]]], ["The ADP-ribose-1 phosphatase may be important in pathogenicity of IBV because it has been shown to play a role in ADP ribosylation, a post-translational protein modification involved in DNA damage repair and transcription regulation [14] .", [["ADP", "CHEMICAL", 4, 7], ["ribose", "CHEMICAL", 8, 14], ["ADP", "CHEMICAL", 114, 117], ["ADP", "CHEMICAL", 4, 7], ["ribose", "CHEMICAL", 8, 14], ["ADP", "CHEMICAL", 114, 117], ["ADP-ribose-1 phosphatase", "GENE_OR_GENE_PRODUCT", 4, 28], ["IBV", "ORGANISM", 66, 69], ["ADP", "SIMPLE_CHEMICAL", 114, 117], ["DNA", "CELLULAR_COMPONENT", 186, 189], ["ADP-ribose-1 phosphatase", "PROTEIN", 4, 28], ["IBV", "SPECIES", 66, 69], ["The ADP-ribose-1 phosphatase", "TEST", 0, 28], ["IBV", "TREATMENT", 66, 69], ["ADP ribosylation", "TREATMENT", 114, 130], ["a post-translational protein modification", "TREATMENT", 132, 173], ["DNA damage repair", "TREATMENT", 186, 203]]], ["In addition, it was reported that the ADP-ribose-1 is dispensable for viral replication in tissue culture, suggesting that this domain is involved in regulation of viral replication rather than the actual replication process [36] .DiscussionThe PL2 domain is a papain-like protease that is responsible for the cleavage of the nsp 2/3 and 3/4 sites.", [["tissue culture", "ANATOMY", 91, 105], ["ADP", "CHEMICAL", 38, 41], ["ADP", "CHEMICAL", 38, 41], ["ribose", "CHEMICAL", 42, 48], ["ADP-ribose-1", "GENE_OR_GENE_PRODUCT", 38, 50], ["tissue culture", "CELL", 91, 105], ["PL2", "GENE_OR_GENE_PRODUCT", 245, 248], ["papain", "GENE_OR_GENE_PRODUCT", 261, 267], ["nsp 2/3", "GENE_OR_GENE_PRODUCT", 326, 333], ["PL2 domain", "PROTEIN", 245, 255], ["papain-like protease", "PROTEIN", 261, 281], ["nsp 2/3 and 3/4 sites", "DNA", 326, 347], ["the ADP-ribose", "TEST", 34, 48], ["viral replication", "PROBLEM", 70, 87], ["tissue culture", "TEST", 91, 105], ["viral replication", "TREATMENT", 164, 181], ["a papain-like protease", "TREATMENT", 259, 281], ["dispensable for", "UNCERTAINTY", 54, 69], ["viral replication", "OBSERVATION", 70, 87], ["viral replication", "OBSERVATION", 164, 181]]], ["Most coronaviruses have two papain-like proteases; however, in IBV the PL1 protease is truncated and is nonfunctional [16] .", [["coronaviruses", "ORGANISM", 5, 18], ["papain", "GENE_OR_GENE_PRODUCT", 28, 34], ["IBV", "ORGANISM", 63, 66], ["PL1", "GENE_OR_GENE_PRODUCT", 71, 74], ["papain-like proteases", "PROTEIN", 28, 49], ["PL1 protease", "PROTEIN", 71, 83], ["IBV", "SPECIES", 63, 66], ["Most coronaviruses", "PROBLEM", 0, 18], ["two papain-like proteases", "PROBLEM", 24, 49], ["papain", "OBSERVATION", 28, 34], ["like proteases", "OBSERVATION_MODIFIER", 35, 49]]], ["The structure of the PL2 protease domain was determined to be a ''thumb-palm-finger'' motif [37] .", [["PL2", "GENE_OR_GENE_PRODUCT", 21, 24], ["PL2 protease domain", "PROTEIN", 21, 40], ["thumb-palm-finger'' motif", "PROTEIN", 66, 91], ["the PL2 protease domain", "TREATMENT", 17, 40]]], ["This domain has also been shown to be a potent IFN antagonist by inhibiting the phosphorylation and nuclear translocation of interferon regulatory factor 3 (IRF-3) causing a disruption in the activation of the type I IFN response through Toll-like receptor 3 (TLR 3) or retinoic acid-inducible gene I (RIG-I) [38] .", [["nuclear", "ANATOMY", 100, 107], ["nuclear", "CELLULAR_COMPONENT", 100, 107], ["interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 125, 155], ["IRF-3", "GENE_OR_GENE_PRODUCT", 157, 162], ["type I IFN", "GENE_OR_GENE_PRODUCT", 210, 220], ["Toll-like receptor 3", "GENE_OR_GENE_PRODUCT", 238, 258], ["TLR 3", "GENE_OR_GENE_PRODUCT", 260, 265], ["retinoic acid-inducible gene I", "GENE_OR_GENE_PRODUCT", 270, 300], ["RIG-I", "GENE_OR_GENE_PRODUCT", 302, 307], ["IFN", "PROTEIN", 47, 50], ["interferon regulatory factor 3", "PROTEIN", 125, 155], ["IRF-3", "PROTEIN", 157, 162], ["type I IFN", "PROTEIN", 210, 220], ["Toll-like receptor 3", "PROTEIN", 238, 258], ["TLR 3", "PROTEIN", 260, 265], ["retinoic acid-inducible gene I (RIG-I", "DNA", 270, 307], ["a potent IFN antagonist", "TREATMENT", 38, 61], ["the phosphorylation", "PROBLEM", 76, 95], ["interferon regulatory factor", "TREATMENT", 125, 153], ["a disruption", "PROBLEM", 172, 184], ["Toll-like receptor", "TREATMENT", 238, 256], ["retinoic acid-", "TEST", 270, 284], ["disruption", "OBSERVATION", 174, 184]]], ["Although the catalytic triad of the PL2 protease is conserved, amino acid changes between the pathogenic and attenuated viruses are observed in the PL2 protease, which could affect the efficiency of this IFN antagonist leading to altered viral replication in the cell.", [["cell", "ANATOMY", 263, 267], ["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 63, 73], ["PL2", "GENE_OR_GENE_PRODUCT", 36, 39], ["amino acid", "AMINO_ACID", 63, 73], ["PL2 protease", "GENE_OR_GENE_PRODUCT", 148, 160], ["IFN antagonist", "GENE_OR_GENE_PRODUCT", 204, 218], ["cell", "CELL", 263, 267], ["PL2 protease", "PROTEIN", 36, 48], ["PL2 protease", "PROTEIN", 148, 160], ["IFN", "PROTEIN", 204, 207], ["the PL2 protease", "TREATMENT", 32, 48], ["amino acid changes", "PROBLEM", 63, 81], ["the pathogenic and attenuated viruses", "PROBLEM", 90, 127], ["the PL2 protease", "TREATMENT", 144, 160], ["this IFN antagonist", "TREATMENT", 199, 218], ["altered viral replication in the cell", "PROBLEM", 230, 267], ["amino acid", "OBSERVATION", 63, 73], ["attenuated", "OBSERVATION_MODIFIER", 109, 119], ["viruses", "OBSERVATION", 120, 127], ["viral replication", "OBSERVATION", 238, 255]]], ["The disruption of IFN signaling has been shown in many viral infections, including SARS-CoV, dengue virus, and paramyxoviruses [39] [40] [41] .", [["viral infections", "DISEASE", 55, 71], ["SARS-CoV, dengue virus", "DISEASE", 83, 105], ["IFN", "GENE_OR_GENE_PRODUCT", 18, 21], ["SARS-CoV", "ORGANISM", 83, 91], ["dengue virus", "ORGANISM", 93, 105], ["IFN", "PROTEIN", 18, 21], ["dengue virus", "SPECIES", 93, 105], ["SARS-CoV", "SPECIES", 83, 91], ["dengue virus", "SPECIES", 93, 105], ["The disruption of IFN signaling", "PROBLEM", 0, 31], ["many viral infections", "PROBLEM", 50, 71], ["SARS", "PROBLEM", 83, 87], ["dengue virus", "PROBLEM", 93, 105], ["paramyxoviruses", "PROBLEM", 111, 126], ["viral infections", "OBSERVATION", 55, 71]]], ["The IBV PL2 viral protease was also shown to have characteristics similar to ubiquitin-specific proteases [42] .", [["IBV", "ORGANISM", 4, 7], ["PL2", "GENE_OR_GENE_PRODUCT", 8, 11], ["IBV PL2 viral protease", "PROTEIN", 4, 26], ["ubiquitin-specific proteases", "PROTEIN", 77, 105], ["IBV", "SPECIES", 4, 7], ["The IBV PL2 viral protease", "TREATMENT", 0, 26]]], ["Deubuquitinating proteases, which remove ubiquitin from proteins that have been marked by cellular mechanisms for ATP-dependent degradation, could be a potential mechanism by which the virus can alter the cellular environment favoring replication.DiscussionThe Y domain, containing transmembrane domains at its N-terminus, was originally described by Gorbalenya et al. [43] and has been predicted to consist of three domains Y1, Y2, and Y3, which may act together to form an enzymatic function [32] .", [["cellular", "ANATOMY", 90, 98], ["cellular", "ANATOMY", 205, 213], ["transmembrane", "ANATOMY", 282, 295], ["ATP", "CHEMICAL", 114, 117], ["ATP", "CHEMICAL", 114, 117], ["N", "CHEMICAL", 311, 312], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 41, 50], ["cellular", "CELL", 90, 98], ["ATP", "SIMPLE_CHEMICAL", 114, 117], ["cellular", "CELL", 205, 213], ["transmembrane", "CELLULAR_COMPONENT", 282, 295], ["Y1", "GENE_OR_GENE_PRODUCT", 425, 427], ["Y2", "GENE_OR_GENE_PRODUCT", 429, 431], ["Y3", "GENE_OR_GENE_PRODUCT", 437, 439], ["Deubuquitinating proteases", "PROTEIN", 0, 26], ["ubiquitin", "PROTEIN", 41, 50], ["Y domain", "PROTEIN", 261, 269], ["transmembrane domains", "PROTEIN", 282, 303], ["N-terminus", "PROTEIN", 311, 321], ["Y1", "PROTEIN", 425, 427], ["Y2", "PROTEIN", 429, 431], ["Y3", "PROTEIN", 437, 439], ["Deubuquitinating proteases", "PROBLEM", 0, 26], ["ATP-dependent degradation", "PROBLEM", 114, 139], ["the virus", "PROBLEM", 181, 190], ["marked", "OBSERVATION_MODIFIER", 80, 86], ["dependent", "OBSERVATION_MODIFIER", 118, 127], ["degradation", "OBSERVATION", 128, 139], ["Y3", "ANATOMY", 437, 439]]], ["The transmembrane domain is inserted into the endoplasmic reticulum (ER) membrane co-translationally and plays an important scaffolding role for the replication transcription complex [9] .", [["transmembrane", "ANATOMY", 4, 17], ["endoplasmic reticulum", "ANATOMY", 46, 67], ["ER) membrane", "ANATOMY", 69, 81], ["transmembrane", "CELLULAR_COMPONENT", 4, 17], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 46, 67], ["ER", "GENE_OR_GENE_PRODUCT", 69, 71], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["transmembrane domain", "PROTEIN", 4, 24], ["endoplasmic reticulum (ER) membrane", "PROTEIN", 46, 81], ["replication transcription complex", "PROTEIN", 149, 182], ["The transmembrane domain", "TREATMENT", 0, 24], ["transmembrane domain", "OBSERVATION", 4, 24], ["endoplasmic reticulum", "ANATOMY", 46, 67]]], ["Recently, it was shown that three transmembrane domains were predicted for the SARS-CoV nsp 3 but only two were found to span the ER membrane orienting the protease domain of nsp 3 on the cytoplasmic side where viral replication occurs [13, 15] .", [["transmembrane", "ANATOMY", 34, 47], ["ER membrane", "ANATOMY", 130, 141], ["cytoplasmic", "ANATOMY", 188, 199], ["SARS-CoV nsp 3", "GENE_OR_GENE_PRODUCT", 79, 93], ["ER membrane", "CELLULAR_COMPONENT", 130, 141], ["nsp 3", "GENE_OR_GENE_PRODUCT", 175, 180], ["cytoplasmic", "ORGANISM_SUBSTANCE", 188, 199], ["transmembrane domains", "PROTEIN", 34, 55], ["SARS-CoV nsp 3", "DNA", 79, 93], ["ER", "PROTEIN", 130, 132], ["protease domain", "PROTEIN", 156, 171], ["nsp 3", "PROTEIN", 175, 180], ["SARS-CoV", "SPECIES", 79, 87], ["three transmembrane domains", "PROBLEM", 28, 55], ["the SARS", "TEST", 75, 83], ["CoV nsp", "TEST", 84, 91], ["nsp", "PROBLEM", 175, 178], ["viral replication", "TREATMENT", 211, 228], ["viral replication", "OBSERVATION", 211, 228]]], ["In murine hepatitis virus (MHV), five transmembrane domains were predicted but only two domains were found to span the membrane, also locating the protease domain on the cytoplasm side [13, 15] .", [["transmembrane", "ANATOMY", 38, 51], ["membrane", "ANATOMY", 119, 127], ["cytoplasm", "ANATOMY", 170, 179], ["murine hepatitis virus", "DISEASE", 3, 25], ["murine hepatitis virus", "ORGANISM", 3, 25], ["MHV", "ORGANISM", 27, 30], ["membrane", "CELLULAR_COMPONENT", 119, 127], ["cytoplasm", "ORGANISM_SUBSTANCE", 170, 179], ["transmembrane domains", "PROTEIN", 38, 59], ["protease domain", "PROTEIN", 147, 162], ["murine hepatitis virus", "SPECIES", 3, 25], ["murine hepatitis virus", "SPECIES", 3, 25], ["MHV", "SPECIES", 27, 30], ["murine hepatitis virus", "PROBLEM", 3, 25], ["five transmembrane domains", "TEST", 33, 59], ["hepatitis virus", "OBSERVATION", 10, 25]]], ["Our sequence data for IBV predicts four transmembrane domains within nsp 3.", [["transmembrane", "ANATOMY", 40, 53], ["IBV", "ORGANISM", 22, 25], ["nsp 3", "GENE_OR_GENE_PRODUCT", 69, 74], ["transmembrane domains", "PROTEIN", 40, 61], ["nsp 3", "PROTEIN", 69, 74], ["IBV", "SPECIES", 22, 25], ["Our sequence data", "TEST", 0, 17], ["IBV", "PROBLEM", 22, 25]]], ["Assuming the protease domain is located on the cytoplasm side of the membrane, we predict that either two or all four transmembrane domains would be used.DiscussionA chimera IBV containing the replicase genes 1a and 1a/b from the attenuated Beaudette strain and the structural genes from the pathogenic Mass 41 strain was not pathogenic in chickens, indicating that the replicase proteins appear to be determinants of pathotype in IBV [2, 21] .", [["cytoplasm", "ANATOMY", 47, 56], ["membrane", "ANATOMY", 69, 77], ["cytoplasm", "ORGANISM_SUBSTANCE", 47, 56], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["DiscussionA chimera IBV", "ORGANISM", 154, 177], ["1a", "GENE_OR_GENE_PRODUCT", 209, 211], ["1a", "GENE_OR_GENE_PRODUCT", 216, 218], ["b", "GENE_OR_GENE_PRODUCT", 219, 220], ["Beaudette strain", "ORGANISM", 241, 257], ["Mass 41 strain", "ORGANISM", 303, 317], ["chickens", "ORGANISM", 340, 348], ["IBV", "ORGANISM", 431, 434], ["protease domain", "PROTEIN", 13, 28], ["transmembrane domains", "PROTEIN", 118, 139], ["replicase genes 1a and 1a/b", "DNA", 193, 220], ["structural genes", "DNA", 266, 282], ["replicase proteins", "PROTEIN", 370, 388], ["chickens", "SPECIES", 340, 348], ["IBV", "SPECIES", 174, 177], ["chickens", "SPECIES", 340, 348], ["IBV", "SPECIES", 431, 434], ["the protease domain", "TREATMENT", 9, 28], ["the attenuated Beaudette strain", "PROBLEM", 226, 257], ["the pathogenic Mass", "PROBLEM", 288, 307], ["the replicase proteins", "PROBLEM", 366, 388], ["pathotype", "PROBLEM", 418, 427], ["membrane", "ANATOMY", 69, 77]]], ["Our data strongly support these studies and further indicate that changes in nsp 3 play a key role in IBV pathotype.", [["nsp 3", "GENE_OR_GENE_PRODUCT", 77, 82], ["IBV", "ORGANISM", 102, 105], ["nsp 3", "PROTEIN", 77, 82], ["IBV", "SPECIES", 102, 105], ["Our data", "TEST", 0, 8], ["these studies", "TEST", 26, 39]]], ["It should also be emphasized that pathogenicity in avian coronaviruses is likely polygenic, since we and others [22] observed amino acid substitutions in other viral proteins including spike.", [["avian coronaviruses", "DISEASE", 51, 70], ["amino acid", "CHEMICAL", 126, 136], ["amino acid", "CHEMICAL", 126, 136], ["avian coronaviruses", "ORGANISM", 51, 70], ["amino acid", "AMINO_ACID", 126, 136], ["viral proteins", "PROTEIN", 160, 174], ["avian coronaviruses", "SPECIES", 51, 70], ["pathogenicity in avian coronaviruses", "PROBLEM", 34, 70], ["polygenic", "PROBLEM", 81, 90], ["amino acid substitutions", "PROBLEM", 126, 150], ["other viral proteins", "PROBLEM", 154, 174], ["spike", "PROBLEM", 185, 190], ["likely", "UNCERTAINTY", 74, 80], ["polygenic", "OBSERVATION_MODIFIER", 81, 90]]], ["The 6b ORF detected in TCoV (GenBank accession numbers ACB87503 and ACB87504) is identified in Ark and GA98 viruses herein.", [["Ark", "GENE_OR_GENE_PRODUCT", 95, 98], ["GA98 viruses", "ORGANISM", 103, 115], ["6b ORF", "DNA", 4, 10], ["TCoV", "DNA", 23, 27], ["The 6b ORF", "TEST", 0, 10]]], ["Only one amino acid difference was observed between the Ark viruses, but 43 differences as well as 3 amino acid deletions and 1 insertion are observed between GA98 viruses.", [["amino acid", "CHEMICAL", 9, 19], ["amino acid", "CHEMICAL", 101, 111], ["amino acid", "CHEMICAL", 9, 19], ["amino acid", "CHEMICAL", 101, 111], ["amino acid", "AMINO_ACID", 9, 19], ["amino acid", "AMINO_ACID", 101, 111], ["GA98 viruses", "ORGANISM", 159, 171], ["GA98 viruses", "SPECIES", 159, 171], ["one amino acid difference", "PROBLEM", 5, 30], ["the Ark viruses", "PROBLEM", 52, 67], ["3 amino acid deletions", "TREATMENT", 99, 121], ["1 insertion", "TREATMENT", 126, 137], ["amino", "OBSERVATION", 9, 14], ["acid difference", "OBSERVATION", 15, 30], ["Ark viruses", "OBSERVATION", 56, 67]]], ["An attempt to identify a subpopulation in the GA98/CWL0470/98 pathogenic virus with the GA98attenuated gene 6b was unsuccessful.", [["GA98/CWL0470/98 pathogenic virus", "ORGANISM", 46, 78], ["GA98attenuated gene 6b", "GENE_OR_GENE_PRODUCT", 88, 110], ["GA98attenuated gene 6b", "DNA", 88, 110], ["GA98/CWL0470/98 pathogenic virus", "SPECIES", 46, 78], ["pathogenic virus", "PROBLEM", 62, 78], ["the GA98attenuated gene 6b", "TREATMENT", 84, 110]]], ["It is not clear why gene 6b is so variable between the GA98 viruses but it appears recombination rather than mutations over time may have played a role.", [["gene 6b", "GENE_OR_GENE_PRODUCT", 20, 27], ["GA98 viruses", "ORGANISM", 55, 67], ["the GA98 viruses", "PROBLEM", 51, 67], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15], ["viruses", "OBSERVATION", 60, 67]]], ["A nucleotide blast analysis indicated that the GA98/CWL040/98 virus was 98% similar to Mass H120 a vaccine virus and the GA98-attenuated virus was 98% similar to Ark-DPI a pathogenic virus, suggesting an origin for those genes.", [["nucleotide", "CHEMICAL", 2, 12], ["GA98", "CHEMICAL", 121, 125], ["DPI", "CHEMICAL", 166, 169], ["nucleotide", "CHEMICAL", 2, 12], ["GA98/CWL040/98 virus", "ORGANISM", 47, 67], ["Mass H120", "ORGANISM", 87, 96], ["GA98", "GENE_OR_GENE_PRODUCT", 121, 125], ["Ark-DPI", "ORGANISM", 162, 169], ["GA98/CWL040/98 virus", "SPECIES", 47, 67], ["Mass H120 a vaccine virus", "SPECIES", 87, 112], ["A nucleotide blast analysis", "TEST", 0, 27], ["the GA98/CWL040/98 virus", "TEST", 43, 67], ["Mass", "TEST", 87, 91], ["a vaccine virus", "PROBLEM", 97, 112], ["the GA98", "TEST", 117, 125], ["attenuated virus", "PROBLEM", 126, 142], ["a pathogenic virus", "PROBLEM", 170, 188], ["Mass", "OBSERVATION", 87, 91], ["pathogenic virus", "OBSERVATION", 172, 188]]], ["Nonetheless, assuming the 6b ORF is expressed, it apparently does not play a role in defining pathotype.DiscussionInterestingly, we find differences between pathogenic and attenuated viruses in the 5 0 and 3 0 UTRs.", [["6b", "GENE_OR_GENE_PRODUCT", 26, 28], ["6b ORF", "DNA", 26, 32], ["5 0 and 3 0 UTRs", "DNA", 198, 214], ["the 6b ORF", "PROBLEM", 22, 32], ["pathogenic and attenuated viruses", "PROBLEM", 157, 190], ["attenuated", "OBSERVATION_MODIFIER", 172, 182], ["viruses", "OBSERVATION", 183, 190]]], ["The 5 0 and 3 0 UTRs play key roles in transcription and replication of coronaviruses [44] .", [["5 0 and 3 0 UTRs", "DNA", 4, 20], ["The 5 0 and 3 0 UTRs", "TREATMENT", 0, 20], ["coronaviruses", "PROBLEM", 72, 85]]], ["However, the differences between the Ark and Mass viruses, which are 25 nt and 12 nt, respectively, for the 5 0 UTR, and 6 nt and 2 nt, respectively, for the 3 0 UTR did not appear to affect replication as determined in embryonated eggs.", [["eggs", "ANATOMY", 232, 236], ["Ark", "GENE_OR_GENE_PRODUCT", 37, 40], ["Mass viruses", "ORGANISM", 45, 57], ["5 0 UTR", "DNA", 108, 115], ["3 0 UTR", "DNA", 158, 165], ["the Ark and Mass viruses", "PROBLEM", 33, 57], ["Mass viruses", "OBSERVATION", 45, 57]]], ["The TRS sequences for generation of the subgenomic mRNAs were identical in all of the viruses; however, the leader junction sequences were different for GA98 viruses.", [["GA98 viruses", "ORGANISM", 153, 165], ["TRS sequences", "DNA", 4, 17], ["subgenomic mRNAs", "RNA", 40, 56], ["leader junction sequences", "DNA", 108, 133], ["GA98 viruses", "SPECIES", 153, 165], ["The TRS sequences", "TEST", 0, 17], ["the subgenomic mRNAs", "PROBLEM", 36, 56], ["the leader junction sequences", "PROBLEM", 104, 133], ["GA98 viruses", "PROBLEM", 153, 165], ["subgenomic mRNAs", "OBSERVATION", 40, 56], ["viruses", "OBSERVATION", 86, 93]]], ["Different leader junction sequences could be important for attenuation since efficiency of subgenomic mRNA production would affect growth of the virus [45] .DiscussionDifferences are observed in the amount of virus detected in chickens given viruses with different pathotypes.", [["chickens", "ORGANISM", 227, 235], ["leader junction sequences", "DNA", 10, 35], ["subgenomic mRNA", "RNA", 91, 106], ["chickens", "SPECIES", 227, 235], ["chickens", "SPECIES", 227, 235], ["Different leader junction sequences", "TREATMENT", 0, 35], ["attenuation", "PROBLEM", 59, 70], ["subgenomic mRNA production", "PROBLEM", 91, 117], ["the virus", "PROBLEM", 141, 150], ["virus", "PROBLEM", 209, 214], ["viruses", "PROBLEM", 242, 249], ["different pathotypes", "PROBLEM", 255, 275], ["subgenomic mRNA", "OBSERVATION", 91, 106], ["virus", "OBSERVATION", 209, 214]]], ["When the same amount of virus was administered, birds given the attenuated virus compared to birds given the homologous pathogenic virus had less virus detected in the trachea at all sampling times and the difference was statistically significant for most of the time points.", [["trachea", "ANATOMY", 168, 175], ["birds", "ORGANISM", 48, 53], ["birds", "ORGANISM", 93, 98], ["trachea", "ORGAN", 168, 175], ["virus", "TREATMENT", 24, 29], ["birds", "TREATMENT", 48, 53], ["the attenuated virus", "PROBLEM", 60, 80], ["the homologous pathogenic virus", "PROBLEM", 105, 136], ["less virus", "PROBLEM", 141, 151], ["virus", "OBSERVATION", 24, 29], ["virus", "OBSERVATION", 75, 80], ["pathogenic", "OBSERVATION_MODIFIER", 120, 130], ["virus", "OBSERVATION", 131, 136], ["trachea", "ANATOMY", 168, 175]]], ["Thus, it appears that the amount of IBV replication in the trachea correlates with the ability of the virus to cause disease in chickens.", [["trachea", "ANATOMY", 59, 66], ["IBV", "ORGANISM", 36, 39], ["trachea", "ORGAN", 59, 66], ["chickens", "ORGANISM", 128, 136], ["chickens", "SPECIES", 128, 136], ["IBV", "SPECIES", 36, 39], ["chickens", "SPECIES", 128, 136], ["IBV replication", "TREATMENT", 36, 51], ["the virus", "PROBLEM", 98, 107], ["disease in chickens", "PROBLEM", 117, 136], ["amount", "OBSERVATION_MODIFIER", 26, 32], ["IBV replication", "OBSERVATION", 36, 51], ["trachea", "ANATOMY", 59, 66]]], ["Attachment and entry, and replication of the attenuated virus (for chickens) were not impaired because it grew to the same titer (with the exception of one time point) as the pathogenic virus in 10-day-old embryonated eggs.", [["eggs", "ANATOMY", 218, 222], ["chickens", "ORGANISM", 67, 75], ["embryonated", "ORGANISM", 206, 217], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 218, 222], ["chickens", "SPECIES", 67, 75], ["chickens", "SPECIES", 67, 75], ["the attenuated virus", "PROBLEM", 41, 61], ["the pathogenic virus", "PROBLEM", 171, 191], ["old embryonated eggs", "PROBLEM", 202, 222], ["pathogenic virus", "OBSERVATION", 175, 191]]], ["Inefficient attachment and entry into chicken host cells in vivo could be due to changes in spike.", [["cells", "ANATOMY", 51, 56], ["chicken", "ORGANISM", 38, 45], ["host cells", "CELL", 46, 56], ["chicken host cells", "CELL_TYPE", 38, 56], ["chicken", "SPECIES", 38, 45], ["chicken", "SPECIES", 38, 45], ["Inefficient attachment", "PROBLEM", 0, 22], ["entry into chicken host cells", "TREATMENT", 27, 56], ["changes in spike", "PROBLEM", 81, 97]]], ["And decreased replication of the attenuated viruses could be due to the inability of the virus to overcome some as yet unidentified innate defense mechanism(s) in chicken cells that is not present in embryonic cells.", [["cells", "ANATOMY", 171, 176], ["embryonic cells", "ANATOMY", 200, 215], ["chicken", "ORGANISM", 163, 170], ["cells", "CELL", 171, 176], ["embryonic cells", "CELL", 200, 215], ["chicken cells", "CELL_TYPE", 163, 176], ["embryonic cells", "CELL_TYPE", 200, 215], ["chicken", "SPECIES", 163, 170], ["chicken", "SPECIES", 163, 170], ["the attenuated viruses", "PROBLEM", 29, 51], ["the virus", "PROBLEM", 85, 94], ["innate defense mechanism(s) in chicken cells", "PROBLEM", 132, 176], ["decreased", "OBSERVATION_MODIFIER", 4, 13], ["replication", "OBSERVATION_MODIFIER", 14, 25], ["attenuated", "OBSERVATION_MODIFIER", 33, 43], ["viruses", "OBSERVATION", 44, 51], ["virus", "OBSERVATION", 89, 94], ["not present", "UNCERTAINTY", 185, 196], ["embryonic cells", "OBSERVATION", 200, 215]]], ["Domains within nsp 3 associated with the deubiquitinating protease or IFN antagonists are likely candidates for further research.DiscussionIn summary, we find that most changes associated with attenuation of IBV for chickens are located within nsp 3 and that the attenuated viruses have reduced replication in chickens but not in 10-day-old embryonated eggs.", [["eggs", "ANATOMY", 353, 357], ["nsp 3", "GENE_OR_GENE_PRODUCT", 15, 20], ["IFN antagonists", "GENE_OR_GENE_PRODUCT", 70, 85], ["IBV", "ORGANISM", 208, 211], ["chickens", "ORGANISM", 216, 224], ["nsp 3", "GENE_OR_GENE_PRODUCT", 244, 249], ["chickens", "ORGANISM", 310, 318], ["embryonated", "ORGANISM", 341, 352], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 353, 357], ["nsp 3", "PROTEIN", 15, 20], ["deubiquitinating protease", "PROTEIN", 41, 66], ["IFN", "PROTEIN", 70, 73], ["nsp 3", "DNA", 244, 249], ["chickens", "SPECIES", 216, 224], ["chickens", "SPECIES", 310, 318], ["IBV", "SPECIES", 208, 211], ["chickens", "SPECIES", 216, 224], ["chickens", "SPECIES", 310, 318], ["Domains within nsp", "PROBLEM", 0, 18], ["the deubiquitinating protease", "TREATMENT", 37, 66], ["IFN antagonists", "TREATMENT", 70, 85], ["IBV", "TREATMENT", 208, 211], ["chickens", "PROBLEM", 216, 224], ["the attenuated viruses", "PROBLEM", 259, 281], ["old embryonated eggs", "PROBLEM", 337, 357], ["IBV", "OBSERVATION", 208, 211], ["attenuated", "OBSERVATION_MODIFIER", 263, 273], ["viruses", "OBSERVATION", 274, 281], ["reduced", "OBSERVATION_MODIFIER", 287, 294], ["replication", "OBSERVATION_MODIFIER", 295, 306]]], ["Changes in spike suggest that attachment and entry may have been affected and changes in nsp 3 suggest that the attenuated virus lost the ability to overcome some innate host cell defense mechanism in the mature chicken cell.", [["cell", "ANATOMY", 175, 179], ["cell", "ANATOMY", 220, 224], ["nsp 3", "GENE_OR_GENE_PRODUCT", 89, 94], ["host cell", "CELL", 170, 179], ["chicken", "ORGANISM", 212, 219], ["cell", "CELL", 220, 224], ["nsp 3", "PROTEIN", 89, 94], ["mature chicken cell", "CELL_TYPE", 205, 224], ["chicken", "SPECIES", 212, 219], ["chicken", "SPECIES", 212, 219], ["Changes in spike", "PROBLEM", 0, 16], ["changes in nsp", "PROBLEM", 78, 92], ["the attenuated virus", "PROBLEM", 108, 128], ["attenuated", "OBSERVATION_MODIFIER", 112, 122], ["virus", "OBSERVATION", 123, 128], ["host cell defense", "OBSERVATION", 170, 187], ["mature", "OBSERVATION_MODIFIER", 205, 211], ["chicken cell", "OBSERVATION", 212, 224]]], ["The exact mechanism(s) surrounding the interaction of virus and host processes affecting virus replication have yet to be determined for IBV, but identifying the sequence changes in the virus responsible for reduced replication and attenuation is an important step in elucidating those mechanisms.", [["IBV", "ORGANISM", 137, 140], ["IBV", "SPECIES", 137, 140], ["virus", "PROBLEM", 54, 59], ["virus replication", "TREATMENT", 89, 106], ["IBV", "PROBLEM", 137, 140], ["the sequence changes in the virus", "PROBLEM", 158, 191], ["reduced replication", "PROBLEM", 208, 227], ["virus", "OBSERVATION", 54, 59]]], ["Finally, changes observed in nsp 3 and spike as well as in other viral genes support the polygenic nature of pathogenicity in avian coronaviruses.", [["avian coronaviruses", "DISEASE", 126, 145], ["nsp 3", "GENE_OR_GENE_PRODUCT", 29, 34], ["avian coronaviruses", "ORGANISM", 126, 145], ["nsp 3", "DNA", 29, 34], ["viral genes", "DNA", 65, 76], ["avian coronaviruses", "SPECIES", 126, 145], ["nsp", "PROBLEM", 29, 32], ["spike", "PROBLEM", 39, 44], ["pathogenicity in avian coronaviruses", "PROBLEM", 109, 145], ["pathogenicity", "OBSERVATION", 109, 122], ["avian coronaviruses", "OBSERVATION", 126, 145]]]], "PMC7172981": [["IntroductionAsthma and chronic obstructive pulmonary disease (COPD) are complex, multifactorial airway diseases associated with significant morbidity and mortality worldwide.", [["pulmonary", "ANATOMY", 43, 52], ["airway", "ANATOMY", 96, 102], ["IntroductionAsthma", "DISEASE", 0, 18], ["chronic obstructive pulmonary disease", "DISEASE", 23, 60], ["COPD", "DISEASE", 62, 66], ["airway diseases", "DISEASE", 96, 111], ["pulmonary", "ORGAN", 43, 52], ["airway", "MULTI-TISSUE_STRUCTURE", 96, 102], ["IntroductionAsthma", "TREATMENT", 0, 18], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 23, 67], ["multifactorial airway diseases", "PROBLEM", 81, 111], ["significant morbidity", "PROBLEM", 128, 149], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["obstructive", "OBSERVATION_MODIFIER", 31, 42], ["pulmonary", "ANATOMY", 43, 52], ["disease", "OBSERVATION", 53, 60], ["COPD", "OBSERVATION", 62, 66], ["multifactorial", "OBSERVATION_MODIFIER", 81, 95], ["airway", "ANATOMY", 96, 102], ["diseases", "OBSERVATION", 103, 111], ["significant", "OBSERVATION_MODIFIER", 128, 139], ["morbidity", "OBSERVATION", 140, 149]]], ["Asthma may be caused by allergic responses, and COPD is highly associated with exposure to cigarette smoke (CS), however both diseases may be exacerbated by viral or bacteria infections.", [["Asthma", "DISEASE", 0, 6], ["allergic responses", "DISEASE", 24, 42], ["COPD", "DISEASE", 48, 52], ["viral or bacteria infections", "DISEASE", 157, 185], ["cigarette", "ORGANISM", 91, 100], ["Asthma", "PROBLEM", 0, 6], ["allergic responses", "PROBLEM", 24, 42], ["COPD", "PROBLEM", 48, 52], ["both diseases", "PROBLEM", 121, 134], ["viral or bacteria infections", "PROBLEM", 157, 185], ["may be caused", "UNCERTAINTY", 7, 20], ["allergic", "OBSERVATION", 24, 32], ["COPD", "OBSERVATION", 48, 52], ["diseases", "OBSERVATION", 126, 134], ["may be", "UNCERTAINTY", 135, 141], ["viral", "OBSERVATION", 157, 162], ["bacteria", "OBSERVATION_MODIFIER", 166, 174], ["infections", "OBSERVATION", 175, 185]]], ["In fact, both asthma and COPD are among the top 10 most devastating diseases in the world caused by infectious agents, in terms of loss of life and overall morbidity (Mizgerd, 2006).", [["asthma", "DISEASE", 14, 20], ["COPD", "DISEASE", 25, 29], ["asthma", "PROBLEM", 14, 20], ["COPD", "PROBLEM", 25, 29], ["devastating diseases", "PROBLEM", 56, 76], ["both", "OBSERVATION_MODIFIER", 9, 13], ["asthma", "OBSERVATION", 14, 20], ["COPD", "OBSERVATION", 25, 29], ["devastating", "OBSERVATION_MODIFIER", 56, 67], ["diseases", "OBSERVATION", 68, 76], ["infectious", "OBSERVATION", 100, 110]]], ["Despite this importance, both diseases feature distinct clinical phenotypes which are inadequately controlled by inhaled corticosteroid (GC) based therapies, the mainstay therapy for both diseases.", [["corticosteroid", "SIMPLE_CHEMICAL", 121, 135], ["both diseases feature distinct clinical phenotypes", "PROBLEM", 25, 75], ["inhaled corticosteroid (GC) based therapies", "TREATMENT", 113, 156], ["the mainstay therapy", "TREATMENT", 158, 178], ["both diseases", "PROBLEM", 183, 196], ["distinct", "OBSERVATION_MODIFIER", 47, 55], ["diseases", "OBSERVATION", 188, 196]]], ["The identification of new therapeutic targets therefore remains a research priority for both diseases.IntroductionIntense research efforts have described many of the cells and molecules associated with either disease, and while the aetiology of both diseases is multifactorial, both diseases have a significant inflammatory component.", [["cells", "ANATOMY", 166, 171], ["cells", "CELL", 166, 171], ["both diseases", "PROBLEM", 88, 101], ["either disease", "PROBLEM", 202, 216], ["both diseases", "PROBLEM", 245, 258], ["a significant inflammatory component", "PROBLEM", 297, 333], ["new", "OBSERVATION_MODIFIER", 22, 25], ["therapeutic", "OBSERVATION_MODIFIER", 26, 37], ["diseases", "OBSERVATION", 93, 101], ["disease", "OBSERVATION", 209, 216], ["diseases", "OBSERVATION", 250, 258], ["significant", "OBSERVATION_MODIFIER", 299, 310], ["inflammatory", "OBSERVATION_MODIFIER", 311, 323]]], ["Strikingly, many of the pro-inflammatory chemokines, cytokines, adhesion molecules, respiratory mucins, growth and angiogenic factors are induced via the Rel/Nuclear Factor-\u03baB (NF-\u03baB) family of transcription factors.", [["respiratory mucins", "GENE_OR_GENE_PRODUCT", 84, 102], ["Rel", "GENE_OR_GENE_PRODUCT", 154, 157], ["Nuclear Factor-\u03baB", "GENE_OR_GENE_PRODUCT", 158, 175], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 177, 182], ["pro-inflammatory chemokines", "PROTEIN", 24, 51], ["cytokines", "PROTEIN", 53, 62], ["adhesion molecules", "PROTEIN", 64, 82], ["respiratory mucins", "PROTEIN", 84, 102], ["growth and angiogenic factors", "PROTEIN", 104, 133], ["Rel/Nuclear Factor-\u03baB (NF-\u03baB) family", "PROTEIN", 154, 190], ["transcription factors", "PROTEIN", 194, 215], ["the pro-inflammatory chemokines", "TEST", 20, 51], ["adhesion molecules", "PROBLEM", 64, 82], ["respiratory mucins", "PROBLEM", 84, 102], ["angiogenic factors", "PROBLEM", 115, 133], ["the Rel/Nuclear Factor", "TEST", 150, 172], ["pro-inflammatory chemokines", "OBSERVATION", 24, 51], ["respiratory mucins", "ANATOMY", 84, 102]]], ["This review will provide a timely summary of the literature regarding the importance of NF-\u03baB in asthma and COPD.", [["asthma", "DISEASE", 97, 103], ["COPD", "DISEASE", 108, 112], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 88, 93], ["NF-\u03baB", "PROTEIN", 88, 93], ["asthma", "PROBLEM", 97, 103], ["COPD", "PROBLEM", 108, 112], ["asthma", "OBSERVATION", 97, 103], ["COPD", "OBSERVATION", 108, 112]]], ["We will reflect on the various forms of asthma and COPD, including both stable forms and exacerbations of either disease, and discuss the relative roles of NF-\u03baB in each.", [["asthma", "DISEASE", 40, 46], ["COPD", "DISEASE", 51, 55], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 156, 161], ["NF-\u03baB", "PROTEIN", 156, 161], ["asthma", "PROBLEM", 40, 46], ["COPD", "PROBLEM", 51, 55], ["exacerbations of either disease", "PROBLEM", 89, 120], ["asthma", "OBSERVATION", 40, 46], ["COPD", "OBSERVATION", 51, 55], ["stable", "OBSERVATION_MODIFIER", 72, 78]]], ["We will also argue that asthma and COPD are inflammatory diseases, and that targeting the inflammatory pathways via NF-\u03baB inhibition is a realistic and logical strategy for future therapeutic intervention.", [["asthma", "DISEASE", 24, 30], ["COPD", "DISEASE", 35, 39], ["inflammatory diseases", "DISEASE", 44, 65], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 116, 121], ["NF-\u03baB", "PROTEIN", 116, 121], ["asthma", "PROBLEM", 24, 30], ["COPD", "PROBLEM", 35, 39], ["inflammatory diseases", "PROBLEM", 44, 65], ["the inflammatory pathways", "PROBLEM", 86, 111], ["logical strategy", "TREATMENT", 152, 168], ["future therapeutic intervention", "TREATMENT", 173, 204], ["asthma", "OBSERVATION", 24, 30], ["COPD", "OBSERVATION", 35, 39], ["inflammatory", "OBSERVATION_MODIFIER", 44, 56], ["inflammatory", "OBSERVATION_MODIFIER", 90, 102]]], ["We also discuss how drugs targeting NF-\u03baB may have distinct advantages over inhaled GCs at least for some phenotypes of asthma or COPD.Overview of asthma ::: Asthma and chronic obstructive pulmonary disease are inflammatory airway diseasesAsthma is defined as variable airway obstruction usually accompanied by airway hyperreactivity (AHR).", [["pulmonary", "ANATOMY", 189, 198], ["airway", "ANATOMY", 224, 230], ["airway", "ANATOMY", 269, 275], ["airway", "ANATOMY", 311, 317], ["asthma", "DISEASE", 120, 126], ["COPD", "DISEASE", 130, 134], ["asthma", "DISEASE", 147, 153], ["Asthma", "DISEASE", 158, 164], ["chronic obstructive pulmonary disease", "DISEASE", 169, 206], ["airway diseases", "DISEASE", 224, 239], ["Asthma", "DISEASE", 239, 245], ["airway obstruction", "DISEASE", 269, 287], ["airway hyperreactivity", "DISEASE", 311, 333], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 36, 41], ["pulmonary", "ORGAN", 189, 198], ["airway", "MULTI-TISSUE_STRUCTURE", 224, 230], ["airway obstruction", "PATHOLOGICAL_FORMATION", 269, 287], ["airway", "MULTI-TISSUE_STRUCTURE", 311, 317], ["NF-\u03baB", "PROTEIN", 36, 41], ["inhaled GCs", "TREATMENT", 76, 87], ["asthma", "PROBLEM", 120, 126], ["COPD", "PROBLEM", 130, 134], ["Asthma", "PROBLEM", 158, 164], ["chronic obstructive pulmonary disease", "PROBLEM", 169, 206], ["inflammatory airway diseases", "PROBLEM", 211, 239], ["Asthma", "PROBLEM", 239, 245], ["variable airway obstruction", "PROBLEM", 260, 287], ["airway hyperreactivity", "PROBLEM", 311, 333], ["asthma", "OBSERVATION", 120, 126], ["COPD", "OBSERVATION", 130, 134], ["asthma", "OBSERVATION", 147, 153], ["chronic", "OBSERVATION_MODIFIER", 169, 176], ["obstructive", "OBSERVATION_MODIFIER", 177, 188], ["pulmonary", "ANATOMY", 189, 198], ["disease", "OBSERVATION", 199, 206], ["inflammatory", "OBSERVATION_MODIFIER", 211, 223], ["airway diseases", "OBSERVATION", 224, 239], ["variable", "OBSERVATION_MODIFIER", 260, 268], ["airway", "ANATOMY", 269, 275], ["obstruction", "OBSERVATION", 276, 287], ["airway", "ANATOMY", 311, 317], ["hyperreactivity", "OBSERVATION", 318, 333]]], ["Defining features of asthma include bronchoconstriction due to contraction or hypertrophy of airway smooth muscle (ASM), and inflammation within the airway.", [["airway smooth muscle", "ANATOMY", 93, 113], ["ASM", "ANATOMY", 115, 118], ["airway", "ANATOMY", 149, 155], ["asthma", "DISEASE", 21, 27], ["hypertrophy", "DISEASE", 78, 89], ["inflammation", "DISEASE", 125, 137], ["airway smooth muscle", "TISSUE", 93, 113], ["ASM", "MULTI-TISSUE_STRUCTURE", 115, 118], ["airway", "MULTI-TISSUE_STRUCTURE", 149, 155], ["asthma", "PROBLEM", 21, 27], ["bronchoconstriction", "PROBLEM", 36, 55], ["contraction", "PROBLEM", 63, 74], ["hypertrophy of airway smooth muscle (ASM)", "PROBLEM", 78, 119], ["inflammation within the airway", "PROBLEM", 125, 155], ["asthma", "OBSERVATION", 21, 27], ["bronchoconstriction", "OBSERVATION", 36, 55], ["contraction", "OBSERVATION_MODIFIER", 63, 74], ["hypertrophy", "OBSERVATION", 78, 89], ["airway", "ANATOMY_MODIFIER", 93, 99], ["smooth muscle", "ANATOMY", 100, 113], ["ASM", "ANATOMY", 115, 118], ["inflammation", "OBSERVATION", 125, 137], ["airway", "ANATOMY", 149, 155]]], ["These processes lead to decreased lung function, measured either as changes in peak expiratory flow (PEF) over time, or a decrease in forced expiratory volume (FEV) in 1 s following provocation with histamine.", [["lung", "ANATOMY", 34, 38], ["histamine", "CHEMICAL", 199, 208], ["histamine", "CHEMICAL", 199, 208], ["lung", "ORGAN", 34, 38], ["histamine", "SIMPLE_CHEMICAL", 199, 208], ["decreased lung function", "PROBLEM", 24, 47], ["peak expiratory flow", "TEST", 79, 99], ["a decrease in forced expiratory volume", "PROBLEM", 120, 158], ["histamine", "TREATMENT", 199, 208], ["decreased", "OBSERVATION_MODIFIER", 24, 33], ["lung", "ANATOMY", 34, 38], ["function", "OBSERVATION", 39, 47], ["peak", "OBSERVATION_MODIFIER", 79, 83], ["expiratory flow", "OBSERVATION", 84, 99], ["decrease", "OBSERVATION_MODIFIER", 122, 130], ["forced", "OBSERVATION_MODIFIER", 134, 140], ["expiratory volume", "OBSERVATION", 141, 158]]], ["Symptoms often include dyspnoea, wheeze and tightening of the chest.", [["chest", "ANATOMY", 62, 67], ["dyspnoea", "DISEASE", 23, 31], ["wheeze", "DISEASE", 33, 39], ["chest", "ORGANISM_SUBDIVISION", 62, 67], ["Symptoms", "PROBLEM", 0, 8], ["dyspnoea", "PROBLEM", 23, 31], ["wheeze", "PROBLEM", 33, 39], ["tightening of the chest", "PROBLEM", 44, 67], ["dyspnoea", "OBSERVATION", 23, 31], ["wheeze", "OBSERVATION", 33, 39], ["chest", "ANATOMY", 62, 67]]], ["In most cases, the immediate effect on lung function can be reversed by a short acting \u03b22 agonist.", [["lung", "ANATOMY", 39, 43], ["lung", "ORGAN", 39, 43], ["\u03b22", "GENE_OR_GENE_PRODUCT", 87, 89], ["a short acting \u03b22 agonist", "TREATMENT", 72, 97], ["lung", "ANATOMY", 39, 43]]], ["Asthma is now accepted to be a heterogeneous complex disorder (for a review see Wenzel, 2006), and normally presents as a chronic, stable disease with acute exacerbations, often following acute viral or bacterial infection of the lower airway.", [["lower airway", "ANATOMY", 230, 242], ["Asthma", "DISEASE", 0, 6], ["infection", "DISEASE", 213, 222], ["lower airway", "ORGANISM_SUBDIVISION", 230, 242], ["Asthma", "PROBLEM", 0, 6], ["a heterogeneous complex disorder", "PROBLEM", 29, 61], ["a chronic, stable disease", "PROBLEM", 120, 145], ["acute exacerbations", "PROBLEM", 151, 170], ["acute viral or bacterial infection of the lower airway", "PROBLEM", 188, 242], ["heterogeneous", "OBSERVATION_MODIFIER", 31, 44], ["complex", "OBSERVATION_MODIFIER", 45, 52], ["disorder", "OBSERVATION", 53, 61], ["chronic", "OBSERVATION_MODIFIER", 122, 129], ["stable", "OBSERVATION_MODIFIER", 131, 137], ["disease", "OBSERVATION", 138, 145], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["exacerbations", "OBSERVATION", 157, 170], ["acute", "OBSERVATION_MODIFIER", 188, 193], ["viral", "OBSERVATION", 194, 199], ["bacterial", "OBSERVATION_MODIFIER", 203, 212], ["infection", "OBSERVATION", 213, 222], ["lower", "ANATOMY_MODIFIER", 230, 235], ["airway", "ANATOMY", 236, 242]]], ["Exposure to allergens, and the resulting allergic cascade is also a cause of asthma, and this may work in an additive or synergistic manner with exposure to pollution (Spannhake et al., 2002, Chauhan et al., 2003), or acute respiratory infections (Green et al., 2002).Overview of asthma ::: Asthma and chronic obstructive pulmonary disease are inflammatory airway diseasesAsthma is associated with early onset in life and affects approximately 20% of the population, with an increased incidence in the developed world (Asher et al., 2006).", [["respiratory", "ANATOMY", 224, 235], ["pulmonary", "ANATOMY", 322, 331], ["airway", "ANATOMY", 357, 363], ["allergic cascade", "DISEASE", 41, 57], ["asthma", "DISEASE", 77, 83], ["acute respiratory infections", "DISEASE", 218, 246], ["asthma", "DISEASE", 280, 286], ["Asthma", "DISEASE", 291, 297], ["chronic obstructive pulmonary disease", "DISEASE", 302, 339], ["airway diseases", "DISEASE", 357, 372], ["Asthma", "DISEASE", 372, 378], ["pulmonary", "ORGAN", 322, 331], ["airway", "MULTI-TISSUE_STRUCTURE", 357, 363], ["allergens", "PROBLEM", 12, 21], ["the resulting allergic cascade", "PROBLEM", 27, 57], ["asthma", "PROBLEM", 77, 83], ["acute respiratory infections", "PROBLEM", 218, 246], ["Asthma", "PROBLEM", 291, 297], ["chronic obstructive pulmonary disease", "PROBLEM", 302, 339], ["inflammatory airway diseases", "PROBLEM", 344, 372], ["Asthma", "PROBLEM", 372, 378], ["allergens", "OBSERVATION", 12, 21], ["allergic cascade", "OBSERVATION", 41, 57], ["asthma", "OBSERVATION", 77, 83], ["acute", "OBSERVATION_MODIFIER", 218, 223], ["respiratory", "ANATOMY", 224, 235], ["infections", "OBSERVATION", 236, 246], ["asthma", "OBSERVATION", 280, 286], ["chronic", "OBSERVATION_MODIFIER", 302, 309], ["obstructive", "OBSERVATION_MODIFIER", 310, 321], ["pulmonary", "ANATOMY", 322, 331], ["disease", "OBSERVATION", 332, 339], ["inflammatory", "OBSERVATION_MODIFIER", 344, 356], ["airway diseases", "OBSERVATION", 357, 372], ["associated with", "UNCERTAINTY", 382, 397], ["early", "OBSERVATION_MODIFIER", 398, 403], ["onset", "OBSERVATION_MODIFIER", 404, 409], ["increased", "OBSERVATION_MODIFIER", 475, 484]]], ["Asthma may cause severe morbidity, and even mortality due to exacerbation.", [["Asthma", "DISEASE", 0, 6], ["Asthma", "PROBLEM", 0, 6], ["severe morbidity", "PROBLEM", 17, 33], ["exacerbation", "PROBLEM", 61, 73], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["morbidity", "OBSERVATION", 24, 33], ["exacerbation", "OBSERVATION", 61, 73]]], ["Asthma is a huge burden on healthcare costs world wide.", [["Asthma", "DISEASE", 0, 6], ["Asthma", "PROBLEM", 0, 6], ["huge", "OBSERVATION_MODIFIER", 12, 16], ["burden", "OBSERVATION_MODIFIER", 17, 23]]], ["In the UK, the cost of asthma exacerbations are 3.5 fold higher per patient compared to stable asthma (Hoskins et al., 2000).", [["asthma", "DISEASE", 23, 29], ["asthma", "DISEASE", 95, 101], ["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["asthma exacerbations", "PROBLEM", 23, 43], ["stable asthma", "PROBLEM", 88, 101], ["asthma", "OBSERVATION", 23, 29], ["3.5 fold", "OBSERVATION_MODIFIER", 48, 56], ["stable", "OBSERVATION_MODIFIER", 88, 94], ["asthma", "OBSERVATION", 95, 101]]], ["In raw terms, the annual cost of asthma in terms of GP consultations, emergency room admissions, sick leave, school absenteeism and treatment, is in the order of billions of GBP.Overview of asthma ::: Asthma and chronic obstructive pulmonary disease are inflammatory airway diseasesMuch is known regarding the cells and molecules contributing to asthma.", [["pulmonary", "ANATOMY", 232, 241], ["airway", "ANATOMY", 267, 273], ["cells", "ANATOMY", 310, 315], ["asthma", "DISEASE", 33, 39], ["GBP", "CHEMICAL", 174, 177], ["asthma", "DISEASE", 190, 196], ["Asthma", "DISEASE", 201, 207], ["chronic obstructive pulmonary disease", "DISEASE", 212, 249], ["airway diseases", "DISEASE", 267, 282], ["asthma", "DISEASE", 346, 352], ["GBP", "GENE_OR_GENE_PRODUCT", 174, 177], ["pulmonary", "ORGAN", 232, 241], ["airway", "MULTI-TISSUE_STRUCTURE", 267, 273], ["cells", "CELL", 310, 315], ["asthma", "PROBLEM", 33, 39], ["treatment", "TREATMENT", 132, 141], ["GBP", "PROBLEM", 174, 177], ["Asthma", "PROBLEM", 201, 207], ["chronic obstructive pulmonary disease", "PROBLEM", 212, 249], ["inflammatory airway diseases", "PROBLEM", 254, 282], ["the cells", "PROBLEM", 306, 315], ["asthma", "PROBLEM", 346, 352], ["asthma", "OBSERVATION", 33, 39], ["asthma", "OBSERVATION", 190, 196], ["chronic", "OBSERVATION_MODIFIER", 212, 219], ["obstructive", "OBSERVATION_MODIFIER", 220, 231], ["pulmonary", "ANATOMY", 232, 241], ["disease", "OBSERVATION", 242, 249], ["inflammatory", "OBSERVATION_MODIFIER", 254, 266], ["airway diseases", "OBSERVATION", 267, 282], ["asthma", "OBSERVATION", 346, 352]]], ["The allergic cascade has been a focal point of research interest for decades.", [["allergic cascade", "DISEASE", 4, 20], ["The allergic cascade", "PROBLEM", 0, 20], ["allergic cascade", "OBSERVATION", 4, 20], ["focal", "OBSERVATION_MODIFIER", 32, 37]]], ["Upon allergen exposure, mast cells within the airway sensitised with allergen specific IgE are triggered to release a number of pre-formed mediators packaged in their granules.", [["mast cells", "ANATOMY", 24, 34], ["airway", "ANATOMY", 46, 52], ["granules", "ANATOMY", 167, 175], ["mast cells", "CELL", 24, 34], ["airway", "ORGAN", 46, 52], ["IgE", "GENE_OR_GENE_PRODUCT", 87, 90], ["granules", "CELLULAR_COMPONENT", 167, 175], ["mast cells", "CELL_TYPE", 24, 34], ["IgE", "PROTEIN", 87, 90], ["pre-formed mediators", "PROTEIN", 128, 148], ["mast cells", "PROBLEM", 24, 34], ["mast cells", "OBSERVATION", 24, 34], ["airway", "ANATOMY", 46, 52]]], ["The granules contain histamine, which act on ASM and causes the immediate bronchoconstriction of the airway, observed in asthma.", [["granules", "ANATOMY", 4, 12], ["ASM", "ANATOMY", 45, 48], ["airway", "ANATOMY", 101, 107], ["histamine", "CHEMICAL", 21, 30], ["asthma", "DISEASE", 121, 127], ["histamine", "CHEMICAL", 21, 30], ["granules", "ORGANISM_SUBSTANCE", 4, 12], ["histamine", "SIMPLE_CHEMICAL", 21, 30], ["ASM", "CELL", 45, 48], ["airway", "MULTI-TISSUE_STRUCTURE", 101, 107], ["histamine", "TREATMENT", 21, 30], ["the immediate bronchoconstriction of the airway", "PROBLEM", 60, 107], ["asthma", "PROBLEM", 121, 127], ["histamine", "OBSERVATION_MODIFIER", 21, 30], ["immediate", "OBSERVATION_MODIFIER", 64, 73], ["bronchoconstriction", "OBSERVATION", 74, 93], ["airway", "ANATOMY", 101, 107], ["asthma", "OBSERVATION", 121, 127]]], ["Mast cells synthesise prostaglandins, leukotrienes and kinins which can contribute to bronchoconstriction, and are also a source of the Th2 cytokines IL-4 and IL-13, which serve to increase class switching to IgE in B cells, and augment the production of various Th2 chemokines from epithelial and ASM cells.", [["Mast cells", "ANATOMY", 0, 10], ["B cells", "ANATOMY", 216, 223], ["epithelial", "ANATOMY", 283, 293], ["ASM cells", "ANATOMY", 298, 307], ["prostaglandins", "CHEMICAL", 22, 36], ["leukotrienes", "CHEMICAL", 38, 50], ["prostaglandins", "CHEMICAL", 22, 36], ["Mast cells", "CELL", 0, 10], ["prostaglandins", "SIMPLE_CHEMICAL", 22, 36], ["leukotrienes", "SIMPLE_CHEMICAL", 38, 50], ["kinins", "GENE_OR_GENE_PRODUCT", 55, 61], ["IL-4", "GENE_OR_GENE_PRODUCT", 150, 154], ["IL-13", "GENE_OR_GENE_PRODUCT", 159, 164], ["IgE", "GENE_OR_GENE_PRODUCT", 209, 212], ["B cells", "CELL", 216, 223], ["epithelial", "CELL", 283, 293], ["ASM cells", "CELL", 298, 307], ["Mast cells", "CELL_TYPE", 0, 10], ["Th2 cytokines", "PROTEIN", 136, 149], ["IL-4", "PROTEIN", 150, 154], ["IL-13", "PROTEIN", 159, 164], ["IgE", "PROTEIN", 209, 212], ["B cells", "CELL_TYPE", 216, 223], ["Th2 chemokines", "PROTEIN", 263, 277], ["epithelial and ASM cells", "CELL_TYPE", 283, 307], ["Mast cells synthesise prostaglandins", "TREATMENT", 0, 36], ["leukotrienes", "TREATMENT", 38, 50], ["kinins", "TREATMENT", 55, 61], ["bronchoconstriction", "PROBLEM", 86, 105], ["the Th2 cytokines IL", "TEST", 132, 152], ["IL", "TEST", 159, 161], ["IgE in B cells", "TREATMENT", 209, 223], ["epithelial and ASM cells", "PROBLEM", 283, 307], ["bronchoconstriction", "OBSERVATION", 86, 105], ["epithelial", "ANATOMY", 283, 293], ["ASM cells", "OBSERVATION", 298, 307]]], ["IL-13 is also highly associated with airway hyperreactivity in animal models of asthma (Leigh et al., 2004, Yang et al., 2004).", [["airway", "ANATOMY", 37, 43], ["airway hyperreactivity", "DISEASE", 37, 59], ["asthma", "DISEASE", 80, 86], ["IL-13", "GENE_OR_GENE_PRODUCT", 0, 5], ["airway", "MULTI-TISSUE_STRUCTURE", 37, 43], ["IL-13", "PROTEIN", 0, 5], ["IL", "TEST", 0, 2], ["airway hyperreactivity", "PROBLEM", 37, 59], ["asthma", "PROBLEM", 80, 86], ["highly associated with", "UNCERTAINTY", 14, 36], ["airway", "ANATOMY", 37, 43], ["hyperreactivity", "OBSERVATION", 44, 59], ["asthma", "OBSERVATION", 80, 86]]], ["Mast cells also produce various chemokines attracting inflammatory neutrophils, Th1 and Th2 lymphocytes, and eosinophils into the airway.", [["Mast cells", "ANATOMY", 0, 10], ["neutrophils", "ANATOMY", 67, 78], ["Th2 lymphocytes", "ANATOMY", 88, 103], ["eosinophils", "ANATOMY", 109, 120], ["airway", "ANATOMY", 130, 136], ["Mast cells", "CELL", 0, 10], ["neutrophils", "CELL", 67, 78], ["Th1", "CELL", 80, 83], ["Th2 lymphocytes", "CELL", 88, 103], ["eosinophils", "CELL", 109, 120], ["airway", "MULTI-TISSUE_STRUCTURE", 130, 136], ["Mast cells", "CELL_TYPE", 0, 10], ["chemokines", "PROTEIN", 32, 42], ["inflammatory neutrophils", "CELL_TYPE", 54, 78], ["Th1 and Th2 lymphocytes", "CELL_TYPE", 80, 103], ["eosinophils", "CELL_TYPE", 109, 120], ["Mast cells", "TEST", 0, 10], ["various chemokines", "TEST", 24, 42], ["inflammatory neutrophils", "TEST", 54, 78], ["Th1", "TEST", 80, 83], ["Th2 lymphocytes", "TEST", 88, 103], ["eosinophils", "TEST", 109, 120], ["various", "OBSERVATION_MODIFIER", 24, 31], ["chemokines", "OBSERVATION_MODIFIER", 32, 42], ["inflammatory neutrophils", "OBSERVATION", 54, 78], ["Th2 lymphocytes", "OBSERVATION", 88, 103], ["airway", "ANATOMY", 130, 136]]], ["Th2 lymphocytes are a further source of Th2 cytokines, including IL-5, essential for eosinophil differentiation from bone marrow (for a review, see Renauld, 2001).", [["Th2 lymphocytes", "ANATOMY", 0, 15], ["eosinophil", "ANATOMY", 85, 95], ["bone marrow", "ANATOMY", 117, 128], ["Th2 lymphocytes", "CELL", 0, 15], ["IL-5", "GENE_OR_GENE_PRODUCT", 65, 69], ["eosinophil", "CELL", 85, 95], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 117, 128], ["Th2 lymphocytes", "CELL_TYPE", 0, 15], ["Th2 cytokines", "PROTEIN", 40, 53], ["IL-5", "PROTEIN", 65, 69], ["Th2 cytokines", "TEST", 40, 53], ["IL", "TEST", 65, 67], ["eosinophil differentiation", "PROBLEM", 85, 111], ["lymphocytes", "OBSERVATION", 4, 15], ["Th2 cytokines", "OBSERVATION", 40, 53], ["eosinophil differentiation", "OBSERVATION", 85, 111], ["bone marrow", "ANATOMY", 117, 128]]], ["Recruitment of these various cell types, especially Th2 cells are thought to contribute to the late asthmatic response, (LAR) which features further bronchoconstriction and AHR.", [["cell", "ANATOMY", 29, 33], ["Th2 cells", "ANATOMY", 52, 61], ["cell", "CELL", 29, 33], ["Th2 cells", "CELL", 52, 61], ["Th2 cells", "CELL_TYPE", 52, 61], ["these various cell types", "PROBLEM", 15, 39], ["Th2 cells", "PROBLEM", 52, 61], ["the late asthmatic response", "PROBLEM", 91, 118], ["further bronchoconstriction", "PROBLEM", 141, 168], ["AHR", "PROBLEM", 173, 176], ["various cell types", "OBSERVATION", 21, 39], ["Th2 cells", "OBSERVATION", 52, 61], ["thought to contribute to", "UNCERTAINTY", 66, 90], ["late", "OBSERVATION_MODIFIER", 95, 99], ["asthmatic response", "OBSERVATION", 100, 118]]], ["In severe asthma, increased ASM proliferation, and fibroblast differentiation may contribute to airway remodelling, causing further long term limitations in lung function via increasing basement membrane thickness, and angiogenesis.Overview of asthma ::: Asthma and chronic obstructive pulmonary disease are inflammatory airway diseasesRespiratory viral infections notably human rhinoviruses (RV) respiratory syncytial virus (RSV), coronaviruses and influenza viruses (Johnston et al., 1993, Johnston et al., 1995, Freymuth et al., 1999, Rakes et al., 1999) are responsible for the majority (> 80%) of asthma exacerbations.", [["ASM", "ANATOMY", 28, 31], ["fibroblast", "ANATOMY", 51, 61], ["airway", "ANATOMY", 96, 102], ["lung", "ANATOMY", 157, 161], ["basement membrane", "ANATOMY", 186, 203], ["pulmonary", "ANATOMY", 286, 295], ["airway", "ANATOMY", 321, 327], ["asthma", "DISEASE", 10, 16], ["asthma", "DISEASE", 244, 250], ["Asthma", "DISEASE", 255, 261], ["chronic obstructive pulmonary disease", "DISEASE", 266, 303], ["airway diseases", "DISEASE", 321, 336], ["viral infections", "DISEASE", 348, 364], ["human rhinoviruses (RV) respiratory syncytial virus (RSV), coronaviruses", "DISEASE", 373, 445], ["influenza viruses", "DISEASE", 450, 467], ["asthma", "DISEASE", 602, 608], ["ASM", "CELL", 28, 31], ["fibroblast", "CELL", 51, 61], ["airway", "MULTI-TISSUE_STRUCTURE", 96, 102], ["lung", "ORGAN", 157, 161], ["basement membrane", "CELLULAR_COMPONENT", 186, 203], ["pulmonary", "ORGAN", 286, 295], ["airway", "ORGAN", 321, 327], ["human", "ORGANISM", 373, 378], ["rhinoviruses (RV) respiratory syncytial virus", "ORGANISM", 379, 424], ["RSV", "ORGANISM", 426, 429], ["coronaviruses", "ORGANISM", 432, 445], ["influenza viruses", "ORGANISM", 450, 467], ["human", "SPECIES", 373, 378], ["respiratory syncytial virus (RSV", "SPECIES", 397, 429], ["human rhinoviruses (RV) respiratory syncytial virus", "SPECIES", 373, 424], ["RSV", "SPECIES", 426, 429], ["severe asthma", "PROBLEM", 3, 16], ["increased ASM proliferation", "PROBLEM", 18, 45], ["fibroblast differentiation", "PROBLEM", 51, 77], ["airway remodelling", "PROBLEM", 96, 114], ["further long term limitations", "PROBLEM", 124, 153], ["increasing basement membrane thickness", "PROBLEM", 175, 213], ["angiogenesis", "PROBLEM", 219, 231], ["Asthma", "PROBLEM", 255, 261], ["chronic obstructive pulmonary disease", "PROBLEM", 266, 303], ["inflammatory airway diseases", "PROBLEM", 308, 336], ["Respiratory viral infections", "PROBLEM", 336, 364], ["human rhinoviruses (RV) respiratory syncytial virus (RSV)", "PROBLEM", 373, 430], ["coronaviruses", "PROBLEM", 432, 445], ["influenza viruses", "PROBLEM", 450, 467], ["asthma exacerbations", "PROBLEM", 602, 622], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["asthma", "OBSERVATION", 10, 16], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["ASM proliferation", "OBSERVATION", 28, 45], ["fibroblast differentiation", "OBSERVATION", 51, 77], ["may contribute to", "UNCERTAINTY", 78, 95], ["airway", "ANATOMY", 96, 102], ["remodelling", "OBSERVATION", 103, 114], ["long term", "OBSERVATION_MODIFIER", 132, 141], ["lung", "ANATOMY", 157, 161], ["increasing", "OBSERVATION_MODIFIER", 175, 185], ["basement", "OBSERVATION_MODIFIER", 186, 194], ["membrane thickness", "OBSERVATION_MODIFIER", 195, 213], ["angiogenesis", "OBSERVATION", 219, 231], ["asthma", "OBSERVATION", 244, 250], ["chronic", "OBSERVATION_MODIFIER", 266, 273], ["obstructive", "OBSERVATION_MODIFIER", 274, 285], ["pulmonary", "ANATOMY", 286, 295], ["disease", "OBSERVATION", 296, 303], ["inflammatory", "OBSERVATION_MODIFIER", 308, 320], ["airway", "ANATOMY", 321, 327], ["viral infections", "OBSERVATION", 348, 364], ["respiratory", "ANATOMY", 397, 408], ["syncytial virus", "OBSERVATION", 409, 424], ["asthma", "OBSERVATION", 602, 608]]], ["Atypical bacteria such as Mycoplasma pneumoniae and Chlamydiophila pneumoniae are also associated with asthma exacerbations (Thumerelle et al., 2003).", [["Mycoplasma pneumoniae", "DISEASE", 26, 47], ["asthma", "DISEASE", 103, 109], ["Mycoplasma pneumoniae", "ORGANISM", 26, 47], ["Chlamydiophila pneumoniae", "ORGANISM", 52, 77], ["Mycoplasma pneumoniae", "SPECIES", 26, 47], ["Chlamydiophila pneumoniae", "SPECIES", 52, 77], ["Mycoplasma pneumoniae", "SPECIES", 26, 47], ["Chlamydiophila pneumoniae", "SPECIES", 52, 77], ["Atypical bacteria", "PROBLEM", 0, 17], ["Mycoplasma pneumoniae", "PROBLEM", 26, 47], ["Chlamydiophila pneumoniae", "PROBLEM", 52, 77], ["asthma exacerbations", "PROBLEM", 103, 123], ["bacteria", "OBSERVATION", 9, 17], ["Mycoplasma pneumoniae", "OBSERVATION", 26, 47], ["Chlamydiophila pneumoniae", "OBSERVATION", 52, 77], ["associated with", "UNCERTAINTY", 87, 102], ["asthma", "OBSERVATION", 103, 109]]], ["Both viral and bacterial infection cause upregulation of a plethora of pro-inflammatory molecules in an NF-\u03baB dependent manner, including neutrophil chemokines IL-8/CXCL8 (Johnston et al., 1997, Zhu et al., 1997, Carter et al., 1998, Pizzichini et al., 1998, Cheon et al., 2008), ENA-78/CXCL5 (Donninger et al., 2003) GRO-\u03b1/CXCL1 (Edwards et al., 2006a), T cell chemokines IP-10/CXCL10 (Spurrell et al., 2005), Rantes/CCL5 (Thomas et al., 1998, Rudd et al., 2005, Veckman et al., 2005), and eotaxin/CCL10 (Papadopoulos et al., 2001).", [["neutrophil", "ANATOMY", 138, 148], ["T cell", "ANATOMY", 355, 361], ["infection", "DISEASE", 25, 34], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 104, 109], ["neutrophil", "CELL", 138, 148], ["IL-8", "GENE_OR_GENE_PRODUCT", 160, 164], ["CXCL8", "GENE_OR_GENE_PRODUCT", 165, 170], ["ENA-78", "GENE_OR_GENE_PRODUCT", 280, 286], ["CXCL5", "GENE_OR_GENE_PRODUCT", 287, 292], ["GRO-\u03b1", "GENE_OR_GENE_PRODUCT", 318, 323], ["CXCL1", "GENE_OR_GENE_PRODUCT", 324, 329], ["T cell", "CELL", 355, 361], ["IP-10", "GENE_OR_GENE_PRODUCT", 373, 378], ["CXCL10", "GENE_OR_GENE_PRODUCT", 379, 385], ["CCL5", "GENE_OR_GENE_PRODUCT", 418, 422], ["eotaxin", "GENE_OR_GENE_PRODUCT", 491, 498], ["CCL10", "GENE_OR_GENE_PRODUCT", 499, 504], ["pro-inflammatory molecules", "PROTEIN", 71, 97], ["neutrophil chemokines IL-8", "PROTEIN", 138, 164], ["CXCL8", "PROTEIN", 165, 170], ["CXCL5", "PROTEIN", 287, 292], ["GRO", "PROTEIN", 318, 321], ["\u03b1", "PROTEIN", 322, 323], ["CXCL1", "PROTEIN", 324, 329], ["T cell chemokines IP-10", "PROTEIN", 355, 378], ["CXCL10", "PROTEIN", 379, 385], ["CCL5", "PROTEIN", 418, 422], ["eotaxin", "PROTEIN", 491, 498], ["Both viral and bacterial infection", "PROBLEM", 0, 34], ["pro-inflammatory molecules", "PROBLEM", 71, 97], ["neutrophil chemokines IL", "TREATMENT", 138, 162], ["ENA", "TEST", 280, 283], ["CXCL5", "TEST", 287, 292], ["GRO", "TEST", 318, 321], ["CXCL1", "TEST", 324, 329], ["T cell chemokines", "TEST", 355, 372], ["IP", "TEST", 373, 375], ["CXCL10", "TEST", 379, 385], ["Spurrell et al.", "TEST", 387, 402], ["Rantes", "TEST", 411, 417], ["eotaxin", "TEST", 491, 498], ["viral", "OBSERVATION", 5, 10], ["bacterial infection", "OBSERVATION", 15, 34], ["plethora", "OBSERVATION_MODIFIER", 59, 67], ["pro-inflammatory molecules", "OBSERVATION", 71, 97]]], ["In addition, various cytokines and growth factors are induced, including IL-6 (Zhu et al., 1996, Dallaire et al., 2001, Oliver et al., 2006, Edwards et al., 2007) GM-CSF (Kim et al., 2000, Funkhouser et al., 2004), IL-11 (Einarsson et al., 1996), fibroblast growth factor (FGF)-2 and vascular endothelial growth factor (VEGF) (Volonaki et al., 2006).", [["GM", "CHEMICAL", 163, 165], ["IL-6", "GENE_OR_GENE_PRODUCT", 73, 77], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 163, 169], ["IL-11", "GENE_OR_GENE_PRODUCT", 215, 220], ["fibroblast growth factor (FGF)-2", "GENE_OR_GENE_PRODUCT", 247, 279], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 284, 318], ["VEGF", "GENE_OR_GENE_PRODUCT", 320, 324], ["cytokines", "PROTEIN", 21, 30], ["growth factors", "PROTEIN", 35, 49], ["fibroblast growth factor (FGF)-2", "PROTEIN", 247, 279], ["vascular endothelial growth factor", "PROTEIN", 284, 318], ["VEGF", "PROTEIN", 320, 324], ["various cytokines and growth factors", "PROBLEM", 13, 49], ["IL", "TEST", 215, 217], ["fibroblast growth factor", "TEST", 247, 271], ["FGF", "TEST", 273, 276], ["vascular endothelial growth factor", "PROBLEM", 284, 318], ["various", "OBSERVATION_MODIFIER", 13, 20], ["cytokines", "OBSERVATION", 21, 30], ["vascular endothelial", "ANATOMY", 284, 304]]], ["Adhesion molecules (Papi and Johnston, 1999a, Papi and Johnston, 1999b, Murdoch et al., 2002), respiratory mucins including MUC5AC (He et al., 2004, Inoue et al., 2006) and MUC5B (Inoue et al., 2006) are also produced.", [["mucins", "GENE_OR_GENE_PRODUCT", 107, 113], ["MUC5AC", "GENE_OR_GENE_PRODUCT", 124, 130], ["MUC5B", "GENE_OR_GENE_PRODUCT", 173, 178], ["Adhesion molecules", "PROTEIN", 0, 18], ["MUC5AC", "PROTEIN", 124, 130], ["Adhesion molecules", "PROBLEM", 0, 18], ["respiratory mucins", "ANATOMY", 95, 113]]], ["Macrophages, possibly through recognition of viral and bacterial products including single stranded RNA (ssRNA), double stranded RNA (dsRNA) and lipopolysaccharide (LPS) produce TNF-\u03b1 (Laza-Stanca et al., 2006, Liu et al., 2008, Oliver et al., 2008), a highly inflammatory cytokine serving to maintain the pro-inflammatory environment within the airway, and is a further inducer of neutrophil and T cell attracting chemokines.", [["Macrophages", "ANATOMY", 0, 11], ["airway", "ANATOMY", 346, 352], ["neutrophil", "ANATOMY", 382, 392], ["T cell", "ANATOMY", 397, 403], ["lipopolysaccharide", "CHEMICAL", 145, 163], ["LPS", "CHEMICAL", 165, 168], ["Macrophages", "CELL", 0, 11], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 145, 163], ["LPS", "SIMPLE_CHEMICAL", 165, 168], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 178, 183], ["airway", "MULTI-TISSUE_STRUCTURE", 346, 352], ["neutrophil", "CELL", 382, 392], ["T cell", "CELL", 397, 403], ["Macrophages", "CELL_TYPE", 0, 11], ["viral and bacterial products", "PROTEIN", 45, 73], ["single stranded RNA", "RNA", 84, 103], ["ssRNA", "RNA", 105, 110], ["double stranded RNA", "RNA", 113, 132], ["TNF", "PROTEIN", 178, 181], ["inflammatory cytokine", "PROTEIN", 260, 281], ["neutrophil", "CELL_TYPE", 382, 392], ["chemokines", "PROTEIN", 415, 425], ["Macrophages", "PROBLEM", 0, 11], ["viral and bacterial products", "PROBLEM", 45, 73], ["single stranded RNA (ssRNA)", "PROBLEM", 84, 111], ["double stranded RNA (dsRNA)", "PROBLEM", 113, 140], ["lipopolysaccharide (LPS)", "TEST", 145, 169], ["TNF", "TEST", 178, 181], ["Laza", "TEST", 185, 189], ["a highly inflammatory cytokine", "PROBLEM", 251, 281], ["neutrophil", "PROBLEM", 382, 392], ["T cell attracting chemokines", "TREATMENT", 397, 425], ["viral", "OBSERVATION", 45, 50], ["bacterial products", "OBSERVATION", 55, 73], ["stranded RNA", "OBSERVATION_MODIFIER", 91, 103], ["stranded RNA", "OBSERVATION_MODIFIER", 120, 132], ["inflammatory", "OBSERVATION_MODIFIER", 260, 272], ["airway", "ANATOMY", 346, 352]]], ["Viral induced asthma exacerbations in asthmatic individuals therefore have all the cellular hallmarks one would expect from the production of the above mediators, and commonly feature increased levels of airway eosinophils, neutrophils, and lymphocytes (Fraenkel et al., 1995, Grunberg et al., 1997, Pizzichini et al., 1998, Message et al., 2008).", [["cellular", "ANATOMY", 83, 91], ["airway eosinophils", "ANATOMY", 204, 222], ["neutrophils", "ANATOMY", 224, 235], ["lymphocytes", "ANATOMY", 241, 252], ["asthma exacerbations", "DISEASE", 14, 34], ["asthmatic", "DISEASE", 38, 47], ["cellular", "CELL", 83, 91], ["airway eosinophils", "CELL", 204, 222], ["neutrophils", "CELL", 224, 235], ["lymphocytes", "CELL", 241, 252], ["airway eosinophils", "CELL_TYPE", 204, 222], ["neutrophils", "CELL_TYPE", 224, 235], ["lymphocytes", "CELL_TYPE", 241, 252], ["Viral induced asthma exacerbations", "PROBLEM", 0, 34], ["asthmatic individuals", "PROBLEM", 38, 59], ["airway eosinophils", "PROBLEM", 204, 222], ["neutrophils", "TEST", 224, 235], ["lymphocytes", "TEST", 241, 252], ["asthma", "OBSERVATION", 14, 20], ["increased", "OBSERVATION_MODIFIER", 184, 193], ["airway eosinophils", "OBSERVATION", 204, 222], ["lymphocytes", "ANATOMY", 241, 252]]], ["Both experimental human and mouse models of rhinovirus induced asthma exacerbations have recently been developed (Bartlett et al., 2008, Message et al., 2008, Newcomb et al., 2008).Overview of asthma ::: Asthma and chronic obstructive pulmonary disease are inflammatory airway diseasesRegarding treatments, GC based therapies have been the most widely used therapy.", [["pulmonary", "ANATOMY", 235, 244], ["airway", "ANATOMY", 270, 276], ["rhinovirus", "DISEASE", 44, 54], ["asthma exacerbations", "DISEASE", 63, 83], ["asthma", "DISEASE", 193, 199], ["Asthma", "DISEASE", 204, 210], ["chronic obstructive pulmonary disease", "DISEASE", 215, 252], ["airway diseases", "DISEASE", 270, 285], ["human", "ORGANISM", 18, 23], ["mouse", "ORGANISM", 28, 33], ["rhinovirus", "ORGANISM", 44, 54], ["pulmonary", "ORGAN", 235, 244], ["airway", "MULTI-TISSUE_STRUCTURE", 270, 276], ["human", "SPECIES", 18, 23], ["mouse", "SPECIES", 28, 33], ["human", "SPECIES", 18, 23], ["mouse", "SPECIES", 28, 33], ["rhinovirus", "PROBLEM", 44, 54], ["asthma exacerbations", "PROBLEM", 63, 83], ["Asthma", "PROBLEM", 204, 210], ["chronic obstructive pulmonary disease", "PROBLEM", 215, 252], ["inflammatory airway diseases", "PROBLEM", 257, 285], ["treatments", "TREATMENT", 295, 305], ["GC based therapies", "TREATMENT", 307, 325], ["rhinovirus", "OBSERVATION", 44, 54], ["asthma", "OBSERVATION", 193, 199], ["chronic", "OBSERVATION_MODIFIER", 215, 222], ["obstructive", "OBSERVATION_MODIFIER", 223, 234], ["pulmonary", "ANATOMY", 235, 244], ["disease", "OBSERVATION", 245, 252], ["inflammatory", "OBSERVATION_MODIFIER", 257, 269], ["airway diseases", "OBSERVATION", 270, 285], ["most widely", "OBSERVATION_MODIFIER", 340, 351]]], ["While very effective in treating stable asthma they are less effective in treating exacerbations (Pauwels et al., 1997, FitzGerald et al., 2004).", [["asthma", "DISEASE", 40, 46], ["stable asthma", "PROBLEM", 33, 46], ["exacerbations", "PROBLEM", 83, 96], ["stable", "OBSERVATION_MODIFIER", 33, 39], ["asthma", "OBSERVATION", 40, 46]]], ["The allergic response has been an intense focus for therapeutic intervention, culminating in clinical trials using IL-4, IL-5 and IgE as therapeutic targets.", [["allergic", "DISEASE", 4, 12], ["IL-4", "GENE_OR_GENE_PRODUCT", 115, 119], ["IL-5", "GENE_OR_GENE_PRODUCT", 121, 125], ["IgE", "GENE_OR_GENE_PRODUCT", 130, 133], ["IgE", "PROTEIN", 130, 133], ["therapeutic intervention", "TREATMENT", 52, 76], ["IL", "TEST", 115, 117], ["IgE", "TREATMENT", 130, 133], ["allergic", "OBSERVATION", 4, 12], ["intense", "OBSERVATION_MODIFIER", 34, 41]]], ["Anti-IgE therapy appears partially effective (Bousquet et al., 2004, Holgate et al., 2004), particularly in severe asthma.", [["asthma", "DISEASE", 115, 121], ["Anti-IgE", "GENE_OR_GENE_PRODUCT", 0, 8], ["IgE", "PROTEIN", 5, 8], ["Anti-IgE therapy", "TREATMENT", 0, 16], ["severe asthma", "PROBLEM", 108, 121], ["IgE therapy", "OBSERVATION", 5, 16], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["asthma", "OBSERVATION", 115, 121]]], ["The outcomes of trials with both soluble IL-4 receptors and humanised anti-IL-5 monoclonal antibodies however have been disappointing (Borish et al., 1999, Leckie et al., 2000, Borish et al., 2001, Kips et al., 2003, O'Byrne et al., 2004).", [["IL-4 receptors", "GENE_OR_GENE_PRODUCT", 41, 55], ["anti-IL-5", "GENE_OR_GENE_PRODUCT", 70, 79], ["IL-4 receptors", "PROTEIN", 41, 55], ["humanised anti-IL-5 monoclonal antibodies", "PROTEIN", 60, 101], ["trials", "TREATMENT", 16, 22], ["both soluble IL", "TREATMENT", 28, 43], ["humanised anti-IL-5 monoclonal antibodies", "TREATMENT", 60, 101]]], ["Recent clinical research programs have focused on anti-TNF-\u03b1 antibodies or soluble TNF-\u03b1 receptors as a therapy (Howarth et al., 2005, Berry et al., 2006, Erin et al., 2006, Morjaria et al., 2008), highlighting the importance of inflammation as well as Th2 responses in asthma.Overview of chronic obstructive pulmonary disease ::: Asthma and chronic obstructive pulmonary disease are inflammatory airway diseasesCOPD is defined as a disease state characterized by chronic airflow limitation that is not fully reversible (ERS/ATS COPD Guidelines 2005).", [["pulmonary", "ANATOMY", 309, 318], ["pulmonary", "ANATOMY", 362, 371], ["airway", "ANATOMY", 397, 403], ["inflammation", "DISEASE", 229, 241], ["asthma", "DISEASE", 270, 276], ["chronic obstructive pulmonary disease", "DISEASE", 289, 326], ["Asthma", "DISEASE", 331, 337], ["chronic obstructive pulmonary disease", "DISEASE", 342, 379], ["airway diseasesCOPD", "DISEASE", 397, 416], ["COPD", "DISEASE", 529, 533], ["TNF-\u03b1 antibodies", "GENE_OR_GENE_PRODUCT", 55, 71], ["TNF-\u03b1 receptors", "GENE_OR_GENE_PRODUCT", 83, 98], ["pulmonary", "ORGAN", 309, 318], ["pulmonary", "ORGAN", 362, 371], ["TNF", "PROTEIN", 55, 58], ["\u03b1 antibodies", "PROTEIN", 59, 71], ["TNF-\u03b1 receptors", "PROTEIN", 83, 98], ["Recent clinical research programs", "PROBLEM", 0, 33], ["anti-TNF", "TREATMENT", 50, 58], ["\u03b1 antibodies", "TREATMENT", 59, 71], ["soluble TNF", "TREATMENT", 75, 86], ["inflammation", "PROBLEM", 229, 241], ["asthma", "PROBLEM", 270, 276], ["chronic obstructive pulmonary disease", "PROBLEM", 289, 326], ["Asthma", "PROBLEM", 331, 337], ["chronic obstructive pulmonary disease", "PROBLEM", 342, 379], ["inflammatory airway diseasesCOPD", "PROBLEM", 384, 416], ["a disease state", "PROBLEM", 431, 446], ["chronic airflow limitation", "PROBLEM", 464, 490], ["inflammation", "OBSERVATION", 229, 241], ["asthma", "OBSERVATION", 270, 276], ["chronic", "OBSERVATION_MODIFIER", 289, 296], ["obstructive", "OBSERVATION", 297, 308], ["pulmonary", "ANATOMY", 309, 318], ["disease", "OBSERVATION", 319, 326], ["chronic", "OBSERVATION_MODIFIER", 342, 349], ["obstructive", "OBSERVATION_MODIFIER", 350, 361], ["pulmonary", "ANATOMY", 362, 371], ["disease", "OBSERVATION", 372, 379], ["inflammatory", "OBSERVATION_MODIFIER", 384, 396], ["airway diseasesCOPD", "OBSERVATION", 397, 416], ["chronic", "OBSERVATION_MODIFIER", 464, 471], ["airflow", "OBSERVATION", 472, 479], ["not", "UNCERTAINTY", 499, 502], ["fully reversible", "OBSERVATION_MODIFIER", 503, 519]]], ["The airflow limitation is usually progressive and is associated with an abnormal inflammatory response following a range of different stimuli including CS, pollution, and pulmonary viral or bacterial infection.", [["pulmonary", "ANATOMY", 171, 180], ["pulmonary viral or bacterial infection", "DISEASE", 171, 209], ["pulmonary", "ORGAN", 171, 180], ["The airflow limitation", "PROBLEM", 0, 22], ["an abnormal inflammatory response", "PROBLEM", 69, 102], ["CS", "PROBLEM", 152, 154], ["pulmonary viral or bacterial infection", "PROBLEM", 171, 209], ["airflow limitation", "OBSERVATION", 4, 22], ["progressive", "OBSERVATION_MODIFIER", 34, 45], ["abnormal", "OBSERVATION_MODIFIER", 72, 80], ["inflammatory response", "OBSERVATION", 81, 102], ["pulmonary", "ANATOMY", 171, 180], ["viral", "OBSERVATION", 181, 186], ["bacterial", "OBSERVATION_MODIFIER", 190, 199], ["infection", "OBSERVATION", 200, 209]]], ["The clinical characteristics of cough, shortness of breath and sputum production reflect the underlying pathological changes.", [["sputum", "ANATOMY", 63, 69], ["cough", "DISEASE", 32, 37], ["shortness of breath", "DISEASE", 39, 58], ["sputum", "ORGANISM_SUBSTANCE", 63, 69], ["cough", "PROBLEM", 32, 37], ["shortness of breath", "PROBLEM", 39, 58], ["sputum production", "PROBLEM", 63, 80], ["the underlying pathological changes", "PROBLEM", 89, 124], ["cough", "OBSERVATION", 32, 37], ["pathological", "OBSERVATION", 104, 116]]], ["Mucus hypersecretion and cillary dysfunction lead to collapse of damaged small airways producing airflow limitation, gas trapping and the characteristic obstructive picture on spirometry.", [["Mucus", "ANATOMY", 0, 5], ["cillary", "ANATOMY", 25, 32], ["airways", "ANATOMY", 79, 86], ["cillary dysfunction", "DISEASE", 25, 44], ["Mucus", "MULTI-TISSUE_STRUCTURE", 0, 5], ["airways", "MULTI-TISSUE_STRUCTURE", 79, 86], ["Mucus hypersecretion", "PROBLEM", 0, 20], ["cillary dysfunction", "PROBLEM", 25, 44], ["collapse of damaged small airways", "PROBLEM", 53, 86], ["airflow limitation", "PROBLEM", 97, 115], ["gas trapping", "PROBLEM", 117, 129], ["the characteristic obstructive picture", "PROBLEM", 134, 172], ["hypersecretion", "OBSERVATION", 6, 20], ["cillary dysfunction", "OBSERVATION", 25, 44], ["collapse", "OBSERVATION", 53, 61], ["damaged", "OBSERVATION_MODIFIER", 65, 72], ["small", "OBSERVATION_MODIFIER", 73, 78], ["airways", "ANATOMY", 79, 86], ["airflow limitation", "OBSERVATION", 97, 115], ["gas trapping", "OBSERVATION", 117, 129], ["characteristic", "OBSERVATION_MODIFIER", 138, 152], ["obstructive", "OBSERVATION_MODIFIER", 153, 164]]], ["While the aetiology of COPD is certainly associated with smoking, the phenotype observed in COPD is variable and complex, and is likely the result of both various genetic and environmental factors.Overview of chronic obstructive pulmonary disease ::: Asthma and chronic obstructive pulmonary disease are inflammatory airway diseasesCOPD is associated with an onset later in life, and the incidence is increasing with an ageing population.", [["pulmonary", "ANATOMY", 229, 238], ["pulmonary", "ANATOMY", 282, 291], ["airway", "ANATOMY", 317, 323], ["COPD", "DISEASE", 23, 27], ["COPD", "DISEASE", 92, 96], ["chronic obstructive pulmonary disease", "DISEASE", 209, 246], ["Asthma", "DISEASE", 251, 257], ["chronic obstructive pulmonary disease", "DISEASE", 262, 299], ["airway diseasesCOPD", "DISEASE", 317, 336], ["pulmonary", "ORGAN", 229, 238], ["pulmonary", "ORGAN", 282, 291], ["airway", "MULTI-TISSUE_STRUCTURE", 317, 323], ["COPD", "PROBLEM", 23, 27], ["the phenotype", "PROBLEM", 66, 79], ["COPD", "PROBLEM", 92, 96], ["chronic obstructive pulmonary disease", "PROBLEM", 209, 246], ["Asthma", "PROBLEM", 251, 257], ["chronic obstructive pulmonary disease", "PROBLEM", 262, 299], ["inflammatory airway diseasesCOPD", "PROBLEM", 304, 336], ["COPD", "OBSERVATION", 23, 27], ["COPD", "OBSERVATION", 92, 96], ["chronic", "OBSERVATION_MODIFIER", 209, 216], ["obstructive", "OBSERVATION", 217, 228], ["pulmonary", "ANATOMY", 229, 238], ["disease", "OBSERVATION", 239, 246], ["chronic", "OBSERVATION_MODIFIER", 262, 269], ["obstructive", "OBSERVATION_MODIFIER", 270, 281], ["pulmonary", "ANATOMY", 282, 291], ["disease", "OBSERVATION", 292, 299], ["inflammatory", "OBSERVATION_MODIFIER", 304, 316], ["airway diseasesCOPD", "OBSERVATION", 317, 336], ["onset", "OBSERVATION_MODIFIER", 359, 364], ["increasing", "OBSERVATION_MODIFIER", 401, 411]]], ["It affects over 5% adults, is the fourth leading cause of death worldwide and is the only major cause of death that is still rising (Pauwels & Rabe, 2004).", [["death", "DISEASE", 58, 63], ["death", "DISEASE", 105, 110], ["death", "PROBLEM", 58, 63], ["death", "PROBLEM", 105, 110], ["death", "OBSERVATION", 105, 110], ["rising", "OBSERVATION_MODIFIER", 125, 131]]], ["It has been predicted from the increasing prevalence that COPD will be the third leading cause of death worldwide by 2020 (Murray & Lopez, 1997).Overview of chronic obstructive pulmonary disease ::: Asthma and chronic obstructive pulmonary disease are inflammatory airway diseasesStable COPD is punctuated by exacerbations, 50\u201370% of which are associated with infection by bacteria and viruses (Ball, 1995, Seemungal et al., 2000, Papi et al., 2006).", [["pulmonary", "ANATOMY", 177, 186], ["pulmonary", "ANATOMY", 230, 239], ["airway", "ANATOMY", 265, 271], ["COPD", "DISEASE", 58, 62], ["death", "DISEASE", 98, 103], ["chronic obstructive pulmonary disease", "DISEASE", 157, 194], ["Asthma", "DISEASE", 199, 205], ["chronic obstructive pulmonary disease", "DISEASE", 210, 247], ["airway diseases", "DISEASE", 265, 280], ["COPD", "DISEASE", 287, 291], ["infection", "DISEASE", 360, 369], ["pulmonary", "ORGAN", 177, 186], ["pulmonary", "ORGAN", 230, 239], ["airway", "MULTI-TISSUE_STRUCTURE", 265, 271], ["COPD", "PROBLEM", 58, 62], ["chronic obstructive pulmonary disease", "PROBLEM", 157, 194], ["Asthma", "PROBLEM", 199, 205], ["chronic obstructive pulmonary disease", "PROBLEM", 210, 247], ["inflammatory airway diseases", "PROBLEM", 252, 280], ["Stable COPD", "PROBLEM", 280, 291], ["exacerbations", "PROBLEM", 309, 322], ["infection", "PROBLEM", 360, 369], ["bacteria", "PROBLEM", 373, 381], ["COPD", "OBSERVATION", 58, 62], ["chronic", "OBSERVATION_MODIFIER", 157, 164], ["obstructive", "OBSERVATION", 165, 176], ["pulmonary", "ANATOMY", 177, 186], ["disease", "OBSERVATION", 187, 194], ["chronic", "OBSERVATION_MODIFIER", 210, 217], ["obstructive", "OBSERVATION_MODIFIER", 218, 229], ["pulmonary", "ANATOMY", 230, 239], ["disease", "OBSERVATION", 240, 247], ["inflammatory", "OBSERVATION_MODIFIER", 252, 264], ["airway diseases", "OBSERVATION", 265, 280], ["COPD", "OBSERVATION", 287, 291], ["punctuated", "OBSERVATION_MODIFIER", 295, 305], ["exacerbations", "OBSERVATION_MODIFIER", 309, 322], ["associated with", "UNCERTAINTY", 344, 359], ["infection", "OBSERVATION", 360, 369]]], ["The noncapsulated bacteria Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis are the most frequently isolated bacteria in stable COPD and during exacerbations (Monso et al., 1995).", [["Haemophilus influenzae", "DISEASE", 27, 49], ["Streptococcus pneumoniae", "DISEASE", 51, 75], ["COPD", "DISEASE", 155, 159], ["noncapsulated bacteria", "ORGANISM", 4, 26], ["Haemophilus influenzae", "ORGANISM", 27, 49], ["Streptococcus pneumoniae", "ORGANISM", 51, 75], ["Moraxella catarrhalis", "ORGANISM", 81, 102], ["Haemophilus influenzae", "SPECIES", 27, 49], ["Streptococcus pneumoniae", "SPECIES", 51, 75], ["Moraxella catarrhalis", "SPECIES", 81, 102], ["Haemophilus influenzae", "SPECIES", 27, 49], ["Streptococcus pneumoniae", "SPECIES", 51, 75], ["Moraxella catarrhalis", "SPECIES", 81, 102], ["The noncapsulated bacteria Haemophilus influenzae", "PROBLEM", 0, 49], ["Streptococcus pneumoniae", "PROBLEM", 51, 75], ["Moraxella catarrhalis", "PROBLEM", 81, 102], ["stable COPD", "PROBLEM", 148, 159], ["bacteria", "OBSERVATION_MODIFIER", 18, 26], ["Haemophilus influenzae", "OBSERVATION", 27, 49], ["Streptococcus pneumoniae", "OBSERVATION", 51, 75], ["Moraxella catarrhalis", "OBSERVATION", 81, 102], ["bacteria", "OBSERVATION_MODIFIER", 136, 144], ["stable", "OBSERVATION_MODIFIER", 148, 154], ["COPD", "OBSERVATION", 155, 159]]], ["Viruses are detected in at least 40% of COPD exacerbations, and commonly include RV and RSV (Seemungal et al., 2001).Overview of chronic obstructive pulmonary disease ::: Asthma and chronic obstructive pulmonary disease are inflammatory airway diseasesExacerbations are the major cause of morbidity and mortality in COPD.", [["pulmonary", "ANATOMY", 149, 158], ["pulmonary", "ANATOMY", 202, 211], ["airway", "ANATOMY", 237, 243], ["COPD", "DISEASE", 40, 44], ["chronic obstructive pulmonary disease", "DISEASE", 129, 166], ["Asthma", "DISEASE", 171, 177], ["chronic obstructive pulmonary disease", "DISEASE", 182, 219], ["airway diseases", "DISEASE", 237, 252], ["COPD", "DISEASE", 316, 320], ["RSV", "ORGANISM", 88, 91], ["pulmonary", "ORGAN", 149, 158], ["pulmonary", "ORGAN", 202, 211], ["airway", "MULTI-TISSUE_STRUCTURE", 237, 243], ["RSV", "SPECIES", 88, 91], ["Viruses", "PROBLEM", 0, 7], ["COPD exacerbations", "PROBLEM", 40, 58], ["RV", "TEST", 81, 83], ["chronic obstructive pulmonary disease", "PROBLEM", 129, 166], ["Asthma", "PROBLEM", 171, 177], ["chronic obstructive pulmonary disease", "PROBLEM", 182, 219], ["inflammatory airway diseasesExacerbations", "PROBLEM", 224, 265], ["morbidity", "PROBLEM", 289, 298], ["COPD", "PROBLEM", 316, 320], ["COPD", "OBSERVATION", 40, 44], ["RV", "ANATOMY", 81, 83], ["chronic", "OBSERVATION_MODIFIER", 129, 136], ["obstructive", "OBSERVATION", 137, 148], ["pulmonary", "ANATOMY", 149, 158], ["disease", "OBSERVATION", 159, 166], ["chronic", "OBSERVATION_MODIFIER", 182, 189], ["obstructive", "OBSERVATION_MODIFIER", 190, 201], ["pulmonary", "ANATOMY", 202, 211], ["disease", "OBSERVATION", 212, 219], ["inflammatory", "OBSERVATION_MODIFIER", 224, 236], ["airway", "ANATOMY", 237, 243], ["diseases", "OBSERVATION", 244, 252], ["morbidity", "OBSERVATION", 289, 298], ["COPD", "OBSERVATION", 316, 320]]], ["Exacerbations result in a faster decline in lung function (Donaldson et al., 2002), the number and severity increase with worsening disease (Donaldson et al., 2003), and they are associated with a 7.4% mortality rate in hospitalised patients (Price et al., 2006).Overview of chronic obstructive pulmonary disease ::: Asthma and chronic obstructive pulmonary disease are inflammatory airway diseasesRecently much has been learnt regarding the mechanism by which CS and pulmonary infections contribute to COPD.", [["lung", "ANATOMY", 44, 48], ["pulmonary", "ANATOMY", 295, 304], ["pulmonary", "ANATOMY", 348, 357], ["airway", "ANATOMY", 383, 389], ["pulmonary", "ANATOMY", 468, 477], ["chronic obstructive pulmonary disease", "DISEASE", 275, 312], ["Asthma", "DISEASE", 317, 323], ["chronic obstructive pulmonary disease", "DISEASE", 328, 365], ["airway diseases", "DISEASE", 383, 398], ["pulmonary infections", "DISEASE", 468, 488], ["COPD", "DISEASE", 503, 507], ["lung", "ORGAN", 44, 48], ["patients", "ORGANISM", 233, 241], ["pulmonary", "ORGAN", 295, 304], ["pulmonary", "ORGAN", 348, 357], ["airway", "MULTI-TISSUE_STRUCTURE", 383, 389], ["pulmonary", "ORGAN", 468, 477], ["patients", "SPECIES", 233, 241], ["Exacerbations", "PROBLEM", 0, 13], ["a faster decline in lung function", "PROBLEM", 24, 57], ["worsening disease", "PROBLEM", 122, 139], ["chronic obstructive pulmonary disease", "PROBLEM", 275, 312], ["Asthma", "PROBLEM", 317, 323], ["chronic obstructive pulmonary disease", "PROBLEM", 328, 365], ["inflammatory airway diseases", "PROBLEM", 370, 398], ["pulmonary infections", "PROBLEM", 468, 488], ["COPD", "PROBLEM", 503, 507], ["faster", "OBSERVATION_MODIFIER", 26, 32], ["decline", "OBSERVATION_MODIFIER", 33, 40], ["lung", "ANATOMY", 44, 48], ["severity", "OBSERVATION_MODIFIER", 99, 107], ["increase", "OBSERVATION_MODIFIER", 108, 116], ["worsening", "OBSERVATION_MODIFIER", 122, 131], ["disease", "OBSERVATION", 132, 139], ["chronic", "OBSERVATION_MODIFIER", 275, 282], ["obstructive", "OBSERVATION", 283, 294], ["pulmonary", "ANATOMY", 295, 304], ["disease", "OBSERVATION", 305, 312], ["chronic", "OBSERVATION_MODIFIER", 328, 335], ["obstructive", "OBSERVATION_MODIFIER", 336, 347], ["pulmonary", "ANATOMY", 348, 357], ["disease", "OBSERVATION", 358, 365], ["inflammatory", "OBSERVATION_MODIFIER", 370, 382], ["airway diseases", "OBSERVATION", 383, 398], ["pulmonary", "ANATOMY", 468, 477], ["infections", "OBSERVATION", 478, 488], ["COPD", "OBSERVATION", 503, 507]]], ["Stable COPD is generally associated with increased airway CD8+ T lymphocytes, macrophages and neutrophilia (Saetta et al., 1998, Saetta et al., 1999, Qiu et al., 2003, Baraldo et al., 2004), and in some patients, eosinophils (Rutgers et al., 2000).", [["airway CD8+ T lymphocytes", "ANATOMY", 51, 76], ["macrophages", "ANATOMY", 78, 89], ["eosinophils", "ANATOMY", 213, 224], ["COPD", "DISEASE", 7, 11], ["neutrophilia", "DISEASE", 94, 106], ["CD8", "GENE_OR_GENE_PRODUCT", 58, 61], ["macrophages", "CELL", 78, 89], ["patients", "ORGANISM", 203, 211], ["eosinophils", "CELL", 213, 224], ["airway CD8+ T lymphocytes", "CELL_TYPE", 51, 76], ["macrophages", "CELL_TYPE", 78, 89], ["eosinophils", "CELL_TYPE", 213, 224], ["patients", "SPECIES", 203, 211], ["Stable COPD", "PROBLEM", 0, 11], ["increased airway CD8", "PROBLEM", 41, 61], ["T lymphocytes", "PROBLEM", 63, 76], ["macrophages", "PROBLEM", 78, 89], ["neutrophilia", "PROBLEM", 94, 106], ["COPD", "OBSERVATION", 7, 11], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["airway", "ANATOMY", 51, 57], ["CD8", "OBSERVATION", 58, 61], ["T lymphocytes", "OBSERVATION", 63, 76], ["macrophages", "ANATOMY", 78, 89], ["neutrophilia", "OBSERVATION_MODIFIER", 94, 106]]], ["COPD and CS are also highly associated with reactive oxygen, as measured by 8-Isoprostane analysis (Montuschi et al., 2000), reactive oxygen is believed to be central to COPD, by inducing lung damage and hence the initiation of inflammation.", [["lung", "ANATOMY", 188, 192], ["COPD", "DISEASE", 0, 4], ["oxygen", "CHEMICAL", 53, 59], ["8-Isoprostane", "CHEMICAL", 76, 89], ["oxygen", "CHEMICAL", 134, 140], ["COPD", "DISEASE", 170, 174], ["lung damage", "DISEASE", 188, 199], ["inflammation", "DISEASE", 228, 240], ["oxygen", "CHEMICAL", 53, 59], ["8-Isoprostane", "CHEMICAL", 76, 89], ["oxygen", "CHEMICAL", 134, 140], ["oxygen", "SIMPLE_CHEMICAL", 53, 59], ["8-Isoprostane", "SIMPLE_CHEMICAL", 76, 89], ["oxygen", "SIMPLE_CHEMICAL", 134, 140], ["lung", "ORGAN", 188, 192], ["COPD", "PROBLEM", 0, 4], ["CS", "PROBLEM", 9, 11], ["reactive oxygen", "PROBLEM", 44, 59], ["Isoprostane analysis", "TEST", 78, 98], ["reactive oxygen", "TREATMENT", 125, 140], ["COPD", "PROBLEM", 170, 174], ["lung damage", "PROBLEM", 188, 199], ["inflammation", "PROBLEM", 228, 240], ["CS", "OBSERVATION", 9, 11], ["reactive", "OBSERVATION_MODIFIER", 44, 52], ["oxygen", "OBSERVATION_MODIFIER", 53, 59], ["reactive oxygen", "OBSERVATION", 125, 140], ["believed to be", "UNCERTAINTY", 144, 158], ["COPD", "OBSERVATION", 170, 174], ["lung", "ANATOMY", 188, 192], ["damage", "OBSERVATION", 193, 199], ["inflammation", "OBSERVATION", 228, 240]]], ["During exacerbations, the cellular infiltrate may be more variable, and also demonstrate increased neutrophil chemokines such as ENA-78 and IL-8 (Qiu et al., 2003).", [["cellular infiltrate", "ANATOMY", 26, 45], ["neutrophil", "ANATOMY", 99, 109], ["cellular", "CELL", 26, 34], ["neutrophil", "CELL", 99, 109], ["ENA-78", "GENE_OR_GENE_PRODUCT", 129, 135], ["IL-8", "GENE_OR_GENE_PRODUCT", 140, 144], ["neutrophil chemokines", "PROTEIN", 99, 120], ["ENA", "PROTEIN", 129, 132], ["exacerbations", "PROBLEM", 7, 20], ["the cellular infiltrate", "PROBLEM", 22, 45], ["increased neutrophil chemokines", "PROBLEM", 89, 120], ["ENA", "TEST", 129, 132], ["IL", "TEST", 140, 142], ["cellular", "OBSERVATION_MODIFIER", 26, 34], ["infiltrate", "OBSERVATION", 35, 45], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["neutrophil chemokines", "OBSERVATION", 99, 120]]], ["COPD exacerbations are also related to an increase in systemic inflammatory molecules, including c-reactive protein and TNF-\u03b1 (Gan et al., 2004).", [["COPD", "DISEASE", 0, 4], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 120, 125], ["systemic inflammatory molecules", "PROTEIN", 54, 85], ["c-reactive protein", "PROTEIN", 97, 115], ["TNF", "PROTEIN", 120, 123], ["COPD exacerbations", "PROBLEM", 0, 18], ["an increase in systemic inflammatory molecules", "PROBLEM", 39, 85], ["c-reactive protein", "TEST", 97, 115], ["TNF", "TEST", 120, 123], ["exacerbations", "OBSERVATION", 5, 18], ["increase", "OBSERVATION_MODIFIER", 42, 50], ["systemic", "OBSERVATION_MODIFIER", 54, 62], ["inflammatory molecules", "OBSERVATION", 63, 85]]], ["Recently, a small pilot study has demonstrated that experimental RV challenge is feasible in COPD patients, and induced changes typically experienced during exacerbations of COPD (Mallia et al., 2006).Overview of chronic obstructive pulmonary disease ::: Asthma and chronic obstructive pulmonary disease are inflammatory airway diseasesBoth inhaled long acting B2 agonists (LABAs) and short acting B2 agonists are used in the symptomatic treatment of COPD.", [["pulmonary", "ANATOMY", 233, 242], ["pulmonary", "ANATOMY", 286, 295], ["airway", "ANATOMY", 321, 327], ["COPD", "DISEASE", 93, 97], ["COPD", "DISEASE", 174, 178], ["chronic obstructive pulmonary disease", "DISEASE", 213, 250], ["Asthma", "DISEASE", 255, 261], ["chronic obstructive pulmonary disease", "DISEASE", 266, 303], ["airway diseases", "DISEASE", 321, 336], ["LABAs", "CHEMICAL", 374, 379], ["COPD", "DISEASE", 451, 455], ["patients", "ORGANISM", 98, 106], ["pulmonary", "ORGAN", 233, 242], ["pulmonary", "ORGAN", 286, 295], ["airway", "MULTI-TISSUE_STRUCTURE", 321, 327], ["long acting B2 agonists", "SIMPLE_CHEMICAL", 349, 372], ["LABAs", "SIMPLE_CHEMICAL", 374, 379], ["patients", "SPECIES", 98, 106], ["a small pilot study", "TEST", 10, 29], ["experimental RV challenge", "TREATMENT", 52, 77], ["COPD patients", "PROBLEM", 93, 106], ["COPD", "PROBLEM", 174, 178], ["chronic obstructive pulmonary disease", "PROBLEM", 213, 250], ["Asthma", "PROBLEM", 255, 261], ["chronic obstructive pulmonary disease", "PROBLEM", 266, 303], ["inflammatory airway diseases", "PROBLEM", 308, 336], ["inhaled long acting B2 agonists", "TREATMENT", 341, 372], ["LABAs)", "TREATMENT", 374, 380], ["short acting B2 agonists", "TREATMENT", 385, 409], ["COPD", "PROBLEM", 451, 455], ["small", "OBSERVATION_MODIFIER", 12, 17], ["RV", "ANATOMY", 65, 67], ["COPD", "OBSERVATION", 93, 97], ["COPD", "OBSERVATION", 174, 178], ["chronic", "OBSERVATION_MODIFIER", 213, 220], ["obstructive", "OBSERVATION", 221, 232], ["pulmonary", "ANATOMY", 233, 242], ["disease", "OBSERVATION", 243, 250], ["chronic", "OBSERVATION_MODIFIER", 266, 273], ["obstructive", "OBSERVATION_MODIFIER", 274, 285], ["pulmonary", "ANATOMY", 286, 295], ["disease", "OBSERVATION", 296, 303], ["inflammatory", "OBSERVATION_MODIFIER", 308, 320], ["airway", "ANATOMY", 321, 327], ["diseases", "OBSERVATION", 328, 336], ["COPD", "OBSERVATION", 451, 455]]], ["Anti-cholinergics are also administered, and both B2 agonist and anti-cholinergic therapy act mainly by inducing bronchodilation, thereby reducing dyspnoea and may also reduce exacerbation frequency.", [["dyspnoea", "DISEASE", 147, 155], ["Anti-cholinergics", "SIMPLE_CHEMICAL", 0, 17], ["anti-cholinergic", "SIMPLE_CHEMICAL", 65, 81], ["Anti-cholinergics", "TREATMENT", 0, 17], ["both B2 agonist", "TREATMENT", 45, 60], ["anti-cholinergic therapy", "TREATMENT", 65, 89], ["reducing dyspnoea", "PROBLEM", 138, 155], ["exacerbation frequency", "PROBLEM", 176, 198]]], ["The use of inhaled GCs in COPD remains controversial, with inhaled GC use recommended for moderate/severe COPD rather than mild COPD.", [["COPD", "DISEASE", 26, 30], ["COPD", "DISEASE", 106, 110], ["COPD", "DISEASE", 128, 132], ["GCs", "MULTI-TISSUE_STRUCTURE", 19, 22], ["inhaled GCs", "TREATMENT", 11, 22], ["COPD", "PROBLEM", 26, 30], ["inhaled GC use", "TREATMENT", 59, 73], ["moderate/severe COPD", "PROBLEM", 90, 110], ["mild COPD", "PROBLEM", 123, 132], ["COPD", "OBSERVATION", 26, 30], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["COPD", "OBSERVATION", 106, 110], ["mild", "OBSERVATION_MODIFIER", 123, 127], ["COPD", "OBSERVATION", 128, 132]]], ["Recently, a large clinical trial has shown improvements in lung function, and exacerbation frequency in individuals receiving combined inhaled GC and LABA treatment versus placebo (Calverley et al., 2007).", [["lung", "ANATOMY", 59, 63], ["LABA", "CHEMICAL", 150, 154], ["LABA", "CHEMICAL", 150, 154], ["lung", "ORGAN", 59, 63], ["LABA", "SIMPLE_CHEMICAL", 150, 154], ["exacerbation frequency in individuals", "PROBLEM", 78, 115], ["combined inhaled GC", "TREATMENT", 126, 145], ["LABA treatment", "TREATMENT", 150, 164], ["placebo", "TREATMENT", 172, 179], ["large", "OBSERVATION_MODIFIER", 12, 17], ["improvements", "OBSERVATION_MODIFIER", 43, 55], ["lung", "ANATOMY", 59, 63], ["function", "OBSERVATION", 64, 72], ["exacerbation", "OBSERVATION_MODIFIER", 78, 90]]], ["Oral GC therapy is also recommended for the treatment of COPD exacerbations.", [["Oral", "ANATOMY", 0, 4], ["GC", "CHEMICAL", 5, 7], ["COPD", "DISEASE", 57, 61], ["Oral GC therapy", "TREATMENT", 0, 15], ["COPD exacerbations", "PROBLEM", 57, 75], ["GC therapy", "OBSERVATION", 5, 15], ["COPD", "OBSERVATION", 57, 61]]], ["An update on current treatment regimes for COPD is provided by the Global Strategy for the Diagnosis Management and Prevention of COPD (Rabe et al., 2007).Nuclear factor-\u03baB signalling and the Rel protein familyNF-\u03baB is a transcription factor expressed in numerous cell types, which plays a key role in the expression of many pro-inflammatory genes, leading to the synthesis of cytokines, adhesion molecules, chemokines, growth factors and enzymes (reviewed in Baldwin, 2001).", [["cell", "ANATOMY", 264, 268], ["COPD", "DISEASE", 43, 47], ["COPD", "DISEASE", 130, 134], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 155, 172], ["Rel", "GENE_OR_GENE_PRODUCT", 192, 195], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 210, 215], ["cell types", "CELL", 264, 274], ["Nuclear factor-\u03baB", "PROTEIN", 155, 172], ["Rel protein family", "PROTEIN", 192, 210], ["NF-\u03baB", "PROTEIN", 210, 215], ["transcription factor", "PROTEIN", 221, 241], ["pro-inflammatory genes", "DNA", 325, 347], ["cytokines", "PROTEIN", 377, 386], ["adhesion molecules", "PROTEIN", 388, 406], ["chemokines", "PROTEIN", 408, 418], ["growth factors", "PROTEIN", 420, 434], ["enzymes", "PROTEIN", 439, 446], ["current treatment regimes", "TREATMENT", 13, 38], ["COPD", "PROBLEM", 43, 47], ["the Diagnosis Management", "TREATMENT", 87, 111], ["COPD", "PROBLEM", 130, 134], ["Nuclear factor", "TEST", 155, 169], ["a transcription factor", "PROBLEM", 219, 241], ["many pro-inflammatory genes", "PROBLEM", 320, 347], ["the synthesis of cytokines", "PROBLEM", 360, 386], ["adhesion molecules", "PROBLEM", 388, 406], ["enzymes", "TEST", 439, 446], ["COPD", "OBSERVATION", 130, 134], ["numerous cell types", "OBSERVATION", 255, 274], ["pro-inflammatory genes", "OBSERVATION", 325, 347]]], ["NF-\u03baB or Rel family members are believed to play a central role in a variety of acute and chronic inflammatory diseases.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["Rel", "GENE_OR_GENE_PRODUCT", 9, 12], ["NF-\u03baB", "PROTEIN", 0, 5], ["Rel family members", "PROTEIN", 9, 27], ["acute and chronic inflammatory diseases", "PROBLEM", 80, 119], ["central", "ANATOMY_MODIFIER", 51, 58], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["chronic", "OBSERVATION_MODIFIER", 90, 97], ["inflammatory", "OBSERVATION", 98, 110]]], ["For this reason the NF-\u03baB signalling pathway has been the focus of extensive research over the last 20 years.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 20, 25], ["NF-\u03baB", "PROTEIN", 20, 25], ["extensive", "OBSERVATION_MODIFIER", 67, 76]]], ["NF-\u03baB is activated in response to a number of stimuli, including physical and chemical stress, LPS, dsRNA, ssRNA, T and B cell mitogens and pro-inflammatory cytokines (Rothwarf and Karin, 1999, Karin and Lin, 2002, Li and Verma, 2002, Karin et al., 2004).", [["B cell", "ANATOMY", 120, 126], ["LPS", "CHEMICAL", 95, 98], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["LPS", "SIMPLE_CHEMICAL", 95, 98], ["T", "CELL", 114, 115], ["B cell", "CELL", 120, 126], ["NF-\u03baB", "PROTEIN", 0, 5], ["T and B cell mitogens", "PROTEIN", 114, 135], ["pro-inflammatory cytokines", "PROTEIN", 140, 166], ["LPS", "TEST", 95, 98], ["dsRNA", "PROBLEM", 100, 105], ["ssRNA", "PROBLEM", 107, 112], ["T and B cell mitogens", "TEST", 114, 135], ["pro-inflammatory cytokines", "TEST", 140, 166], ["Rothwarf", "TEST", 168, 176], ["Karin", "TEST", 181, 186], ["Lin", "ANATOMY", 204, 207]]], ["NF-\u03baB induced gene expression is controlled by a complex series of enzymatic signalling events, at multiple levels.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["NF-\u03baB", "PROTEIN", 0, 5], ["enzymatic signalling events", "PROBLEM", 67, 94], ["gene expression", "OBSERVATION", 14, 29], ["enzymatic signalling events", "OBSERVATION", 67, 94]]], ["An overview of the NF-\u03baB activation cascade is depicted in Fig. 1.Nuclear factor-\u03baB signalling and the Rel protein familyRel family members share an N-terminal Rel homology domain (RHD) which mediates dimerisation, nuclear translocation, and the binding of specific \u03baB sites within promoters of affected genes.", [["nuclear", "ANATOMY", 215, 222], ["N-", "CHEMICAL", 149, 151], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 19, 24], ["Nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 66, 82], ["B", "GENE_OR_GENE_PRODUCT", 82, 83], ["Rel", "GENE_OR_GENE_PRODUCT", 103, 106], ["Rel", "GENE_OR_GENE_PRODUCT", 121, 124], ["nuclear", "CELLULAR_COMPONENT", 215, 222], ["\u03baB", "GENE_OR_GENE_PRODUCT", 266, 268], ["NF-\u03baB", "PROTEIN", 19, 24], ["Nuclear factor-\u03ba", "PROTEIN", 66, 82], ["Rel protein family", "PROTEIN", 103, 121], ["Rel family members", "PROTEIN", 121, 139], ["N-terminal Rel homology domain", "PROTEIN", 149, 179], ["RHD", "PROTEIN", 181, 184], ["\u03baB sites", "DNA", 266, 274], ["promoters", "DNA", 282, 291], ["Nuclear factor", "TEST", 66, 80], ["nuclear translocation", "PROBLEM", 215, 236], ["affected genes", "OBSERVATION", 295, 309]]], ["The consensus \u03baB site is the decameric sequence 5\u2032-GGGAATTTCC-3\u2032, however extensive variations exist.", [["\u03baB", "GENE_OR_GENE_PRODUCT", 14, 16], ["consensus \u03baB site", "DNA", 4, 21], ["decameric sequence 5\u2032-GGGAATTTCC-3\u2032", "DNA", 29, 64], ["the decameric sequence", "TEST", 25, 47], ["GGGAATTTCC", "TEST", 51, 61], ["extensive", "OBSERVATION_MODIFIER", 74, 83], ["variations", "OBSERVATION", 84, 94]]], ["In mammals there are five known members of the Rel family: p50 (NF-\u03baB1, precursor of which is p105), p65 (Rel A, NF-\u03baB3), p52 (NF-\u03baB2, precursor of which is p100), c-Rel and Rel B. The p50 and p65 subunits are ubiquitously expressed, whereas the other three are generally restricted to specific differentiated cell types (reviewed in Siebenlist et al., 1994).", [["cell", "ANATOMY", 310, 314], ["Rel", "GENE_OR_GENE_PRODUCT", 47, 50], ["p50", "GENE_OR_GENE_PRODUCT", 59, 62], ["NF-\u03baB1", "GENE_OR_GENE_PRODUCT", 64, 70], ["p65", "GENE_OR_GENE_PRODUCT", 101, 104], ["Rel A", "GENE_OR_GENE_PRODUCT", 106, 111], ["NF-\u03baB3", "GENE_OR_GENE_PRODUCT", 113, 119], ["p52", "GENE_OR_GENE_PRODUCT", 122, 125], ["NF-\u03baB2", "GENE_OR_GENE_PRODUCT", 127, 133], ["c-Rel", "GENE_OR_GENE_PRODUCT", 164, 169], ["Rel B.", "GENE_OR_GENE_PRODUCT", 174, 180], ["p50", "GENE_OR_GENE_PRODUCT", 185, 188], ["p65", "GENE_OR_GENE_PRODUCT", 193, 196], ["cell", "CELL", 310, 314], ["Rel family", "PROTEIN", 47, 57], ["p50", "PROTEIN", 59, 62], ["NF-\u03baB1", "PROTEIN", 64, 70], ["p105", "PROTEIN", 94, 98], ["p65", "PROTEIN", 101, 104], ["Rel A", "PROTEIN", 106, 111], ["NF", "PROTEIN", 113, 115], ["\u03baB3", "PROTEIN", 116, 119], ["p52", "PROTEIN", 122, 125], ["NF", "PROTEIN", 127, 129], ["\u03baB2", "PROTEIN", 130, 133], ["p100", "PROTEIN", 157, 161], ["Rel", "PROTEIN", 166, 169], ["Rel B.", "PROTEIN", 174, 180], ["p50", "PROTEIN", 185, 188], ["p65 subunits", "PROTEIN", 193, 205], ["differentiated cell types", "CELL_TYPE", 295, 320], ["NF", "TEST", 127, 129], ["c-Rel and Rel B. The p50", "TEST", 164, 188], ["differentiated cell types", "OBSERVATION", 295, 320]]], ["In resting cells, the majority of NF-\u03baB is bound to I\u03baB inhibitory protein which masks the nuclear localisation sequence (NLS) and holds the complex in the cytoplasm.", [["cells", "ANATOMY", 11, 16], ["nuclear", "ANATOMY", 91, 98], ["cytoplasm", "ANATOMY", 156, 165], ["cells", "CELL", 11, 16], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 34, 39], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 52, 55], ["nuclear", "CELLULAR_COMPONENT", 91, 98], ["cytoplasm", "ORGANISM_SUBSTANCE", 156, 165], ["resting cells", "CELL_TYPE", 3, 16], ["NF-\u03baB", "PROTEIN", 34, 39], ["I\u03baB inhibitory protein", "PROTEIN", 52, 74], ["nuclear localisation sequence", "PROTEIN", 91, 120], ["NLS", "PROTEIN", 122, 125], ["NF", "TEST", 34, 36], ["the nuclear localisation sequence", "TEST", 87, 120], ["resting cells", "OBSERVATION", 3, 16]]], ["There are a number of different I\u03baB proteins such as I\u03baB\u03b1, I\u03baB\u03b2, I\u03baB\u03b3, I\u03baB\u025b and Bcl-3.", [["I\u03baB", "GENE_OR_GENE_PRODUCT", 32, 35], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 53, 57], ["I\u03baB\u03b2", "GENE_OR_GENE_PRODUCT", 59, 63], ["I\u03baB\u03b3", "GENE_OR_GENE_PRODUCT", 65, 69], ["I\u03baB\u025b", "GENE_OR_GENE_PRODUCT", 71, 75], ["Bcl-3", "GENE_OR_GENE_PRODUCT", 80, 85], ["I\u03baB proteins", "PROTEIN", 32, 44], ["I\u03baB\u03b1", "PROTEIN", 53, 57], ["I\u03baB\u03b2", "PROTEIN", 59, 63], ["I\u03baB\u03b3", "PROTEIN", 65, 69], ["I\u03baB\u025b", "PROTEIN", 71, 75], ["Bcl-3", "PROTEIN", 80, 85], ["different I\u03baB proteins", "PROBLEM", 22, 44], ["I\u03baB\u03b1", "TEST", 53, 57], ["I\u03baB\u03b2", "TEST", 59, 63], ["I\u03baB\u03b3", "TEST", 65, 69], ["I\u03baB", "TEST", 71, 74], ["Bcl", "TEST", 80, 83], ["Bcl", "ANATOMY", 80, 83]]], ["It is generally believed that the different isoforms are associated with particular Rel protein dimers, bound via their RHD.", [["Rel", "GENE_OR_GENE_PRODUCT", 84, 87], ["Rel protein dimers", "PROTEIN", 84, 102], ["RHD", "PROTEIN", 120, 123], ["particular Rel protein dimers", "PROBLEM", 73, 102], ["protein dimers", "OBSERVATION", 88, 102]]], ["For example I\u03baB\u03b1 and I\u03baB\u03b2 associate with p65:p50 and p50:c-Rel, whereas I\u03baB\u025b only binds to p65 and c-Rel hetero and homodimers.", [["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 12, 16], ["I\u03baB\u03b2", "GENE_OR_GENE_PRODUCT", 21, 25], ["p65", "GENE_OR_GENE_PRODUCT", 41, 44], ["p50", "GENE_OR_GENE_PRODUCT", 45, 48], ["p50:c-Rel", "GENE_OR_GENE_PRODUCT", 53, 62], ["I\u03baB\u025b", "GENE_OR_GENE_PRODUCT", 72, 76], ["p65", "GENE_OR_GENE_PRODUCT", 91, 94], ["c-Rel", "GENE_OR_GENE_PRODUCT", 99, 104], ["I\u03baB\u03b1", "PROTEIN", 12, 16], ["I\u03baB\u03b2", "PROTEIN", 21, 25], ["p65", "PROTEIN", 41, 44], ["p50", "PROTEIN", 45, 48], ["p50:c", "PROTEIN", 53, 58], ["Rel", "PROTEIN", 59, 62], ["I\u03baB\u025b", "PROTEIN", 72, 76], ["p65", "PROTEIN", 91, 94], ["c", "PROTEIN", 99, 100], ["Rel hetero", "PROTEIN", 101, 111], ["homodimers", "PROTEIN", 116, 126], ["p50", "TEST", 45, 48], ["p50:c", "TEST", 53, 58], ["p65", "TEST", 91, 94], ["c-Rel hetero and homodimers", "TREATMENT", 99, 126]]], ["Upon appropriate stimulation, the I\u03baB protein is phosphorylated and ubiquinated, and subsequent 26S proteasome-mediated degradation.", [["I\u03baB", "GENE_OR_GENE_PRODUCT", 34, 37], ["26S", "GENE_OR_GENE_PRODUCT", 96, 99], ["I\u03baB protein", "PROTEIN", 34, 45], ["26S proteasome", "PROTEIN", 96, 110], ["the I\u03baB protein", "TEST", 30, 45]]], ["I\u03baB isoform phosphorylation is stimulus specific, for example I\u03baB\u03b2 is only phosphorylated by certain stimuli including LPS and IL-1\u03b2, whereas I\u03baB\u03b1 phosphorylation is triggered by most NF-\u03baB activators.", [["I\u03baB", "GENE_OR_GENE_PRODUCT", 0, 3], ["I\u03baB\u03b2", "GENE_OR_GENE_PRODUCT", 62, 66], ["LPS", "SIMPLE_CHEMICAL", 119, 122], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 127, 132], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 142, 146], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 184, 189], ["I\u03baB", "PROTEIN", 0, 3], ["I\u03baB\u03b2", "PROTEIN", 62, 66], ["IL-1\u03b2", "PROTEIN", 127, 132], ["I\u03baB\u03b1", "PROTEIN", 142, 146], ["NF-\u03baB", "PROTEIN", 184, 189], ["LPS", "TEST", 119, 122], ["IL", "TEST", 127, 129]]], ["This level of control is also thought to impact on the cell type specificity and kinetics of the response, which in turn can influence the duration of transcription.Nuclear factor-\u03baB signalling and the Rel protein familyI\u03baB phosphorylation and activation of Rel proteins can occur via the classical (canonical) or alternative pathway.", [["cell", "ANATOMY", 55, 59], ["cell", "CELL", 55, 59], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 165, 182], ["Rel protein familyI\u03baB", "GENE_OR_GENE_PRODUCT", 202, 223], ["Rel", "GENE_OR_GENE_PRODUCT", 258, 261], ["Nuclear factor-\u03baB", "PROTEIN", 165, 182], ["Rel protein family", "PROTEIN", 202, 220], ["I\u03baB", "PROTEIN", 220, 223], ["Rel proteins", "PROTEIN", 258, 270], ["Nuclear factor", "TEST", 165, 179], ["activation of Rel proteins", "TREATMENT", 244, 270]]], ["In the classical pathway, a critical phosphorylation of the I\u03baB protein is performed by the I\u03baB kinase (IKK) complex, which consists of at least three subunits, two catalytic subunits IKK-\u03b1/IKK-1 and IKK-\u03b2/IKK-2 and a regulatory subunit IKK-\u03b3/NF-\u03baB essential modulator (NEMO) (Scheidereit, 1998, Karin, 1999, Courtois et al., 2001).", [["I\u03baB", "GENE_OR_GENE_PRODUCT", 60, 63], ["I\u03baB kinase", "GENE_OR_GENE_PRODUCT", 92, 102], ["IKK", "GENE_OR_GENE_PRODUCT", 104, 107], ["IKK-\u03b1", "GENE_OR_GENE_PRODUCT", 184, 189], ["IKK-1", "GENE_OR_GENE_PRODUCT", 190, 195], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 200, 205], ["IKK-2", "GENE_OR_GENE_PRODUCT", 206, 211], ["IKK-\u03b3", "GENE_OR_GENE_PRODUCT", 237, 242], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 243, 248], ["NEMO", "GENE_OR_GENE_PRODUCT", 270, 274], ["I\u03baB protein", "PROTEIN", 60, 71], ["I\u03baB kinase (IKK) complex", "PROTEIN", 92, 116], ["catalytic subunits", "PROTEIN", 165, 183], ["IKK", "PROTEIN", 184, 187], ["\u03b1", "PROTEIN", 188, 189], ["IKK", "PROTEIN", 190, 193], ["IKK", "PROTEIN", 200, 203], ["\u03b2", "PROTEIN", 204, 205], ["IKK-2", "PROTEIN", 206, 211], ["IKK", "PROTEIN", 237, 240], ["\u03b3", "PROTEIN", 241, 242], ["NF-\u03baB", "PROTEIN", 243, 248], ["NEMO", "PROTEIN", 270, 274], ["the I\u03baB protein", "TEST", 56, 71], ["the I\u03baB kinase", "TEST", 88, 102], ["two catalytic subunits IKK", "TEST", 161, 187], ["IKK", "TEST", 190, 193], ["IKK", "TEST", 200, 203], ["IKK", "TEST", 206, 209], ["a regulatory subunit IKK", "TEST", 216, 240], ["NF", "TEST", 243, 245]]], ["Of the two catalytic subunits IKK-\u03b2 is 20 fold more active than IKK-\u03b1 in phosphorylation of I\u03baB (Mercurio et al., 1997).", [["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 30, 35], ["IKK-\u03b1", "GENE_OR_GENE_PRODUCT", 64, 69], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 92, 95], ["catalytic subunits", "PROTEIN", 11, 29], ["IKK", "PROTEIN", 30, 33], ["\u03b2", "PROTEIN", 34, 35], ["IKK", "PROTEIN", 64, 67], ["\u03b1", "PROTEIN", 68, 69], ["I\u03baB", "PROTEIN", 92, 95], ["the two catalytic subunits IKK", "TEST", 3, 33], ["IKK", "TEST", 64, 67], ["IKK", "OBSERVATION_MODIFIER", 30, 33], ["20 fold", "OBSERVATION_MODIFIER", 39, 46], ["active", "OBSERVATION_MODIFIER", 52, 58]]], ["In the classical pathway, it has been shown that IKK-\u03b2, and not IKK-\u03b1, is important in NF-\u03baB activation, and the two kinases have distinct rather than overlapping functions (Hu et al., 1999, Li et al., 1999a, Li et al., 1999b, Takeda et al., 1999).", [["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 49, 54], ["IKK-\u03b1", "GENE_OR_GENE_PRODUCT", 64, 69], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 87, 92], ["IKK", "PROTEIN", 49, 52], ["\u03b2", "PROTEIN", 53, 54], ["IKK", "PROTEIN", 64, 67], ["\u03b1", "PROTEIN", 68, 69], ["NF-\u03baB", "PROTEIN", 87, 92], ["kinases", "PROTEIN", 117, 124], ["IKK", "TEST", 49, 52], ["IKK", "TEST", 64, 67]]], ["The classical pathway includes signalling from TLR/IL-1R family members, intracellular pattern recognition receptors including retinoic acid inducible gene (RIG-I), melanoma differentiation associated factor-5 (MDA-5), and protein kinase R (PKR).", [["intracellular", "ANATOMY", 73, 86], ["retinoic acid", "CHEMICAL", 127, 140], ["retinoic acid", "CHEMICAL", 127, 140], ["TLR", "GENE_OR_GENE_PRODUCT", 47, 50], ["IL-1R", "GENE_OR_GENE_PRODUCT", 51, 56], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 73, 86], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 87, 116], ["retinoic acid inducible gene", "GENE_OR_GENE_PRODUCT", 127, 155], ["RIG-I", "GENE_OR_GENE_PRODUCT", 157, 162], ["melanoma differentiation associated factor-5", "GENE_OR_GENE_PRODUCT", 165, 209], ["MDA-5", "GENE_OR_GENE_PRODUCT", 211, 216], ["protein kinase R", "GENE_OR_GENE_PRODUCT", 223, 239], ["PKR", "GENE_OR_GENE_PRODUCT", 241, 244], ["TLR/IL-1R family members", "PROTEIN", 47, 71], ["intracellular pattern recognition receptors", "PROTEIN", 73, 116], ["retinoic acid inducible gene", "DNA", 127, 155], ["RIG-I", "DNA", 157, 162], ["melanoma differentiation associated factor-5", "PROTEIN", 165, 209], ["MDA", "PROTEIN", 211, 214], ["protein kinase R", "PROTEIN", 223, 239], ["PKR", "PROTEIN", 241, 244], ["intracellular pattern recognition receptors", "PROBLEM", 73, 116], ["retinoic acid inducible gene (RIG-I)", "PROBLEM", 127, 163], ["melanoma differentiation associated factor", "PROBLEM", 165, 207], ["MDA", "TEST", 211, 214], ["protein kinase", "TEST", 223, 237], ["PKR", "TEST", 241, 244], ["melanoma", "OBSERVATION", 165, 173]]], ["Ligation of the T-cell receptor (TCR), and signalling from the TNFR are also examples of the classical pathway (reviewed in (Hacker & Karin, 2006) (Fig. 1).Nuclear factor-\u03baB signalling and the Rel protein familyThe alternative pathway is activated by mediators such as lymphotoxin-\u03b2, CD40 ligand, and receptor activator of NF-\u03baB ligand (RANKL) (Dejardin et al., 2002, Novack et al., 2003), as shown in Fig. 1.", [["T-cell", "ANATOMY", 16, 22], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 16, 31], ["TCR", "GENE_OR_GENE_PRODUCT", 33, 36], ["TNFR", "GENE_OR_GENE_PRODUCT", 63, 67], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 156, 173], ["Rel", "GENE_OR_GENE_PRODUCT", 193, 196], ["lymphotoxin-\u03b2", "GENE_OR_GENE_PRODUCT", 269, 282], ["CD40", "GENE_OR_GENE_PRODUCT", 284, 288], ["receptor activator of NF-\u03baB ligand", "GENE_OR_GENE_PRODUCT", 301, 335], ["RANKL", "GENE_OR_GENE_PRODUCT", 337, 342], ["T-cell receptor", "PROTEIN", 16, 31], ["TCR", "PROTEIN", 33, 36], ["TNFR", "PROTEIN", 63, 67], ["Nuclear factor-\u03baB", "PROTEIN", 156, 173], ["Rel protein family", "PROTEIN", 193, 211], ["lymphotoxin", "PROTEIN", 269, 280], ["\u03b2", "PROTEIN", 281, 282], ["CD40 ligand", "PROTEIN", 284, 295], ["receptor activator of NF-\u03baB ligand", "PROTEIN", 301, 335], ["RANKL", "PROTEIN", 337, 342], ["Ligation", "TREATMENT", 0, 8], ["the T-cell receptor", "TREATMENT", 12, 31], ["Nuclear factor", "TEST", 156, 170], ["lymphotoxin", "TREATMENT", 269, 280], ["CD40 ligand", "TREATMENT", 284, 295]]], ["This pathway involves IKK-\u03b1 phosphorylating and processing of the p52 precursor p100, and nuclear translocation of the heterodimer p52:Rel B (Senftleben et al., 2001).", [["nuclear", "ANATOMY", 90, 97], ["IKK-\u03b1", "GENE_OR_GENE_PRODUCT", 22, 27], ["p52", "GENE_OR_GENE_PRODUCT", 66, 69], ["nuclear", "CELLULAR_COMPONENT", 90, 97], ["p52", "GENE_OR_GENE_PRODUCT", 131, 134], ["Rel B", "GENE_OR_GENE_PRODUCT", 135, 140], ["IKK", "PROTEIN", 22, 25], ["\u03b1", "PROTEIN", 26, 27], ["p52 precursor p100", "PROTEIN", 66, 84], ["heterodimer p52", "PROTEIN", 119, 134], ["Rel B", "PROTEIN", 135, 140], ["IKK", "TEST", 22, 25]]], ["This pathway is believed to play key roles in secondary lymphoid organogenesis and adaptive immunity (reviewed in (Lawrence & Bebien, 2007).Nuclear factor-\u03baB signalling and the Rel protein familyThe NF-\u03baB pathway can be further controlled by post translation modifications, including modulating the interaction of Rel proteins with other components of the transcriptional machinery, and altering their kinetics in and out of the nucleus.", [["lymphoid", "ANATOMY", 56, 64], ["nucleus", "ANATOMY", 429, 436], ["lymphoid", "CELL", 56, 64], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 140, 157], ["Rel", "GENE_OR_GENE_PRODUCT", 177, 180], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 199, 204], ["Rel", "GENE_OR_GENE_PRODUCT", 314, 317], ["nucleus", "CELLULAR_COMPONENT", 429, 436], ["Nuclear factor-\u03baB", "PROTEIN", 140, 157], ["Rel protein family", "PROTEIN", 177, 195], ["NF-\u03baB", "PROTEIN", 199, 204], ["Rel proteins", "PROTEIN", 314, 326], ["secondary lymphoid organogenesis", "PROBLEM", 46, 78], ["Nuclear factor", "TEST", 140, 154], ["Rel proteins", "TREATMENT", 314, 326], ["the transcriptional machinery", "TREATMENT", 352, 381], ["secondary lymphoid organogenesis", "OBSERVATION", 46, 78], ["nucleus", "ANATOMY", 429, 436]]], ["The phosphorylation status of NF-\u03baB can influence activation, for example phosphorylation of p65 may enhance transcriptional activation, however phosphorylation of p105 can reduce its processing into p50 (Naumann & Scheidereit, 1994).", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 30, 35], ["p65", "GENE_OR_GENE_PRODUCT", 93, 96], ["p50", "GENE_OR_GENE_PRODUCT", 200, 203], ["NF-\u03baB", "PROTEIN", 30, 35], ["p65", "PROTEIN", 93, 96], ["p105", "PROTEIN", 164, 168], ["p50", "PROTEIN", 200, 203], ["example phosphorylation of p65", "PROBLEM", 66, 96], ["transcriptional activation", "PROBLEM", 109, 135], ["phosphorylation of p", "TREATMENT", 145, 165]]], ["NF-\u03baB can also associate with other transcriptional proteins such as histone acetyltransferase (HAT) and histone deacetylase (HDAC) (reviewed in Ito et al., 2007).", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["histone acetyltransferase (HAT)", "GENE_OR_GENE_PRODUCT", 69, 100], ["histone deacetylase", "GENE_OR_GENE_PRODUCT", 105, 124], ["HDAC", "GENE_OR_GENE_PRODUCT", 126, 130], ["NF-\u03baB", "PROTEIN", 0, 5], ["transcriptional proteins", "PROTEIN", 36, 60], ["histone acetyltransferase", "PROTEIN", 69, 94], ["HAT", "PROTEIN", 96, 99], ["histone deacetylase", "PROTEIN", 105, 124], ["HDAC", "PROTEIN", 126, 130], ["other transcriptional proteins", "TREATMENT", 30, 60], ["histone acetyltransferase (HAT)", "TREATMENT", 69, 100], ["histone deacetylase (HDAC", "TREATMENT", 105, 130]]], ["Similarly acetylation of the Rel proteins can increase the time it is located in the nucleus (Chen et al., 2002).", [["nucleus", "ANATOMY", 85, 92], ["Rel", "GENE_OR_GENE_PRODUCT", 29, 32], ["nucleus", "CELLULAR_COMPONENT", 85, 92], ["Rel proteins", "PROTEIN", 29, 41], ["the Rel proteins", "TREATMENT", 25, 41], ["acetylation", "OBSERVATION_MODIFIER", 10, 21], ["increase", "OBSERVATION_MODIFIER", 46, 54], ["nucleus", "ANATOMY", 85, 92]]], ["Furthermore recent data would suggest that these two modification steps occur in a stepwise manner, phosphorylation of RelA is required prior to and enhances acetylation of Rel A, and improved transcriptional activity (Chen et al., 2005).", [["RelA", "GENE_OR_GENE_PRODUCT", 119, 123], ["Rel A", "GENE_OR_GENE_PRODUCT", 173, 178], ["RelA", "PROTEIN", 119, 123], ["Rel A", "PROTEIN", 173, 178], ["phosphorylation of RelA", "TREATMENT", 100, 123]]], ["Hence the NF-\u03baB pathway represents a well studied signal transduction pathway, relevant to many human diseases.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 10, 15], ["human", "ORGANISM", 96, 101], ["NF-\u03baB", "PROTEIN", 10, 15], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["many human diseases", "PROBLEM", 91, 110]]], ["The next part of this article will focus on how this knowledge has been applied to generating new therapies for asthma and COPD.Asthma ::: Nuclear factor-\u03baB in asthma and chronic obstructive pulmonary disease: evidence from expression levels in diseased tissue, models using gene deficient mice, and in vitro assaysSeveral lines of evidence indicate enhanced NF-\u03baB pathway activation in asthmatic tissues.", [["pulmonary", "ANATOMY", 191, 200], ["tissue", "ANATOMY", 254, 260], ["tissues", "ANATOMY", 397, 404], ["asthma", "DISEASE", 112, 118], ["COPD", "DISEASE", 123, 127], ["Asthma", "DISEASE", 128, 134], ["asthma", "DISEASE", 160, 166], ["chronic obstructive pulmonary disease", "DISEASE", 171, 208], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 139, 156], ["pulmonary", "ORGAN", 191, 200], ["tissue", "TISSUE", 254, 260], ["mice", "ORGANISM", 290, 294], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 359, 364], ["asthmatic tissues", "TISSUE", 387, 404], ["Nuclear factor-\u03baB", "PROTEIN", 139, 156], ["NF-\u03baB", "PROTEIN", 359, 364], ["mice", "SPECIES", 290, 294], ["new therapies", "TREATMENT", 94, 107], ["asthma", "PROBLEM", 112, 118], ["COPD", "PROBLEM", 123, 127], ["Asthma", "PROBLEM", 128, 134], ["Nuclear factor", "TEST", 139, 153], ["asthma", "PROBLEM", 160, 166], ["chronic obstructive pulmonary disease", "PROBLEM", 171, 208], ["expression levels in diseased tissue", "PROBLEM", 224, 260], ["gene deficient mice", "TREATMENT", 275, 294], ["vitro assays", "TEST", 303, 315], ["enhanced NF", "PROBLEM", 350, 361], ["asthmatic tissues", "PROBLEM", 387, 404], ["COPD", "OBSERVATION", 123, 127], ["asthma", "OBSERVATION", 160, 166], ["chronic", "OBSERVATION_MODIFIER", 171, 178], ["obstructive", "OBSERVATION", 179, 190], ["pulmonary", "ANATOMY", 191, 200], ["disease", "OBSERVATION", 201, 208], ["diseased tissue", "OBSERVATION_MODIFIER", 245, 260], ["lines", "OBSERVATION", 323, 328], ["evidence indicate", "UNCERTAINTY", 332, 349], ["enhanced", "OBSERVATION_MODIFIER", 350, 358], ["asthmatic tissues", "OBSERVATION", 387, 404]]], ["Peripheral blood mononuclear cells (PBMCs) of adult uncontrolled, severe and moderate asthmatics have higher levels of NF-\u03baB p65 protein expression, I\u03baB phosphorylation and IKK-\u03b2 protein levels than normal individuals (Gagliardo et al., 2003).", [["Peripheral blood mononuclear cells", "ANATOMY", 0, 34], ["PBMCs", "ANATOMY", 36, 41], ["Peripheral blood mononuclear cells", "CELL", 0, 34], ["PBMCs", "CELL", 36, 41], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 119, 128], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 149, 152], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 173, 178], ["Peripheral blood mononuclear cells", "CELL_TYPE", 0, 34], ["PBMCs", "CELL_TYPE", 36, 41], ["NF-\u03baB p65 protein", "PROTEIN", 119, 136], ["I\u03baB", "PROTEIN", 149, 152], ["IKK", "PROTEIN", 173, 176], ["Peripheral blood mononuclear cells", "TEST", 0, 34], ["PBMCs", "TEST", 36, 41], ["adult uncontrolled", "PROBLEM", 46, 64], ["severe and moderate asthmatics", "PROBLEM", 66, 96], ["NF", "TEST", 119, 121], ["protein expression", "TEST", 129, 147], ["I\u03baB phosphorylation", "TEST", 149, 168], ["IKK", "TEST", 173, 176], ["protein levels", "TEST", 179, 193], ["blood", "ANATOMY", 11, 16], ["mononuclear cells", "OBSERVATION", 17, 34], ["uncontrolled", "OBSERVATION_MODIFIER", 52, 64], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["moderate", "OBSERVATION_MODIFIER", 77, 85], ["asthmatics", "OBSERVATION", 86, 96]]], ["Also in children, NF-\u03baB p65 protein abundance and I\u03baB phosphorylation are also higher in moderate asthmatic PBMCs when compared to normal individuals (La Grutta et al., 2003).", [["PBMCs", "ANATOMY", 108, 113], ["children", "ORGANISM", 8, 16], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 18, 27], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 50, 53], ["PBMCs", "CELL", 108, 113], ["NF-\u03baB p65 protein", "PROTEIN", 18, 35], ["I\u03baB", "PROTEIN", 50, 53], ["asthmatic PBMCs", "CELL_TYPE", 98, 113], ["children", "SPECIES", 8, 16], ["protein abundance", "TEST", 28, 45], ["I\u03baB phosphorylation", "TEST", 50, 69], ["moderate asthmatic PBMCs", "PROBLEM", 89, 113], ["higher", "OBSERVATION_MODIFIER", 79, 85], ["moderate", "OBSERVATION_MODIFIER", 89, 97], ["asthmatic PBMCs", "OBSERVATION", 98, 113]]], ["Furthermore, when compared to non-asthmatic individuals, nuclear extracts from bronchial biopsies, sputum cells (Hart et al., 1998), and cultured bronchial epithelial cells (Zhao et al., 2001) from stable, untreated asthmatics have greater levels of NF-\u03baB p65 and p50 activation, as measured by gel shift assays and immunofluorescence of nuclear NF-\u03baB p65 protein.Asthma ::: Nuclear factor-\u03baB in asthma and chronic obstructive pulmonary disease: evidence from expression levels in diseased tissue, models using gene deficient mice, and in vitro assaysSmall animal models of allergic asthma using gene deficient mice highlight the importance of NF-\u03baB in disease pathogenesis.", [["nuclear extracts", "ANATOMY", 57, 73], ["bronchial biopsies", "ANATOMY", 79, 97], ["sputum cells", "ANATOMY", 99, 111], ["bronchial epithelial cells", "ANATOMY", 146, 172], ["nuclear", "ANATOMY", 338, 345], ["pulmonary", "ANATOMY", 427, 436], ["tissue", "ANATOMY", 490, 496], ["Asthma", "DISEASE", 364, 370], ["asthma", "DISEASE", 396, 402], ["chronic obstructive pulmonary disease", "DISEASE", 407, 444], ["allergic asthma", "DISEASE", 574, 589], ["nuclear extracts", "ORGANISM_SUBSTANCE", 57, 73], ["bronchial biopsies", "MULTI-TISSUE_STRUCTURE", 79, 97], ["sputum cells", "CELL", 99, 111], ["bronchial epithelial cells", "CELL", 146, 172], ["asthmatics", "ORGANISM", 216, 226], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 250, 259], ["p50", "GENE_OR_GENE_PRODUCT", 264, 267], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 346, 355], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 375, 392], ["pulmonary", "ORGAN", 427, 436], ["tissue", "TISSUE", 490, 496], ["mice", "ORGANISM", 526, 530], ["mice", "ORGANISM", 611, 615], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 644, 649], ["sputum cells", "CELL_TYPE", 99, 111], ["cultured bronchial epithelial cells", "CELL_LINE", 137, 172], ["NF-\u03baB p65", "PROTEIN", 250, 259], ["p50", "PROTEIN", 264, 267], ["nuclear NF-\u03baB p65 protein", "PROTEIN", 338, 363], ["Nuclear factor-\u03baB", "PROTEIN", 375, 392], ["NF-\u03baB", "PROTEIN", 644, 649], ["mice", "SPECIES", 526, 530], ["mice", "SPECIES", 611, 615], ["mice", "SPECIES", 611, 615], ["non-asthmatic individuals", "PROBLEM", 30, 55], ["nuclear extracts", "TEST", 57, 73], ["bronchial biopsies", "TEST", 79, 97], ["sputum cells", "TEST", 99, 111], ["cultured bronchial epithelial cells", "PROBLEM", 137, 172], ["untreated asthmatics", "PROBLEM", 206, 226], ["NF", "TEST", 250, 252], ["p50 activation", "TEST", 264, 278], ["immunofluorescence", "TEST", 316, 334], ["nuclear NF", "TEST", 338, 348], ["Asthma", "PROBLEM", 364, 370], ["Nuclear factor", "TEST", 375, 389], ["asthma", "PROBLEM", 396, 402], ["chronic obstructive pulmonary disease", "PROBLEM", 407, 444], ["expression levels in diseased tissue", "PROBLEM", 460, 496], ["gene deficient mice", "TREATMENT", 511, 530], ["vitro assays", "TEST", 539, 551], ["allergic asthma", "PROBLEM", 574, 589], ["disease pathogenesis", "PROBLEM", 653, 673], ["bronchial", "ANATOMY", 79, 88], ["biopsies", "OBSERVATION", 89, 97], ["bronchial", "ANATOMY", 146, 155], ["epithelial cells", "OBSERVATION", 156, 172], ["stable", "OBSERVATION_MODIFIER", 198, 204], ["asthma", "OBSERVATION", 396, 402], ["chronic", "OBSERVATION_MODIFIER", 407, 414], ["obstructive", "OBSERVATION", 415, 426], ["pulmonary", "ANATOMY", 427, 436], ["disease", "OBSERVATION", 437, 444], ["diseased tissue", "OBSERVATION_MODIFIER", 481, 496], ["allergic asthma", "OBSERVATION", 574, 589], ["disease", "OBSERVATION", 653, 660]]], ["While a wealth of small animal studies have demonstrated the role of NF-\u03baB in inflammation following respiratory viral or bacterial infections (Haeberle et al., 2002, Haeberle et al., 2004, Sadikot et al., 2006, Quinton et al., 2007), NF-\u03baB also appears to be important in the allergic response.", [["inflammation", "DISEASE", 78, 90], ["respiratory viral or bacterial infections", "DISEASE", 101, 142], ["allergic", "DISEASE", 277, 285], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 69, 74], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 235, 240], ["NF-\u03baB", "PROTEIN", 69, 74], ["NF-\u03baB", "PROTEIN", 235, 240], ["small animal studies", "TEST", 18, 38], ["NF", "PROBLEM", 69, 71], ["inflammation", "PROBLEM", 78, 90], ["respiratory viral or bacterial infections", "PROBLEM", 101, 142], ["the allergic response", "PROBLEM", 273, 294], ["inflammation", "OBSERVATION", 78, 90], ["respiratory", "ANATOMY", 101, 112], ["viral", "OBSERVATION", 113, 118], ["bacterial", "OBSERVATION_MODIFIER", 122, 131], ["infections", "OBSERVATION", 132, 142], ["appears to be", "UNCERTAINTY", 246, 259], ["allergic response", "OBSERVATION", 277, 294]]], ["In the ovalbumin (OVA) sensitisation and challenge model, total lung extracts from Brown-Norway rats exhibit enhanced NF-\u03baB activity (Lin et al., 2000).", [["lung extracts", "ANATOMY", 64, 77], ["lung extracts", "ORGANISM_SUBSTANCE", 64, 77], ["Brown-Norway rats", "ORGANISM", 83, 100], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 118, 123], ["NF-\u03baB", "PROTEIN", 118, 123], ["rats", "SPECIES", 96, 100], ["the ovalbumin (OVA) sensitisation", "TREATMENT", 3, 36], ["challenge model", "TEST", 41, 56], ["total lung extracts", "TEST", 58, 77], ["enhanced NF", "PROBLEM", 109, 120], ["lung", "ANATOMY", 64, 68]]], ["In a murine model, bronchial epithelium exhibits robust and rapid NF-\u03baB p65 nuclear translocation and IKK-\u03b1/\u03b2 activity, compared to controls (Poynter et al., 2002).", [["bronchial epithelium", "ANATOMY", 19, 39], ["nuclear", "ANATOMY", 76, 83], ["murine", "ORGANISM", 5, 11], ["bronchial epithelium", "TISSUE", 19, 39], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 66, 75], ["IKK-\u03b1", "GENE_OR_GENE_PRODUCT", 102, 107], ["\u03b2", "GENE_OR_GENE_PRODUCT", 108, 109], ["NF-\u03baB p65", "PROTEIN", 66, 75], ["IKK", "PROTEIN", 102, 105], ["\u03b1", "PROTEIN", 106, 107], ["\u03b2", "PROTEIN", 108, 109], ["murine", "SPECIES", 5, 11], ["bronchial epithelium", "PROBLEM", 19, 39], ["rapid NF", "TEST", 60, 68], ["nuclear translocation", "TEST", 76, 97], ["IKK", "TEST", 102, 105], ["bronchial epithelium", "ANATOMY", 19, 39], ["robust", "OBSERVATION_MODIFIER", 49, 55], ["rapid", "OBSERVATION_MODIFIER", 60, 65]]], ["Mice that lack NF-\u03baB p50 have reduced eosinophilic responses to aerolised allergen.", [["eosinophilic", "ANATOMY", 38, 50], ["Mice", "ORGANISM", 0, 4], ["NF-\u03baB p50", "GENE_OR_GENE_PRODUCT", 15, 24], ["NF-\u03baB p50", "PROTEIN", 15, 24], ["Mice", "SPECIES", 0, 4], ["reduced eosinophilic responses", "PROBLEM", 30, 60], ["aerolised allergen", "TREATMENT", 64, 82], ["reduced", "OBSERVATION_MODIFIER", 30, 37], ["eosinophilic responses", "OBSERVATION", 38, 60]]], ["This effect was shown to be due to a lack of T cell production of Th2 cytokines, IL-13, IL-4 and the eosinophil growth factor IL-5 (Das et al., 2001), and also the chemokine eotaxin (Yang et al., 1998).Asthma ::: Nuclear factor-\u03baB in asthma and chronic obstructive pulmonary disease: evidence from expression levels in diseased tissue, models using gene deficient mice, and in vitro assaysSince, IKK-\u03b2 plays a crucial role in the classical NF-\u03baB pathway, there has been considerable interest in studying and developing ways to manipulate this kinase.", [["T cell", "ANATOMY", 45, 51], ["pulmonary", "ANATOMY", 265, 274], ["tissue", "ANATOMY", 328, 334], ["Asthma", "DISEASE", 202, 208], ["asthma", "DISEASE", 234, 240], ["chronic obstructive pulmonary disease", "DISEASE", 245, 282], ["T cell", "CELL", 45, 51], ["IL-13", "GENE_OR_GENE_PRODUCT", 81, 86], ["IL-4", "GENE_OR_GENE_PRODUCT", 88, 92], ["eosinophil", "CELL", 101, 111], ["IL-5", "GENE_OR_GENE_PRODUCT", 126, 130], ["eotaxin", "GENE_OR_GENE_PRODUCT", 174, 181], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 213, 230], ["pulmonary", "ORGAN", 265, 274], ["tissue", "TISSUE", 328, 334], ["mice", "ORGANISM", 364, 368], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 396, 401], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 440, 445], ["Th2 cytokines", "PROTEIN", 66, 79], ["IL-13", "PROTEIN", 81, 86], ["IL-4", "PROTEIN", 88, 92], ["eosinophil growth factor IL-5", "PROTEIN", 101, 130], ["chemokine", "PROTEIN", 164, 173], ["eotaxin", "PROTEIN", 174, 181], ["Nuclear factor-\u03baB", "PROTEIN", 213, 230], ["IKK", "PROTEIN", 396, 399], ["-\u03b2", "PROTEIN", 399, 401], ["NF-\u03baB", "PROTEIN", 440, 445], ["kinase", "PROTEIN", 543, 549], ["mice", "SPECIES", 364, 368], ["T cell production", "PROBLEM", 45, 62], ["Th2 cytokines", "TEST", 66, 79], ["IL", "TEST", 81, 83], ["IL", "TEST", 88, 90], ["the eosinophil growth factor IL", "TEST", 97, 128], ["the chemokine eotaxin", "TREATMENT", 160, 181], ["Asthma", "PROBLEM", 202, 208], ["Nuclear factor", "TEST", 213, 227], ["asthma", "PROBLEM", 234, 240], ["chronic obstructive pulmonary disease", "PROBLEM", 245, 282], ["expression levels in diseased tissue", "PROBLEM", 298, 334], ["gene deficient mice", "TREATMENT", 349, 368], ["vitro assays", "TEST", 377, 389], ["asthma", "OBSERVATION", 234, 240], ["chronic", "OBSERVATION_MODIFIER", 245, 252], ["obstructive", "OBSERVATION", 253, 264], ["pulmonary", "ANATOMY", 265, 274], ["disease", "OBSERVATION", 275, 282], ["diseased tissue", "OBSERVATION_MODIFIER", 319, 334]]], ["Initial IKK-\u03b2 gene deletion studies in mice resulted in TNF\u03b1-dependent liver degeneration which led to embryonic lethality (Li et al., 1999a, Li et al., 1999b).", [["liver", "ANATOMY", 71, 76], ["embryonic", "ANATOMY", 103, 112], ["liver degeneration", "DISEASE", 71, 89], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 8, 13], ["mice", "ORGANISM", 39, 43], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 56, 60], ["liver", "ORGAN", 71, 76], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 103, 112], ["IKK", "PROTEIN", 8, 11], ["TNF\u03b1", "PROTEIN", 56, 60], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 39, 43], ["Initial IKK", "TEST", 0, 11], ["gene deletion studies", "TEST", 14, 35], ["TNF", "PROBLEM", 56, 59], ["dependent liver degeneration", "PROBLEM", 61, 89], ["embryonic lethality", "PROBLEM", 103, 122], ["liver", "ANATOMY", 71, 76], ["degeneration", "OBSERVATION", 77, 89]]], ["This limitation has been overcome through the creation of tissue specific deficient mice, with targeted deletion of IKK-\u03b2 in Clara epithelial cells in the bronchial tissue (Broide et al., 2005).", [["tissue", "ANATOMY", 58, 64], ["Clara epithelial cells", "ANATOMY", 125, 147], ["bronchial tissue", "ANATOMY", 155, 171], ["tissue", "TISSUE", 58, 64], ["mice", "ORGANISM", 84, 88], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 116, 121], ["Clara epithelial cells", "CELL", 125, 147], ["bronchial tissue", "TISSUE", 155, 171], ["IKK", "PROTEIN", 116, 119], ["\u03b2", "PROTEIN", 120, 121], ["Clara epithelial cells", "CELL_TYPE", 125, 147], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["IKK", "TEST", 116, 119], ["IKK", "OBSERVATION_MODIFIER", 116, 119], ["Clara epithelial cells", "OBSERVATION", 125, 147], ["bronchial tissue", "ANATOMY", 155, 171]]], ["Upon OVA sensitisation and challenge, airway eosinophils, mucus, peribronchiolar fibrosis, eotaxin and the Th2 T cell chemokine TARC were reduced compared to littermate controls with functional IKK-\u03b2.", [["airway eosinophils", "ANATOMY", 38, 56], ["mucus", "ANATOMY", 58, 63], ["peribronchiolar", "ANATOMY", 65, 80], ["Th2 T cell", "ANATOMY", 107, 117], ["fibrosis", "DISEASE", 81, 89], ["airway eosinophils", "CELL", 38, 56], ["mucus", "MULTI-TISSUE_STRUCTURE", 58, 63], ["eotaxin", "GENE_OR_GENE_PRODUCT", 91, 98], ["Th2 T cell chemokine TARC", "GENE_OR_GENE_PRODUCT", 107, 132], ["IKK", "GENE_OR_GENE_PRODUCT", 194, 197], ["airway eosinophils", "CELL_TYPE", 38, 56], ["eotaxin", "PROTEIN", 91, 98], ["Th2 T cell chemokine", "PROTEIN", 107, 127], ["TARC", "PROTEIN", 128, 132], ["IKK", "PROTEIN", 194, 197], ["OVA sensitisation", "TEST", 5, 22], ["airway eosinophils", "TEST", 38, 56], ["mucus", "PROBLEM", 58, 63], ["peribronchiolar fibrosis", "PROBLEM", 65, 89], ["eotaxin", "TREATMENT", 91, 98], ["the Th2 T cell chemokine TARC", "TREATMENT", 103, 132], ["airway", "ANATOMY", 38, 44], ["mucus", "ANATOMY", 58, 63], ["peribronchiolar fibrosis", "OBSERVATION", 65, 89]]], ["This work demonstrated the importance of NF-\u03baB signalling in both allergic inflammation and mucus production that are relevant to asthma.Asthma ::: Nuclear factor-\u03baB in asthma and chronic obstructive pulmonary disease: evidence from expression levels in diseased tissue, models using gene deficient mice, and in vitro assaysThere is also an extensive literature concerning NF-\u03baB inhibition in lung cells in vitro, using a range of pharmacological inhibitors, dominant negative kinase mutants (Nasuhara et al., 1999, Li et al., 2003, Catley et al., 2005) and constitutively expressed I\u03baB proteins that sequester NF-\u03baB in the cytoplasm (Thomas et al., 1998, Ciesielski et al., 2002).", [["mucus", "ANATOMY", 92, 97], ["pulmonary", "ANATOMY", 200, 209], ["tissue", "ANATOMY", 263, 269], ["lung cells", "ANATOMY", 393, 403], ["cytoplasm", "ANATOMY", 624, 633], ["allergic inflammation", "DISEASE", 66, 87], ["asthma", "DISEASE", 130, 136], ["Asthma", "DISEASE", 137, 143], ["asthma", "DISEASE", 169, 175], ["chronic obstructive pulmonary disease", "DISEASE", 180, 217], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 41, 46], ["mucus", "ORGANISM_SUBSTANCE", 92, 97], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 148, 165], ["pulmonary", "ORGAN", 200, 209], ["tissue", "TISSUE", 263, 269], ["mice", "ORGANISM", 299, 303], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 373, 378], ["lung cells", "CELL", 393, 403], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 583, 586], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 611, 616], ["cytoplasm", "ORGANISM_SUBSTANCE", 624, 633], ["NF-\u03baB", "PROTEIN", 41, 46], ["Nuclear factor-\u03baB", "PROTEIN", 148, 165], ["NF-\u03baB", "PROTEIN", 373, 378], ["lung cells", "CELL_TYPE", 393, 403], ["dominant negative kinase mutants", "PROTEIN", 459, 491], ["I\u03baB proteins", "PROTEIN", 583, 595], ["NF-\u03baB", "PROTEIN", 611, 616], ["mice", "SPECIES", 299, 303], ["both allergic inflammation", "PROBLEM", 61, 87], ["mucus production", "PROBLEM", 92, 108], ["asthma", "PROBLEM", 130, 136], ["Asthma", "PROBLEM", 137, 143], ["Nuclear factor", "TEST", 148, 162], ["asthma", "PROBLEM", 169, 175], ["chronic obstructive pulmonary disease", "PROBLEM", 180, 217], ["expression levels in diseased tissue", "PROBLEM", 233, 269], ["gene deficient mice", "TREATMENT", 284, 303], ["vitro assays", "TEST", 312, 324], ["NF", "PROBLEM", 373, 375], ["B inhibition in lung cells", "PROBLEM", 377, 403], ["pharmacological inhibitors", "TREATMENT", 431, 457], ["dominant negative kinase mutants", "PROBLEM", 459, 491], ["both", "OBSERVATION_MODIFIER", 61, 65], ["allergic inflammation", "OBSERVATION", 66, 87], ["mucus production", "OBSERVATION", 92, 108], ["asthma", "OBSERVATION", 130, 136], ["asthma", "OBSERVATION", 169, 175], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["obstructive", "OBSERVATION", 188, 199], ["pulmonary", "ANATOMY", 200, 209], ["disease", "OBSERVATION", 210, 217], ["diseased tissue", "OBSERVATION_MODIFIER", 254, 269], ["extensive", "OBSERVATION_MODIFIER", 341, 350], ["lung", "ANATOMY", 393, 397]]], ["These studies not only further underscore the importance of NF-\u03baB signalling in the generation of pro-inflammatory cytokines, chemokines and adhesion molecules (Nasuhara et al., 1999, Catley et al., 2004, Birrell et al., 2005a, Catley et al., 2005, Catley et al., 2006, Li et al., 2006, Dajani et al., 2007, Newton et al., 2007), and also as outcomes of both viral (Zhu et al., 1996, Zhu et al., 1997, Kim et al., 2000, Edwards et al., 2006b, Edwards et al., 2007) and bacterial infection (Krull et al., 2006), but provide a highly useful testing ground for research and development into improved therapeutics.Chronic obstructive pulmonary disease ::: Nuclear factor-\u03baB in asthma and chronic obstructive pulmonary disease: evidence from expression levels in diseased tissue, models using gene deficient mice, and in vitro assaysAs with asthma, much of the research effort in developing treatments has focused on inhibiting the inflammation associated with COPD.", [["pulmonary", "ANATOMY", 630, 639], ["pulmonary", "ANATOMY", 704, 713], ["tissue", "ANATOMY", 767, 773], ["bacterial infection", "DISEASE", 469, 488], ["Chronic obstructive pulmonary disease", "DISEASE", 610, 647], ["asthma", "DISEASE", 673, 679], ["chronic obstructive pulmonary disease", "DISEASE", 684, 721], ["asthma", "DISEASE", 836, 842], ["inflammation", "DISEASE", 927, 939], ["COPD", "DISEASE", 956, 960], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 60, 65], ["pulmonary", "ORGAN", 630, 639], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 652, 669], ["pulmonary", "ORGAN", 704, 713], ["tissue", "TISSUE", 767, 773], ["mice", "ORGANISM", 803, 807], ["NF-\u03baB", "PROTEIN", 60, 65], ["pro-inflammatory cytokines", "PROTEIN", 98, 124], ["chemokines", "PROTEIN", 126, 136], ["adhesion molecules", "PROTEIN", 141, 159], ["Nuclear factor-\u03baB", "PROTEIN", 652, 669], ["mice", "SPECIES", 803, 807], ["These studies", "TEST", 0, 13], ["pro-inflammatory cytokines", "TREATMENT", 98, 124], ["bacterial infection", "PROBLEM", 469, 488], ["Chronic obstructive pulmonary disease", "PROBLEM", 610, 647], ["Nuclear factor", "TEST", 652, 666], ["asthma", "PROBLEM", 673, 679], ["chronic obstructive pulmonary disease", "PROBLEM", 684, 721], ["expression levels in diseased tissue", "PROBLEM", 737, 773], ["gene deficient mice", "TREATMENT", 788, 807], ["vitro assays", "TEST", 816, 828], ["asthma", "PROBLEM", 836, 842], ["developing treatments", "TREATMENT", 875, 896], ["the inflammation", "PROBLEM", 923, 939], ["COPD", "PROBLEM", 956, 960], ["pro-inflammatory cytokines", "OBSERVATION", 98, 124], ["bacterial", "OBSERVATION_MODIFIER", 469, 478], ["infection", "OBSERVATION", 479, 488], ["obstructive", "OBSERVATION_MODIFIER", 618, 629], ["pulmonary", "ANATOMY", 630, 639], ["disease", "OBSERVATION", 640, 647], ["asthma", "OBSERVATION", 673, 679], ["chronic", "OBSERVATION_MODIFIER", 684, 691], ["obstructive", "OBSERVATION", 692, 703], ["pulmonary", "ANATOMY", 704, 713], ["disease", "OBSERVATION", 714, 721], ["diseased tissue", "OBSERVATION_MODIFIER", 758, 773], ["asthma", "OBSERVATION", 836, 842], ["inflammation", "OBSERVATION", 927, 939], ["COPD", "OBSERVATION", 956, 960]]], ["Increased markers of NF-\u03baB pathway activity have been demonstrated in the airways of, or samples from, COPD patients, including sputum macrophages (Caramori et al., 2003) during exacerbations of COPD, and also in bronchial biopsies of stable COPD patients (Di Stefano et al., 2002).", [["airways", "ANATOMY", 74, 81], ["samples", "ANATOMY", 89, 96], ["sputum macrophages", "ANATOMY", 128, 146], ["bronchial biopsies", "ANATOMY", 213, 231], ["COPD", "DISEASE", 103, 107], ["COPD", "DISEASE", 195, 199], ["COPD", "DISEASE", 242, 246], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 21, 26], ["airways", "MULTI-TISSUE_STRUCTURE", 74, 81], ["patients", "ORGANISM", 108, 116], ["sputum macrophages", "CELL", 128, 146], ["bronchial biopsies", "MULTI-TISSUE_STRUCTURE", 213, 231], ["patients", "ORGANISM", 247, 255], ["NF-\u03baB", "PROTEIN", 21, 26], ["sputum macrophages", "CELL_TYPE", 128, 146], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 247, 255], ["Increased markers of NF", "PROBLEM", 0, 23], ["COPD", "PROBLEM", 103, 107], ["sputum macrophages", "PROBLEM", 128, 146], ["COPD", "PROBLEM", 195, 199], ["bronchial biopsies", "TEST", 213, 231], ["airways", "ANATOMY", 74, 81], ["COPD", "OBSERVATION", 195, 199], ["bronchial", "ANATOMY", 213, 222], ["biopsies", "OBSERVATION", 223, 231], ["stable", "OBSERVATION_MODIFIER", 235, 241], ["COPD", "OBSERVATION", 242, 246]]], ["In rodent models of COPD involving CS exposure (Marwick et al., 2004) and over expression of the Th2 cytokine IL-13 (Chapoval et al., 2007), NF-\u03baB activation has been implicated in disease pathogenesis.Chronic obstructive pulmonary disease ::: Nuclear factor-\u03baB in asthma and chronic obstructive pulmonary disease: evidence from expression levels in diseased tissue, models using gene deficient mice, and in vitro assaysIt has been shown that over expression of IKK-\u03b2 in mouse airway epithelial cells results in an increase in inflammatory mediators and neutrophilic inflammation that is reminiscent of the COPD airway following bacterial challenge (Sadikot et al., 2006).", [["pulmonary", "ANATOMY", 222, 231], ["pulmonary", "ANATOMY", 296, 305], ["tissue", "ANATOMY", 359, 365], ["airway epithelial cells", "ANATOMY", 477, 500], ["neutrophilic", "ANATOMY", 554, 566], ["airway", "ANATOMY", 612, 618], ["COPD", "DISEASE", 20, 24], ["Chronic obstructive pulmonary disease", "DISEASE", 202, 239], ["asthma", "DISEASE", 265, 271], ["chronic obstructive pulmonary disease", "DISEASE", 276, 313], ["inflammation", "DISEASE", 567, 579], ["COPD", "DISEASE", 607, 611], ["IL-13", "GENE_OR_GENE_PRODUCT", 110, 115], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 141, 146], ["pulmonary", "ORGAN", 222, 231], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 244, 261], ["pulmonary", "ORGAN", 296, 305], ["tissue", "TISSUE", 359, 365], ["mice", "ORGANISM", 395, 399], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 462, 467], ["mouse", "ORGANISM", 471, 476], ["airway epithelial cells", "CELL", 477, 500], ["airway", "MULTI-TISSUE_STRUCTURE", 612, 618], ["Th2 cytokine IL-13", "PROTEIN", 97, 115], ["NF-\u03baB", "PROTEIN", 141, 146], ["Nuclear factor-\u03baB", "PROTEIN", 244, 261], ["IKK", "PROTEIN", 462, 465], ["\u03b2", "PROTEIN", 466, 467], ["mouse airway epithelial cells", "CELL_TYPE", 471, 500], ["inflammatory mediators", "PROTEIN", 527, 549], ["mice", "SPECIES", 395, 399], ["mouse", "SPECIES", 471, 476], ["mouse", "SPECIES", 471, 476], ["COPD", "PROBLEM", 20, 24], ["CS exposure", "PROBLEM", 35, 46], ["the Th2 cytokine IL", "TREATMENT", 93, 112], ["disease pathogenesis", "PROBLEM", 181, 201], ["Chronic obstructive pulmonary disease", "PROBLEM", 202, 239], ["Nuclear factor", "TEST", 244, 258], ["asthma", "PROBLEM", 265, 271], ["chronic obstructive pulmonary disease", "PROBLEM", 276, 313], ["expression levels in diseased tissue", "PROBLEM", 329, 365], ["gene deficient mice", "TREATMENT", 380, 399], ["vitro assays", "TEST", 408, 420], ["IKK", "TEST", 462, 465], ["mouse airway epithelial cells", "PROBLEM", 471, 500], ["inflammatory mediators", "PROBLEM", 527, 549], ["neutrophilic inflammation", "PROBLEM", 554, 579], ["the COPD airway", "PROBLEM", 603, 618], ["bacterial challenge", "TREATMENT", 629, 648], ["COPD", "OBSERVATION", 20, 24], ["obstructive", "OBSERVATION_MODIFIER", 210, 221], ["pulmonary", "ANATOMY", 222, 231], ["disease", "OBSERVATION", 232, 239], ["asthma", "OBSERVATION", 265, 271], ["chronic", "OBSERVATION_MODIFIER", 276, 283], ["obstructive", "OBSERVATION", 284, 295], ["pulmonary", "ANATOMY", 296, 305], ["disease", "OBSERVATION", 306, 313], ["diseased tissue", "OBSERVATION_MODIFIER", 350, 365], ["airway", "ANATOMY", 477, 483], ["epithelial cells", "OBSERVATION", 484, 500], ["increase", "OBSERVATION_MODIFIER", 515, 523], ["inflammatory", "OBSERVATION_MODIFIER", 527, 539], ["neutrophilic inflammation", "OBSERVATION", 554, 579], ["COPD", "OBSERVATION", 607, 611], ["airway", "ANATOMY", 612, 618]]], ["In addition, inhibition of IKK-\u03b2 in vivo and in vitro reduced TNF-\u03b1 induced MUC5AC production, one of the major components of respiratory mucus (Lora et al., 2005).", [["respiratory mucus", "ANATOMY", 126, 143], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 27, 32], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 62, 67], ["MUC5AC", "GENE_OR_GENE_PRODUCT", 76, 82], ["mucus", "ORGANISM_SUBSTANCE", 138, 143], ["IKK", "PROTEIN", 27, 30], ["\u03b2", "PROTEIN", 31, 32], ["TNF", "PROTEIN", 62, 65], ["MUC5AC", "PROTEIN", 76, 82], ["IKK", "TEST", 27, 30], ["TNF", "TEST", 62, 65], ["MUC5AC production", "PROBLEM", 76, 93], ["reduced", "OBSERVATION_MODIFIER", 54, 61], ["TNF", "OBSERVATION", 62, 65], ["respiratory mucus", "ANATOMY", 126, 143]]], ["Production of another important respiratory mucin, MUC5B has also been shown to be IKK-\u03b2 dependent, following RV infection in vitro (N. Bartlett, unpublished observations).", [["RV infection", "DISEASE", 110, 122], ["mucin", "GENE_OR_GENE_PRODUCT", 44, 49], ["MUC5B", "GENE_OR_GENE_PRODUCT", 51, 56], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 83, 88], ["respiratory mucin", "PROTEIN", 32, 49], ["MUC5B", "PROTEIN", 51, 56], ["IKK", "PROTEIN", 83, 86], ["\u03b2", "PROTEIN", 87, 88], ["IKK", "TEST", 83, 86], ["\u03b2 dependent", "PROBLEM", 87, 98], ["RV infection", "PROBLEM", 110, 122], ["respiratory mucin", "OBSERVATION", 32, 49], ["RV", "ANATOMY", 110, 112], ["infection", "OBSERVATION", 113, 122]]], ["Hence growing evidence supports a role of NF-\u03baB signalling in COPD pathogenesis.Chronic obstructive pulmonary disease ::: Nuclear factor-\u03baB in asthma and chronic obstructive pulmonary disease: evidence from expression levels in diseased tissue, models using gene deficient mice, and in vitro assaysIn vitro systems have also been used to highlight a critical role for IKK-\u03b2 in the activation of NF-\u03baB (Conron et al., 2002).", [["pulmonary", "ANATOMY", 100, 109], ["pulmonary", "ANATOMY", 174, 183], ["tissue", "ANATOMY", 237, 243], ["COPD", "DISEASE", 62, 66], ["Chronic obstructive pulmonary disease", "DISEASE", 80, 117], ["asthma", "DISEASE", 143, 149], ["chronic obstructive pulmonary disease", "DISEASE", 154, 191], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 42, 47], ["pulmonary", "ORGAN", 100, 109], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 122, 139], ["pulmonary", "ORGAN", 174, 183], ["tissue", "TISSUE", 237, 243], ["mice", "ORGANISM", 273, 277], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 368, 373], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 395, 400], ["NF-\u03baB", "PROTEIN", 42, 47], ["Nuclear factor-\u03baB", "PROTEIN", 122, 139], ["IKK", "PROTEIN", 368, 371], ["\u03b2", "PROTEIN", 372, 373], ["NF-\u03baB", "PROTEIN", 395, 400], ["mice", "SPECIES", 273, 277], ["NF", "PROBLEM", 42, 44], ["COPD pathogenesis", "PROBLEM", 62, 79], ["Chronic obstructive pulmonary disease", "PROBLEM", 80, 117], ["Nuclear factor", "TEST", 122, 136], ["asthma", "PROBLEM", 143, 149], ["chronic obstructive pulmonary disease", "PROBLEM", 154, 191], ["expression levels in diseased tissue", "PROBLEM", 207, 243], ["gene deficient mice", "TREATMENT", 258, 277], ["vitro assays", "TEST", 286, 298], ["IKK", "TEST", 368, 371], ["COPD", "OBSERVATION", 62, 66], ["obstructive", "OBSERVATION_MODIFIER", 88, 99], ["pulmonary", "ANATOMY", 100, 109], ["disease", "OBSERVATION", 110, 117], ["asthma", "OBSERVATION", 143, 149], ["chronic", "OBSERVATION_MODIFIER", 154, 161], ["obstructive", "OBSERVATION", 162, 173], ["pulmonary", "ANATOMY", 174, 183], ["disease", "OBSERVATION", 184, 191], ["diseased tissue", "OBSERVATION_MODIFIER", 228, 243]]], ["Transfection of alveolar macrophages with adenovirus constructs expressing defective IKK-\u03b2 but not NIK proteins inhibited macrophage activation of NF-\u03baB, and expression of TNF-\u03b1, IL-8/CXCL8 and IL-6.", [["alveolar macrophages", "ANATOMY", 16, 36], ["macrophage", "ANATOMY", 122, 132], ["alveolar macrophages", "CELL", 16, 36], ["adenovirus", "ORGANISM", 42, 52], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 85, 90], ["NIK", "GENE_OR_GENE_PRODUCT", 99, 102], ["macrophage", "CELL", 122, 132], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 147, 152], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 172, 177], ["IL-8", "GENE_OR_GENE_PRODUCT", 179, 183], ["CXCL8", "GENE_OR_GENE_PRODUCT", 184, 189], ["IL-6", "GENE_OR_GENE_PRODUCT", 194, 198], ["alveolar macrophages", "CELL_TYPE", 16, 36], ["IKK", "PROTEIN", 85, 88], ["\u03b2", "PROTEIN", 89, 90], ["NIK proteins", "PROTEIN", 99, 111], ["NF-\u03baB", "PROTEIN", 147, 152], ["TNF", "PROTEIN", 172, 175], ["IL-8", "PROTEIN", 179, 183], ["CXCL8", "PROTEIN", 184, 189], ["IL-6", "PROTEIN", 194, 198], ["alveolar macrophages", "PROBLEM", 16, 36], ["adenovirus constructs", "PROBLEM", 42, 63], ["defective IKK", "TEST", 75, 88], ["NIK proteins", "PROBLEM", 99, 111], ["macrophage activation", "TEST", 122, 143], ["NF", "TEST", 147, 149], ["TNF", "TEST", 172, 175], ["IL", "TEST", 179, 181], ["CXCL8", "TEST", 184, 189], ["IL", "TEST", 194, 196], ["alveolar macrophages", "OBSERVATION", 16, 36]]], ["Monocyte derived macrophages infected in vitro with RV produce TNF-\u03b1 in a NF-\u03baB dependent manner, which is sensitive to treatment with the IKK-\u03b2 inhibitor AS206828 (Laza-Stanca et al., 2006).Chronic obstructive pulmonary disease ::: Nuclear factor-\u03baB in asthma and chronic obstructive pulmonary disease: evidence from expression levels in diseased tissue, models using gene deficient mice, and in vitro assaysOne possible caveat to NF-\u03baB inhibition in asthma or COPD is the suppression of beneficial host responses.", [["Monocyte", "ANATOMY", 0, 8], ["macrophages", "ANATOMY", 17, 28], ["pulmonary", "ANATOMY", 211, 220], ["pulmonary", "ANATOMY", 285, 294], ["tissue", "ANATOMY", 348, 354], ["AS206828", "CHEMICAL", 155, 163], ["Chronic obstructive pulmonary disease", "DISEASE", 191, 228], ["asthma", "DISEASE", 254, 260], ["chronic obstructive pulmonary disease", "DISEASE", 265, 302], ["asthma", "DISEASE", 452, 458], ["COPD", "DISEASE", 462, 466], ["AS206828", "CHEMICAL", 155, 163], ["Monocyte derived macrophages", "CELL", 0, 28], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 63, 68], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 74, 79], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 139, 144], ["AS206828", "SIMPLE_CHEMICAL", 155, 163], ["pulmonary", "ORGAN", 211, 220], ["Nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 233, 250], ["pulmonary", "ORGAN", 285, 294], ["tissue", "TISSUE", 348, 354], ["mice", "ORGANISM", 384, 388], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 432, 437], ["Monocyte derived macrophages", "CELL_TYPE", 0, 28], ["TNF", "PROTEIN", 63, 66], ["IKK", "PROTEIN", 139, 142], ["Nuclear factor-\u03baB", "PROTEIN", 233, 250], ["NF-\u03baB", "PROTEIN", 432, 437], ["mice", "SPECIES", 384, 388], ["Monocyte derived macrophages", "PROBLEM", 0, 28], ["treatment", "TREATMENT", 120, 129], ["the IKK", "TREATMENT", 135, 142], ["inhibitor", "TREATMENT", 145, 154], ["Chronic obstructive pulmonary disease", "PROBLEM", 191, 228], ["Nuclear factor", "TEST", 233, 247], ["asthma", "PROBLEM", 254, 260], ["chronic obstructive pulmonary disease", "PROBLEM", 265, 302], ["expression levels in diseased tissue", "PROBLEM", 318, 354], ["gene deficient mice", "TREATMENT", 369, 388], ["vitro assays", "TEST", 397, 409], ["caveat to NF", "PROBLEM", 422, 434], ["\u03baB inhibition", "PROBLEM", 435, 448], ["asthma", "PROBLEM", 452, 458], ["COPD", "PROBLEM", 462, 466], ["macrophages", "OBSERVATION_MODIFIER", 17, 28], ["infected", "OBSERVATION", 29, 37], ["TNF", "OBSERVATION", 63, 66], ["obstructive", "OBSERVATION_MODIFIER", 199, 210], ["pulmonary", "ANATOMY", 211, 220], ["disease", "OBSERVATION", 221, 228], ["asthma", "OBSERVATION", 254, 260], ["chronic", "OBSERVATION_MODIFIER", 265, 272], ["obstructive", "OBSERVATION", 273, 284], ["pulmonary", "ANATOMY", 285, 294], ["disease", "OBSERVATION", 295, 302], ["diseased tissue", "OBSERVATION_MODIFIER", 339, 354], ["asthma", "OBSERVATION", 452, 458], ["COPD", "OBSERVATION", 462, 466]]], ["This is most likely in asthma or COPD exacerbations, which have a viral or bacterial aetiology.", [["asthma", "DISEASE", 23, 29], ["COPD", "DISEASE", 33, 37], ["asthma", "PROBLEM", 23, 29], ["COPD exacerbations", "PROBLEM", 33, 51], ["a viral or bacterial aetiology", "PROBLEM", 64, 94], ["most likely", "UNCERTAINTY", 8, 19], ["asthma", "OBSERVATION", 23, 29], ["COPD", "OBSERVATION", 33, 37], ["viral", "OBSERVATION_MODIFIER", 66, 71], ["bacterial aetiology", "OBSERVATION", 75, 94]]], ["In asthma, recent data highlight the importance of type I IFN-\u03b2 and type III IFN-\u03bbs as crucial to the host defence against viral infections (Wark et al., 2005, Contoli et al., 2006).", [["asthma", "DISEASE", 3, 9], ["viral infections", "DISEASE", 123, 139], ["type I IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 51, 63], ["type III IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 68, 83], ["type I IFN", "PROTEIN", 51, 61], ["\u03b2", "PROTEIN", 62, 63], ["type III IFN-\u03bbs", "PROTEIN", 68, 83], ["asthma", "PROBLEM", 3, 9], ["type I IFN", "PROBLEM", 51, 61], ["type III IFN-\u03bbs", "PROBLEM", 68, 83], ["viral infections", "PROBLEM", 123, 139], ["asthma", "OBSERVATION", 3, 9]]], ["As IFN-\u03b2 and IFN-\u03bb are induced by viruses in an NF-\u03baB dependent manner (Thanos and Maniatis, 1995, Wathelet et al., 1998, Chu et al., 1999, Osterlund et al., 2005), targeting NF-\u03baB in asthma and COPD may not only reduce harmful pro-inflammatory and allergen induced responses, but may also reduce beneficial anti-viral responses.", [["asthma", "DISEASE", 184, 190], ["COPD", "DISEASE", 195, 199], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 3, 8], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 13, 18], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 48, 53], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 175, 180], ["IFN", "PROTEIN", 3, 6], ["\u03b2", "PROTEIN", 7, 8], ["IFN", "PROTEIN", 13, 16], ["\u03bb", "PROTEIN", 17, 18], ["NF-\u03baB", "PROTEIN", 175, 180], ["IFN", "TEST", 3, 6], ["IFN", "PROBLEM", 13, 16], ["asthma", "PROBLEM", 184, 190], ["COPD", "PROBLEM", 195, 199], ["viruses", "OBSERVATION", 34, 41], ["asthma", "OBSERVATION", 184, 190], ["COPD", "OBSERVATION", 195, 199]]], ["This issue requires clarification in appropriate animal models before targeting NF-\u03baB in viral induced asthma exacerbations can be applied in human studies.", [["asthma", "DISEASE", 103, 109], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 80, 85], ["human", "ORGANISM", 142, 147], ["NF-\u03baB", "PROTEIN", 80, 85], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147], ["NF", "PROBLEM", 80, 82], ["viral induced asthma exacerbations", "PROBLEM", 89, 123], ["human studies", "TEST", 142, 155], ["viral induced", "OBSERVATION_MODIFIER", 89, 102], ["asthma", "OBSERVATION", 103, 109]]], ["A list of cytokines, chemokines and other molecules regulated in an NF-\u03baB dependent manner associated with asthma or COPD is provided in Table 1.Corticosteroid based treatments ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBInhaled or oral GCs remain the most effective treatment for asthma and COPD.", [["oral", "ANATOMY", 256, 260], ["asthma", "DISEASE", 107, 113], ["COPD", "DISEASE", 117, 121], ["asthma", "DISEASE", 305, 311], ["COPD", "DISEASE", 316, 320], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 68, 73], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 228, 244], ["cytokines", "PROTEIN", 10, 19], ["chemokines", "PROTEIN", 21, 31], ["NF-\u03baB", "PROTEIN", 68, 73], ["cytokines", "TREATMENT", 10, 19], ["chemokines", "TREATMENT", 21, 31], ["asthma", "PROBLEM", 107, 113], ["COPD", "PROBLEM", 117, 121], ["Corticosteroid based treatments", "TREATMENT", 145, 176], ["Available inhibitors", "TREATMENT", 181, 201], ["nuclear factor", "TEST", 228, 242], ["oral GCs", "PROBLEM", 256, 264], ["asthma", "PROBLEM", 305, 311], ["COPD", "PROBLEM", 316, 320], ["asthma", "OBSERVATION", 107, 113], ["COPD", "OBSERVATION", 117, 121], ["asthma", "OBSERVATION", 305, 311], ["COPD", "OBSERVATION", 316, 320]]], ["The glucocorticoid receptor (GR) is a cytoplasmic steroid hormone receptor that undergoes a conformational change and dimerisation upon ligation with GC, and rapid nuclear translocation.", [["cytoplasmic", "ANATOMY", 38, 49], ["nuclear", "ANATOMY", 164, 171], ["steroid", "CHEMICAL", 50, 57], ["steroid", "CHEMICAL", 50, 57], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 4, 27], ["GR", "GENE_OR_GENE_PRODUCT", 29, 31], ["cytoplasmic", "ORGANISM_SUBSTANCE", 38, 49], ["nuclear", "CELLULAR_COMPONENT", 164, 171], ["glucocorticoid receptor", "PROTEIN", 4, 27], ["GR", "PROTEIN", 29, 31], ["cytoplasmic steroid hormone receptor", "PROTEIN", 38, 74], ["The glucocorticoid receptor (GR)", "TREATMENT", 0, 32], ["a cytoplasmic steroid hormone receptor", "TREATMENT", 36, 74], ["a conformational change and dimerisation upon ligation", "TREATMENT", 90, 144], ["GC", "TEST", 150, 152], ["rapid nuclear translocation", "PROBLEM", 158, 185], ["rapid", "OBSERVATION_MODIFIER", 158, 163], ["nuclear translocation", "OBSERVATION", 164, 185]]], ["In vitro studies show that GR acts via a range of different mechanisms, including prevention of NF-\u03baB interacting with it's cis-acting site, with other transcription factors, or structural proteins required for transcription through the process broadly known as trans-repression (Tuckermann et al., 1999, Tao et al., 2001).", [["GR", "GENE_OR_GENE_PRODUCT", 27, 29], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 96, 101], ["GR", "PROTEIN", 27, 29], ["NF-\u03baB", "PROTEIN", 96, 101], ["cis-acting site", "DNA", 124, 139], ["transcription factors", "PROTEIN", 152, 173], ["structural proteins", "PROTEIN", 178, 197], ["vitro studies", "TEST", 3, 16], ["GR acts", "PROBLEM", 27, 34], ["NF", "PROBLEM", 96, 98], ["other transcription factors", "PROBLEM", 146, 173], ["structural proteins", "PROBLEM", 178, 197]]], ["GR activation can lead to expression of phosphatases that prevent inflammatory kinases from signalling (Issa et al., 2007), or via recruiting HDACs that prevent histone acetylation, disassociation of chromatin, and therefore NF-\u03baB binding at a given promoter (Ito et al., 2000, Ito et al., 2001).", [["chromatin", "ANATOMY", 200, 209], ["GR", "GENE_OR_GENE_PRODUCT", 0, 2], ["HDACs", "GENE_OR_GENE_PRODUCT", 142, 147], ["histone", "GENE_OR_GENE_PRODUCT", 161, 168], ["chromatin", "CELLULAR_COMPONENT", 200, 209], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 225, 230], ["GR", "PROTEIN", 0, 2], ["phosphatases", "PROTEIN", 40, 52], ["inflammatory kinases", "PROTEIN", 66, 86], ["HDACs", "PROTEIN", 142, 147], ["histone", "PROTEIN", 161, 168], ["chromatin", "DNA", 200, 209], ["NF-\u03baB", "PROTEIN", 225, 230], ["expression of phosphatases", "PROBLEM", 26, 52], ["inflammatory kinases", "PROBLEM", 66, 86], ["histone acetylation", "PROBLEM", 161, 180], ["disassociation of chromatin", "PROBLEM", 182, 209], ["inflammatory", "OBSERVATION_MODIFIER", 66, 78], ["histone acetylation", "OBSERVATION", 161, 180]]], ["How GCs impact on NF-\u03baB signalling, is shown in Fig. 2.Corticosteroid based treatments ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBGCs are often used in conjunction with other therapies, such as LABAs or leukotriene receptor antagonists.", [["leukotriene", "CHEMICAL", 228, 239], ["LABAs", "CHEMICAL", 219, 224], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 18, 23], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 138, 154], ["LABAs", "SIMPLE_CHEMICAL", 219, 224], ["leukotriene receptor antagonists", "GENE_OR_GENE_PRODUCT", 228, 260], ["NF-\u03baB", "PROTEIN", 18, 23], ["nuclear factor-\u03baBGCs", "PROTEIN", 138, 158], ["Corticosteroid based treatments", "TREATMENT", 55, 86], ["Available inhibitors", "TREATMENT", 91, 111], ["nuclear factor", "TEST", 138, 152], ["BGCs", "PROBLEM", 154, 158], ["other therapies", "TREATMENT", 194, 209], ["LABAs", "TREATMENT", 219, 224], ["leukotriene receptor antagonists", "TREATMENT", 228, 260]]], ["GC based therapies are most effective in the treatment of stable or allergic asthma, are less effective in COPD, and even less so for exacerbations of either disease (Pauwels et al., 1997, Calverley et al., 2003).", [["allergic asthma", "DISEASE", 68, 83], ["COPD", "DISEASE", 107, 111], ["GC based therapies", "TREATMENT", 0, 18], ["allergic asthma", "PROBLEM", 68, 83], ["COPD", "PROBLEM", 107, 111], ["exacerbations", "PROBLEM", 134, 147], ["either disease", "PROBLEM", 151, 165], ["most effective", "OBSERVATION_MODIFIER", 23, 37], ["stable", "OBSERVATION_MODIFIER", 58, 64], ["allergic asthma", "OBSERVATION", 68, 83], ["less", "OBSERVATION_MODIFIER", 89, 93], ["effective", "OBSERVATION_MODIFIER", 94, 103], ["COPD", "OBSERVATION", 107, 111]]], ["Despite the continued reliance on GC based therapies in asthma and COPD, a major research objective is to find better treatments for exacerbations of asthma and COPD.Corticosteroid based treatments ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBSeveral studies have examined the efficacy of GC based therapies in reducing NF-\u03baB activity from ex vivo material, with mixed results.", [["asthma", "DISEASE", 56, 62], ["COPD", "DISEASE", 67, 71], ["asthma", "DISEASE", 150, 156], ["COPD", "DISEASE", 161, 165], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 249, 265], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 343, 348], ["nuclear factor-\u03ba", "PROTEIN", 249, 265], ["NF-\u03baB", "PROTEIN", 343, 348], ["GC based therapies", "TREATMENT", 34, 52], ["asthma", "PROBLEM", 56, 62], ["COPD", "PROBLEM", 67, 71], ["exacerbations", "PROBLEM", 133, 146], ["asthma", "PROBLEM", 150, 156], ["COPD", "PROBLEM", 161, 165], ["Corticosteroid based treatments", "TREATMENT", 166, 197], ["Available inhibitors", "TREATMENT", 202, 222], ["nuclear factor", "TEST", 249, 263], ["BSeveral studies", "TEST", 265, 281], ["GC based therapies", "TREATMENT", 312, 330], ["reducing NF", "TREATMENT", 334, 345], ["asthma", "OBSERVATION", 56, 62], ["COPD", "OBSERVATION", 67, 71], ["asthma", "OBSERVATION", 150, 156], ["COPD", "OBSERVATION", 161, 165]]], ["In patients with stable asthma undergoing treatment with budesonide, budesonide increased GR\u2013DNA binding in bronchial biopsies and reduced NF-\u03baB-DNA binding (Hancox et al., 1999).", [["bronchial biopsies", "ANATOMY", 108, 126], ["asthma", "DISEASE", 24, 30], ["budesonide", "CHEMICAL", 57, 67], ["budesonide", "CHEMICAL", 69, 79], ["budesonide", "CHEMICAL", 57, 67], ["budesonide", "CHEMICAL", 69, 79], ["patients", "ORGANISM", 3, 11], ["budesonide", "SIMPLE_CHEMICAL", 57, 67], ["budesonide", "SIMPLE_CHEMICAL", 69, 79], ["DNA", "CELLULAR_COMPONENT", 93, 96], ["bronchial biopsies", "MULTI-TISSUE_STRUCTURE", 108, 126], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 139, 144], ["DNA", "CELLULAR_COMPONENT", 145, 148], ["NF-\u03baB", "PROTEIN", 139, 144], ["patients", "SPECIES", 3, 11], ["stable asthma", "PROBLEM", 17, 30], ["treatment", "TREATMENT", 42, 51], ["budesonide", "TREATMENT", 57, 67], ["budesonide", "TREATMENT", 69, 79], ["bronchial biopsies", "TEST", 108, 126], ["reduced NF", "PROBLEM", 131, 141], ["stable", "OBSERVATION_MODIFIER", 17, 23], ["asthma", "OBSERVATION", 24, 30], ["bronchial", "ANATOMY", 108, 117], ["biopsies", "OBSERVATION", 118, 126]]], ["In support, Wilson et al. have demonstrated a reduction in activated NF-\u03baB staining after treatment with budesonide or the LABA formoterol (Wilson et al., 2001).", [["budesonide", "CHEMICAL", 105, 115], ["LABA", "CHEMICAL", 123, 127], ["formoterol", "CHEMICAL", 128, 138], ["budesonide", "CHEMICAL", 105, 115], ["LABA formoterol", "CHEMICAL", 123, 138], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 69, 74], ["budesonide", "SIMPLE_CHEMICAL", 105, 115], ["LABA", "SIMPLE_CHEMICAL", 123, 127], ["formoterol", "SIMPLE_CHEMICAL", 128, 138], ["NF-\u03baB", "PROTEIN", 69, 74], ["a reduction", "TREATMENT", 44, 55], ["activated NF", "TREATMENT", 59, 71], ["treatment", "TREATMENT", 90, 99], ["budesonide", "TREATMENT", 105, 115], ["the LABA formoterol", "TREATMENT", 119, 138], ["reduction", "OBSERVATION_MODIFIER", 46, 55]]], ["Bronchial biopsies from budesonide treated individuals also had significantly less IL-8, TNF-\u03b1 and GM-CSF, however no difference was observed for formoterol treated samples.", [["Bronchial biopsies", "ANATOMY", 0, 18], ["samples", "ANATOMY", 165, 172], ["budesonide", "CHEMICAL", 24, 34], ["GM", "CHEMICAL", 99, 101], ["formoterol", "CHEMICAL", 146, 156], ["budesonide", "CHEMICAL", 24, 34], ["formoterol", "CHEMICAL", 146, 156], ["Bronchial biopsies", "MULTI-TISSUE_STRUCTURE", 0, 18], ["budesonide", "SIMPLE_CHEMICAL", 24, 34], ["IL-8", "GENE_OR_GENE_PRODUCT", 83, 87], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 89, 94], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 99, 105], ["formoterol", "SIMPLE_CHEMICAL", 146, 156], ["IL-8", "PROTEIN", 83, 87], ["TNF", "PROTEIN", 89, 92], ["GM", "PROTEIN", 99, 101], ["CSF", "PROTEIN", 102, 105], ["Bronchial biopsies", "TEST", 0, 18], ["budesonide treated individuals", "TEST", 24, 54], ["IL", "TEST", 83, 85], ["TNF", "TEST", 89, 92], ["GM-CSF", "TEST", 99, 105], ["formoterol treated samples", "TREATMENT", 146, 172], ["biopsies", "OBSERVATION", 10, 18], ["CSF", "ANATOMY", 102, 105]]], ["In contrast, Hart et al., studying NF-\u03baB\u2013DNA binding in stable asthmatic bronchial biopsies and alveolar macrophages after treatment with fluticasone propionate, showed no decrease in NF-\u03baB activity compared to a placebo administered control group.", [["bronchial biopsies", "ANATOMY", 73, 91], ["alveolar macrophages", "ANATOMY", 96, 116], ["fluticasone propionate", "CHEMICAL", 138, 160], ["fluticasone propionate", "CHEMICAL", 138, 160], ["NF-\u03baB\u2013DNA", "GENE_OR_GENE_PRODUCT", 35, 44], ["bronchial biopsies", "MULTI-TISSUE_STRUCTURE", 73, 91], ["alveolar macrophages", "CELL", 96, 116], ["fluticasone propionate", "SIMPLE_CHEMICAL", 138, 160], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 184, 189], ["alveolar macrophages", "CELL_TYPE", 96, 116], ["NF-\u03baB", "PROTEIN", 184, 189], ["stable asthmatic bronchial biopsies", "TREATMENT", 56, 91], ["alveolar macrophages", "PROBLEM", 96, 116], ["fluticasone propionate", "TREATMENT", 138, 160], ["decrease in NF", "PROBLEM", 172, 186], ["a placebo administered control group", "TREATMENT", 211, 247], ["stable", "OBSERVATION_MODIFIER", 56, 62], ["asthmatic", "OBSERVATION_MODIFIER", 63, 72], ["bronchial", "ANATOMY", 73, 82], ["biopsies", "OBSERVATION", 83, 91], ["alveolar macrophages", "OBSERVATION", 96, 116], ["no", "UNCERTAINTY", 169, 171], ["decrease", "OBSERVATION_MODIFIER", 172, 180]]], ["Fluticasone was effective however at reducing BAL eosinophils and improved lung function (Hart et al., 2000).", [["BAL eosinophils", "ANATOMY", 46, 61], ["lung", "ANATOMY", 75, 79], ["Fluticasone", "CHEMICAL", 0, 11], ["Fluticasone", "CHEMICAL", 0, 11], ["Fluticasone", "SIMPLE_CHEMICAL", 0, 11], ["BAL eosinophils", "CELL", 46, 61], ["lung", "ORGAN", 75, 79], ["BAL eosinophils", "CELL_TYPE", 46, 61], ["Fluticasone", "TREATMENT", 0, 11], ["BAL eosinophils", "TEST", 46, 61], ["improved", "OBSERVATION_MODIFIER", 66, 74], ["lung", "ANATOMY", 75, 79]]], ["Together, the data suggest that in lung tissue, GCs are incompletely effective in blocking NF-\u03baB activity and that the anti-inflammatory activity of GCs may act via other mechanisms.Corticosteroid based treatments ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBThe effectiveness of GCs in controlling NF-\u03baB mediated allergic responses from lymphocytes has also been examined.", [["lung tissue", "ANATOMY", 35, 46], ["GCs", "ANATOMY", 48, 51], ["lymphocytes", "ANATOMY", 361, 372], ["allergic", "DISEASE", 337, 345], ["lung tissue", "TISSUE", 35, 46], ["GCs", "CELL", 48, 51], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 91, 96], ["GCs", "SIMPLE_CHEMICAL", 149, 152], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 265, 281], ["GCs", "CELL", 303, 306], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 322, 327], ["lymphocytes", "CELL", 361, 372], ["NF-\u03baB", "PROTEIN", 91, 96], ["nuclear factor-\u03ba", "PROTEIN", 265, 281], ["NF-\u03baB", "PROTEIN", 322, 327], ["lymphocytes", "CELL_TYPE", 361, 372], ["the data", "TEST", 10, 18], ["GCs", "TEST", 48, 51], ["Corticosteroid based treatments", "TREATMENT", 182, 213], ["Available inhibitors", "TREATMENT", 218, 238], ["nuclear factor", "TEST", 265, 279], ["GCs", "TEST", 303, 306], ["B mediated allergic responses", "PROBLEM", 326, 355], ["lung tissue", "ANATOMY", 35, 46]]], ["T cell clones from stable asthmatics synthesised IL-5 upon stimulation with anti-TCR antibodies or IL-2 treatment (Mori et al., 1997).", [["T cell clones", "ANATOMY", 0, 13], ["T cell clones", "CELL", 0, 13], ["IL-5", "GENE_OR_GENE_PRODUCT", 49, 53], ["anti-TCR antibodies", "GENE_OR_GENE_PRODUCT", 76, 95], ["IL-2", "GENE_OR_GENE_PRODUCT", 99, 103], ["T cell clones", "CELL_LINE", 0, 13], ["IL-5", "PROTEIN", 49, 53], ["anti-TCR antibodies", "PROTEIN", 76, 95], ["T cell clones", "PROBLEM", 0, 13], ["stable asthmatics synthesised IL", "TREATMENT", 19, 51], ["anti-TCR antibodies", "TREATMENT", 76, 95], ["IL-2 treatment", "TREATMENT", 99, 113], ["cell clones", "OBSERVATION", 2, 13], ["stable", "OBSERVATION_MODIFIER", 19, 25], ["asthmatics", "OBSERVATION", 26, 36]]], ["Dexamethasone effectively reduced IL-5 synthesis in both models.", [["Dexamethasone", "CHEMICAL", 0, 13], ["Dexamethasone", "CHEMICAL", 0, 13], ["Dexamethasone", "SIMPLE_CHEMICAL", 0, 13], ["IL-5", "GENE_OR_GENE_PRODUCT", 34, 38], ["IL-5", "PROTEIN", 34, 38], ["Dexamethasone effectively reduced IL", "TREATMENT", 0, 36], ["reduced", "OBSERVATION_MODIFIER", 26, 33], ["IL", "OBSERVATION_MODIFIER", 34, 36]]], ["The authors also demonstrated that the targets for GC action were likely to be NF-\u03baB and AP-1.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 79, 84], ["AP-1", "GENE_OR_GENE_PRODUCT", 89, 93], ["NF-\u03baB", "PROTEIN", 79, 84], ["AP-1", "PROTEIN", 89, 93], ["GC action", "TEST", 51, 60], ["NF", "TEST", 79, 81], ["AP", "TEST", 89, 91]]], ["Fluticasone and salmeterol also caused decreased phospho-I\u03baB levels in asthmatic T cells (Pace et al., 2004), suggesting that I\u03baB may also be a target for GC action.Corticosteroid based treatments ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBThere are currently very few studies examining the effects of GC based therapies on NF-\u03baB expression following asthma or COPD exacerbations.", [["T cells", "ANATOMY", 81, 88], ["Fluticasone", "CHEMICAL", 0, 11], ["salmeterol", "CHEMICAL", 16, 26], ["asthma", "DISEASE", 376, 382], ["COPD", "DISEASE", 386, 390], ["Fluticasone", "CHEMICAL", 0, 11], ["salmeterol", "CHEMICAL", 16, 26], ["Fluticasone", "SIMPLE_CHEMICAL", 0, 11], ["salmeterol", "SIMPLE_CHEMICAL", 16, 26], ["phospho-I\u03baB", "GENE_OR_GENE_PRODUCT", 49, 60], ["asthmatic T cells", "CELL", 71, 88], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 126, 129], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 248, 264], ["GC", "SIMPLE_CHEMICAL", 327, 329], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 349, 354], ["I\u03baB", "PROTEIN", 57, 60], ["asthmatic T cells", "CELL_TYPE", 71, 88], ["I\u03baB", "PROTEIN", 126, 129], ["nuclear factor-\u03ba", "PROTEIN", 248, 264], ["NF-\u03baB", "PROTEIN", 349, 354], ["Fluticasone", "TREATMENT", 0, 11], ["salmeterol", "TREATMENT", 16, 26], ["decreased phospho", "PROBLEM", 39, 56], ["asthmatic T cells", "PROBLEM", 71, 88], ["GC action", "TREATMENT", 155, 164], ["Corticosteroid based treatments", "TREATMENT", 165, 196], ["Available inhibitors", "TREATMENT", 201, 221], ["nuclear factor", "TEST", 248, 262], ["GC based therapies", "TREATMENT", 327, 345], ["NF", "TREATMENT", 349, 351], ["asthma", "PROBLEM", 376, 382], ["COPD exacerbations", "PROBLEM", 386, 404], ["asthma", "OBSERVATION", 376, 382], ["COPD", "OBSERVATION", 386, 390]]], ["While clearly less effective than in stable disease, the lack of efficacy in exacerbations remains poorly understood.", [["exacerbations", "PROBLEM", 77, 90], ["less", "OBSERVATION_MODIFIER", 14, 18], ["effective", "OBSERVATION_MODIFIER", 19, 28], ["stable", "OBSERVATION_MODIFIER", 37, 43], ["disease", "OBSERVATION", 44, 51]]], ["One theory is that as most exacerbations have viral and bacterial aetiologies, this may involve distinct mechanisms, involving different cells and or molecules than in stable forms of either disease.", [["cells", "ANATOMY", 137, 142], ["cells", "CELL", 137, 142], ["viral and bacterial aetiologies", "PROBLEM", 46, 77], ["distinct mechanisms", "PROBLEM", 96, 115], ["different cells", "PROBLEM", 127, 142], ["either disease", "PROBLEM", 184, 198], ["bacterial aetiologies", "OBSERVATION", 56, 77], ["stable", "OBSERVATION_MODIFIER", 168, 174], ["disease", "OBSERVATION", 191, 198]]], ["In vitro, in normal tissue, GC based therapies reduce inflammatory mediators induced by viral and non-viral stimuli (IL-1\u03b2) with about the same efficacy (Edwards et al., 2006a, Edwards et al., 2007), arguing against the above.", [["tissue", "ANATOMY", 20, 26], ["tissue", "TISSUE", 20, 26], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 117, 122], ["inflammatory mediators", "PROTEIN", 54, 76], ["GC based therapies", "TREATMENT", 28, 46], ["inflammatory mediators", "PROBLEM", 54, 76], ["normal tissue", "OBSERVATION_MODIFIER", 13, 26]]], ["This is also supported by the fact that much of the underlying inflammation in both stable, non-viral and viral or bacterial induced exacerbations involves NF-\u03baB.", [["inflammation", "DISEASE", 63, 75], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 156, 160], ["the underlying inflammation", "PROBLEM", 48, 75], ["non-viral and viral or bacterial induced exacerbations", "PROBLEM", 92, 146], ["inflammation", "OBSERVATION", 63, 75], ["stable", "OBSERVATION_MODIFIER", 84, 90], ["bacterial induced exacerbations", "OBSERVATION", 115, 146]]], ["More research, particularly in asthmatic and COPD tissue, and the testing of known NF-\u03baB inhibitors in models of asthma or COPD exacerbation are required to carefully scrutinize these mechanisms.Decoy oligonucleotides ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBAs the cis-acting sites within various promoters have a conserved motif, NF-\u03baB decoy oligonucleotides which bind activated Rel proteins and prevent them from binding to their nuclear targets represent potential therapeutic agents.", [["COPD tissue", "ANATOMY", 45, 56], ["nuclear", "ANATOMY", 461, 468], ["asthmatic", "DISEASE", 31, 40], ["COPD", "DISEASE", 45, 49], ["asthma", "DISEASE", 113, 119], ["COPD", "DISEASE", 123, 127], ["COPD tissue", "TISSUE", 45, 56], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 83, 88], ["nuclear factor-\u03baBAs", "GENE_OR_GENE_PRODUCT", 269, 288], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 359, 364], ["Rel", "GENE_OR_GENE_PRODUCT", 409, 412], ["nuclear", "CELLULAR_COMPONENT", 461, 468], ["NF-\u03baB", "PROTEIN", 83, 88], ["nuclear factor-\u03baBAs", "PROTEIN", 269, 288], ["cis-acting sites", "DNA", 293, 309], ["promoters", "DNA", 325, 334], ["Rel proteins", "PROTEIN", 409, 421], ["asthmatic and COPD tissue", "PROBLEM", 31, 56], ["the testing", "TEST", 62, 73], ["known NF", "PROBLEM", 77, 85], ["\u03baB inhibitors", "TREATMENT", 86, 99], ["asthma", "PROBLEM", 113, 119], ["COPD exacerbation", "PROBLEM", 123, 140], ["Decoy oligonucleotides", "TREATMENT", 195, 217], ["Available inhibitors", "TREATMENT", 222, 242], ["nuclear factor", "TEST", 269, 283], ["a conserved motif", "TREATMENT", 340, 357], ["NF", "TREATMENT", 359, 361], ["B decoy oligonucleotides", "TREATMENT", 363, 387], ["activated Rel proteins", "TREATMENT", 399, 421], ["therapeutic agents", "TREATMENT", 497, 515], ["asthmatic", "OBSERVATION", 31, 40], ["COPD", "OBSERVATION", 45, 49], ["asthma", "OBSERVATION", 113, 119], ["COPD", "OBSERVATION", 123, 127]]], ["These oligonucleotides, or their DNA-peptide orthologs, have shown proof of concept in vitro (Tomita et al., 1998, Mischiati et al., 1999, Romanelli et al., 2001) and have been studied in various animal models including sepsis (Matsuda et al., 2004) and asthma (Desmet et al., 2004).", [["sepsis", "DISEASE", 220, 226], ["asthma", "DISEASE", 254, 260], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["These oligonucleotides", "TREATMENT", 0, 22], ["sepsis", "PROBLEM", 220, 226], ["asthma", "PROBLEM", 254, 260], ["sepsis", "OBSERVATION", 220, 226], ["asthma", "OBSERVATION", 254, 260]]], ["Furthermore, decoy oligonucleotides to the cell cycle regulator E2F have been trialled ex vivo in clinical trials for the treatment of vein graft rejection (Mann et al., 1999, Alexander et al., 2005).Decoy oligonucleotides ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBUsing the OVA challenged and sensitised mouse model of asthma, Desmet et al. assessed the efficacy of NF-\u03baB decoy oligonucleotides during ovalbumin induced allergic airway inflammation (Desmet et al., 2004).", [["cell", "ANATOMY", 43, 47], ["vein graft", "ANATOMY", 135, 145], ["airway", "ANATOMY", 456, 462], ["asthma", "DISEASE", 346, 352], ["allergic airway inflammation", "DISEASE", 447, 475], ["cell", "CELL", 43, 47], ["E2F", "GENE_OR_GENE_PRODUCT", 64, 67], ["vein graft", "MULTI-TISSUE_STRUCTURE", 135, 145], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 274, 290], ["mouse", "ORGANISM", 331, 336], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 393, 398], ["airway", "MULTI-TISSUE_STRUCTURE", 456, 462], ["cell cycle regulator", "PROTEIN", 43, 63], ["E2F", "PROTEIN", 64, 67], ["nuclear factor-\u03ba", "PROTEIN", 274, 290], ["NF-\u03baB", "PROTEIN", 393, 398], ["mouse", "SPECIES", 331, 336], ["mouse", "SPECIES", 331, 336], ["decoy oligonucleotides", "TREATMENT", 13, 35], ["the cell cycle regulator E2F", "TREATMENT", 39, 67], ["the treatment", "TREATMENT", 118, 131], ["vein graft rejection", "TREATMENT", 135, 155], ["Decoy oligonucleotides", "TREATMENT", 200, 222], ["Available inhibitors", "TREATMENT", 227, 247], ["nuclear factor", "TEST", 274, 288], ["the OVA challenged", "TREATMENT", 297, 315], ["asthma", "PROBLEM", 346, 352], ["NF", "PROBLEM", 393, 395], ["B decoy oligonucleotides", "TREATMENT", 397, 421], ["allergic airway inflammation", "PROBLEM", 447, 475], ["vein", "ANATOMY", 135, 139], ["graft rejection", "OBSERVATION", 140, 155], ["asthma", "OBSERVATION", 346, 352], ["allergic", "OBSERVATION_MODIFIER", 447, 455], ["airway", "ANATOMY", 456, 462], ["inflammation", "OBSERVATION", 463, 475]]], ["Initial experiments demonstrated that the target cell population within the lung consisted of DCs, T cells, macrophages and granulocytes, located with the bronchial and perivascular areas of the lung.", [["cell", "ANATOMY", 49, 53], ["lung", "ANATOMY", 76, 80], ["DCs", "ANATOMY", 94, 97], ["T cells", "ANATOMY", 99, 106], ["macrophages", "ANATOMY", 108, 119], ["granulocytes", "ANATOMY", 124, 136], ["bronchial", "ANATOMY", 155, 164], ["perivascular areas", "ANATOMY", 169, 187], ["lung", "ANATOMY", 195, 199], ["cell", "CELL", 49, 53], ["lung", "ORGAN", 76, 80], ["DCs", "CELL", 94, 97], ["T cells", "CELL", 99, 106], ["macrophages", "CELL", 108, 119], ["granulocytes", "CELL", 124, 136], ["bronchial", "MULTI-TISSUE_STRUCTURE", 155, 164], ["perivascular areas", "TISSUE", 169, 187], ["lung", "ORGAN", 195, 199], ["DCs", "CELL_TYPE", 94, 97], ["T cells", "CELL_TYPE", 99, 106], ["macrophages", "CELL_TYPE", 108, 119], ["granulocytes", "CELL_TYPE", 124, 136], ["the target cell population", "PROBLEM", 38, 64], ["macrophages", "PROBLEM", 108, 119], ["granulocytes", "TEST", 124, 136], ["target cell population", "OBSERVATION", 42, 64], ["lung", "ANATOMY", 76, 80], ["macrophages", "OBSERVATION_MODIFIER", 108, 119], ["granulocytes", "OBSERVATION", 124, 136], ["bronchial", "ANATOMY", 155, 164], ["perivascular", "ANATOMY_MODIFIER", 169, 181], ["areas", "ANATOMY_MODIFIER", 182, 187], ["lung", "ANATOMY", 195, 199]]], ["Interestingly, structural cells, including bronchial epithelial cells were not transfected in this study.", [["cells", "ANATOMY", 26, 31], ["bronchial epithelial cells", "ANATOMY", 43, 69], ["cells", "CELL", 26, 31], ["bronchial epithelial cells", "CELL", 43, 69], ["structural cells", "CELL_TYPE", 15, 31], ["bronchial epithelial cells", "CELL_TYPE", 43, 69], ["bronchial epithelial cells", "PROBLEM", 43, 69], ["this study", "TEST", 94, 104], ["structural cells", "OBSERVATION", 15, 31], ["bronchial", "ANATOMY", 43, 52], ["epithelial cells", "OBSERVATION", 53, 69]]], ["At 24 h post treatment, mice treated with NF-\u03baB decoy oligonucleotides exhibited lower BAL eosinophils, neutrophils, lymphocytes and macrophages compared to untreated, ovalbumin challenged mice or mice treated with a scrambled, non-specific oligonucleotide.", [["BAL eosinophils", "ANATOMY", 87, 102], ["neutrophils", "ANATOMY", 104, 115], ["lymphocytes", "ANATOMY", 117, 128], ["macrophages", "ANATOMY", 133, 144], ["mice", "ORGANISM", 24, 28], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 42, 47], ["BAL eosinophils", "CELL", 87, 102], ["neutrophils", "CELL", 104, 115], ["lymphocytes", "CELL", 117, 128], ["macrophages", "CELL", 133, 144], ["mice", "ORGANISM", 189, 193], ["mice", "ORGANISM", 197, 201], ["BAL eosinophils", "CELL_TYPE", 87, 102], ["neutrophils", "CELL_TYPE", 104, 115], ["lymphocytes", "CELL_TYPE", 117, 128], ["macrophages", "CELL_TYPE", 133, 144], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 189, 193], ["mice", "SPECIES", 197, 201], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 189, 193], ["mice", "SPECIES", 197, 201], ["treatment", "TREATMENT", 13, 22], ["NF", "TREATMENT", 42, 44], ["\u03baB decoy oligonucleotides", "TREATMENT", 45, 70], ["lower BAL eosinophils", "PROBLEM", 81, 102], ["neutrophils", "TEST", 104, 115], ["lymphocytes", "TEST", 117, 128], ["macrophages", "PROBLEM", 133, 144], ["a scrambled, non-specific oligonucleotide", "TREATMENT", 215, 256], ["lower", "ANATOMY_MODIFIER", 81, 86], ["BAL eosinophils", "OBSERVATION", 87, 102], ["neutrophils", "ANATOMY", 104, 115], ["lymphocytes", "ANATOMY", 117, 128], ["macrophages", "OBSERVATION", 133, 144]]], ["Differences were also observed in BAL cytokines, with IL-13, IL-5, IFN-\u03b3, and eotaxin being lower in mice challenged with ovalbumin and treated with the NF-\u03baB decoy oligonucleotide.", [["BAL", "ANATOMY", 34, 37], ["BAL", "ORGANISM_SUBSTANCE", 34, 37], ["IL-13", "GENE_OR_GENE_PRODUCT", 54, 59], ["IL-5", "GENE_OR_GENE_PRODUCT", 61, 65], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 67, 72], ["eotaxin", "GENE_OR_GENE_PRODUCT", 78, 85], ["mice", "ORGANISM", 101, 105], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 153, 158], ["BAL cytokines", "PROTEIN", 34, 47], ["IFN", "PROTEIN", 67, 70], ["eotaxin", "PROTEIN", 78, 85], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["BAL cytokines", "TEST", 34, 47], ["IL", "TEST", 54, 56], ["IL", "TEST", 61, 63], ["IFN", "TEST", 67, 70], ["eotaxin", "TREATMENT", 78, 85], ["ovalbumin", "TREATMENT", 122, 131], ["the NF", "TREATMENT", 149, 155], ["B decoy oligonucleotide", "TREATMENT", 157, 180], ["BAL cytokines", "OBSERVATION", 34, 47]]], ["Treated animals also exhibited less AHR than control groups, strongly suggesting that inhibiting NF-\u03baB can directly affect lung function in this model.", [["lung", "ANATOMY", 123, 127], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 97, 102], ["lung", "ORGAN", 123, 127], ["NF-\u03baB", "PROTEIN", 97, 102], ["less", "OBSERVATION_MODIFIER", 31, 35], ["lung", "ANATOMY", 123, 127]]], ["Finally PAS staining of lung sections revealed lower levels of mucin protein in OVA challenged NF-\u03baB decoy oligonucleotide treated animals compared to control animals.", [["lung sections", "ANATOMY", 24, 37], ["PAS", "SIMPLE_CHEMICAL", 8, 11], ["lung sections", "MULTI-TISSUE_STRUCTURE", 24, 37], ["mucin", "GENE_OR_GENE_PRODUCT", 63, 68], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 95, 100], ["mucin protein", "PROTEIN", 63, 76], ["PAS staining", "TEST", 8, 20], ["lung sections", "TEST", 24, 37], ["mucin protein", "TREATMENT", 63, 76], ["B decoy oligonucleotide", "TREATMENT", 99, 122], ["lung", "ANATOMY", 24, 28], ["lower levels", "OBSERVATION_MODIFIER", 47, 59], ["mucin protein", "OBSERVATION", 63, 76]]], ["IL-4, and IgE levels were not affected, suggesting that not all components of the allergic cascade can be affected using this strategy.Small molecule inhibitors of I-\u03baB kinase-\u03b2 ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBAs described above, there is now substantial data to suggest that inhibition of IKK-\u03b2 could have beneficial disease modifying properties.", [["allergic", "DISEASE", 82, 90], ["IL-4", "GENE_OR_GENE_PRODUCT", 0, 4], ["IgE", "GENE_OR_GENE_PRODUCT", 10, 13], ["I-\u03baB kinase-\u03b2", "GENE_OR_GENE_PRODUCT", 164, 177], ["nuclear factor-\u03baBAs", "GENE_OR_GENE_PRODUCT", 229, 248], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 326, 331], ["IL", "PROTEIN", 0, 2], ["IgE", "PROTEIN", 10, 13], ["I-\u03baB kinase", "PROTEIN", 164, 175], ["-\u03b2", "PROTEIN", 175, 177], ["nuclear factor-\u03baBAs", "PROTEIN", 229, 248], ["IKK", "PROTEIN", 326, 329], ["\u03b2", "PROTEIN", 330, 331], ["IL", "TEST", 0, 2], ["IgE levels", "TEST", 10, 20], ["the allergic cascade", "PROBLEM", 78, 98], ["this strategy", "TREATMENT", 121, 134], ["Small molecule inhibitors", "TEST", 135, 160], ["Available inhibitors", "TREATMENT", 182, 202], ["nuclear factor", "TEST", 229, 243], ["IKK", "TEST", 326, 329], ["beneficial disease modifying properties", "PROBLEM", 343, 382], ["allergic", "OBSERVATION", 82, 90], ["molecule inhibitors", "OBSERVATION", 141, 160]]], ["Targeting IKK-\u03b2 represents a growing area of interest for academic researchers and industry alike, as a plethora of small molecule inhibitors have recently become available.", [["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 10, 15], ["IKK", "PROTEIN", 10, 13], ["\u03b2", "PROTEIN", 14, 15], ["IKK", "TEST", 10, 13], ["small molecule inhibitors", "PROBLEM", 116, 141], ["growing", "OBSERVATION_MODIFIER", 29, 36], ["area", "OBSERVATION_MODIFIER", 37, 41], ["small molecule", "OBSERVATION", 116, 130]]], ["As yet, there has been no clinical trials using IKK-\u03b2 inhibitors in asthma or COPD, however several inhibitors have been used in phase I and II clinical trials in other disorders, notably cancer (reviewed in Karin et al., 2004).", [["cancer", "ANATOMY", 188, 194], ["asthma", "DISEASE", 68, 74], ["COPD", "DISEASE", 78, 82], ["cancer", "DISEASE", 188, 194], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 48, 53], ["cancer", "CANCER", 188, 194], ["IKK", "PROTEIN", 48, 51], ["IKK-\u03b2 inhibitors", "TREATMENT", 48, 64], ["asthma", "PROBLEM", 68, 74], ["COPD", "PROBLEM", 78, 82], ["several inhibitors", "TREATMENT", 92, 110], ["other disorders", "PROBLEM", 163, 178], ["cancer", "PROBLEM", 188, 194], ["no", "UNCERTAINTY", 23, 25], ["COPD", "OBSERVATION", 78, 82], ["cancer", "OBSERVATION", 188, 194]]], ["These compounds are widely used in research, particularly in small animal models.", [["widely", "OBSERVATION_MODIFIER", 20, 26], ["small", "OBSERVATION_MODIFIER", 61, 66]]], ["Currently there are at least eight small molecule inhibitors of IKK-\u03b2 available, with efficacies in cell based in vitro assays in the low micromolar range.", [["cell", "ANATOMY", 100, 104], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 64, 69], ["cell", "CELL", 100, 104], ["IKK", "PROTEIN", 64, 67], ["\u03b2", "PROTEIN", 68, 69], ["IKK", "TEST", 64, 67], ["efficacies in cell", "PROBLEM", 86, 104], ["vitro assays", "TEST", 114, 126], ["small", "OBSERVATION_MODIFIER", 35, 40], ["molecule inhibitors", "OBSERVATION", 41, 60], ["low micromolar", "OBSERVATION_MODIFIER", 134, 148]]], ["A list of these inhibitors is presented in Table 2.Small molecule inhibitors of I-\u03baB kinase-\u03b2 ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBIKK-\u03b2 inhibitors have been rigorously tested in cell based assay systems and show reliable anti-inflammatory activity using a range of stimuli (Birrell et al., 2005a, Ziegelbauer et al., 2005, Catley et al., 2006, Issa et al., 2006, Newton et al., 2007).", [["cell", "ANATOMY", 210, 214], ["I-\u03baB kinase-\u03b2", "GENE_OR_GENE_PRODUCT", 80, 93], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 145, 161], ["BIKK-\u03b2", "GENE_OR_GENE_PRODUCT", 161, 167], ["cell", "CELL", 210, 214], ["I-\u03baB kinase", "PROTEIN", 80, 91], ["-\u03b2", "PROTEIN", 91, 93], ["nuclear factor-\u03ba", "PROTEIN", 145, 161], ["BIKK", "PROTEIN", 161, 165], ["these inhibitors", "TREATMENT", 10, 26], ["Small molecule inhibitors", "TEST", 51, 76], ["Available inhibitors", "TREATMENT", 98, 118], ["nuclear factor", "TEST", 145, 159], ["BIKK-\u03b2 inhibitors", "TREATMENT", 161, 178], ["cell based assay systems", "TEST", 210, 234], ["molecule inhibitors", "OBSERVATION", 57, 76], ["anti-inflammatory activity", "OBSERVATION", 253, 279]]], ["It would appear that IKK-\u03b2 inhibitors may possess a more comprehensive anti-inflammatory profile to that of GCs, for instance IL-1\u03b2 induced G-CSF release from primary ASM is virtually steroid resistant, whereas it is completely blocked by two structurally different IKK-\u03b2 inhibitors (Birrell et al., 2005a).", [["GCs", "ANATOMY", 108, 111], ["ASM", "ANATOMY", 167, 170], ["steroid", "CHEMICAL", 184, 191], ["steroid", "CHEMICAL", 184, 191], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 21, 26], ["GCs", "CELL", 108, 111], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 126, 131], ["G-CSF", "GENE_OR_GENE_PRODUCT", 140, 145], ["ASM", "CELL", 167, 170], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 266, 271], ["IKK", "PROTEIN", 21, 24], ["IL-1\u03b2", "PROTEIN", 126, 131], ["CSF", "PROTEIN", 142, 145], ["IKK", "PROTEIN", 266, 269], ["IKK-\u03b2 inhibitors", "TREATMENT", 21, 37], ["GCs", "TEST", 108, 111], ["instance IL", "TEST", 117, 128], ["CSF release", "PROBLEM", 142, 153], ["primary ASM", "PROBLEM", 159, 170], ["virtually steroid resistant", "PROBLEM", 174, 201], ["steroid resistant", "OBSERVATION", 184, 201]]], ["This is potentially very exciting, because the inflammation in COPD patients, and a sub-population of asthmatics are reportedly resistant to GC treatment.", [["inflammation", "DISEASE", 47, 59], ["COPD", "DISEASE", 63, 67], ["patients", "ORGANISM", 68, 76], ["asthmatics", "ORGANISM", 102, 112], ["patients", "SPECIES", 68, 76], ["the inflammation in COPD patients", "PROBLEM", 43, 76], ["asthmatics", "PROBLEM", 102, 112], ["GC treatment", "TREATMENT", 141, 153], ["inflammation", "OBSERVATION", 47, 59], ["COPD", "OBSERVATION", 63, 67], ["sub", "OBSERVATION_MODIFIER", 84, 87], ["asthmatics", "OBSERVATION", 102, 112]]], ["Peroxynitrite, and nitration of HDACs, caused by reactive oxygen produced by CS, have been implicated in causing steroid resistance in COPD (Barnes et al., 2004, Ito et al., 2005).", [["Peroxynitrite", "CHEMICAL", 0, 13], ["oxygen", "CHEMICAL", 58, 64], ["steroid", "CHEMICAL", 113, 120], ["COPD", "DISEASE", 135, 139], ["Peroxynitrite", "CHEMICAL", 0, 13], ["oxygen", "CHEMICAL", 58, 64], ["steroid", "CHEMICAL", 113, 120], ["Peroxynitrite", "SIMPLE_CHEMICAL", 0, 13], ["HDACs", "GENE_OR_GENE_PRODUCT", 32, 37], ["oxygen", "SIMPLE_CHEMICAL", 58, 64], ["CS", "SIMPLE_CHEMICAL", 77, 79], ["steroid", "SIMPLE_CHEMICAL", 113, 120], ["HDACs", "PROTEIN", 32, 37], ["Peroxynitrite", "TREATMENT", 0, 13], ["nitration of HDACs", "TREATMENT", 19, 37], ["steroid resistance", "PROBLEM", 113, 131], ["COPD", "PROBLEM", 135, 139], ["reactive oxygen", "OBSERVATION", 49, 64], ["steroid resistance", "OBSERVATION", 113, 131]]], ["Also, a sub population of asthmatics, are believed to have reduced GR levels, GR translocation and recruitment of HDAC, reducing GC efficacy (Adcock et al., 1995a, Adcock et al., 1995b, Matthews et al., 2004).", [["asthmatics", "ORGANISM", 26, 36], ["GR", "GENE_OR_GENE_PRODUCT", 67, 69], ["GR", "GENE_OR_GENE_PRODUCT", 78, 80], ["HDAC", "GENE_OR_GENE_PRODUCT", 114, 118], ["GR", "PROTEIN", 67, 69], ["GR", "PROTEIN", 78, 80], ["HDAC", "PROTEIN", 114, 118], ["asthmatics", "PROBLEM", 26, 36], ["reduced GR levels", "PROBLEM", 59, 76], ["GR translocation", "PROBLEM", 78, 94], ["recruitment of HDAC", "TREATMENT", 99, 118], ["sub", "OBSERVATION_MODIFIER", 8, 11], ["asthmatics", "OBSERVATION", 26, 36], ["GR translocation", "OBSERVATION", 78, 94], ["recruitment", "OBSERVATION_MODIFIER", 99, 110]]], ["Hence a distinct advantage of IKK-\u03b2 inhibition is to bypass these problems associated with GC based therapies.", [["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 30, 35], ["IKK", "PROTEIN", 30, 33], ["\u03b2", "PROTEIN", 34, 35], ["bypass", "TREATMENT", 53, 59], ["GC based therapies", "TREATMENT", 91, 109]]], ["Furthermore, a recent publication has suggested that IKK-\u03b2 inhibition may have additional anti-inflammatory activity which is separate to the impact on NF-\u03baB signalling, as shown using the IKK-\u03b2 inhibitor TCPA-1, a structural different IKK-\u03b1/\u03b2 inhibitor, and dominant negative IKK-\u03b2 (Tudhope et al., 2007).", [["TCPA-1", "CHEMICAL", 205, 211], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 53, 58], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 152, 157], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 189, 194], ["TCPA-1", "GENE_OR_GENE_PRODUCT", 205, 211], ["IKK-\u03b1", "GENE_OR_GENE_PRODUCT", 236, 241], ["\u03b2", "GENE_OR_GENE_PRODUCT", 242, 243], ["IKK", "GENE_OR_GENE_PRODUCT", 277, 280], ["IKK", "PROTEIN", 53, 56], ["NF-\u03baB", "PROTEIN", 152, 157], ["IKK", "PROTEIN", 189, 192], ["IKK", "PROTEIN", 236, 239], ["\u03b1", "PROTEIN", 240, 241], ["dominant negative IKK-\u03b2", "PROTEIN", 259, 282], ["IKK-\u03b2 inhibition", "PROBLEM", 53, 69], ["anti-inflammatory activity", "PROBLEM", 90, 116], ["the IKK", "TEST", 185, 192], ["TCPA", "TEST", 205, 209], ["a structural different IKK", "TEST", 213, 239], ["anti-inflammatory activity", "OBSERVATION", 90, 116]]], ["Also, a cell permeable peptide which specifically disrupts the IKK-\u03b2/NEMO interaction (May et al., 2000), has been used in vitro to block NF-\u03baB signalling in an IKK-\u03b2 dependent manner (Dai et al., 2004).", [["cell", "ANATOMY", 8, 12], ["cell", "CELL", 8, 12], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 63, 68], ["NEMO", "GENE_OR_GENE_PRODUCT", 69, 73], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 138, 143], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 161, 166], ["IKK", "PROTEIN", 63, 66], ["\u03b2", "PROTEIN", 67, 68], ["NEMO", "PROTEIN", 69, 73], ["NF-\u03baB", "PROTEIN", 138, 143], ["IKK", "PROTEIN", 161, 164], ["a cell permeable peptide", "PROBLEM", 6, 30], ["cell permeable", "OBSERVATION", 8, 22]]], ["Such small peptide inhibitors are also valuable tools, to highlight mechanisms in vitro and perhaps also as therapeutics in vivo.Small molecule inhibitors of I-\u03baB kinase-\u03b2 ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBIn small animal models of asthma, IKK-\u03b2 inhibitors have been shown to impact on a number of relevant end points.", [["asthma", "DISEASE", 266, 272], ["I-\u03baB kinase-\u03b2", "GENE_OR_GENE_PRODUCT", 158, 171], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 223, 239], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 274, 279], ["I-\u03baB kinase", "PROTEIN", 158, 169], ["-\u03b2", "PROTEIN", 169, 171], ["nuclear factor-\u03ba", "PROTEIN", 223, 239], ["IKK", "PROTEIN", 274, 277], ["Such small peptide inhibitors", "PROBLEM", 0, 29], ["Small molecule inhibitors", "TEST", 129, 154], ["Available inhibitors", "TREATMENT", 176, 196], ["nuclear factor", "TEST", 223, 237], ["asthma", "PROBLEM", 266, 272], ["IKK", "TEST", 274, 277], ["\u03b2 inhibitors", "TREATMENT", 278, 290], ["small", "OBSERVATION_MODIFIER", 5, 10], ["peptide inhibitors", "OBSERVATION", 11, 29], ["molecule inhibitors", "OBSERVATION", 135, 154], ["small", "OBSERVATION_MODIFIER", 243, 248], ["animal models", "OBSERVATION_MODIFIER", 249, 262], ["asthma", "OBSERVATION", 266, 272]]], ["These include inflammatory cytokines, mucus, LAR, AHR and fibrosis (Birrell et al., 2005a, Ziegelbauer et al., 2005, Chapoval et al., 2007).", [["fibrosis", "DISEASE", 58, 66], ["mucus", "MULTI-TISSUE_STRUCTURE", 38, 43], ["LAR", "GENE_OR_GENE_PRODUCT", 45, 48], ["inflammatory cytokines", "PROTEIN", 14, 36], ["inflammatory cytokines", "PROBLEM", 14, 36], ["mucus, LAR", "PROBLEM", 38, 48], ["AHR", "PROBLEM", 50, 53], ["fibrosis", "PROBLEM", 58, 66], ["inflammatory", "OBSERVATION_MODIFIER", 14, 26], ["mucus", "OBSERVATION", 38, 43], ["LAR", "OBSERVATION_MODIFIER", 45, 48], ["fibrosis", "OBSERVATION", 58, 66]]], ["For example, the selective IKK-\u03b2 inhibitor TCPA-1 reduced TNF-\u03b1 and IL-1\u03b2, eotaxin, and Th2 cytokines IL-4, IL-5 and IL-13 induced by OVA in a rat model of allergen sensitisation and challenge.", [["allergen sensitisation", "DISEASE", 156, 178], ["TCPA-1", "CHEMICAL", 43, 49], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 27, 32], ["TCPA-1", "GENE_OR_GENE_PRODUCT", 43, 49], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 68, 73], ["eotaxin", "GENE_OR_GENE_PRODUCT", 75, 82], ["IL-4", "GENE_OR_GENE_PRODUCT", 102, 106], ["IL-5", "GENE_OR_GENE_PRODUCT", 108, 112], ["IL-13", "GENE_OR_GENE_PRODUCT", 117, 122], ["OVA", "SIMPLE_CHEMICAL", 134, 137], ["rat", "ORGANISM", 143, 146], ["IKK", "PROTEIN", 27, 30], ["TNF", "PROTEIN", 58, 61], ["IL-1\u03b2", "PROTEIN", 68, 73], ["eotaxin", "PROTEIN", 75, 82], ["cytokines", "PROTEIN", 92, 101], ["IL-13", "PROTEIN", 117, 122], ["rat", "SPECIES", 143, 146], ["rat", "SPECIES", 143, 146], ["the selective IKK", "TEST", 13, 30], ["TCPA", "TEST", 43, 47], ["TNF", "TEST", 58, 61], ["IL", "TEST", 68, 70], ["eotaxin", "TREATMENT", 75, 82], ["Th2 cytokines IL", "TREATMENT", 88, 104], ["IL", "TREATMENT", 117, 119], ["allergen sensitisation", "TREATMENT", 156, 178], ["allergen sensitisation", "OBSERVATION", 156, 178]]], ["Recruitment of neutrophils and eosinophils into the airway and the late response to allergen challenge were also markedly reduced following TCPA-1 administration (Birrell et al., 2005a).", [["neutrophils", "ANATOMY", 15, 26], ["eosinophils", "ANATOMY", 31, 42], ["airway", "ANATOMY", 52, 58], ["TCPA-1", "CHEMICAL", 140, 146], ["TCPA-1", "CHEMICAL", 140, 146], ["neutrophils", "CELL", 15, 26], ["eosinophils", "CELL", 31, 42], ["airway", "MULTI-TISSUE_STRUCTURE", 52, 58], ["TCPA-1", "GENE_OR_GENE_PRODUCT", 140, 146], ["neutrophils", "CELL_TYPE", 15, 26], ["eosinophils", "CELL_TYPE", 31, 42], ["neutrophils", "TEST", 15, 26], ["eosinophils", "TEST", 31, 42], ["allergen challenge", "TREATMENT", 84, 102], ["neutrophils", "OBSERVATION", 15, 26], ["airway", "ANATOMY", 52, 58]]], ["Importantly, these results highlight the ability of TCPA-1 to reduce both Th2 induced responses and general inflammation following allergen challenge.Small molecule inhibitors of I-\u03baB kinase-\u03b2 ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBAs yet, less has been reported on the impact of IKK-\u03b2 inhibitors in similar models of COPD.", [["inflammation", "DISEASE", 108, 120], ["COPD", "DISEASE", 347, 351], ["TCPA-1", "CHEMICAL", 52, 58], ["TCPA-1", "GENE_OR_GENE_PRODUCT", 52, 58], ["I-\u03baB kinase-\u03b2", "GENE_OR_GENE_PRODUCT", 179, 192], ["nuclear factor-\u03baBAs", "GENE_OR_GENE_PRODUCT", 244, 263], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 309, 314], ["I-\u03baB kinase", "PROTEIN", 179, 190], ["-\u03b2", "PROTEIN", 190, 192], ["nuclear factor-\u03baBAs", "PROTEIN", 244, 263], ["IKK", "PROTEIN", 309, 312], ["TCPA", "TEST", 52, 56], ["both Th2 induced responses", "PROBLEM", 69, 95], ["general inflammation", "PROBLEM", 100, 120], ["allergen challenge", "TREATMENT", 131, 149], ["Small molecule inhibitors", "TEST", 150, 175], ["Available inhibitors", "TREATMENT", 197, 217], ["nuclear factor", "TEST", 244, 258], ["IKK-\u03b2 inhibitors", "TREATMENT", 309, 325], ["COPD", "PROBLEM", 347, 351], ["Th2", "OBSERVATION", 74, 77], ["inflammation", "OBSERVATION", 108, 120], ["molecule inhibitors", "OBSERVATION", 156, 175], ["COPD", "OBSERVATION", 347, 351]]], ["IKK-\u03b2 inhibition has been effective in LPS models of COPD (Ziegelbauer et al., 2005, Birrell et al., 2006).", [["COPD", "DISEASE", 53, 57], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["LPS", "SIMPLE_CHEMICAL", 39, 42], ["IKK", "PROTEIN", 0, 3], ["\u03b2", "PROTEIN", 4, 5], ["IKK", "TEST", 0, 3], ["COPD", "PROBLEM", 53, 57], ["effective", "OBSERVATION_MODIFIER", 26, 35], ["COPD", "OBSERVATION", 53, 57]]], ["Similarly, IL-13 induced inflammation in the mouse is reduced with an IKK-\u03b2 inhibitor (Chapoval et al., 2007).", [["inflammation", "DISEASE", 25, 37], ["IL-13", "GENE_OR_GENE_PRODUCT", 11, 16], ["mouse", "ORGANISM", 45, 50], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 70, 75], ["IL-13", "PROTEIN", 11, 16], ["IKK", "PROTEIN", 70, 73], ["mouse", "SPECIES", 45, 50], ["mouse", "SPECIES", 45, 50], ["IL", "TREATMENT", 11, 13], ["inflammation in the mouse", "PROBLEM", 25, 50], ["an IKK", "TEST", 67, 73], ["13 induced", "OBSERVATION_MODIFIER", 14, 24], ["inflammation", "OBSERVATION", 25, 37], ["mouse", "ANATOMY", 45, 50], ["reduced", "OBSERVATION_MODIFIER", 54, 61]]], ["One might question the clinical relevance of these animal models; for example unlike the inflammation in clinical COPD, the LPS induced inflammation is modulated by GC treatment.", [["inflammation", "DISEASE", 89, 101], ["COPD", "DISEASE", 114, 118], ["LPS", "CHEMICAL", 124, 127], ["inflammation", "DISEASE", 136, 148], ["LPS", "SIMPLE_CHEMICAL", 124, 127], ["the inflammation", "PROBLEM", 85, 101], ["clinical COPD", "PROBLEM", 105, 118], ["the LPS induced inflammation", "PROBLEM", 120, 148], ["GC treatment", "TREATMENT", 165, 177], ["inflammation", "OBSERVATION", 89, 101], ["COPD", "OBSERVATION", 114, 118], ["LPS induced", "OBSERVATION_MODIFIER", 124, 135], ["inflammation", "OBSERVATION", 136, 148]]], ["Another rodent model of COPD utilising elastase as a stimulus, which is known to be steroid resistant has also recently been shown to also be resistant to an IKK-\u03b2 inhibitor (Birrell et al., 2006).", [["COPD", "DISEASE", 24, 28], ["steroid", "CHEMICAL", 84, 91], ["steroid", "CHEMICAL", 84, 91], ["elastase", "GENE_OR_GENE_PRODUCT", 39, 47], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 158, 163], ["elastase", "PROTEIN", 39, 47], ["IKK", "PROTEIN", 158, 161], ["COPD utilising elastase", "PROBLEM", 24, 47], ["steroid resistant", "PROBLEM", 84, 101], ["an IKK-\u03b2 inhibitor", "TREATMENT", 155, 173], ["COPD", "OBSERVATION", 24, 28], ["elastase", "OBSERVATION", 39, 47], ["known to be", "UNCERTAINTY", 72, 83], ["steroid resistant", "OBSERVATION", 84, 101]]], ["This result might be expected, as the inflammation observed in this model appears to occur without any obvious signs of NF-\u03baB pathway involvement (Birrell et al., 2005b).", [["inflammation", "DISEASE", 38, 50], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 120, 125], ["NF-\u03baB", "PROTEIN", 120, 125], ["the inflammation", "PROBLEM", 34, 50], ["NF", "PROBLEM", 120, 122], ["inflammation", "OBSERVATION", 38, 50]]], ["Again one may question the clinical relevance of this model, especially considering the apparent increase in the NF-\u03baB pathway activity in patients with COPD (Caramori et al., 2003).", [["COPD", "DISEASE", 153, 157], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 113, 118], ["patients", "ORGANISM", 139, 147], ["NF-\u03baB", "PROTEIN", 113, 118], ["patients", "SPECIES", 139, 147], ["COPD", "PROBLEM", 153, 157], ["increase", "OBSERVATION_MODIFIER", 97, 105], ["COPD", "OBSERVATION", 153, 157]]], ["However, regardless of whether this model represents human COPD, it appears to demonstrate NF-\u03baB-independent, GC resistant inflammation which could be very interesting to explore.", [["COPD", "DISEASE", 59, 63], ["inflammation", "DISEASE", 123, 135], ["human", "ORGANISM", 53, 58], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 91, 96], ["\u03baB", "PROTEIN", 94, 96], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["human COPD", "PROBLEM", 53, 63], ["GC resistant inflammation", "PROBLEM", 110, 135], ["COPD", "OBSERVATION", 59, 63], ["inflammation", "OBSERVATION", 123, 135]]], ["As yet there are no reports on the impact of an IKK-\u03b2 inhibitor in the more accepted CS driven animal model of COPD.", [["COPD", "DISEASE", 111, 115], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 48, 53], ["IKK", "PROTEIN", 48, 51], ["an IKK-\u03b2 inhibitor", "TREATMENT", 45, 63], ["COPD", "PROBLEM", 111, 115], ["COPD", "OBSERVATION", 111, 115]]], ["These studies are crucial for the further validation of IKK-\u03b2 inhibitors in COPD.Proteasome inhibitors ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBThe ubiquitin\u2013proteasome system (UPS) regulates protein turnover in eukaryotic cells and is central to the regulation of NF-\u03baB activity.", [["cells", "ANATOMY", 250, 255], ["COPD", "DISEASE", 76, 80], ["IKK-\u03b2", "GENE_OR_GENE_PRODUCT", 56, 61], ["Proteasome", "GENE_OR_GENE_PRODUCT", 81, 91], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 154, 170], ["BThe ubiquitin\u2013proteasome system", "GENE_OR_GENE_PRODUCT", 170, 202], ["UPS", "GENE_OR_GENE_PRODUCT", 204, 207], ["eukaryotic cells", "CELL", 239, 255], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 292, 297], ["IKK", "PROTEIN", 56, 59], ["nuclear factor-\u03ba", "PROTEIN", 154, 170], ["BThe ubiquitin\u2013proteasome system", "PROTEIN", 170, 202], ["UPS", "PROTEIN", 204, 207], ["eukaryotic cells", "CELL_TYPE", 239, 255], ["NF-\u03baB", "PROTEIN", 292, 297], ["These studies", "TEST", 0, 13], ["IKK-\u03b2 inhibitors", "TREATMENT", 56, 72], ["COPD", "PROBLEM", 76, 80], ["Proteasome inhibitors", "TREATMENT", 81, 102], ["Available inhibitors", "TREATMENT", 107, 127], ["nuclear factor", "TEST", 154, 168], ["BThe ubiquitin\u2013proteasome system", "TREATMENT", 170, 202], ["protein turnover in eukaryotic cells", "PROBLEM", 219, 255], ["COPD", "OBSERVATION", 76, 80], ["eukaryotic cells", "OBSERVATION", 239, 255]]], ["Protein degradation through the UPS involves ubiquitin conjugation to proteins destined for destruction and is mediated by the enzymes E1, E2 and E3.", [["UPS", "GENE_OR_GENE_PRODUCT", 32, 35], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 45, 54], ["E1", "GENE_OR_GENE_PRODUCT", 135, 137], ["E2", "GENE_OR_GENE_PRODUCT", 139, 141], ["E3", "GENE_OR_GENE_PRODUCT", 146, 148], ["UPS", "PROTEIN", 32, 35], ["E1", "PROTEIN", 135, 137], ["E2", "PROTEIN", 139, 141], ["E3", "PROTEIN", 146, 148], ["Protein degradation", "PROBLEM", 0, 19], ["the UPS", "TEST", 28, 35], ["ubiquitin conjugation", "TREATMENT", 45, 66], ["destruction", "PROBLEM", 92, 103], ["the enzymes", "TEST", 123, 134]]], ["Polyubiquinated proteins are recognised by the proteasome which de-ubiquinates, unfolds and destroys the target protein (reviewed in Nalepa et al., 2006).", [["Polyubiquinated proteins", "PROTEIN", 0, 24], ["proteasome", "PROTEIN", 47, 57], ["de-ubiquinates", "PROTEIN", 64, 78], ["target protein", "PROTEIN", 105, 119], ["Polyubiquinated proteins", "PROBLEM", 0, 24], ["proteins", "OBSERVATION", 16, 24]]], ["The 26S proteasome is an ATP-dependent proteolytic complex consisting of a proteolytic core particle, the 20S proteosome, capped on each end by two regulatory complexes.", [["ATP", "CHEMICAL", 25, 28], ["ATP", "CHEMICAL", 25, 28], ["26S", "GENE_OR_GENE_PRODUCT", 4, 7], ["ATP", "SIMPLE_CHEMICAL", 25, 28], ["20S proteosome", "GENE_OR_GENE_PRODUCT", 106, 120], ["26S proteasome", "PROTEIN", 4, 18], ["ATP-dependent proteolytic complex", "PROTEIN", 25, 58], ["proteolytic core particle", "PROTEIN", 75, 100], ["20S proteosome", "PROTEIN", 106, 120], ["regulatory complexes", "PROTEIN", 148, 168], ["The 26S proteasome", "TEST", 0, 18], ["an ATP-dependent proteolytic complex", "PROBLEM", 22, 58], ["a proteolytic core particle", "PROBLEM", 73, 100], ["the 20S proteosome", "TREATMENT", 102, 120], ["26S proteasome", "OBSERVATION", 4, 18], ["ATP-dependent", "OBSERVATION_MODIFIER", 25, 38], ["proteolytic complex", "OBSERVATION_MODIFIER", 39, 58], ["particle", "OBSERVATION_MODIFIER", 92, 100]]], ["The 20S proteasome contains 3 pairs of active sites with distinct specificities termed chymotrypsin-like, trypsin-like and caspase-like (reviewed in Gilmore and Herscovitch, 2006).", [["20S", "GENE_OR_GENE_PRODUCT", 4, 7], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 87, 99], ["trypsin", "GENE_OR_GENE_PRODUCT", 106, 113], ["caspase", "GENE_OR_GENE_PRODUCT", 123, 130], ["20S proteasome", "PROTEIN", 4, 18], ["chymotrypsin", "PROTEIN", 87, 99], ["trypsin", "PROTEIN", 106, 113], ["caspase", "PROTEIN", 123, 130], ["The 20S proteasome", "TREATMENT", 0, 18], ["active sites", "PROBLEM", 39, 51], ["distinct specificities termed chymotrypsin", "PROBLEM", 57, 99], ["trypsin", "TREATMENT", 106, 113], ["20S proteasome", "OBSERVATION", 4, 18], ["active", "OBSERVATION_MODIFIER", 39, 45]]], ["There are several classes of reversible and irreversible proteasome inhibitors all of which target the 20S proteasome, some of which have been utilised in asthma or COPD research.", [["asthma", "DISEASE", 155, 161], ["COPD", "DISEASE", 165, 169], ["20S", "GENE_OR_GENE_PRODUCT", 103, 106], ["20S proteasome", "PROTEIN", 103, 117], ["reversible and irreversible proteasome inhibitors", "PROBLEM", 29, 78], ["the 20S proteasome", "TREATMENT", 99, 117], ["asthma", "PROBLEM", 155, 161], ["COPD research", "PROBLEM", 165, 178], ["several", "OBSERVATION_MODIFIER", 10, 17], ["classes", "OBSERVATION_MODIFIER", 18, 25], ["reversible", "OBSERVATION_MODIFIER", 29, 39], ["irreversible", "OBSERVATION_MODIFIER", 44, 56], ["proteasome inhibitors", "OBSERVATION", 57, 78], ["asthma", "OBSERVATION", 155, 161], ["COPD", "OBSERVATION", 165, 169]]], ["Several studies have reported modulation of eosinophil function by blocking NF-\u03baB signalling using proteasome inhibitors.", [["eosinophil", "ANATOMY", 44, 54], ["eosinophil", "CELL", 44, 54], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 76, 81], ["NF-\u03baB", "PROTEIN", 76, 81], ["proteasome", "PROTEIN", 99, 109], ["Several studies", "TEST", 0, 15], ["eosinophil function", "PROBLEM", 44, 63], ["blocking NF", "TREATMENT", 67, 78], ["proteasome inhibitors", "TREATMENT", 99, 120], ["eosinophil function", "OBSERVATION", 44, 63]]], ["Eosinophils secrete a variety of potentially damaging mediators in response to pro-inflammatory- and microbial stimuli in an NF-\u03baB dependent manner (Rankin et al., 2000).", [["Eosinophils", "ANATOMY", 0, 11], ["Eosinophils", "CELL", 0, 11], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 125, 130], ["Eosinophils", "CELL_TYPE", 0, 11], ["Eosinophils", "TEST", 0, 11], ["microbial stimuli", "TEST", 101, 118]]], ["The activity of the lactocystin-derivative proteasome inhibitor PS-519 was examined in a rat model of OVA induced pulmonary eosinophilia.", [["pulmonary", "ANATOMY", 114, 123], ["lactocystin", "CHEMICAL", 20, 31], ["PS-519", "CHEMICAL", 64, 70], ["pulmonary eosinophilia", "DISEASE", 114, 136], ["lactocystin", "CHEMICAL", 20, 31], ["PS-519", "CHEMICAL", 64, 70], ["lactocystin", "SIMPLE_CHEMICAL", 20, 31], ["PS-519", "SIMPLE_CHEMICAL", 64, 70], ["rat", "ORGANISM", 89, 92], ["OVA", "SIMPLE_CHEMICAL", 102, 105], ["pulmonary", "ORGAN", 114, 123], ["rat", "SPECIES", 89, 92], ["rat", "SPECIES", 89, 92], ["the lactocystin-derivative proteasome inhibitor PS", "TREATMENT", 16, 66], ["OVA induced pulmonary eosinophilia", "PROBLEM", 102, 136], ["pulmonary", "ANATOMY", 114, 123], ["eosinophilia", "OBSERVATION", 124, 136]]], ["Intratracheal dosing of PS-519 before and after allergen exposure significantly reduced the number of eosinophils in sensitised lungs.", [["Intratracheal", "ANATOMY", 0, 13], ["eosinophils", "ANATOMY", 102, 113], ["lungs", "ANATOMY", 128, 133], ["PS-519", "CHEMICAL", 24, 30], ["PS-519", "CHEMICAL", 24, 30], ["Intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["PS-519", "SIMPLE_CHEMICAL", 24, 30], ["eosinophils", "CELL", 102, 113], ["lungs", "ORGAN", 128, 133], ["eosinophils", "CELL_TYPE", 102, 113], ["Intratracheal dosing of PS", "TREATMENT", 0, 26], ["allergen exposure", "PROBLEM", 48, 65], ["eosinophils", "OBSERVATION", 102, 113], ["lungs", "ANATOMY", 128, 133]]], ["Furthermore, a low dose of PS-519 was similarly effective at decreasing eosinophilic inflammation in the airways when used in combination with the GC budesonide, demonstrating the potential for combination treatment regimens with GCs (Elliott et al., 1999).Proteasome inhibitors ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBMG-132 is a member of the peptide aldehyde class of proteasome inhibitors and blocks the chymotrypsin-like activity of the proteasome complex (Palombella et al., 1994).", [["eosinophilic", "ANATOMY", 72, 84], ["airways", "ANATOMY", 105, 112], ["PS-519", "CHEMICAL", 27, 33], ["inflammation", "DISEASE", 85, 97], ["budesonide", "CHEMICAL", 150, 160], ["BMG-132", "CHEMICAL", 346, 353], ["aldehyde", "CHEMICAL", 381, 389], ["PS-519", "CHEMICAL", 27, 33], ["budesonide", "CHEMICAL", 150, 160], ["aldehyde", "CHEMICAL", 381, 389], ["PS-519", "SIMPLE_CHEMICAL", 27, 33], ["airways", "MULTI-TISSUE_STRUCTURE", 105, 112], ["budesonide", "SIMPLE_CHEMICAL", 150, 160], ["Proteasome", "GENE_OR_GENE_PRODUCT", 257, 267], ["BMG-132", "GENE_OR_GENE_PRODUCT", 346, 353], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 436, 448], ["nuclear factor-\u03baBMG-132", "PROTEIN", 330, 353], ["chymotrypsin", "PROTEIN", 436, 448], ["proteasome complex", "PROTEIN", 470, 488], ["a low dose of PS", "TREATMENT", 13, 29], ["decreasing eosinophilic inflammation in the airways", "PROBLEM", 61, 112], ["the GC budesonide", "TREATMENT", 143, 160], ["combination treatment regimens", "TREATMENT", 194, 224], ["GCs", "TEST", 230, 233], ["Proteasome inhibitors", "TREATMENT", 257, 278], ["Available inhibitors", "TREATMENT", 283, 303], ["nuclear factor", "TEST", 330, 344], ["BMG", "TEST", 346, 349], ["proteasome inhibitors", "TREATMENT", 399, 420], ["the chymotrypsin", "TREATMENT", 432, 448], ["decreasing", "OBSERVATION_MODIFIER", 61, 71], ["eosinophilic", "OBSERVATION_MODIFIER", 72, 84], ["inflammation", "OBSERVATION", 85, 97], ["airways", "ANATOMY", 105, 112]]], ["Several studies have demonstrated that MG-132 mediated NF-\u03baB inhibition modulates eosinophil activity and reduces allergic inflammation.", [["eosinophil", "ANATOMY", 82, 92], ["MG-132", "CHEMICAL", 39, 45], ["allergic inflammation", "DISEASE", 114, 135], ["MG-132", "CHEMICAL", 39, 45], ["MG-132", "GENE_OR_GENE_PRODUCT", 39, 45], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 55, 60], ["eosinophil", "CELL", 82, 92], ["NF-\u03baB", "PROTEIN", 55, 60], ["Several studies", "TEST", 0, 15], ["MG", "TEST", 39, 41], ["NF", "TEST", 55, 57], ["eosinophil activity", "PROBLEM", 82, 101], ["allergic inflammation", "PROBLEM", 114, 135], ["eosinophil activity", "OBSERVATION", 82, 101], ["allergic inflammation", "OBSERVATION", 114, 135]]], ["TNF-\u03b1 induced IL-8 by purified human eosinophils was blocked by pre-treatment with MG-132.", [["eosinophils", "ANATOMY", 37, 48], ["MG-132", "CHEMICAL", 83, 89], ["MG-132", "CHEMICAL", 83, 89], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-8", "GENE_OR_GENE_PRODUCT", 14, 18], ["human", "ORGANISM", 31, 36], ["eosinophils", "CELL", 37, 48], ["MG-132", "SIMPLE_CHEMICAL", 83, 89], ["TNF", "PROTEIN", 0, 3], ["IL-8", "PROTEIN", 14, 18], ["human eosinophils", "CELL_TYPE", 31, 48], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["TNF", "TEST", 0, 3], ["IL", "TEST", 14, 16], ["MG", "TEST", 83, 85]]], ["Additionally, inhibition of NF-\u03baB signalling by MG-132 enabled TNF-\u03b1 to induce eosinophil apoptosis rather than induce IL-8 production (Fujihara et al., 2002).", [["eosinophil", "ANATOMY", 79, 89], ["MG-132", "CHEMICAL", 48, 54], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 28, 33], ["MG-132", "SIMPLE_CHEMICAL", 48, 54], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 63, 68], ["eosinophil", "CELL", 79, 89], ["IL-8", "GENE_OR_GENE_PRODUCT", 119, 123], ["NF-\u03baB", "PROTEIN", 28, 33], ["TNF", "PROTEIN", 63, 66], ["NF", "TEST", 28, 30], ["MG", "TEST", 48, 50], ["TNF", "TEST", 63, 66], ["eosinophil apoptosis", "PROBLEM", 79, 99], ["IL", "TEST", 119, 121], ["eosinophil apoptosis", "OBSERVATION", 79, 99]]], ["The expression of cell adhesion molecules such as the \u03b22 integrin CD18 are critical to eosinophil homing to sites of inflammation, and can be induced by TNF-\u03b1 or co-culture with bronchial epithelial cells (Teixeira et al., 1994).", [["cell", "ANATOMY", 18, 22], ["eosinophil", "ANATOMY", 87, 97], ["sites", "ANATOMY", 108, 113], ["bronchial epithelial cells", "ANATOMY", 178, 204], ["inflammation", "DISEASE", 117, 129], ["cell", "CELL", 18, 22], ["\u03b22 integrin CD18", "GENE_OR_GENE_PRODUCT", 54, 70], ["eosinophil", "CELL", 87, 97], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 153, 158], ["bronchial epithelial cells", "CELL", 178, 204], ["cell adhesion molecules", "PROTEIN", 18, 41], ["\u03b22 integrin CD18", "PROTEIN", 54, 70], ["TNF", "PROTEIN", 153, 156], ["bronchial epithelial cells", "CELL_TYPE", 178, 204], ["cell adhesion molecules", "TREATMENT", 18, 41], ["the \u03b22 integrin CD18", "TREATMENT", 50, 70], ["inflammation", "PROBLEM", 117, 129], ["TNF", "TEST", 153, 156], ["co-culture", "PROBLEM", 162, 172], ["bronchial epithelial cells", "PROBLEM", 178, 204], ["cell adhesion molecules", "OBSERVATION", 18, 41], ["inflammation", "OBSERVATION", 117, 129], ["bronchial", "ANATOMY", 178, 187], ["epithelial cells", "OBSERVATION", 188, 204]]], ["TNF-\u03b1 also initiates ICAM-1 expression on bronchial epithelial cells via NF-\u03baB activation (Chen et al., 2001).", [["bronchial epithelial cells", "ANATOMY", 42, 68], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 21, 27], ["bronchial epithelial cells", "CELL", 42, 68], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 73, 78], ["TNF", "PROTEIN", 0, 3], ["ICAM-1", "PROTEIN", 21, 27], ["bronchial epithelial cells", "CELL_TYPE", 42, 68], ["NF-\u03baB", "PROTEIN", 73, 78], ["TNF", "TEST", 0, 3], ["ICAM", "TEST", 21, 25], ["bronchial epithelial cells", "TEST", 42, 68], ["bronchial epithelial", "ANATOMY", 42, 62]]], ["MG-132 treatment reduced expression of CD18 on eosinophils and ICAM-1 on BEAS-2B cells following co-culture, irrespective of the presence of TNF-\u03b1, highlighting a role for bronchial epithelial cells in NF-\u03baB mediated upregulation of cell adhesion molecules on eosinophils (Wong et al., 2006).Proteasome inhibitors ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBThe potential to modulate airway chemotactic activity and reduce T cell recruitment via inhibition of the proteasome has also been investigated.", [["eosinophils", "ANATOMY", 47, 58], ["BEAS-2B cells", "ANATOMY", 73, 86], ["bronchial epithelial cells", "ANATOMY", 172, 198], ["cell", "ANATOMY", 233, 237], ["eosinophils", "ANATOMY", 260, 271], ["airway", "ANATOMY", 408, 414], ["T cell", "ANATOMY", 447, 453], ["MG-132", "CHEMICAL", 0, 6], ["MG-132", "CHEMICAL", 0, 6], ["MG-132", "SIMPLE_CHEMICAL", 0, 6], ["CD18", "GENE_OR_GENE_PRODUCT", 39, 43], ["eosinophils", "CELL", 47, 58], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 63, 69], ["BEAS-2B cells", "CELL", 73, 86], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 141, 146], ["bronchial epithelial cells", "CELL", 172, 198], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 202, 207], ["cell", "CELL", 233, 237], ["eosinophils", "CELL", 260, 271], ["Proteasome", "GENE_OR_GENE_PRODUCT", 292, 302], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 365, 381], ["airway", "MULTI-TISSUE_STRUCTURE", 408, 414], ["T cell", "CELL", 447, 453], ["CD18", "PROTEIN", 39, 43], ["eosinophils", "CELL_TYPE", 47, 58], ["ICAM-1", "PROTEIN", 63, 69], ["BEAS-2B cells", "CELL_LINE", 73, 86], ["TNF-\u03b1", "PROTEIN", 141, 146], ["bronchial epithelial cells", "CELL_TYPE", 172, 198], ["NF-\u03baB", "PROTEIN", 202, 207], ["cell adhesion molecules", "PROTEIN", 233, 256], ["eosinophils", "CELL_TYPE", 260, 271], ["nuclear factor-\u03ba", "PROTEIN", 365, 381], ["proteasome", "PROTEIN", 488, 498], ["MG", "TEST", 0, 2], ["treatment", "TREATMENT", 7, 16], ["CD18", "TEST", 39, 43], ["eosinophils", "TEST", 47, 58], ["ICAM", "TEST", 63, 67], ["BEAS", "TEST", 73, 77], ["co-culture", "TEST", 97, 107], ["TNF", "TEST", 141, 144], ["bronchial epithelial cells", "PROBLEM", 172, 198], ["NF", "TEST", 202, 204], ["cell adhesion molecules", "PROBLEM", 233, 256], ["eosinophils", "TEST", 260, 271], ["Proteasome inhibitors", "TREATMENT", 292, 313], ["Available inhibitors", "TREATMENT", 318, 338], ["nuclear factor", "TEST", 365, 379], ["modulate airway chemotactic activity", "PROBLEM", 399, 435], ["T cell recruitment", "TREATMENT", 447, 465], ["the proteasome", "TREATMENT", 484, 498], ["bronchial", "ANATOMY", 172, 181], ["epithelial cells", "OBSERVATION", 182, 198], ["cell adhesion", "OBSERVATION", 233, 246], ["airway", "ANATOMY", 408, 414], ["chemotactic activity", "OBSERVATION", 415, 435]]], ["Bronchial biopsies from atopic asthmatics treated with the proteosomal inhibitor CBz-Ile-Glu(OtBu)-Ala-leucinal exhibited both reduced T cell chemotactic activity and production of IL-16 (Hidi et al., 2000).", [["Bronchial biopsies", "ANATOMY", 0, 18], ["T cell", "ANATOMY", 135, 141], ["atopic asthmatics", "DISEASE", 24, 41], ["CBz-Ile-Glu", "CHEMICAL", 81, 92], ["OtBu", "CHEMICAL", 93, 97], ["Ala-leucinal", "CHEMICAL", 99, 111], ["CBz-Ile-Glu", "CHEMICAL", 81, 92], ["Bronchial biopsies", "MULTI-TISSUE_STRUCTURE", 0, 18], ["CBz-Ile-Glu", "SIMPLE_CHEMICAL", 81, 92], ["OtBu)-Ala-leucinal", "SIMPLE_CHEMICAL", 93, 111], ["T cell", "CELL", 135, 141], ["IL-16", "GENE_OR_GENE_PRODUCT", 181, 186], ["IL", "PROTEIN", 181, 183], ["Bronchial biopsies", "TEST", 0, 18], ["atopic asthmatics", "PROBLEM", 24, 41], ["the proteosomal inhibitor CBz", "TEST", 55, 84], ["Ala-leucinal", "TREATMENT", 99, 111], ["reduced T cell chemotactic activity", "TREATMENT", 127, 162], ["IL", "TEST", 181, 183], ["biopsies", "OBSERVATION", 10, 18], ["atopic asthmatics", "OBSERVATION", 24, 41], ["reduced", "OBSERVATION_MODIFIER", 127, 134], ["T cell chemotactic activity", "OBSERVATION", 135, 162]]], ["TLR agonists are potent activators of the classical NF-\u03baB pathway.", [["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 52, 57], ["TLR", "PROTEIN", 0, 3], ["NF-\u03baB", "PROTEIN", 52, 57], ["TLR agonists", "TREATMENT", 0, 12]]], ["Inhibition of the proteasome by MG-132 has also revealed a role for NF-\u03baB and TLR3/4 stimulation in tracheal contraction.", [["tracheal", "ANATOMY", 100, 108], ["MG-132", "CHEMICAL", 32, 38], ["MG-132", "SIMPLE_CHEMICAL", 32, 38], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 68, 73], ["TLR3/4", "GENE_OR_GENE_PRODUCT", 78, 84], ["tracheal", "ORGAN", 100, 108], ["proteasome", "PROTEIN", 18, 28], ["NF-\u03baB", "PROTEIN", 68, 73], ["TLR3/4", "PROTEIN", 78, 84], ["the proteasome", "TREATMENT", 14, 28], ["NF", "TEST", 68, 70], ["TLR3/4 stimulation", "TREATMENT", 78, 96], ["tracheal contraction", "ANATOMY", 100, 120]]], ["One study demonstrated that the expression of TLR2, TLR3 and TLR4 in the smooth muscle layer of mouse trachea increased contractile response to bradykinin following stimulation with TLR agonists LPS and polyIC.", [["smooth muscle layer", "ANATOMY", 73, 92], ["trachea", "ANATOMY", 102, 109], ["bradykinin", "CHEMICAL", 144, 154], ["LPS", "CHEMICAL", 195, 198], ["polyIC", "CHEMICAL", 203, 209], ["bradykinin", "CHEMICAL", 144, 154], ["TLR2", "GENE_OR_GENE_PRODUCT", 46, 50], ["TLR3", "GENE_OR_GENE_PRODUCT", 52, 56], ["TLR4", "GENE_OR_GENE_PRODUCT", 61, 65], ["smooth muscle layer", "TISSUE", 73, 92], ["mouse", "ORGANISM", 96, 101], ["trachea", "ORGAN", 102, 109], ["bradykinin", "SIMPLE_CHEMICAL", 144, 154], ["TLR", "GENE_OR_GENE_PRODUCT", 182, 185], ["LPS", "SIMPLE_CHEMICAL", 195, 198], ["polyIC", "SIMPLE_CHEMICAL", 203, 209], ["TLR2", "PROTEIN", 46, 50], ["TLR3", "PROTEIN", 52, 56], ["TLR4", "PROTEIN", 61, 65], ["TLR", "PROTEIN", 182, 185], ["mouse", "SPECIES", 96, 101], ["mouse", "SPECIES", 96, 101], ["One study", "TEST", 0, 9], ["TLR2, TLR3 and TLR4", "TREATMENT", 46, 65], ["mouse trachea", "PROBLEM", 96, 109], ["bradykinin following stimulation", "TREATMENT", 144, 176], ["TLR agonists LPS", "TREATMENT", 182, 198], ["polyIC", "TEST", 203, 209], ["TLR2", "ANATOMY_MODIFIER", 46, 50], ["smooth muscle", "ANATOMY", 73, 86], ["layer", "ANATOMY_MODIFIER", 87, 92], ["mouse", "ANATOMY_MODIFIER", 96, 101], ["trachea", "ANATOMY", 102, 109], ["contractile response", "OBSERVATION", 120, 140]]], ["This response was associated with nuclear translocation of p65 and up-regulation of kinin B1 and B2 receptor mRNA and could be inhibited by MG-132 (Bachar et al., 2004).Proteasome inhibitors ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBWhile the role of TLR signalling and NF-\u03baB activation in asthma has been well studied, much less is known about CS induced, TLR mediated inflammation in COPD.", [["nuclear", "ANATOMY", 34, 41], ["MG-132", "CHEMICAL", 140, 146], ["asthma", "DISEASE", 316, 322], ["inflammation", "DISEASE", 396, 408], ["COPD", "DISEASE", 412, 416], ["MG-132", "CHEMICAL", 140, 146], ["nuclear", "CELLULAR_COMPONENT", 34, 41], ["p65", "GENE_OR_GENE_PRODUCT", 59, 62], ["kinin B1", "GENE_OR_GENE_PRODUCT", 84, 92], ["B2 receptor", "GENE_OR_GENE_PRODUCT", 97, 108], ["MG-132", "SIMPLE_CHEMICAL", 140, 146], ["Proteasome", "GENE_OR_GENE_PRODUCT", 169, 179], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 242, 258], ["TLR", "GENE_OR_GENE_PRODUCT", 277, 280], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 296, 301], ["CS", "SIMPLE_CHEMICAL", 371, 373], ["TLR", "GENE_OR_GENE_PRODUCT", 383, 386], ["p65", "PROTEIN", 59, 62], ["kinin B1 and B2 receptor mRNA", "RNA", 84, 113], ["nuclear factor-\u03ba", "PROTEIN", 242, 258], ["TLR", "PROTEIN", 277, 280], ["NF-\u03baB", "PROTEIN", 296, 301], ["TLR", "PROTEIN", 383, 386], ["nuclear translocation of p65", "PROBLEM", 34, 62], ["kinin B1", "TREATMENT", 84, 92], ["MG", "TEST", 140, 142], ["Proteasome inhibitors", "TREATMENT", 169, 190], ["Available inhibitors", "TREATMENT", 195, 215], ["nuclear factor", "TEST", 242, 256], ["NF", "PROBLEM", 296, 298], ["asthma", "PROBLEM", 316, 322], ["TLR mediated inflammation", "PROBLEM", 383, 408], ["COPD", "PROBLEM", 412, 416], ["inflammation", "OBSERVATION", 396, 408], ["COPD", "OBSERVATION", 412, 416]]], ["Stimulation of macrophages via TLR4 leads to NF-\u03baB activation and production of IL-8 (Brightbill et al., 1999).", [["macrophages", "ANATOMY", 15, 26], ["macrophages", "CELL", 15, 26], ["TLR4", "GENE_OR_GENE_PRODUCT", 31, 35], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 45, 50], ["IL-8", "GENE_OR_GENE_PRODUCT", 80, 84], ["macrophages", "CELL_TYPE", 15, 26], ["TLR4", "PROTEIN", 31, 35], ["NF-\u03baB", "PROTEIN", 45, 50], ["Stimulation of macrophages", "TREATMENT", 0, 26], ["NF", "TEST", 45, 47]]], ["To assess the role of CS and induction of NF-\u03baB regulated pro-inflammatory gene expression, human monocyte-derived macrophages were treated with CS in vitro and increased IL-8 production was observed.", [["monocyte", "ANATOMY", 98, 106], ["macrophages", "ANATOMY", 115, 126], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 42, 47], ["human", "ORGANISM", 92, 97], ["monocyte-derived macrophages", "CELL", 98, 126], ["IL-8", "GENE_OR_GENE_PRODUCT", 171, 175], ["NF-\u03baB", "PROTEIN", 42, 47], ["human monocyte", "CELL_TYPE", 92, 106], ["macrophages", "CELL_TYPE", 115, 126], ["IL", "PROTEIN", 171, 173], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["NF", "TEST", 42, 44], ["CS in vitro", "TREATMENT", 145, 156], ["increased IL", "TREATMENT", 161, 173]]], ["This response was dependent on TLR4 activation and was associated with phosphorylation of IRAK and activation of NF-\u03baB.", [["TLR4", "GENE_OR_GENE_PRODUCT", 31, 35], ["IRAK", "GENE_OR_GENE_PRODUCT", 90, 94], ["NF-\u03baB.", "GENE_OR_GENE_PRODUCT", 113, 119], ["TLR4", "PROTEIN", 31, 35], ["IRAK", "PROTEIN", 90, 94], ["NF-\u03baB.", "PROTEIN", 113, 119], ["TLR4 activation", "TREATMENT", 31, 46], ["phosphorylation of IRAK", "TREATMENT", 71, 94], ["activation of NF", "TREATMENT", 99, 115], ["dependent", "OBSERVATION_MODIFIER", 18, 27]]], ["MG-132 mediated proteasomal inhibition prevented CS induced I\u03baB\u03b1 degradation (Karimi et al., 2006).", [["proteasomal", "ANATOMY", 16, 27], ["MG-132", "CHEMICAL", 0, 6], ["MG-132", "CHEMICAL", 0, 6], ["MG-132", "SIMPLE_CHEMICAL", 0, 6], ["CS", "SIMPLE_CHEMICAL", 49, 51], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 60, 64], ["I\u03baB\u03b1", "PROTEIN", 60, 64], ["MG", "TEST", 0, 2], ["proteasomal inhibition", "TREATMENT", 16, 38], ["CS induced I\u03baB\u03b1 degradation", "PROBLEM", 49, 76]]], ["The peptide boronic acids, also known as dipeptidyl boronates, originally used as inhibitors of serine proteases, comprise another class of protease inhibitors blocking the chymotrypsin-like site in the 20S subunit core.", [["boronic acids", "CHEMICAL", 12, 25], ["dipeptidyl boronates", "CHEMICAL", 41, 61], ["boronic acids", "CHEMICAL", 12, 25], ["dipeptidyl boronates", "CHEMICAL", 41, 61], ["serine", "CHEMICAL", 96, 102], ["peptide boronic acids", "SIMPLE_CHEMICAL", 4, 25], ["dipeptidyl boronates", "SIMPLE_CHEMICAL", 41, 61], ["serine", "AMINO_ACID", 96, 102], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 173, 185], ["serine proteases", "PROTEIN", 96, 112], ["chymotrypsin-like site", "DNA", 173, 195], ["20S subunit core", "PROTEIN", 203, 219], ["The peptide boronic acids", "TREATMENT", 0, 25], ["dipeptidyl boronates", "TREATMENT", 41, 61], ["serine proteases", "TREATMENT", 96, 112], ["protease inhibitors", "TREATMENT", 140, 159], ["the chymotrypsin", "TREATMENT", 169, 185], ["boronic acids", "OBSERVATION", 12, 25]]], ["While these have shown efficacy against several tumours, there is little data describing their use in treating airway inflammation (reviewed in Gilmore & Herscovitch, 2006).", [["tumours", "ANATOMY", 48, 55], ["airway", "ANATOMY", 111, 117], ["airway inflammation", "DISEASE", 111, 130], ["tumours", "CANCER", 48, 55], ["airway", "MULTI-TISSUE_STRUCTURE", 111, 117], ["several tumours", "PROBLEM", 40, 55], ["airway inflammation", "PROBLEM", 111, 130], ["several", "OBSERVATION_MODIFIER", 40, 47], ["tumours", "OBSERVATION", 48, 55], ["airway", "ANATOMY", 111, 117], ["inflammation", "OBSERVATION", 118, 130]]], ["Large clinical trials using proteasome inhibitors also highlight potential side effects associated with proteasome inhibitor use.", [["proteasome", "PROTEIN", 104, 114], ["Large clinical trials", "TREATMENT", 0, 21], ["proteasome inhibitors", "TREATMENT", 28, 49], ["potential side effects", "PROBLEM", 65, 87], ["proteasome inhibitor", "TREATMENT", 104, 124]]], ["A clinical trial utilising Bortezomib, a boronic acid dipeptide, induced several side effects including thrombocytopenia, fatigue, peripheral neuropathy and neutropenia (Richardson et al., 2003).", [["Bortezomib", "CHEMICAL", 27, 37], ["boronic acid", "CHEMICAL", 41, 53], ["thrombocytopenia", "DISEASE", 104, 120], ["fatigue", "DISEASE", 122, 129], ["peripheral neuropathy", "DISEASE", 131, 152], ["neutropenia", "DISEASE", 157, 168], ["Bortezomib", "CHEMICAL", 27, 37], ["boronic acid dipeptide", "CHEMICAL", 41, 63], ["Bortezomib", "SIMPLE_CHEMICAL", 27, 37], ["boronic acid dipeptide", "SIMPLE_CHEMICAL", 41, 63], ["Bortezomib", "TREATMENT", 27, 37], ["a boronic acid dipeptide", "TREATMENT", 39, 63], ["several side effects", "PROBLEM", 73, 93], ["thrombocytopenia", "PROBLEM", 104, 120], ["fatigue", "PROBLEM", 122, 129], ["peripheral neuropathy", "PROBLEM", 131, 152], ["neutropenia", "PROBLEM", 157, 168], ["side effects", "OBSERVATION_MODIFIER", 81, 93], ["thrombocytopenia", "OBSERVATION", 104, 120], ["peripheral", "ANATOMY_MODIFIER", 131, 141], ["neuropathy", "OBSERVATION", 142, 152], ["neutropenia", "OBSERVATION", 157, 168]]], ["It is thought that the side effects could be the result of the expression of many genes and cellular processes influenced by proteasome inhibition, and this concept requires consideration before being applied to studies in asthma and COPD.Antisense and small interfering ribonucleic acid ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBWhile decoy oligonucleotides competitively bind free NF-\u03baB dimers thus preventing their interaction with cis-acting sites within promoter regions, antisense and small interfering RNA (siRNA) are nucleic acid based agents that target a specific mRNA such as NF-\u03baB and reduce the abundance of the corresponding protein.", [["cellular", "ANATOMY", 92, 100], ["asthma", "DISEASE", 223, 229], ["COPD", "DISEASE", 234, 238], ["ribonucleic acid", "CHEMICAL", 271, 287], ["nucleic acid", "CHEMICAL", 551, 563], ["cellular", "CELL", 92, 100], ["proteasome", "GENE_OR_GENE_PRODUCT", 125, 135], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 339, 355], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 409, 414], ["nucleic acid", "SIMPLE_CHEMICAL", 551, 563], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 613, 618], ["proteasome", "PROTEIN", 125, 135], ["nuclear factor-\u03ba", "PROTEIN", 339, 355], ["NF-\u03baB dimers", "PROTEIN", 409, 421], ["cis-acting sites", "DNA", 461, 477], ["promoter regions", "DNA", 485, 501], ["antisense and small interfering RNA", "RNA", 503, 538], ["mRNA", "RNA", 600, 604], ["NF-\u03baB", "PROTEIN", 613, 618], ["the side effects", "PROBLEM", 19, 35], ["many genes and cellular processes", "PROBLEM", 77, 110], ["proteasome inhibition", "TREATMENT", 125, 146], ["asthma", "PROBLEM", 223, 229], ["COPD", "PROBLEM", 234, 238], ["Antisense", "TREATMENT", 239, 248], ["Available inhibitors", "TREATMENT", 292, 312], ["nuclear factor", "TEST", 339, 353], ["decoy oligonucleotides", "TREATMENT", 362, 384], ["B dimers", "TREATMENT", 413, 421], ["small interfering RNA (siRNA)", "TREATMENT", 517, 546], ["nucleic acid based agents", "TREATMENT", 551, 576], ["cellular processes", "OBSERVATION", 92, 110], ["asthma", "OBSERVATION", 223, 229], ["COPD", "OBSERVATION", 234, 238], ["small", "OBSERVATION_MODIFIER", 253, 258], ["small", "OBSERVATION_MODIFIER", 517, 522]]], ["Antisense technology uses stablilised phosphothionate oligonucleotides to bind to complementary mRNA, thus blocking translation.", [["phosphothionate", "CHEMICAL", 38, 53], ["complementary mRNA", "RNA", 82, 100], ["Antisense technology", "TREATMENT", 0, 20], ["stablilised phosphothionate oligonucleotides", "TREATMENT", 26, 70]]], ["OVA sensitised mice injected intravenously twice with a p65 antisense oligonucleotide show a significant reduction in the level of p65 protein and NF-\u03baB activation in the lung.", [["intravenously", "ANATOMY", 29, 42], ["lung", "ANATOMY", 171, 175], ["OVA", "ORGANISM", 0, 3], ["mice", "ORGANISM", 15, 19], ["p65", "GENE_OR_GENE_PRODUCT", 56, 59], ["p65", "GENE_OR_GENE_PRODUCT", 131, 134], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 147, 152], ["lung", "ORGAN", 171, 175], ["p65", "PROTEIN", 56, 59], ["p65 protein", "PROTEIN", 131, 142], ["NF-\u03baB", "PROTEIN", 147, 152], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["a p65 antisense oligonucleotide", "TREATMENT", 54, 85], ["a significant reduction", "PROBLEM", 91, 114], ["p65 protein", "TEST", 131, 142], ["NF", "TEST", 147, 149], ["B activation in the lung", "PROBLEM", 151, 175], ["significant", "OBSERVATION_MODIFIER", 93, 104], ["reduction", "OBSERVATION_MODIFIER", 105, 114], ["lung", "ANATOMY", 171, 175]]], ["The reduction of p65 protein was associated with reduced airway inflammation cell recruitment, AHR, and both pro-inflammatory and Th2 cytokine production in BAL and OVA specific IgE in serum (Choi et al., 2004).Antisense and small interfering ribonucleic acid ::: Available inhibitors for in vivo inhibition of nuclear factor-\u03baBThe mRNA of a target protein can also be reduced using siRNA technology, via the process of RNA interference (for a review see Shrivastava & Srivastava, 2008).", [["airway", "ANATOMY", 57, 63], ["cell", "ANATOMY", 77, 81], ["BAL", "ANATOMY", 157, 160], ["serum", "ANATOMY", 185, 190], ["ribonucleic acid", "CHEMICAL", 243, 259], ["p65", "GENE_OR_GENE_PRODUCT", 17, 20], ["airway inflammation cell", "CELL", 57, 81], ["AHR", "GENE_OR_GENE_PRODUCT", 95, 98], ["BAL", "CELL", 157, 160], ["OVA", "SIMPLE_CHEMICAL", 165, 168], ["IgE", "GENE_OR_GENE_PRODUCT", 178, 181], ["serum", "ORGANISM_SUBSTANCE", 185, 190], ["nuclear factor-\u03ba", "GENE_OR_GENE_PRODUCT", 311, 327], ["p65 protein", "PROTEIN", 17, 28], ["cytokine", "PROTEIN", 134, 142], ["IgE", "PROTEIN", 178, 181], ["nuclear factor-\u03ba", "PROTEIN", 311, 327], ["BThe mRNA", "RNA", 327, 336], ["p65 protein", "TEST", 17, 28], ["reduced airway inflammation cell recruitment", "PROBLEM", 49, 93], ["AHR", "PROBLEM", 95, 98], ["both pro-inflammatory and Th2 cytokine production in BAL", "PROBLEM", 104, 160], ["Antisense", "TREATMENT", 211, 220], ["Available inhibitors", "TREATMENT", 264, 284], ["nuclear factor", "TEST", 311, 325], ["a target protein", "TREATMENT", 340, 356], ["siRNA technology", "TREATMENT", 383, 399], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["p65 protein", "OBSERVATION", 17, 28], ["reduced", "OBSERVATION_MODIFIER", 49, 56], ["airway", "ANATOMY", 57, 63], ["inflammation cell recruitment", "OBSERVATION", 64, 93], ["pro-inflammatory", "OBSERVATION_MODIFIER", 109, 125], ["small", "OBSERVATION_MODIFIER", 225, 230]]], ["Once delivered, siRNA transiently silences gene expression by directing sequence-specific degradation of a target mRNA by an endogeneous RNA-induced silencing complex (Elbashir et al., 2001).", [["target mRNA", "RNA", 107, 118], ["endogeneous RNA-induced silencing complex", "PROTEIN", 125, 166], ["an endogeneous RNA", "PROBLEM", 122, 140]]], ["The majority of reports to date describing the use of siRNA to treat lung disease in vivo have targeted respiratory virus infections (Bitko et al., 2005), demonstrating the general usefulness of delivering siRNA to the airway in vivo.", [["lung", "ANATOMY", 69, 73], ["airway", "ANATOMY", 219, 225], ["lung disease", "DISEASE", 69, 81], ["respiratory virus infections", "DISEASE", 104, 132], ["lung", "ORGAN", 69, 73], ["respiratory virus", "ORGANISM", 104, 121], ["airway", "MULTI-TISSUE_STRUCTURE", 219, 225], ["siRNA", "TREATMENT", 54, 59], ["lung disease", "PROBLEM", 69, 81], ["targeted respiratory virus infections", "PROBLEM", 95, 132], ["lung", "ANATOMY", 69, 73], ["disease", "OBSERVATION", 74, 81], ["respiratory virus", "OBSERVATION", 104, 121], ["airway", "ANATOMY", 219, 225]]], ["Also, studies using cultured airway epithelial cells have demonstrated the utility of siRNA targeting p65 in reducing TNF-\u03b1 induced pro-inflammatory cytokine production.", [["airway epithelial cells", "ANATOMY", 29, 52], ["airway epithelial cells", "CELL", 29, 52], ["p65", "GENE_OR_GENE_PRODUCT", 102, 105], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 118, 123], ["cultured airway epithelial cells", "CELL_LINE", 20, 52], ["p65", "PROTEIN", 102, 105], ["TNF", "PROTEIN", 118, 121], ["cytokine", "PROTEIN", 149, 157], ["cultured airway epithelial cells", "TEST", 20, 52], ["siRNA targeting p65", "PROBLEM", 86, 105], ["TNF", "TEST", 118, 121], ["pro-inflammatory cytokine production", "PROBLEM", 132, 168], ["epithelial cells", "OBSERVATION", 36, 52], ["pro-inflammatory cytokine production", "OBSERVATION", 132, 168]]], ["Primary epithelial cells transfected with p65-targeting siRNA produced less IL-6 and IL-8 in response to TNF-\u03b1, however this depended on the cells being undifferentiated at the time of transfection (Platz et al., 2005).", [["Primary epithelial cells", "ANATOMY", 0, 24], ["cells", "ANATOMY", 141, 146], ["Primary epithelial cells", "CELL", 0, 24], ["p65", "GENE_OR_GENE_PRODUCT", 42, 45], ["IL-6", "GENE_OR_GENE_PRODUCT", 76, 80], ["IL-8", "GENE_OR_GENE_PRODUCT", 85, 89], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 105, 110], ["cells", "CELL", 141, 146], ["Primary epithelial cells", "CELL_TYPE", 0, 24], ["p65", "PROTEIN", 42, 45], ["IL-6", "PROTEIN", 76, 80], ["IL-8", "PROTEIN", 85, 89], ["TNF", "PROTEIN", 105, 108], ["Primary epithelial cells", "TEST", 0, 24], ["p65", "TEST", 42, 45], ["siRNA", "TEST", 56, 61], ["IL", "TEST", 76, 78], ["IL", "TEST", 85, 87], ["TNF", "TEST", 105, 108], ["the cells", "PROBLEM", 137, 146], ["epithelial cells", "OBSERVATION", 8, 24]]], ["An alternative to using transfection to deliver siRNA to the lungs, is to use a viral delivery system.", [["lungs", "ANATOMY", 61, 66], ["lungs", "ORGAN", 61, 66], ["transfection", "TREATMENT", 24, 36], ["siRNA", "TREATMENT", 48, 53], ["a viral delivery system", "TREATMENT", 78, 101], ["lungs", "ANATOMY", 61, 66]]], ["Another study has employed a recombinant adeno-associated virus expressing a p65-targeting siRNA.", [["adeno-associated virus", "ORGANISM", 41, 63], ["p65", "GENE_OR_GENE_PRODUCT", 77, 80], ["p65", "PROTEIN", 77, 80], ["adeno-associated virus", "SPECIES", 41, 63], ["Another study", "TEST", 0, 13], ["a recombinant adeno-associated virus", "PROBLEM", 27, 63]]], ["Using a similar cellular model to the previous study, expression of siRNA against p65 suppressed secretion of IL-8 by TNF-\u03b1-stimulated BEAS-2B cells (Pinkenburg et al., 2004).", [["cellular", "ANATOMY", 16, 24], ["BEAS-2B cells", "ANATOMY", 135, 148], ["cellular", "CELL", 16, 24], ["p65", "GENE_OR_GENE_PRODUCT", 82, 85], ["IL-8", "GENE_OR_GENE_PRODUCT", 110, 114], ["TNF-\u03b1-", "GENE_OR_GENE_PRODUCT", 118, 124], ["BEAS-2B cells", "CELL", 135, 148], ["p65", "PROTEIN", 82, 85], ["IL-8", "PROTEIN", 110, 114], ["TNF", "PROTEIN", 118, 121], ["BEAS-2B cells", "CELL_LINE", 135, 148], ["the previous study", "TEST", 34, 52], ["siRNA", "PROBLEM", 68, 73], ["IL", "TEST", 110, 112], ["TNF", "TEST", 118, 121], ["stimulated BEAS", "TEST", 124, 139]]], ["While the application of this technology in vitro or in vivo is relatively recent, there is growing interest in this field, and as the methodology associated with both the design and delivery of siRNA expands, this approach is certain to broaden the range of therapeutic options available for asthma and COPD.Summary and concluding remarksThe NF-\u03baB pathway is central to the pathogenesis of both asthma and COPD.", [["asthma", "DISEASE", 293, 299], ["COPD", "DISEASE", 304, 308], ["asthma", "DISEASE", 396, 402], ["COPD", "DISEASE", 407, 411], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 343, 348], ["NF-\u03baB", "PROTEIN", 343, 348], ["siRNA expands", "PROBLEM", 195, 208], ["therapeutic options", "TREATMENT", 259, 278], ["asthma", "PROBLEM", 293, 299], ["COPD", "PROBLEM", 304, 308], ["both asthma", "PROBLEM", 391, 402], ["COPD", "PROBLEM", 407, 411], ["growing", "OBSERVATION_MODIFIER", 92, 99], ["COPD", "OBSERVATION", 304, 308], ["central", "OBSERVATION_MODIFIER", 360, 367], ["both", "OBSERVATION_MODIFIER", 391, 395], ["asthma", "OBSERVATION", 396, 402], ["COPD", "OBSERVATION", 407, 411]]], ["A large body of evidence has convincingly demonstrated a clear role for NF-\u03baB transcription factors and their signalling kinases in both the stable and exacerbation forms of either disease.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 72, 77], ["NF-\u03baB", "PROTEIN", 72, 77], ["transcription factors", "PROTEIN", 78, 99], ["signalling kinases", "PROTEIN", 110, 128], ["NF", "PROBLEM", 72, 74], ["B transcription factors", "TREATMENT", 76, 99], ["their signalling kinases", "PROBLEM", 104, 128], ["either disease", "PROBLEM", 174, 188], ["large", "OBSERVATION_MODIFIER", 2, 7], ["clear", "OBSERVATION", 57, 62], ["stable", "OBSERVATION_MODIFIER", 141, 147], ["disease", "OBSERVATION", 181, 188]]], ["These data are the sum of several lines of evidence, and are apparent in investigations using diseased tissue, animal models of disease, and in vitro culture cell systems.", [["tissue", "ANATOMY", 103, 109], ["cell", "ANATOMY", 158, 162], ["tissue", "TISSUE", 103, 109], ["culture cell", "CELL", 150, 162], ["diseased tissue", "PROBLEM", 94, 109], ["disease", "PROBLEM", 128, 135], ["vitro culture cell systems", "TEST", 144, 170], ["diseased tissue", "OBSERVATION", 94, 109], ["disease", "OBSERVATION", 128, 135]]], ["While the role of the NF-\u03baB pathway is clear, and methodologies to inhibit NF-\u03baB are encouraging in animal models, which molecules to specifically target and appropriate methods of their inhibition in human studies are less so.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 22, 27], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 75, 80], ["human", "ORGANISM", 201, 206], ["NF-\u03baB", "PROTEIN", 22, 27], ["NF-\u03baB", "PROTEIN", 75, 80], ["human", "SPECIES", 201, 206], ["human", "SPECIES", 201, 206], ["human studies", "TEST", 201, 214], ["clear", "OBSERVATION", 39, 44]]], ["There is good evidence for small molecule inhibition methodologies, and also for the use of oligonucleotide based methodologies, including decoy oligonucleotides and siRNA.", [["small molecule inhibition methodologies", "PROBLEM", 27, 66], ["oligonucleotide based methodologies", "TREATMENT", 92, 127], ["decoy oligonucleotides", "TREATMENT", 139, 161], ["siRNA", "PROBLEM", 166, 171], ["good evidence for", "UNCERTAINTY", 9, 26], ["small", "OBSERVATION_MODIFIER", 27, 32], ["molecule inhibition", "OBSERVATION", 33, 52]]], ["Further, carefully controlled studies in reliable animal models must be performed to address this complex issue before any form of inhibition can be tested in human studies.", [["human", "ORGANISM", 159, 164], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 159, 164], ["carefully controlled studies", "TEST", 9, 37], ["human studies", "TEST", 159, 172]]], ["Which NF-\u03baB signalling molecule represents the best therapeutic target is again a perplexing question.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 6, 11], ["NF-\u03baB signalling molecule", "PROTEIN", 6, 31], ["B signalling molecule", "PROBLEM", 10, 31]]], ["While knowledge of each NF-\u03baB signalling molecule is expanding, researchers need to respect many variables, including cell type specificity, and which aspect of pathogenesis to inhibit (allergic versus non allergic inflammation, secreted cytokine/chemokine or non-secreted enzyme, adhesion molecule).", [["cell", "ANATOMY", 118, 122], ["allergic", "DISEASE", 186, 194], ["allergic inflammation", "DISEASE", 206, 227], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 24, 29], ["cell", "CELL", 118, 122], ["non-secreted enzyme, adhesion molecule", "GENE_OR_GENE_PRODUCT", 260, 298], ["NF-\u03baB signalling molecule", "PROTEIN", 24, 49], ["secreted cytokine", "PROTEIN", 229, 246], ["chemokine", "PROTEIN", 247, 256], ["non-secreted enzyme", "PROTEIN", 260, 279], ["adhesion molecule", "PROTEIN", 281, 298], ["B signalling molecule", "PROBLEM", 28, 49], ["cell type specificity", "TEST", 118, 139], ["allergic", "PROBLEM", 186, 194], ["non allergic inflammation", "PROBLEM", 202, 227], ["secreted cytokine/chemokine or non-secreted enzyme", "TREATMENT", 229, 279]]], ["Another important point worth considering is which end points are most important, especially in animal models.", [["most important", "UNCERTAINTY", 66, 80]]], ["While inhibiting NF-\u03baB clearly affects a range of different end points, including allergic and non-allergic inflammation, and AHR, there does exist some heterogeneity between different models.", [["allergic and non-allergic inflammation", "DISEASE", 82, 120], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 17, 22], ["NF-\u03baB", "PROTEIN", 17, 22], ["allergic", "PROBLEM", 82, 90], ["non-allergic inflammation", "PROBLEM", 95, 120], ["AHR", "PROBLEM", 126, 129], ["some heterogeneity between different models", "PROBLEM", 148, 191], ["allergic", "OBSERVATION_MODIFIER", 82, 90], ["non-allergic inflammation", "OBSERVATION", 95, 120], ["some", "OBSERVATION_MODIFIER", 148, 152], ["heterogeneity", "OBSERVATION", 153, 166]]], ["This is a truly salient point, differential targeting of the NF-\u03baB pathway in different cell types may alter various end points and disease outcome in these animal models.", [["cell", "ANATOMY", 88, 92], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 61, 66], ["cell", "CELL", 88, 92], ["NF-\u03baB", "PROTEIN", 61, 66], ["the NF", "TEST", 57, 63], ["disease outcome", "PROBLEM", 132, 147], ["different cell types", "OBSERVATION", 78, 98]]], ["It is likely that each outcome may be model dependent; hence the results of different models need to be interpreted with caution.", [["model dependent", "PROBLEM", 38, 53], ["is likely", "UNCERTAINTY", 3, 12], ["dependent", "OBSERVATION_MODIFIER", 44, 53]]], ["The above points need to be thoroughly considered in future studies if NF-\u03baB is going to be a serious contender for therapeutic intervention in human disease.Summary and concluding remarksThe wealth of literature focusing on NF-\u03baB in asthma and COPD has also teased out several controversies regarding the suitability and or role of NF-\u03baB in asthma and COPD.", [["asthma", "DISEASE", 234, 240], ["COPD", "DISEASE", 245, 249], ["asthma", "DISEASE", 342, 348], ["COPD", "DISEASE", 353, 357], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 71, 76], ["human", "ORGANISM", 144, 149], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 225, 230], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 333, 338], ["NF-\u03baB", "PROTEIN", 71, 76], ["NF-\u03baB", "PROTEIN", 225, 230], ["NF-\u03baB", "PROTEIN", 333, 338], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 144, 149], ["therapeutic intervention", "TREATMENT", 116, 140], ["human disease", "PROBLEM", 144, 157], ["asthma", "PROBLEM", 234, 240], ["COPD", "PROBLEM", 245, 249], ["asthma", "PROBLEM", 342, 348], ["COPD", "PROBLEM", 353, 357], ["asthma", "OBSERVATION", 234, 240], ["COPD", "OBSERVATION", 245, 249], ["asthma", "OBSERVATION", 342, 348], ["COPD", "OBSERVATION", 353, 357]]], ["Firstly, there is the consideration of the role of NF-\u03baB to beneficial host responses to infectious agents.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 51, 56], ["NF-\u03baB", "PROTEIN", 51, 56], ["infectious agents", "TREATMENT", 89, 106]]], ["Secondly, there is the conundrum of why known NF-\u03baB inhibitors such as GCs work poorly in controlling exacerbations of asthma and COPD.", [["asthma", "DISEASE", 119, 125], ["COPD", "DISEASE", 130, 134], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 46, 51], ["NF-\u03baB inhibitors", "TREATMENT", 46, 62], ["asthma", "PROBLEM", 119, 125], ["COPD", "PROBLEM", 130, 134], ["asthma", "OBSERVATION", 119, 125], ["COPD", "OBSERVATION", 130, 134]]], ["While the answers are clearly complex, a better understanding, and better defining of each disease in human systems will be important in future studies.", [["human", "ORGANISM", 102, 107], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["each disease in human systems", "PROBLEM", 86, 115]]], ["Also, particularly for COPD, and exacerbations of both diseases, the design of useful animal models with clinically useful end points is also required.", [["COPD", "DISEASE", 23, 27], ["COPD", "PROBLEM", 23, 27], ["exacerbations", "PROBLEM", 33, 46], ["both diseases", "PROBLEM", 50, 63], ["COPD", "OBSERVATION", 23, 27], ["both", "OBSERVATION_MODIFIER", 50, 54], ["diseases", "OBSERVATION", 55, 63]]], ["The potential of targeting the NF-\u03baB pathway in asthma and COPD is therefore an excellent example in the study of clinical pharmacology.", [["asthma", "DISEASE", 48, 54], ["COPD", "DISEASE", 59, 63], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 31, 36], ["NF-\u03baB", "PROTEIN", 31, 36], ["asthma", "PROBLEM", 48, 54], ["COPD", "PROBLEM", 59, 63], ["the study", "TEST", 101, 110], ["asthma", "OBSERVATION", 48, 54], ["COPD", "OBSERVATION", 59, 63]]], ["As the technology and therapeutic agents become increasingly available, so does the opportunity to trial new treatments, and learn more about the mechanisms behind these important diseases.", [["new treatments", "TREATMENT", 105, 119], ["these important diseases", "PROBLEM", 164, 188]]]], "PMC7115307": [["Materials and methodsThis cluster of NEC was identified by the physicians on February 5, 2007, after the first 5 cases were diagnosed.", [["NEC", "DISEASE", 37, 40], ["NEC", "CANCER", 37, 40], ["NEC", "PROBLEM", 37, 40], ["NEC", "OBSERVATION", 37, 40]]], ["Cases were defined according to modified Bell's staging.1, 6 (In 1978, Bell et al7 developed a uniform staging system for NEC, which was modified by Walsh et al6 in 1986 to more explicitly describe the systemic, intestinal, and radiographic signs.)", [["intestinal", "ANATOMY", 212, 222], ["NEC", "DISEASE", 122, 125], ["intestinal", "ORGAN", 212, 222], ["modified Bell's staging", "TEST", 32, 55], ["NEC", "PROBLEM", 122, 125], ["intestinal", "ANATOMY", 212, 222]]], ["Annual rates of NEC at this hospital were calculated for 2005, 2006, and 2007.", [["NEC", "DISEASE", 16, 19], ["NEC", "PROBLEM", 16, 19], ["NEC", "OBSERVATION", 16, 19]]], ["Medical charts for each case-patient were reviewed, and the following information was collected based on factors identified from previous reports of NEC clusters and the judgment of the clinical staff and investigative team: date of birth; estimated gestational age; birth weight; sex; admission date; APGAR score; date of NEC onset; NEC staging and accompanying signs and symptoms; previous diagnosis of NEC; detailed feeding history for \u22647 days before symptom onset; antimicrobial therapy and other pharmaceutical treatments; umbilical catheter; surgical treatment; hyaline membrane disease; and maternal risk factors, including prenatal care, gestational diabetes, drug abuse, and preeclampsia.", [["umbilical", "ANATOMY", 528, 537], ["hyaline membrane", "ANATOMY", 568, 584], ["NEC", "DISEASE", 149, 152], ["NEC", "DISEASE", 323, 326], ["NEC", "DISEASE", 334, 337], ["NEC", "DISEASE", 405, 408], ["hyaline membrane disease", "DISEASE", 568, 592], ["gestational diabetes", "DISEASE", 646, 666], ["drug abuse", "DISEASE", 668, 678], ["preeclampsia", "DISEASE", 684, 696], ["patient", "ORGANISM", 29, 36], ["hyaline membrane", "MULTI-TISSUE_STRUCTURE", 568, 584], ["patient", "SPECIES", 29, 36], ["NEC clusters", "PROBLEM", 149, 161], ["APGAR score", "TEST", 302, 313], ["NEC onset", "PROBLEM", 323, 332], ["NEC staging", "PROBLEM", 334, 345], ["accompanying signs and symptoms", "PROBLEM", 350, 381], ["NEC", "PROBLEM", 405, 408], ["symptom onset", "PROBLEM", 454, 467], ["antimicrobial therapy", "TREATMENT", 469, 490], ["other pharmaceutical treatments", "TREATMENT", 495, 526], ["umbilical catheter", "TREATMENT", 528, 546], ["surgical treatment", "TREATMENT", 548, 566], ["hyaline membrane disease", "PROBLEM", 568, 592], ["maternal risk factors", "PROBLEM", 598, 619], ["prenatal care", "TREATMENT", 631, 644], ["gestational diabetes", "PROBLEM", 646, 666], ["preeclampsia", "PROBLEM", 684, 696], ["NEC", "OBSERVATION", 405, 408], ["umbilical", "ANATOMY", 528, 537], ["catheter", "OBSERVATION", 538, 546], ["hyaline membrane disease", "OBSERVATION", 568, 592], ["preeclampsia", "OBSERVATION", 684, 696]]], ["Information regarding bed location and number of nurses and other health care providers caring for case-patients during the 2 days before symptom onset was also collected.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112]]], ["Enhanced surveillance for NEC was conducted for 2 months following the last case of the cluster.Materials and methodsAll clinical samples were processed through the hospital laboratory.", [["samples", "ANATOMY", 130, 137], ["NEC", "DISEASE", 26, 29], ["Enhanced surveillance", "TEST", 0, 21], ["NEC", "PROBLEM", 26, 29], ["All clinical samples", "TEST", 117, 137]]], ["Blood cultures were ordered for each case-patient, and, after the outbreak was detected, stool was tested for the following pathogens: Clostridium difficile via toxin test (n = 7), norovirus (n = 7), rotavirus (n = 6), and other enteric pathogens (n = 6).", [["Blood cultures", "ANATOMY", 0, 14], ["stool", "ANATOMY", 89, 94], ["Clostridium difficile", "DISEASE", 135, 156], ["norovirus", "DISEASE", 181, 190], ["rotavirus", "DISEASE", 200, 209], ["enteric pathogens", "DISEASE", 229, 246], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["patient", "ORGANISM", 42, 49], ["stool", "ORGANISM_SUBSTANCE", 89, 94], ["Clostridium difficile", "ORGANISM", 135, 156], ["patient", "SPECIES", 42, 49], ["Clostridium difficile", "SPECIES", 135, 156], ["Clostridium difficile", "SPECIES", 135, 156], ["rotavirus", "SPECIES", 200, 209], ["Blood cultures", "TEST", 0, 14], ["the outbreak", "PROBLEM", 62, 74], ["stool", "TEST", 89, 94], ["Clostridium difficile via toxin test", "TEST", 135, 171], ["norovirus", "PROBLEM", 181, 190], ["rotavirus", "PROBLEM", 200, 209], ["other enteric pathogens", "PROBLEM", 223, 246], ["enteric", "ANATOMY", 229, 236], ["pathogens", "OBSERVATION", 237, 246]]], ["Anaerobic testing of stool or environmental samples was not available through the New Mexico Scientific Laboratory Division or local private laboratories limiting the ability to identify anaerobic pathogens.Materials and methodsWhen the cluster was identified, the nursing and dietary staff immediately isolated all remaining commercial feeding products for possible testing.", [["stool", "ANATOMY", 21, 26], ["samples", "ANATOMY", 44, 51], ["stool", "ORGANISM_SUBSTANCE", 21, 26], ["Anaerobic testing of stool or environmental samples", "TEST", 0, 51], ["anaerobic pathogens", "PROBLEM", 187, 206], ["commercial feeding products", "TREATMENT", 326, 353], ["testing", "TEST", 367, 374]]], ["Human milk fortifier (HMF) (Enfamil; Mead Johnson, Glenview, IL) and single-use liquid formula with and without iron in 20- and 24-calories/oz formulations were among the isolated products and were sent to New Mexico Scientific Laboratory Division for aerobic bacterial contamination testing.", [["milk", "ANATOMY", 6, 10], ["HMF", "CHEMICAL", 22, 25], ["iron", "CHEMICAL", 112, 116], ["iron", "CHEMICAL", 112, 116], ["Human", "ORGANISM", 0, 5], ["milk", "ORGANISM_SUBSTANCE", 6, 10], ["HMF", "SIMPLE_CHEMICAL", 22, 25], ["iron", "SIMPLE_CHEMICAL", 112, 116], ["Human", "SPECIES", 0, 5], ["milk", "SPECIES", 6, 10], ["Human", "SPECIES", 0, 5], ["Human milk fortifier (HMF) (Enfamil; Mead Johnson, Glenview, IL)", "TREATMENT", 0, 64], ["single-use liquid formula", "TREATMENT", 69, 94], ["iron", "TREATMENT", 112, 116], ["calories/oz formulations", "TREATMENT", 131, 155], ["aerobic bacterial contamination testing", "TEST", 252, 291]]], ["HMF, used to increase levels of nutrients and calories in expressed breast milk, was available in single-use, 0.71-g packets of dry powder.", [["breast milk", "ANATOMY", 68, 79], ["HMF", "CHEMICAL", 0, 3], ["HMF", "CHEMICAL", 0, 3], ["HMF", "SIMPLE_CHEMICAL", 0, 3], ["breast milk", "TISSUE", 68, 79], ["HMF", "TREATMENT", 0, 3], ["levels of nutrients and calories in expressed breast milk", "TREATMENT", 22, 79], ["dry powder", "TREATMENT", 128, 138], ["breast", "ANATOMY", 68, 74]]], ["Because of the limited volume in each HMF packet, contents from multiple packets sharing the same prefix lot code were combined to produce sufficient volume for testing.", [["HMF", "CHEMICAL", 38, 41], ["the limited volume in each HMF packet", "TREATMENT", 11, 48], ["testing", "TEST", 161, 168], ["multiple", "OBSERVATION_MODIFIER", 64, 72]]], ["Microsoft Excel, 2003, (Microsoft Corp, Redmond, WA) was used for all data management, descriptive analyses, and cluster analysis.ResultsThe rate of NEC in this NICU during the outbreak period of January 22 to February 13, 2007, was 16.9 of 100 infants, compared with 3.3 of 100 infants and 2.4 of 100 infants in 2006 and 2005, respectively.", [["NEC", "DISEASE", 149, 152], ["NEC", "PATHOLOGICAL_FORMATION", 149, 152], ["infants", "ORGANISM", 245, 252], ["infants", "SPECIES", 245, 252], ["infants", "SPECIES", 279, 286], ["infants", "SPECIES", 302, 309], ["descriptive analyses", "TEST", 87, 107], ["cluster analysis", "TEST", 113, 129], ["NEC", "PROBLEM", 149, 152], ["NEC", "OBSERVATION", 149, 152]]], ["(The annual rate of NEC decreased to 3.4 of 100 infants by the end of 2007 in this NICU.)", [["NEC", "DISEASE", 20, 23], ["infants", "SPECIES", 48, 55], ["The annual rate", "TEST", 1, 16], ["NEC", "PROBLEM", 20, 23]]], ["The median estimated gestational age of case-patients was 33 weeks (range, 27-37 weeks), and the median time from birth to NEC onset was 8 days (range, 5-81 days).", [["NEC", "DISEASE", 123, 126], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["Seven case-patients were male, and 4 were female.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["Distribution of staging was as follows: 3 stage I (suspect), 5 stage II (definite), and 3 stage III (advanced).", [["staging", "TEST", 16, 23], ["5 stage II (definite)", "PROBLEM", 61, 82], ["staging", "OBSERVATION", 16, 23], ["stage II", "OBSERVATION_MODIFIER", 63, 71], ["stage III", "OBSERVATION_MODIFIER", 90, 99]]], ["All patients experiencing advanced NEC required surgical resection, and 1 died.", [["NEC", "ANATOMY", 35, 38], ["NEC", "DISEASE", 35, 38], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["advanced NEC", "PROBLEM", 26, 38], ["surgical resection", "TREATMENT", 48, 66], ["advanced", "OBSERVATION_MODIFIER", 26, 34], ["NEC", "OBSERVATION", 35, 38], ["surgical resection", "OBSERVATION", 48, 66]]], ["No other infants died.ResultsHealth care providers maintained a heightened index of suspicion (increased awareness of Bell's stage I criteria) for NEC for 2 months from the last identified patient.", [["NEC", "DISEASE", 147, 150], ["infants", "ORGANISM", 9, 16], ["patient", "ORGANISM", 189, 196], ["infants", "SPECIES", 9, 16], ["patient", "SPECIES", 189, 196], ["NEC", "PROBLEM", 147, 150], ["died", "OBSERVATION", 17, 21]]], ["One case of NEC was identified 22 days (March 7) after the last case associated with the cluster.", [["NEC", "DISEASE", 12, 15], ["NEC", "PATHOLOGICAL_FORMATION", 12, 15], ["NEC", "PROBLEM", 12, 15], ["NEC", "OBSERVATION", 12, 15]]], ["Although data were collected regarding this infant (by using 2 months of surveillance data), we decided to exclude it from the cluster under investigation because of the relatively substantial time between the preceding cluster and this case.", [["infant", "ORGANISM", 44, 50], ["infant", "SPECIES", 44, 50], ["surveillance data", "TEST", 73, 90]]], ["The epidemic curve summarizing the time line for this outbreak is depicted in Fig 1, stratified by NEC staging.", [["NEC", "DISEASE", 99, 102], ["The epidemic curve", "PROBLEM", 0, 18], ["NEC staging", "TEST", 99, 110], ["NEC", "OBSERVATION", 99, 102]]], ["Each patient had multiple, previously recognized risk factors for NEC (Table 1).", [["NEC", "DISEASE", 66, 69], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["NEC", "PROBLEM", 66, 69]]], ["Patients had a median of 5 (range, 3-8) risk factors for NEC.", [["NEC", "DISEASE", 57, 60], ["Patients", "ORGANISM", 0, 8], ["NEC", "PATHOLOGICAL_FORMATION", 57, 60], ["Patients", "SPECIES", 0, 8], ["NEC", "PROBLEM", 57, 60], ["NEC", "OBSERVATION", 57, 60]]], ["The median 1-minute (and 5 minute) APGAR scores for stages I, II, and III were 7 (8), 7 (9), and 6 (8), respectively.", [["APGAR", "PROTEIN", 35, 40], ["APGAR scores", "TEST", 35, 47]]], ["No appreciable patterns were detected regarding antibiotic use or other medications prescribed.", [["appreciable patterns", "PROBLEM", 3, 23], ["antibiotic use", "TREATMENT", 48, 62], ["other medications", "TREATMENT", 66, 83], ["appreciable", "OBSERVATION_MODIFIER", 3, 14], ["patterns", "OBSERVATION", 15, 23]]], ["Three of the infants' mothers (1 from each stage) had <5 prenatal care visits.", [["infants", "ORGANISM", 13, 20], ["mothers", "ORGANISM", 22, 29], ["infants", "SPECIES", 13, 20]]], ["A total of 48 nurses cared for the patients in the 2 days before diagnosis.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43]]], ["No single nurse or physician was identified as a common caregiver to all case-patients.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86]]], ["Case-patients were distributed throughout the NICU.ResultsThree different organisms (Klebsiella pneumonia, Staphylococcus aureus, and Enterobacter hormaechei) were isolated from blood cultures from 3 different patients, and C difficile toxin was detected in a fourth patient.", [["blood cultures", "ANATOMY", 178, 192], ["Klebsiella pneumonia", "DISEASE", 85, 105], ["patients", "ORGANISM", 5, 13], ["Klebsiella pneumonia", "ORGANISM", 85, 105], ["Staphylococcus aureus", "ORGANISM", 107, 128], ["Enterobacter hormaechei", "ORGANISM", 134, 157], ["blood cultures", "ORGANISM_SUBSTANCE", 178, 192], ["patients", "ORGANISM", 210, 218], ["C difficile toxin", "ORGANISM", 224, 241], ["patient", "ORGANISM", 267, 274], ["patients", "SPECIES", 5, 13], ["Klebsiella pneumonia", "SPECIES", 85, 105], ["Staphylococcus aureus", "SPECIES", 107, 128], ["Enterobacter hormaechei", "SPECIES", 134, 157], ["patients", "SPECIES", 210, 218], ["C difficile toxin", "SPECIES", 224, 241], ["patient", "SPECIES", 267, 274], ["Klebsiella pneumonia", "SPECIES", 85, 105], ["Staphylococcus aureus", "SPECIES", 107, 128], ["Enterobacter hormaechei", "SPECIES", 134, 157], ["C difficile", "SPECIES", 224, 235], ["Klebsiella pneumonia", "PROBLEM", 85, 105], ["Staphylococcus aureus", "PROBLEM", 107, 128], ["Enterobacter hormaechei)", "PROBLEM", 134, 158], ["blood cultures", "TEST", 178, 192], ["C difficile toxin", "PROBLEM", 224, 241], ["Klebsiella pneumonia", "OBSERVATION", 85, 105], ["Staphylococcus aureus", "OBSERVATION", 107, 128]]], ["No stool cultures were positive for enteric pathogens.ResultsInfant formula and HMF lot codes were not routinely recorded or tracked by the NICU staff.", [["stool cultures", "ANATOMY", 3, 17], ["enteric pathogens", "DISEASE", 36, 53], ["HMF", "CHEMICAL", 80, 83], ["stool cultures", "TEST", 3, 17], ["enteric pathogens", "PROBLEM", 36, 53], ["stool", "OBSERVATION", 3, 8], ["enteric", "ANATOMY", 36, 43], ["pathogens", "OBSERVATION", 44, 53]]], ["Seven (64%) of the case-patients received HMF before symptom onset, and 9 (82%) affected infants received 1 or more types of liquid formula.", [["HMF", "CHEMICAL", 42, 45], ["HMF", "CHEMICAL", 42, 45], ["patients", "ORGANISM", 24, 32], ["infants", "ORGANISM", 89, 96], ["patients", "SPECIES", 24, 32], ["infants", "SPECIES", 89, 96], ["HMF", "TREATMENT", 42, 45], ["liquid formula", "TREATMENT", 125, 139]]], ["One affected infant was fed an amino acid-based formula and was not exposed to HMF or standard formula.ResultsOf the 4 lot codes of HMF tested, 1 contained 100 colony-forming units (cfu)/g of Bacillus cereus, 1 contained 10 cfu/g of B cereus, and 2 contained <10 cfu/g of B cereus.", [["amino acid", "CHEMICAL", 31, 41], ["HMF", "CHEMICAL", 79, 82], ["HMF", "CHEMICAL", 132, 135], ["amino acid", "CHEMICAL", 31, 41], ["HMF", "CHEMICAL", 79, 82], ["HMF", "CHEMICAL", 132, 135], ["infant", "ORGANISM", 13, 19], ["amino acid", "AMINO_ACID", 31, 41], ["HMF", "SIMPLE_CHEMICAL", 79, 82], ["HMF", "SIMPLE_CHEMICAL", 132, 135], ["Bacillus cereus", "ORGANISM", 192, 207], ["B cereus", "ORGANISM", 233, 241], ["B cereus", "ORGANISM", 272, 280], ["infant", "SPECIES", 13, 19], ["Bacillus cereus", "SPECIES", 192, 207], ["B cereus", "SPECIES", 233, 241], ["B cereus", "SPECIES", 272, 280], ["Bacillus cereus", "SPECIES", 192, 207], ["B cereus", "SPECIES", 233, 241], ["B cereus", "SPECIES", 272, 280], ["an amino acid-based formula", "TREATMENT", 28, 55], ["HMF", "TEST", 132, 135], ["Bacillus cereus", "PROBLEM", 192, 207], ["B cereus", "TEST", 233, 241], ["B cereus", "PROBLEM", 272, 280], ["Bacillus cereus", "ANATOMY", 192, 207], ["B cereus", "OBSERVATION", 272, 280]]], ["No other bacteria were recovered from HMF, and all single-use liquid formula sampled tested negative for bacterial contamination.", [["HMF", "CHEMICAL", 38, 41], ["HMF", "CHEMICAL", 38, 41], ["HMF", "SIMPLE_CHEMICAL", 38, 41], ["other bacteria", "PROBLEM", 3, 17], ["liquid formula", "TEST", 62, 76], ["bacterial contamination", "PROBLEM", 105, 128], ["bacteria", "OBSERVATION", 9, 17], ["bacterial contamination", "OBSERVATION", 105, 128]]], ["None of the infant blood specimens tested positive for B cereus, and stool samples were not specifically cultured for B cereus because it is not part of the standard microbiologic panel and there was no stool available for additional testing once the environmental tests were performed.", [["blood specimens", "ANATOMY", 19, 34], ["stool samples", "ANATOMY", 69, 82], ["infant", "ORGANISM", 12, 18], ["blood specimens", "ORGANISM_SUBSTANCE", 19, 34], ["B cereus", "ORGANISM", 55, 63], ["stool samples", "ORGANISM_SUBSTANCE", 69, 82], ["B cereus", "ORGANISM", 118, 126], ["infant", "SPECIES", 12, 18], ["B cereus", "SPECIES", 55, 63], ["B cereus", "SPECIES", 118, 126], ["B cereus", "SPECIES", 55, 63], ["B cereus", "SPECIES", 118, 126], ["the infant blood specimens", "TEST", 8, 34], ["B cereus", "PROBLEM", 55, 63], ["stool samples", "TEST", 69, 82], ["B cereus", "PROBLEM", 118, 126], ["the standard microbiologic panel", "TEST", 153, 185], ["stool", "PROBLEM", 203, 208], ["additional testing", "TEST", 223, 241], ["the environmental tests", "TEST", 247, 270]]], ["The finding of 100 cfu/g of B cereus in 1 sample is at the US Food and Drug Administration's (FDA) upper microbiologic limit for healthy term infants.", [["B cereus", "ORGANISM", 28, 36], ["infants", "ORGANISM", 142, 149], ["B cereus", "SPECIES", 28, 36], ["infants", "SPECIES", 142, 149], ["B cereus", "SPECIES", 28, 36], ["B cereus", "PROBLEM", 28, 36], ["Drug Administration", "TREATMENT", 71, 90]]], ["No limit is available for preterm infants.ResultsWe recommended that patients be placed under contact isolation and reemphasized the need for strict adherence to hand hygiene and appropriate use of personal protective equipment for both health care personnel and visitors.", [["hand", "ANATOMY", 162, 166], ["infants", "ORGANISM", 34, 41], ["patients", "ORGANISM", 69, 77], ["hand", "ORGANISM_SUBDIVISION", 162, 166], ["infants", "SPECIES", 34, 41], ["patients", "SPECIES", 69, 77], ["contact isolation", "TREATMENT", 94, 111], ["hand hygiene", "TREATMENT", 162, 174], ["personal protective equipment", "TREATMENT", 198, 227]]], ["A 1-time thorough environmental cleaning of the entire NICU was performed with a 1:10 dilution of household bleach (ie, 5000 parts/million of hypochlorite), and infants and nurses cohorted when possible.", [["hypochlorite", "CHEMICAL", 142, 154], ["hypochlorite", "CHEMICAL", 142, 154], ["hypochlorite", "SIMPLE_CHEMICAL", 142, 154], ["infants", "ORGANISM", 161, 168], ["infants", "SPECIES", 161, 168], ["hypochlorite", "TREATMENT", 142, 154]]], ["The hospital also elected to change to new lot codes of HMF and formula.", [["HMF", "CHEMICAL", 56, 59], ["HMF", "CHEMICAL", 56, 59], ["HMF", "SIMPLE_CHEMICAL", 56, 59], ["new lot codes of HMF and formula", "TREATMENT", 39, 71]]], ["Only 1 isolated case of NEC (previously mentioned) was detected 3 weeks following the implementation of these infection control measures; however, the NEC cluster possibly would have spontaneously resolved regardless.DiscussionA cluster of NEC in a New Mexico NICU was detected and investigated.", [["NEC", "DISEASE", 24, 27], ["infection", "DISEASE", 110, 119], ["NEC", "DISEASE", 151, 154], ["NEC", "DISEASE", 240, 243], ["NEC", "PATHOLOGICAL_FORMATION", 24, 27], ["NEC", "PATHOLOGICAL_FORMATION", 240, 243], ["NEC", "PROBLEM", 24, 27], ["these infection control measures", "TREATMENT", 104, 136], ["the NEC cluster", "PROBLEM", 147, 162], ["NEC", "PROBLEM", 240, 243], ["NEC", "OBSERVATION", 24, 27], ["infection", "OBSERVATION", 110, 119], ["NEC", "OBSERVATION", 240, 243]]], ["No single pathogen was identified, a fact that might not be surprising given the likely multifactorial etiology of NEC.", [["NEC", "DISEASE", 115, 118], ["NEC", "PATHOLOGICAL_FORMATION", 115, 118], ["single pathogen", "PROBLEM", 3, 18], ["NEC", "PROBLEM", 115, 118], ["single", "OBSERVATION_MODIFIER", 3, 9], ["pathogen", "OBSERVATION", 10, 18], ["likely", "UNCERTAINTY", 81, 87], ["multifactorial", "OBSERVATION_MODIFIER", 88, 102], ["NEC", "OBSERVATION", 115, 118]]], ["NICU staff initiated the following additional infection control measures: enhanced cleaning of all surfaces and instruments by using a sporicidal disinfectant, increased attention to hand hygiene, isolating patients until outbreak termination, staff cohorting, and increased index of suspicion for new cases.DiscussionThis report highlights the need for systematic diagnostic testing to cover the spectrum of potential causal organisms when investigating nosocomial outbreaks of NEC, especially for those organisms not routinely isolated by standard blood or stool culture (eg, anaerobic bacteria and B cereus).", [["hand", "ANATOMY", 183, 187], ["blood", "ANATOMY", 550, 555], ["infection", "DISEASE", 46, 55], ["NEC", "DISEASE", 479, 482], ["hand", "ORGANISM_SUBDIVISION", 183, 187], ["patients", "ORGANISM", 207, 215], ["NEC", "PATHOLOGICAL_FORMATION", 479, 482], ["blood", "ORGANISM_SUBSTANCE", 550, 555], ["B cereus", "ORGANISM", 601, 609], ["patients", "SPECIES", 207, 215], ["B cereus", "SPECIES", 601, 609], ["B cereus", "SPECIES", 601, 609], ["additional infection control measures", "TREATMENT", 35, 72], ["a sporicidal disinfectant", "TREATMENT", 133, 158], ["hand hygiene", "TREATMENT", 183, 195], ["systematic diagnostic testing", "TEST", 354, 383], ["potential causal organisms", "PROBLEM", 409, 435], ["NEC", "PROBLEM", 479, 482], ["those organisms", "PROBLEM", 499, 514], ["stool culture", "TEST", 559, 572], ["anaerobic bacteria and B cereus", "PROBLEM", 578, 609], ["infection", "OBSERVATION", 46, 55]]], ["Three blood cultures were positive with 3 different organisms (K pneumonia, S aureus, and E hormaechei).", [["blood cultures", "ANATOMY", 6, 20], ["pneumonia", "DISEASE", 65, 74], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["K pneumonia", "ORGANISM", 63, 74], ["S aureus", "ORGANISM", 76, 84], ["E hormaechei", "ORGANISM", 90, 102], ["S aureus", "SPECIES", 76, 84], ["E hormaechei", "SPECIES", 90, 102], ["K pneumonia", "SPECIES", 63, 74], ["S aureus", "SPECIES", 76, 84], ["E hormaechei", "SPECIES", 90, 102], ["Three blood cultures", "TEST", 0, 20], ["3 different organisms", "PROBLEM", 40, 61], ["K pneumonia", "PROBLEM", 63, 74], ["S aureus", "TEST", 76, 84], ["pneumonia", "OBSERVATION", 65, 74]]], ["This finding would not be unusual for sporadic cases of NEC, but, given the clustering of these cases, a common exposure increasing the risk of sepsis with the identified organisms is possible.", [["NEC", "ANATOMY", 56, 59], ["NEC", "DISEASE", 56, 59], ["sepsis", "DISEASE", 144, 150], ["NEC", "PATHOLOGICAL_FORMATION", 56, 59], ["NEC", "PROBLEM", 56, 59], ["sepsis", "PROBLEM", 144, 150], ["the identified organisms", "PROBLEM", 156, 180], ["NEC", "OBSERVATION", 56, 59], ["sepsis", "OBSERVATION", 144, 150]]], ["Although comprehensive testing might not always be necessary in sporadic cases of NEC, it is critical in establishing the etiology when a substantial cluster or outbreak is identified.", [["NEC", "DISEASE", 82, 85], ["NEC", "PATHOLOGICAL_FORMATION", 82, 85], ["comprehensive testing", "TEST", 9, 30], ["NEC", "PROBLEM", 82, 85], ["outbreak", "PROBLEM", 161, 169], ["NEC", "OBSERVATION", 82, 85], ["substantial", "OBSERVATION_MODIFIER", 138, 149], ["cluster", "OBSERVATION_MODIFIER", 150, 157], ["outbreak", "OBSERVATION", 161, 169]]], ["Specifically, testing for anaerobic pathogens (eg, Clostridium species), coronavirus, rotavirus, and echovirus might be added to the initial set of diagnostic tests because they have been implicated in past outbreaks.1 Unfortunately, systematic testing was not performed on all infants in this cluster.", [["echovirus", "DISEASE", 101, 110], ["Clostridium species", "ORGANISM", 51, 70], ["coronavirus", "ORGANISM", 73, 84], ["rotavirus", "ORGANISM", 86, 95], ["infants", "ORGANISM", 278, 285], ["coronavirus", "SPECIES", 73, 84], ["infants", "SPECIES", 278, 285], ["rotavirus", "SPECIES", 86, 95], ["testing", "TEST", 14, 21], ["anaerobic pathogens (eg, Clostridium species", "PROBLEM", 26, 70], ["coronavirus", "PROBLEM", 73, 84], ["rotavirus", "PROBLEM", 86, 95], ["echovirus", "PROBLEM", 101, 110], ["diagnostic tests", "TEST", 148, 164], ["systematic testing", "TEST", 234, 252]]], ["Echovirus and coronavirus testing were not performed, stool cultures were not ordered for the first 5 patients, and tissue samples were not available.", [["tissue samples", "ANATOMY", 116, 130], ["Echovirus", "GENE_OR_GENE_PRODUCT", 0, 9], ["coronavirus", "ORGANISM", 14, 25], ["patients", "ORGANISM", 102, 110], ["tissue samples", "CANCER", 116, 130], ["patients", "SPECIES", 102, 110], ["Echovirus", "PROBLEM", 0, 9], ["coronavirus testing", "TEST", 14, 33], ["stool cultures", "TEST", 54, 68], ["tissue samples", "TEST", 116, 130]]], ["The only testing for Clostridium species consisted of C difficile toxin testing.", [["C difficile toxin", "GENE_OR_GENE_PRODUCT", 54, 71], ["C difficile", "SPECIES", 54, 65], ["C difficile", "SPECIES", 54, 65], ["Clostridium species", "PROBLEM", 21, 40], ["C difficile toxin testing", "PROBLEM", 54, 79]]], ["The clinical significance of a positive C difficile toxin test in this age group is uncertain.DiscussionThe potential role of HMF in this outbreak cannot be excluded.", [["HMF", "CHEMICAL", 126, 129], ["HMF", "CHEMICAL", 126, 129], ["C difficile toxin", "GENE_OR_GENE_PRODUCT", 40, 57], ["HMF", "SIMPLE_CHEMICAL", 126, 129], ["C difficile toxin", "SPECIES", 40, 57], ["C difficile", "SPECIES", 40, 51], ["a positive C difficile toxin test", "PROBLEM", 29, 62], ["cannot be excluded", "UNCERTAINTY", 147, 165]]], ["Specifically, prematurity is a widely reported risk factor for NEC,3 which might be associated with prematurity of the gastrointestinal tract.2, 3, 8 In addition, formula-fed infants are reported to have 6 to 20 times the risk of experiencing NEC compared with breast milk-fed infants.9, 10, 11 An increased risk of NEC among preterm infants who were fed HMF has also been reported,12, 13 and contamination14 (including with B cereus15, 16) has been postulated as a potential mechanism.", [["gastrointestinal tract", "ANATOMY", 119, 141], ["breast milk", "ANATOMY", 261, 272], ["prematurity", "DISEASE", 14, 25], ["NEC", "DISEASE", 63, 66], ["prematurity of the gastrointestinal tract", "DISEASE", 100, 141], ["NEC", "DISEASE", 243, 246], ["NEC", "DISEASE", 316, 319], ["HMF", "CHEMICAL", 355, 358], ["HMF", "CHEMICAL", 355, 358], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 119, 141], ["infants", "ORGANISM", 175, 182], ["NEC", "PATHOLOGICAL_FORMATION", 243, 246], ["infants", "ORGANISM", 277, 284], ["NEC", "PATHOLOGICAL_FORMATION", 316, 319], ["infants", "ORGANISM", 334, 341], ["B cereus15", "GENE_OR_GENE_PRODUCT", 425, 435], ["infants", "SPECIES", 175, 182], ["infants", "SPECIES", 277, 284], ["infants", "SPECIES", 334, 341], ["B cereus15", "SPECIES", 425, 435], ["prematurity", "PROBLEM", 14, 25], ["NEC", "PROBLEM", 63, 66], ["prematurity of the gastrointestinal tract", "PROBLEM", 100, 141], ["NEC", "PROBLEM", 243, 246], ["NEC", "PROBLEM", 316, 319], ["prematurity", "OBSERVATION", 14, 25], ["might be associated with", "UNCERTAINTY", 75, 99], ["prematurity", "OBSERVATION", 100, 111], ["gastrointestinal tract", "ANATOMY", 119, 141], ["NEC", "OBSERVATION", 243, 246], ["increased", "OBSERVATION_MODIFIER", 298, 307], ["NEC", "OBSERVATION_MODIFIER", 316, 319]]], ["In this investigation, 1 lot code of sequestered HMF tested positive for B cereus at the FDA's upper microbiologic limit (100 cfu/g).17 Risk assessment models have concluded that powdered infant formula containing \u2264100 cfu/g of B cereus and reconstituted with cooled boiled water (25 \u00b0C) and stored for \u226424 hours at \u226410 \u00b0C would not expose term infants to an infectious dose of B cereus; however, the risk to premature infants is unknown.", [["HMF", "CHEMICAL", 49, 52], ["B cereus", "CHEMICAL", 228, 236], ["HMF", "CHEMICAL", 49, 52], ["HMF", "SIMPLE_CHEMICAL", 49, 52], ["B cereus", "ORGANISM", 73, 81], ["B cereus", "ORGANISM", 228, 236], ["infants", "ORGANISM", 345, 352], ["B cereus", "ORGANISM", 378, 386], ["infants", "ORGANISM", 419, 426], ["B cereus", "SPECIES", 73, 81], ["B cereus", "SPECIES", 228, 236], ["infants", "SPECIES", 345, 352], ["B cereus", "SPECIES", 378, 386], ["infants", "SPECIES", 419, 426], ["B cereus", "SPECIES", 73, 81], ["B cereus", "SPECIES", 228, 236], ["B cereus", "SPECIES", 378, 386], ["sequestered HMF", "TEST", 37, 52], ["B cereus", "PROBLEM", 73, 81], ["Risk assessment models", "TEST", 136, 158], ["powdered infant formula", "TREATMENT", 179, 202], ["B cereus", "TREATMENT", 228, 236], ["premature infants", "PROBLEM", 409, 426]]], ["Thus, because of similarities in ingredients and manufacturing processes between powdered formula and HMF, potential to improperly reconstitute and store fortified breast milk, and the unknown risk that B cereus poses to premature infants, a common mechanism might be shared by formula and HMF and warrants additional examination.", [["breast milk", "ANATOMY", 164, 175], ["HMF", "CHEMICAL", 102, 105], ["B cereus", "DISEASE", 203, 211], ["HMF", "CHEMICAL", 290, 293], ["HMF", "CHEMICAL", 102, 105], ["HMF", "CHEMICAL", 290, 293], ["HMF", "SIMPLE_CHEMICAL", 102, 105], ["breast", "ORGANISM_SUBDIVISION", 164, 170], ["milk", "ORGANISM_SUBSTANCE", 171, 175], ["B cereus", "ORGANISM", 203, 211], ["infants", "ORGANISM", 231, 238], ["HMF", "SIMPLE_CHEMICAL", 290, 293], ["B cereus", "SPECIES", 203, 211], ["infants", "SPECIES", 231, 238], ["B cereus", "SPECIES", 203, 211], ["HMF", "TREATMENT", 102, 105], ["premature infants", "PROBLEM", 221, 238], ["additional examination", "TEST", 307, 329]]], ["Because anaerobic cultures of HMF were not performed, isolation of B cereus might be a marker of similar or even greater levels of contamination with anaerobic spore-forming organisms (eg, Clostridium species), which have been previously indicated in the etiology of NEC.18 In this instance, the volume of HMF was insufficient to conduct both aerobic and anaerobic cultures.DiscussionFindings in this report are subject to some limitations.", [["HMF", "CHEMICAL", 30, 33], ["NEC", "DISEASE", 267, 270], ["HMF", "CHEMICAL", 306, 309], ["HMF", "CHEMICAL", 30, 33], ["HMF", "CHEMICAL", 306, 309], ["HMF", "SIMPLE_CHEMICAL", 30, 33], ["B cereus", "ORGANISM", 67, 75], ["Clostridium species", "ORGANISM", 189, 208], ["NEC", "PATHOLOGICAL_FORMATION", 267, 270], ["HMF", "SIMPLE_CHEMICAL", 306, 309], ["aerobic and anaerobic cultures", "CELL_LINE", 343, 373], ["B cereus", "SPECIES", 67, 75], ["B cereus", "SPECIES", 67, 75], ["anaerobic cultures of HMF", "TEST", 8, 33], ["isolation of B cereus", "PROBLEM", 54, 75], ["anaerobic spore-forming organisms (eg, Clostridium species", "PROBLEM", 150, 208], ["NEC", "PROBLEM", 267, 270], ["the volume of HMF", "TEST", 292, 309], ["anaerobic cultures", "TEST", 355, 373], ["NEC", "OBSERVATION", 267, 270]]], ["First, pathogens previously implicated in certain NEC outbreaks were not uniformly tested for in this investigation, in part because an outbreak was not apparent until 5 cases had been identified.", [["NEC", "DISEASE", 50, 53], ["pathogens", "PROBLEM", 7, 16], ["certain NEC outbreaks", "PROBLEM", 42, 63], ["this investigation", "TEST", 97, 115]]], ["This includes the lack of cultures for anaerobic bacteria in both clinical and food product specimens.", [["specimens", "ANATOMY", 92, 101], ["cultures", "TEST", 26, 34], ["anaerobic bacteria", "PROBLEM", 39, 57]]], ["Second, no tissue samples from patients' gastrointestinal tracts were available for confirmatory testing.", [["tissue samples", "ANATOMY", 11, 25], ["gastrointestinal tracts", "ANATOMY", 41, 64], ["tissue samples", "CANCER", 11, 25], ["patients", "ORGANISM", 31, 39], ["gastrointestinal tracts", "MULTI-TISSUE_STRUCTURE", 41, 64], ["patients", "SPECIES", 31, 39], ["tissue samples", "TEST", 11, 25], ["patients' gastrointestinal tracts", "TEST", 31, 64], ["confirmatory testing", "TEST", 84, 104], ["no", "UNCERTAINTY", 8, 10], ["tissue", "ANATOMY", 11, 17], ["gastrointestinal tracts", "ANATOMY", 41, 64]]], ["Third, a case-control study would have allowed us to better characterize risk factors for NEC (including HMF) in this outbreak.", [["NEC", "DISEASE", 90, 93], ["NEC", "PATHOLOGICAL_FORMATION", 90, 93], ["a case-control study", "TEST", 7, 27], ["NEC", "PROBLEM", 90, 93]]], ["(A case-control study was not conducted because of the insufficient power this small number of cases would have yielded.)", [["A case-control study", "TEST", 1, 21]]], ["Despite these limitations, this investigation demonstrates that considering other risk factors is critical when investigating NEC clusters and might serve as the basis for conducting more rigorous studies to evaluate the role of HMF consumption in the pathogenesis of NEC.DiscussionNo new cases in this NEC cluster occurred after institution of enhanced infection control interventions and switching lot codes of HMF and formula fed to the neonates; however, no pathogens discovered in HMF were identified in any of the infants, and no causal associations were made to explain this temporal association.", [["NEC", "DISEASE", 126, 129], ["HMF", "CHEMICAL", 229, 232], ["NEC", "DISEASE", 268, 271], ["NEC", "DISEASE", 303, 306], ["infection", "DISEASE", 354, 363], ["HMF", "CHEMICAL", 413, 416], ["HMF", "CHEMICAL", 486, 489], ["HMF", "CHEMICAL", 229, 232], ["HMF", "CHEMICAL", 413, 416], ["HMF", "CHEMICAL", 486, 489], ["HMF", "SIMPLE_CHEMICAL", 229, 232], ["NEC", "PATHOLOGICAL_FORMATION", 268, 271], ["NEC", "CANCER", 303, 306], ["HMF", "SIMPLE_CHEMICAL", 413, 416], ["neonates", "ORGANISM", 440, 448], ["HMF", "SIMPLE_CHEMICAL", 486, 489], ["infants", "ORGANISM", 520, 527], ["infants", "SPECIES", 520, 527], ["this investigation", "TEST", 27, 45], ["NEC clusters", "PROBLEM", 126, 138], ["conducting more rigorous studies", "TEST", 172, 204], ["NEC", "PROBLEM", 268, 271], ["enhanced infection control interventions", "TREATMENT", 345, 385], ["HMF and formula", "TREATMENT", 413, 428], ["pathogens", "PROBLEM", 462, 471], ["NEC", "OBSERVATION", 268, 271], ["infection", "OBSERVATION", 354, 363]]], ["Because powdered formula products, including HMF, are not sterile, careful attention should be given to contraindications for their use.", [["HMF", "CHEMICAL", 45, 48], ["HMF", "CHEMICAL", 45, 48], ["HMF", "SIMPLE_CHEMICAL", 45, 48], ["powdered formula products", "TREATMENT", 8, 33], ["HMF", "TREATMENT", 45, 48]]], ["NICU staff should consider documenting lot codes of nutritional products administered to their patients.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["nutritional products", "TREATMENT", 52, 72]]], ["Strict adherence to proper infection control practices is a key recommendation in controlling NEC clusters.1 Systematic testing of blood, stool, and tissue specimens (when available) is necessary for better understanding of the etiology of NEC clusters.DiscussionThe authors thank Erika Fernandez, MD, in the newborn intensive care unit at the University of New Mexico hospitals; Paul Torres, MS, Scientific Laboratory Division, NMDOH; Mark Mueller, MPH, Epidemiology and Response Division, NMDOH; Susan Kellie, MD, Ann-Marie Yaroslaski, RD, Pam Iwamoto, CIC, University of New Mexico hospitals; Matthew Arduino, DrPH, Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases; Anna Bowen, MD, Division of Bacterial and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases for contributing the data on which this report, in part, is based.", [["blood", "ANATOMY", 131, 136], ["stool", "ANATOMY", 138, 143], ["tissue specimens", "ANATOMY", 149, 165], ["infection", "DISEASE", 27, 36], ["NEC", "DISEASE", 94, 97], ["NEC", "DISEASE", 240, 243], ["MPH", "CHEMICAL", 450, 453], ["Infectious Diseases", "DISEASE", 721, 740], ["Bacterial and Mycotic Diseases", "DISEASE", 770, 800], ["Enteric Diseases", "DISEASE", 850, 866], ["NEC clusters", "CANCER", 94, 106], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["stool", "ORGANISM_SUBSTANCE", 138, 143], ["tissue specimens", "TISSUE", 149, 165], ["NEC", "PATHOLOGICAL_FORMATION", 240, 243], ["proper infection control practices", "TREATMENT", 20, 54], ["Systematic testing of blood, stool, and tissue specimens", "TEST", 109, 165], ["NEC clusters", "PROBLEM", 240, 252], ["Bacterial and Mycotic Diseases", "PROBLEM", 770, 800], ["Enteric Diseases", "PROBLEM", 850, 866], ["infection", "OBSERVATION", 27, 36], ["NEC", "OBSERVATION", 240, 243], ["Infectious", "OBSERVATION", 721, 731], ["Bacterial", "OBSERVATION_MODIFIER", 770, 779], ["Mycotic", "OBSERVATION_MODIFIER", 784, 791], ["Enteric", "ANATOMY", 850, 857], ["Diseases", "OBSERVATION", 858, 866]]]], "PMC2040158": [["BackgroundOngoing concerns about the emergence of an influenza pandemic continue as the number of avian and human infections with the H5N1 virus mount [1,2].", [["influenza pandemic", "DISEASE", 53, 71], ["infections", "DISEASE", 114, 124], ["avian", "ORGANISM", 98, 103], ["human", "ORGANISM", 108, 113], ["H5N1 virus", "ORGANISM", 134, 144], ["human", "SPECIES", 108, 113], ["H5N1 virus", "SPECIES", 134, 144], ["human", "SPECIES", 108, 113], ["H5N1 virus", "SPECIES", 134, 144], ["an influenza pandemic", "PROBLEM", 50, 71], ["human infections", "PROBLEM", 108, 124], ["the H5N1 virus mount", "TREATMENT", 130, 150]]], ["Adequate amounts of vaccine or antivirals are unlikely to be available early on in a pandemic, and the latter could become ineffective because of resistance [3].", [["vaccine", "TREATMENT", 20, 27], ["antivirals", "TREATMENT", 31, 41], ["amounts", "OBSERVATION_MODIFIER", 9, 16]]], ["These factors have focused attention on the use of non-pharmaceutical public health interventions to inhibit human-to-human transmission and fueled interest in answering important questions about influenza epidemiology and transmission [4-9].", [["influenza", "DISEASE", 196, 205], ["human", "ORGANISM", 109, 114], ["human", "ORGANISM", 118, 123], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 118, 123], ["non-pharmaceutical public health interventions", "TREATMENT", 51, 97]]], ["In light of the need to prepare for a possible pandemic despite concerns about the poor quality of the literature, combining available evidence with expert opinion about the relative merits of non-pharmaceutical interventions for pandemic influenza may lead to a more informed and widely accepted set of recommendations.BackgroundAt the request of the US.", [["influenza", "DISEASE", 239, 248], ["pandemic", "PROBLEM", 47, 55], ["non-pharmaceutical interventions", "TREATMENT", 193, 225], ["pandemic influenza", "PROBLEM", 230, 248], ["the US", "TEST", 348, 354]]], ["Department of Health and Human Services, we evaluated the evidence base for non-pharmaceutical public health interventions by reviewing recent published literature, including historical reviews, convening a meeting of experts, and formally eliciting and quantifying expert opinion about the relative efficacy and effectiveness of specific non-pharmaceutical interventions for pandemic influenza.", [["influenza", "DISEASE", 385, 394], ["Human", "ORGANISM", 25, 30], ["Human", "SPECIES", 25, 30], ["non-pharmaceutical public health interventions", "TREATMENT", 76, 122], ["specific non-pharmaceutical interventions", "TREATMENT", 330, 371], ["pandemic influenza", "PROBLEM", 376, 394]]], ["Based on this collective evidence, we identified a set of recommendations for and against interventions that are specific to both the setting in which an intervention may be used and the pandemic phase, and which can be used by policymakers to prepare for a pandemic until scientific evidence can definitively respond to planners' needs.", [["interventions", "TREATMENT", 90, 103], ["an intervention", "TREATMENT", 151, 166]]], ["We also identified important areas of uncertainty that warrant further research.Literature review ::: MethodsWe identified scientific articles through a MEDLINE search that combined communicable and infectious disease with non-vaccine and non-pharmaceutical intervention search terms.", [["communicable and infectious disease", "DISEASE", 182, 217], ["infectious disease", "PROBLEM", 199, 217], ["non-vaccine", "TREATMENT", 223, 234], ["non-pharmaceutical intervention", "TREATMENT", 239, 270]]], ["We searched various combinations of the Medical Subject Headings (MeSH) headings in biomedical and infections control journals back to 1966 [see Additional file 1].", [["infections", "DISEASE", 99, 109], ["the Medical Subject Headings (MeSH)", "TREATMENT", 36, 71]]], ["We also performed additional searches for review articles in the following journals from 2000 to 2005: Nature, Journal of the American Medical Association, New England Journal of Medicine, Annals of Internal Medicine, British Medical Journal, Science, Lancet, Emerging Infectious Diseases, Journal of Infectious Disease, and Clinical Infectious Disease.", [["Infectious Diseases", "DISEASE", 269, 288], ["Infectious Disease", "DISEASE", 301, 319], ["Infectious Disease", "DISEASE", 334, 352], ["Infectious", "OBSERVATION_MODIFIER", 334, 344]]], ["Using a modified rating scale derived from West et al., we then formally rated the strength of the scientific evidence presented in each of the relevant articles [11].", [["a modified rating scale", "TREATMENT", 6, 29]]], ["We have presented a list of the final articles selected for full review and classification [see Additional file 2].Elicitation of expert knowledge and opinion ::: MethodsWhile completing the literature review, we convened a meeting of experts on January 17 and 18, 2006, in Arlington, VA.", [["Methods", "TREATMENT", 163, 170]]], ["Attendees represented a broad range of disciplines, including biomedical research, virology, clinical practice, infection control, epidemiology, public health, ethics, law, history, and health policy.", [["infection", "DISEASE", 112, 121], ["infection control", "TREATMENT", 112, 129]]], ["Participants identified a set of non-pharmaceutical public health interventions that could potentially mitigate an influenza pandemic and grouped them into four categories: (1) infection control and prevention to reduce transmission when contact occurs between infected and uninfected individuals; (2) patient management to reduce contact between infected and uninfected individuals; (3) contact management to reduce contact between possibly infected and uninfected individuals; and (4) voluntary and mandatory community restrictions to reduce contact between groups that may contain infected persons (Table 3).Elicitation of expert knowledge and opinion ::: MethodsParticipants qualitatively evaluated each intervention considering a broad range of factors, including efficacy (effects under ideal conditions) and various aspects of effectiveness (effects under real-world constraints).", [["influenza pandemic", "DISEASE", 115, 133], ["infection", "DISEASE", 177, 186], ["patient", "ORGANISM", 302, 309], ["Participants", "SPECIES", 0, 12], ["patient", "SPECIES", 302, 309], ["persons", "SPECIES", 593, 600], ["non-pharmaceutical public health interventions", "TREATMENT", 33, 79], ["an influenza pandemic", "PROBLEM", 112, 133], ["infection control", "TREATMENT", 177, 194]]], ["The latter included feasibility, cost, logistics, operational and infrastructure constraints, and acceptability in terms of concerns surrounding legality and ethics, equity, public confidence, and potential unintended consequences.", [["legality", "OBSERVATION", 145, 153]]], ["In their deliberations, the experts also considered the different settings in which these interventions might be applied (healthcare facilities, community-based institutions, and private households).", [["these interventions", "TREATMENT", 84, 103]]], ["They also considered the epidemic phases in which the use of these interventions should be evaluated (no pandemic, no US pandemic, early localized US pandemic, and advanced US pandemic).Elicitation of expert knowledge and opinion ::: MethodsFollowing the meeting, we asked each expert to rate 200 unique intervention-setting-phase triads identified during the meeting based on the totality of their knowledge.", [["pandemic", "DISEASE", 176, 184], ["these interventions", "TREATMENT", 61, 80], ["pandemic", "PROBLEM", 105, 113], ["pandemic", "PROBLEM", 121, 129]]], ["Among those items for which there was agreement, items with ratings of 4 or 5 were classified as a recommendation for use, and items with ratings of 1 or 2 were classified as a recommendation against use [12].Hand hygiene and respiratory etiquette ::: Interventions recommended for use ::: ResultsHospital-based infection control measures such as hand hygiene and respiratory etiquette to prevent the spread of infection are widely supported in the literature and broadly accepted [15-20].", [["hand", "ANATOMY", 347, 351], ["infection", "DISEASE", 312, 321], ["infection", "DISEASE", 411, 420], ["hand", "ORGANISM_SUBDIVISION", 347, 351], ["ResultsHospital", "TREATMENT", 290, 305], ["based infection control measures", "TREATMENT", 306, 338], ["hand hygiene", "TREATMENT", 347, 359], ["respiratory etiquette", "TREATMENT", 364, 385], ["infection", "PROBLEM", 411, 420], ["infection", "OBSERVATION", 312, 321], ["infection", "OBSERVATION", 411, 420]]], ["Many controlled studies have shown a protective effect of hand hygiene in reducing upper respiratory infections, although few of the infections studied were due to influenza [9,21-27].", [["hand", "ANATOMY", 58, 62], ["respiratory", "ANATOMY", 89, 100], ["upper respiratory infections", "DISEASE", 83, 111], ["infections", "DISEASE", 133, 143], ["influenza", "DISEASE", 164, 173], ["hand", "ORGANISM_SUBDIVISION", 58, 62], ["upper respiratory", "ORGANISM_SUBDIVISION", 83, 100], ["Many controlled studies", "TEST", 0, 23], ["hand hygiene", "TREATMENT", 58, 70], ["reducing upper respiratory infections", "PROBLEM", 74, 111], ["the infections", "PROBLEM", 129, 143], ["influenza", "PROBLEM", 164, 173], ["protective effect", "OBSERVATION_MODIFIER", 37, 54], ["upper", "ANATOMY_MODIFIER", 83, 88], ["respiratory", "ANATOMY", 89, 100], ["infections", "OBSERVATION", 101, 111], ["few", "OBSERVATION_MODIFIER", 122, 125], ["infections", "OBSERVATION", 133, 143]]], ["Some studies suggest that use of an alcohol-based hand sanitizer is more effective in preventing carriage of non-spore forming bacteria and direct spread of most infections than antimicrobial soap or no hand washing, but antimicrobial handwashing products have not been shown to offer an advantage over soap and water [9,23,28-34].Hand hygiene and respiratory etiquette ::: Interventions recommended for use ::: ResultsThe experts recommended rigorous and routine hand hygiene as an important strategy for healthcare workers and the general public in all settings and at all phases of a pandemic, including prior to a pandemic (Table 4 - see figure 1).", [["hand", "ANATOMY", 50, 54], ["hand", "ANATOMY", 203, 207], ["hand", "ANATOMY", 464, 468], ["alcohol", "CHEMICAL", 36, 43], ["infections", "DISEASE", 162, 172], ["alcohol", "CHEMICAL", 36, 43], ["alcohol", "SIMPLE_CHEMICAL", 36, 43], ["hand", "ORGANISM_SUBDIVISION", 50, 54], ["water", "SIMPLE_CHEMICAL", 312, 317], ["hand", "ORGANISM_SUBDIVISION", 464, 468], ["Some studies", "TEST", 0, 12], ["an alcohol-based hand sanitizer", "TREATMENT", 33, 64], ["non-spore forming bacteria", "PROBLEM", 109, 135], ["most infections", "PROBLEM", 157, 172], ["antimicrobial soap", "TREATMENT", 178, 196], ["hand washing", "TREATMENT", 203, 215], ["antimicrobial handwashing products", "TREATMENT", 221, 255], ["routine hand hygiene", "TREATMENT", 456, 476], ["healthcare workers", "TREATMENT", 506, 524]]], ["However, important barriers to the effective use of hand hygiene were noted, including adherence, the supply and cost of commercially available disinfectant soaps and alcohol-based rubs, and the pervasive practice of hand-shaking.Hand hygiene and respiratory etiquette ::: Interventions recommended for use ::: ResultsExperts also recommended respiratory etiquette as an important means of preventing transmission for all patients and providers in all pandemic phases, and in the community and/or home when the US pandemic is early and localized.", [["hand", "ANATOMY", 52, 56], ["hand", "ANATOMY", 217, 221], ["alcohol", "CHEMICAL", 167, 174], ["alcohol", "CHEMICAL", 167, 174], ["hand", "ORGANISM_SUBDIVISION", 52, 56], ["alcohol", "SIMPLE_CHEMICAL", 167, 174], ["hand", "ORGANISM_SUBDIVISION", 217, 221], ["patients", "ORGANISM", 422, 430], ["patients", "SPECIES", 422, 430], ["hand hygiene", "TREATMENT", 52, 64], ["disinfectant soaps", "TREATMENT", 144, 162], ["shaking", "PROBLEM", 222, 229]]], ["Respiratory hygiene and cough etiquette is generally held to include covering the mouth and nose with a tissue or into the upper sleeve when coughing or sneezing, and refraining from spitting [35].", [["Respiratory", "ANATOMY", 0, 11], ["mouth", "ANATOMY", 82, 87], ["nose", "ANATOMY", 92, 96], ["tissue", "ANATOMY", 104, 110], ["cough", "DISEASE", 24, 29], ["sneezing", "DISEASE", 153, 161], ["mouth", "ORGANISM_SUBDIVISION", 82, 87], ["nose", "ORGANISM_SUBDIVISION", 92, 96], ["tissue", "TISSUE", 104, 110], ["upper sleeve", "ORGANISM_SUBDIVISION", 123, 135], ["Respiratory hygiene", "TREATMENT", 0, 19], ["cough etiquette", "TREATMENT", 24, 39], ["coughing", "PROBLEM", 141, 149], ["sneezing", "PROBLEM", 153, 161], ["mouth", "ANATOMY", 82, 87], ["nose", "ANATOMY", 92, 96], ["upper sleeve", "ANATOMY", 123, 135]]], ["However, they urged that the promotion of respiratory etiquette be coupled with a compelling public education campaign that includes information regarding the signs and symptoms of influenza.Human surveillance and case reporting ::: Interventions recommended for use ::: ResultsWe found little direct empirical evidence on the efficacy or effectiveness of surveillance and case reporting in the context of influenza.", [["influenza", "DISEASE", 181, 190], ["influenza", "DISEASE", 406, 415], ["Human", "ORGANISM", 191, 196], ["Human", "SPECIES", 191, 196], ["Human", "SPECIES", 191, 196], ["the signs and symptoms", "PROBLEM", 155, 177], ["influenza", "PROBLEM", 181, 190], ["surveillance", "TEST", 356, 368], ["influenza", "PROBLEM", 406, 415], ["influenza", "OBSERVATION", 181, 190], ["influenza", "OBSERVATION", 406, 415]]], ["Nevertheless, in light of experience with SARS, the experts recommended both as important to containing the spread of a pandemic [36].", [["SARS", "DISEASE", 42, 46], ["SARS", "PROBLEM", 42, 46]]], ["Influenza surveillance supports a range of necessary preparedness activities, including: 1) providing information regarding the presence and epidemiology of influenza viruses in the community, 2) determining appropriate interventions, 3) targeting interventions, and 4) generating current accurate information for public health officials, providers and the public.", [["Influenza", "DISEASE", 0, 9], ["influenza viruses", "DISEASE", 157, 174], ["Influenza surveillance", "TREATMENT", 0, 22], ["influenza viruses", "PROBLEM", 157, 174], ["targeting interventions", "TREATMENT", 238, 261]]], ["While the experts agreed that human surveillance and case reporting are efficacious and likely to be effective during any pandemic phase, broad endorsement was qualified by concerns about resource constraints, especially in a large outbreak, potential difficulties in cooperation between providers and governmental and non-governmental entities, the cost of scaling up capacity to report and investigate influenza-like illness, privacy rights and the right to informed consent [5].Rapid viral diagnosis ::: Interventions recommended for use ::: ResultsThe key limitation of currently available rapid tests for influenza is suboptimal sensitivity, especially in adults [37-40].", [["influenza-like illness", "DISEASE", 404, 426], ["influenza", "DISEASE", 610, 619], ["human", "ORGANISM", 30, 35], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["human surveillance", "TEST", 30, 48], ["a large outbreak", "PROBLEM", 224, 240], ["influenza", "PROBLEM", 404, 413], ["rapid tests", "TEST", 594, 605], ["influenza", "PROBLEM", 610, 619], ["suboptimal sensitivity", "PROBLEM", 623, 645], ["large", "OBSERVATION_MODIFIER", 226, 231]]], ["New and more sensitive technologies for rapid diagnosis of influenza that can reliably identify influenza among patients with respiratory syndromes would greatly aid in the efficient allocation of limited resources such as isolation facilities.", [["respiratory", "ANATOMY", 126, 137], ["influenza", "DISEASE", 59, 68], ["influenza", "DISEASE", 96, 105], ["respiratory syndromes", "DISEASE", 126, 147], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["influenza", "PROBLEM", 59, 68], ["influenza", "PROBLEM", 96, 105], ["respiratory syndromes", "PROBLEM", 126, 147], ["isolation facilities", "TREATMENT", 223, 243], ["more sensitive", "OBSERVATION_MODIFIER", 8, 22], ["influenza", "OBSERVATION", 59, 68]]], ["The experts agreed on the need for increased investment in the development and deployment of improved rapid diagnostic tests for influenza, arguing that such testing will be invaluable for effective surveillance and in managing all but the most advanced phases of a US pandemic.", [["influenza", "DISEASE", 129, 138], ["increased investment", "TREATMENT", 35, 55], ["influenza", "PROBLEM", 129, 138], ["such testing", "TEST", 153, 165]]], ["Moreover, since viral diagnosis of influenza is currently not routine practice, the experts reasoned that education regarding the importance of improved tests will be necessary to increase the adoption of such tests in the US health system.", [["influenza", "DISEASE", 35, 44], ["influenza", "PROBLEM", 35, 44], ["such tests", "TEST", 205, 215], ["influenza", "OBSERVATION", 35, 44]]], ["If new tests can be packaged in a way that facilitates use in non-clinical settings, their potential to facilitate disease containment efforts will be even greater.", [["new tests", "TEST", 3, 12], ["non-clinical settings", "TREATMENT", 62, 83], ["disease containment efforts", "TREATMENT", 115, 142]]], ["However, the lack of incentives for routine use of costly tests could limit development and production of new technologies, creating shortages in a pandemic emergency.Provider and patient use of masks and other personal protective equipment ::: Interventions recommended for use ::: ResultsUncertainty about the mode of influenza transmission has influenced debate about when and whether to use masks or N95 respirators for pandemic influenza.", [["influenza", "DISEASE", 320, 329], ["influenza", "DISEASE", 433, 442], ["patient", "ORGANISM", 180, 187], ["patient", "SPECIES", 180, 187], ["costly tests", "TEST", 51, 63], ["new technologies", "PROBLEM", 106, 122], ["masks", "TREATMENT", 195, 200], ["influenza transmission", "TREATMENT", 320, 342], ["masks", "TREATMENT", 395, 400], ["N95 respirators", "TREATMENT", 404, 419], ["pandemic influenza", "PROBLEM", 424, 442]]], ["Droplet transmission is thought to be the primary mode of transmission, and provides the basis for CDC guidelines that health-care personnel wear masks for close patient contact (i.e., within 3 feet) to control influenza transmission during the influenza season [41].", [["influenza", "DISEASE", 211, 220], ["influenza", "DISEASE", 245, 254], ["patient", "ORGANISM", 162, 169], ["feet", "ORGANISM_SUBDIVISION", 194, 198], ["patient", "SPECIES", 162, 169], ["influenza transmission", "PROBLEM", 211, 233], ["thought to be", "UNCERTAINTY", 24, 37]]], ["But experience from seasonal influenza also provides evidence of contact, droplet and aerosol transmission of influenza that lend support for N95 respirators, which are designed to stop up to 95% of small airborne particles [42].", [["influenza", "DISEASE", 29, 38], ["influenza", "DISEASE", 110, 119], ["seasonal influenza", "PROBLEM", 20, 38], ["influenza", "PROBLEM", 110, 119], ["N95 respirators", "TREATMENT", 142, 157], ["influenza", "OBSERVATION", 29, 38]]], ["A recent Institute of Medicine (IOM) study found that empirical evidence about the efficacy or effectiveness of inexpensive, disposable masks and respirators against influenza is limited [43-46].", [["influenza", "DISEASE", 166, 175], ["inexpensive, disposable masks", "TREATMENT", 112, 141], ["respirators", "TREATMENT", 146, 157], ["influenza", "PROBLEM", 166, 175]]], ["Our experts recognized this as an area of significant controversy and complexity, but they generally recommended reserving surgical masks, N95 respirators and other personal protective equipment for hospital and ambulatory patients and providers when a community outbreak begins or when the pandemic was widespread.", [["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 223, 231], ["reserving surgical masks", "TREATMENT", 113, 137], ["N95 respirators", "TREATMENT", 139, 154], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["controversy", "OBSERVATION", 54, 65]]], ["Moreover, surgical masks and N95 respirators were recognized as a non-invasive technology that would induce no antiviral drug resistance.", [["surgical masks", "TREATMENT", 10, 24], ["N95 respirators", "TREATMENT", 29, 44], ["a non-invasive technology", "TEST", 64, 89], ["antiviral drug resistance", "PROBLEM", 111, 136], ["surgical masks", "OBSERVATION", 10, 24], ["antiviral drug resistance", "OBSERVATION", 111, 136]]], ["The experts qualified their recommendation, noting that poor training, improper use and, for N95 respirators, the need for fit-testing may compromise the overall effectiveness of these measures.Isolation of the sick ::: Interventions recommended for use ::: ResultsThe amount of influenza virus shed by symptomatic individuals is greater than in the asymptomatic phase, but viral shedding typically begins shortly after infection and before the onset of symptoms.", [["influenza virus", "DISEASE", 279, 294], ["infection", "DISEASE", 420, 429], ["influenza virus", "ORGANISM", 279, 294], ["N95 respirators", "TREATMENT", 93, 108], ["fit-testing", "TEST", 123, 134], ["these measures", "TREATMENT", 179, 193], ["influenza virus", "PROBLEM", 279, 294], ["symptomatic individuals", "PROBLEM", 303, 326], ["viral shedding", "PROBLEM", 374, 388], ["infection", "PROBLEM", 420, 429], ["symptoms", "PROBLEM", 454, 462], ["amount", "OBSERVATION_MODIFIER", 269, 275], ["influenza virus", "OBSERVATION", 279, 294], ["symptomatic", "OBSERVATION_MODIFIER", 303, 314], ["greater", "OBSERVATION_MODIFIER", 330, 337], ["asymptomatic phase", "OBSERVATION_MODIFIER", 350, 368]]], ["This limits the efficacy of isolation except for individuals completely quarantined almost immediately after contact with an infected person [47].", [["person", "SPECIES", 134, 140], ["isolation", "TREATMENT", 28, 37]]], ["However, more recent studies report that when numbers are small, isolation in hospitals using appropriate infection control measures may be effective[47].", [["infection", "DISEASE", 106, 115], ["appropriate infection control measures", "TREATMENT", 94, 132], ["small", "OBSERVATION_MODIFIER", 58, 63], ["infection", "OBSERVATION", 106, 115]]], ["While discussions were uniformly supportive of routine infection control measures, the experts did not agree on recommendations for mandatory isolation in any specific setting.", [["infection", "DISEASE", 55, 64], ["routine infection control measures", "TREATMENT", 47, 81], ["mandatory isolation", "TREATMENT", 132, 151], ["infection", "OBSERVATION", 55, 64]]], ["This was because of the inconclusive nature of the evidence, the concern that healthcare facilities are likely to be rapidly overwhelmed, and that overflow into difficult to manage public settings such as arenas would be less effective.", [["overflow", "PROBLEM", 147, 155], ["public settings", "TREATMENT", 181, 196]]], ["Despite the skepticism about mandatory isolation strategies, voluntary self-isolation in the home was recommended for all phases of a US pandemic.Masks and other personal protective equipment for the general public ::: Interventions whose use is not recommended ::: ResultsWith the exception of some evidence from SARS, we did not find any published data that directly support the use of masks, respirators, or other personal protective equipment by the public, or other steps such as disinfecting surfaces beyond usual practices.", [["SARS", "DISEASE", 314, 318], ["mandatory isolation strategies", "TREATMENT", 29, 59], ["voluntary self-isolation", "TREATMENT", 61, 85], ["Masks", "TREATMENT", 146, 151], ["SARS", "PROBLEM", 314, 318], ["respirators", "TREATMENT", 395, 406], ["SARS", "OBSERVATION", 314, 318]]], ["The expert's views were mixed.", [["The expert's views", "TEST", 0, 18]]], ["There was uncertainty regarding requirements for masks or respirators because of uncertainty about the relative roles of droplet versus aerosol transmission.", [["masks", "TREATMENT", 49, 54], ["respirators", "TREATMENT", 58, 69], ["droplet versus aerosol transmission", "TREATMENT", 121, 156]]], ["Concerns about supply, competency in mask and especially respirator fitting and use, adherence by the public, and social impact of mask-wearing all served to undermine the panel's confidence in the feasibility and acceptability of widespread use.", [["competency in mask", "TREATMENT", 23, 41], ["respirator fitting", "TREATMENT", 57, 75], ["mask", "TREATMENT", 131, 135]]], ["On the survey, experts recommended against the use of masks or respirators by the public prior to the arrival of pandemic influenza and in the early localized phase.", [["influenza", "DISEASE", 122, 131], ["masks", "TREATMENT", 54, 59], ["respirators", "TREATMENT", 63, 74], ["pandemic influenza", "PROBLEM", 113, 131]]], ["For similar reasons, experts recommended against the public use of other protective equipment such as gowns, gloves and protective eye wear.Mandatory social distancing measures ::: Interventions whose use is not recommended ::: ResultsAlthough social distancing measures such as workplace closures, limitations on location-based gatherings and events, and mandated travel restrictions have been a recent focus of investigation, and some of these measures were implemented in Asia and North America during SARS, their effectiveness in an influenza outbreak has not yet been established [5,8,48].", [["eye", "ANATOMY", 131, 134], ["SARS", "DISEASE", 505, 509], ["influenza", "DISEASE", 537, 546], ["eye", "ORGAN", 131, 134], ["other protective equipment", "TREATMENT", 67, 93], ["gowns", "TREATMENT", 102, 107], ["gloves", "TREATMENT", 109, 115], ["protective eye wear", "TREATMENT", 120, 139], ["an influenza outbreak", "PROBLEM", 534, 555]]], ["Despite the propensity of influenza epidemics to be amplified in primary schools, data on the effectiveness of school closures for reducing community transmission are contradictory.", [["influenza epidemics", "DISEASE", 26, 45], ["influenza epidemics", "PROBLEM", 26, 45], ["school closures", "TREATMENT", 111, 126]]], ["Most empirical studies suggest a decline in community transmission rates of respiratory infections with school closures[49,50], but the WHO Writing Group also noted older studies showing increases in the spread of disease and subsequent illness after a school holiday, and protective effects when schools remained open [9].", [["respiratory infections", "DISEASE", 76, 98], ["illness", "DISEASE", 237, 244], ["Most empirical studies", "TEST", 0, 22], ["a decline", "PROBLEM", 31, 40], ["respiratory infections", "PROBLEM", 76, 98], ["older studies", "TEST", 165, 178], ["disease", "PROBLEM", 214, 221], ["decline", "OBSERVATION_MODIFIER", 33, 40], ["respiratory infections", "OBSERVATION", 76, 98], ["increases", "OBSERVATION_MODIFIER", 187, 196]]], ["Recent modeling studies generally support school closure and confinement in the home as an effective means of reducing overall attack rates within communities when coupled with antiviral prophylaxis, but predicting the effect of closing schools and workplaces is difficult, since infectious individuals may be displaced into other settings[47,51,52].", [["individuals", "ORGANISM", 291, 302], ["Recent modeling studies", "TEST", 0, 23], ["school closure", "TREATMENT", 42, 56], ["antiviral prophylaxis", "TREATMENT", 177, 198], ["infectious individuals", "PROBLEM", 280, 302]]], ["Models suggest that cancellation of non-essential public gatherings and restrictions on long-distance travel might help to decrease rates of transmission and overall morbidity, but the effectiveness of these interventions has not been quantified.Mandatory social distancing measures ::: Interventions whose use is not recommended ::: ResultsThe experts generally thought that community restrictions could be considered on a case-by-case basis, for example, cancellation of an event to which thousands would travel.", [["long-distance travel", "TREATMENT", 88, 108], ["overall morbidity", "PROBLEM", 158, 175], ["these interventions", "TREATMENT", 202, 221]]], ["There are also important practical and logistical limitations to mandatory long-term community restrictions and compulsory quarantine, in addition to the problem of likely public opposition to such measures [5,53,54].", [["compulsory quarantine", "TREATMENT", 112, 133], ["long-term", "OBSERVATION_MODIFIER", 75, 84]]], ["The same is true for school closures.Mandatory social distancing measures ::: Interventions whose use is not recommended ::: ResultsConsistent with the literature, the experts contended that widespread and sustained screening of travelers would ultimately be impractical and inefficient as long as detecting asymptomatic shedding is not feasible.", [["travelers", "ORGANISM", 229, 238], ["school closures", "TREATMENT", 21, 36], ["asymptomatic shedding", "PROBLEM", 308, 329]]], ["Difficulties with the rapid diagnosis of influenza means that travel bans and screening programs risk detaining a large number of symptomatic persons who do not have influenza.", [["influenza", "DISEASE", 41, 50], ["influenza", "DISEASE", 166, 175], ["persons", "ORGANISM", 142, 149], ["persons", "SPECIES", 142, 149], ["influenza", "PROBLEM", 41, 50], ["influenza", "PROBLEM", 166, 175], ["influenza", "OBSERVATION", 41, 50], ["large", "OBSERVATION_MODIFIER", 114, 119], ["influenza", "OBSERVATION", 166, 175]]], ["There is also the possibility of such measures leading to an international backlash, decreasing cooperation at a time when increased is needed.", [["such measures", "TREATMENT", 33, 46], ["an international backlash", "PROBLEM", 58, 83], ["backlash", "OBSERVATION", 75, 83]]], ["The experts recommended against any mandatory travel restrictions in the advanced phases of a pandemic and did not recommend restrictions on domestic or international departures or entry screening when a pandemic is in the early localized phase.DiscussionWe evaluated the evidence-base for non-pharmaceutical public health interventions in an influenza pandemic by reviewing the recent scientific literature, convening a multidisciplinary meeting of experts, and eliciting expert knowledge qualitatively and quantitatively.", [["influenza pandemic", "DISEASE", 343, 361], ["entry screening", "TEST", 181, 196], ["non-pharmaceutical public health interventions", "TREATMENT", 290, 336], ["an influenza pandemic", "PROBLEM", 340, 361]]], ["Despite the poor quality of the evidence, the use of expert opinion has enabled us to identify strategies that are likely to help slow influenza transmission in a pandemic setting and also do no harm.", [["influenza", "DISEASE", 135, 144], ["slow influenza transmission", "PROBLEM", 130, 157]]], ["Our findings highlight the importance of specifying the setting in which a non-pharmaceutical public health intervention will be used, as well as when its use should be considered.", [["a non-pharmaceutical public health intervention", "TREATMENT", 73, 120]]], ["Although the interplay of these factors and deep uncertainty about the relative efficacy or effectiveness of specific non-pharmaceutical public health interventions prevents us from conclusively pinpointing an optimal set of non-pharmaceutical public health interventions for every circumstance, our study provides some important insights about pandemic planning.DiscussionConsistent with others, we found that the published literature revealed scant confirmatory evidence on efficacy and overall effectiveness of non-pharmaceutical public health interventions in an influenza pandemic, effectively forcing policymakers to turn to expert opinion[8,9].", [["influenza pandemic", "DISEASE", 567, 585], ["specific non-pharmaceutical public health interventions", "TREATMENT", 109, 164], ["non-pharmaceutical public health interventions", "TREATMENT", 225, 271], ["our study", "TEST", 296, 305], ["pandemic planning", "TREATMENT", 345, 362], ["non-pharmaceutical public health interventions", "TREATMENT", 514, 560], ["an influenza pandemic", "PROBLEM", 564, 585]]], ["Some infection control studies classified as systematic reviews, observational studies or evidence-based guidelines constituted stronger evidence, at least for spread of respiratory disease[14].", [["respiratory", "ANATOMY", 170, 181], ["infection", "DISEASE", 5, 14], ["respiratory disease", "DISEASE", 170, 189], ["Some infection control studies", "PROBLEM", 0, 30], ["observational studies", "TEST", 65, 86], ["respiratory disease", "PROBLEM", 170, 189], ["infection", "OBSERVATION", 5, 14], ["respiratory disease", "OBSERVATION", 170, 189]]], ["The remaining scientific evidence is of low strength (further research is very likely to change estimates of effect) or very low strength (effects are quite uncertain), specifically with respect to seasonal and pandemic influenza [14].", [["influenza", "DISEASE", 220, 229], ["low strength", "PROBLEM", 40, 52], ["very low strength", "PROBLEM", 120, 137], ["seasonal and pandemic influenza", "PROBLEM", 198, 229], ["low strength", "OBSERVATION_MODIFIER", 40, 52]]], ["It also included articles drawing inferences from biology and pathophysiology, clinical epidemiology and mathematical modeling studies, rather than from randomized controlled trials evaluating interventions.", [["mathematical modeling studies", "TEST", 105, 134], ["randomized controlled trials evaluating interventions", "TREATMENT", 153, 206]]], ["In this context, expert opinion is particularly useful, and several clear messages emerged.DiscussionFirst, policymakers should actively promote personal responsibility for slowing spread of infection through good hand hygiene and respiratory etiquette in all settings and at all times.", [["hand", "ANATOMY", 214, 218], ["infection", "DISEASE", 191, 200], ["hand", "ORGANISM_SUBDIVISION", 214, 218], ["slowing spread of infection", "PROBLEM", 173, 200], ["respiratory etiquette", "TREATMENT", 231, 252], ["infection", "OBSERVATION", 191, 200]]], ["Use of disinfectant hand soaps and alcohol-based rubs should also be encouraged.", [["hand", "ANATOMY", 20, 24], ["alcohol", "CHEMICAL", 35, 42], ["alcohol", "CHEMICAL", 35, 42], ["alcohol", "SIMPLE_CHEMICAL", 35, 42], ["disinfectant hand soaps", "TREATMENT", 7, 30], ["based rubs", "TREATMENT", 43, 53]]], ["Second, developing the capability and capacity for early rapid viral diagnosis should be a high priority.", [["early rapid viral diagnosis", "PROBLEM", 51, 78], ["capability", "OBSERVATION_MODIFIER", 23, 33]]], ["Third, healthcare providers need to be better trained to maximize the effectiveness of infection control measures, including use of masks, respirators, and other personal protective equipment.", [["infection", "DISEASE", 87, 96], ["infection control measures", "TREATMENT", 87, 113], ["masks", "TREATMENT", 132, 137], ["respirators", "TREATMENT", 139, 150], ["infection", "OBSERVATION", 87, 96]]], ["It may be reasonable to recommend limited use of personal protective measures in certain other settings such as mask-wearing by the ill or perhaps surface disinfection of very heavily trafficked public areas.", [["surface", "ANATOMY", 147, 154], ["ill", "DISEASE", 132, 135], ["personal protective measures", "TREATMENT", 49, 77], ["mask", "TREATMENT", 112, 116], ["surface disinfection", "TREATMENT", 147, 167], ["very", "OBSERVATION_MODIFIER", 171, 175], ["heavily", "OBSERVATION_MODIFIER", 176, 183]]], ["However, other use of personal protective equipment by the general public is not recommended at this time.", [["personal protective equipment", "TREATMENT", 22, 51]]], ["Fourth, and also consistent with other studies, we founds that widespread government mandates to segregate individuals, including isolation, quarantine, sheltering, location-based community restrictions, and travel restrictions, are less likely than voluntary measures to be recommended, especially over the longer-term[55].", [["other studies", "TEST", 33, 46], ["isolation", "TREATMENT", 130, 139], ["quarantine", "TREATMENT", 141, 151], ["sheltering", "TREATMENT", 153, 163], ["consistent with", "UNCERTAINTY", 17, 32], ["widespread", "OBSERVATION_MODIFIER", 63, 73]]], ["This will require education, persuasion, and social support to ensure that medical and non-medical needs are met, with the latter being central to the success of sequestration measures in all settings.", [["social support", "TREATMENT", 45, 59], ["sequestration measures", "TREATMENT", 162, 184], ["sequestration", "OBSERVATION", 162, 175]]], ["Well-controlled observational and especially interventional studies are needed, especially in the context of seasonal influenza.ConclusionThe demand for scientific evidence on non-pharmaceutical public health interventions for influenza is pervasive, and policy recommendations must rely heavily on expert judgment.", [["influenza", "DISEASE", 118, 127], ["influenza", "DISEASE", 227, 236], ["interventional studies", "TEST", 45, 67], ["seasonal influenza", "PROBLEM", 109, 127], ["non-pharmaceutical public health interventions", "TREATMENT", 176, 222], ["influenza", "PROBLEM", 227, 236], ["influenza", "OBSERVATION", 118, 127]]], ["In the absence of a definitive science base, our assessment of the evidence identified areas for further investigation as well as non-pharmaceutical public health interventions that experts believe are likely to be beneficial, feasible, and socially and politically acceptable in an influenza pandemic.", [["influenza", "DISEASE", 283, 292], ["our assessment", "TEST", 45, 59], ["further investigation", "TEST", 97, 118], ["non-pharmaceutical public health interventions", "TREATMENT", 130, 176], ["an influenza pandemic", "PROBLEM", 280, 301]]], ["NL conceived of the study, and participated in its design and coordination, conducted the expert panel, and helped to draft the manuscript.", [["the study", "TEST", 16, 25], ["the expert panel", "TEST", 86, 102]]], ["JW conceived of the study, and participated in its design and coordination, and helped to draft the manuscript.", [["the study", "TEST", 16, 25]]], ["All authors read and approved the final manuscript.Pre-publication historyThe pre-publication history for this paper can be accessed here:Pre-publication history", [["Pre-publication", "DISEASE", 51, 66], ["pre-publication", "DISEASE", 78, 93], ["Pre-publication", "DISEASE", 138, 153]]]], "bfab901132bb4f31381dd086e6c45472fa9b4e44": [["IntroductionThe elderly population is increasing worldwide.", [["increasing", "OBSERVATION_MODIFIER", 38, 48], ["worldwide", "OBSERVATION_MODIFIER", 49, 58]]], ["An estimated 617.1 million people are aged 65 and over in 2015, and this number is projected to increase to 1 billion in 2030, and 1.6 billion in 2050 [1] .", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33]]], ["More than 20% of men and 40% of women aged 65 and older chose an independent lifestyle in many countries [2] .", [["men", "ORGANISM", 17, 20], ["women", "ORGANISM", 32, 37], ["men", "SPECIES", 17, 20], ["women", "SPECIES", 32, 37]]], ["Pimouguet et al. [3] indicated living alone shortened life expectancy by 0.6 years for elderly people.", [["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101]]], ["Elderly individuals living alone would benefit from specialized care, but a shortage in the global workforce of aged-care workers [4] has made this difficult.IntroductionUnder these conditions, smart houses with a sensor network and domestic robots have been built to address the aged-care worker shortage.", [["domestic robots", "TREATMENT", 233, 248]]], ["To ensure the effectiveness of the sensor networks and robots, real test beds were built to conduct experiments for collecting data.", [["the sensor networks", "TREATMENT", 31, 50], ["robots", "TREATMENT", 55, 61], ["real test beds", "TREATMENT", 63, 77], ["collecting data", "TEST", 116, 131]]], ["(1) Manually create a simulation scenario by first building a house and resident body models and defining the activity schedules and movement routes of the virtual resident or controlling the virtual resident manually.", [["body", "ANATOMY", 81, 85], ["body", "ORGANISM_SUBDIVISION", 81, 85], ["resident body models", "TREATMENT", 72, 92], ["the activity schedules", "TREATMENT", 106, 128]]], ["(2) Place virtual sensors, devices, or robots to record data and/or operation performances.", [["virtual sensors, devices", "TREATMENT", 10, 34], ["record data", "TEST", 49, 60]]], ["(3) Analyze recorded data or operation performances and evaluate simulation design.", [["Analyze recorded data", "TEST", 4, 25], ["operation performances", "TEST", 29, 51]]], ["Moreover, the developers may use multiple simulators for different purposes, e.g., using CST Microwave Studio to test the communication of a wireless sensor network, OpenSHS [9] to collect virtual sensor records for sensor arrangement optimization, and Stage [10] to plan the operation policies of mobile robots.", [["multiple simulators", "TREATMENT", 33, 52], ["sensor arrangement optimization", "TREATMENT", 216, 247], ["mobile robots", "TREATMENT", 298, 311]]], ["When the developers use another simulator, they must repeat steps (1) even if they use the same simulation scenario.IntroductionWe propose a simulation tool that provides diverse simulation scenarios and can support smart house developers to complete step (1) automatically in multiple simulation platforms [11] .", [["diverse simulation scenarios", "TREATMENT", 171, 199]]], ["This simulator consists of generators and interfaces as show in Fig. 1 .", [["Fig", "OBSERVATION_MODIFIER", 64, 67]]], ["We proposed a spatial attribute generator [12] and travel pattern generator [11] , and used two interfaces [11] to transfer the data generated by them to models and virtual sensor records of the simulators.IntroductionAs an essential part of our simulator, we propose an activity schedule generator.", [["an activity schedule generator", "TREATMENT", 268, 298]]], ["2, we review related work of daily activity schedule generation.", [["daily activity schedule generation", "TREATMENT", 29, 63]]], ["Section 3 describes the methodology to generate activity schedules.", [["activity schedules", "TREATMENT", 48, 66]]], ["Section 4 details the performance of this generator.", [["this generator", "TREATMENT", 37, 51]]], ["Section 5 introduces how the generated data can be used in simulations.Related WorksA number of scholars generated daily activity schedules as intermediate results to generate sensor records in a virtual smart house, which are essential for simulations.Related WorksRenoux et al. [13] generated activity schedules with a constraint-based planning method.", [["activity schedules", "TREATMENT", 295, 313], ["a constraint-based planning method", "TREATMENT", 319, 353]]], ["The constraints include that the start time and duration of each activity are over reasonable intervals, and a number of activities need to be performed within certain time intervals before their corresponding activities, e.g., preparing lunch for 0 to 5 min before having lunch.Related WorksBouchard et al. [14] generated activity schedules using behavior trees (BTs) as intermediate results to generate the simulated evolution of signal strength between RFID readers and tags.", [["activity schedules", "TREATMENT", 323, 341]]], ["However, designing BTs is complicate, and the authors only showed an example of generating the schedule for making coffee or tea.Related WorksAlshammari et al. [9] replicated and modified schedules originally designed by humans.", [["tea", "ANATOMY", 125, 128], ["tea", "ORGANISM_SUBDIVISION", 125, 128], ["humans", "ORGANISM", 221, 227], ["humans", "SPECIES", 221, 227], ["humans", "SPECIES", 221, 227]]], ["The methods of modification include combining two samples of original schedules and changing the start and end time of activities.", [["original schedules", "TREATMENT", 61, 79]]], ["The activity schedules correspond to virtual binary sensor records, thus, a large number of records are generated simultaneously.", [["large", "OBSERVATION_MODIFIER", 76, 81]]], ["This method is simple, but generated schedules may have high similarity.Related WorksMshali et al. [15] generated long-term activity schedules using a Markov model, and five transition matrices associated to different periods of a day were designed.", [["long-term activity schedules", "TREATMENT", 114, 142], ["a Markov model", "TREATMENT", 149, 163], ["five transition matrices", "TREATMENT", 169, 193]]], ["The authors also proposed an adaptive and context-aware algorithm for monitoring the daily activities of elderly and dependent persons, and generated schedules were used to test the algorithm in simulations.Related WorksLee et al. [16] generated activity schedules with a motivation-driven method.", [["persons", "SPECIES", 127, 134], ["elderly and dependent persons", "TREATMENT", 105, 134], ["activity schedules", "TREATMENT", 246, 264]]], ["A motivation value (MV) represents the desire of a virtual agent to perform a class of activities with the agent performing an activity when its corresponding MV reaches its threshold.", [["MV", "SPECIES", 159, 161], ["A motivation value", "TEST", 0, 18], ["a virtual agent", "TREATMENT", 49, 64], ["the agent", "TREATMENT", 103, 112]]], ["Motivations are classified by levels; if two MVs reach their thresholds at the same time, the agent will perform the activity that corresponds to the higher-level motivation.", [["MVs", "ANATOMY", 45, 48], ["MVs", "CELL", 45, 48], ["MVs", "CELL_TYPE", 45, 48]]], ["This method has sufficient potential for improvement if the mechanism of evolution of the MVs is designed carefully.Problem StatementTo build our activity schedule generator module, we need to improve upon the methods mentioned in Sect.", [["MVs", "ANATOMY", 90, 93], ["MVs", "CELL", 90, 93], ["the MVs", "PROBLEM", 86, 93], ["our activity schedule generator module", "TREATMENT", 142, 180]]], ["As our simulator contributes to provide diverse simulation scenarios by producing diverse layouts, we need a method that can process dynamic activity lists.", [["diverse simulation scenarios", "TREATMENT", 40, 68], ["a method", "TREATMENT", 107, 115]]], ["2) The above methods generate schedules whose timelines include unspecified times between the end time of an activity and the start time of the next one.", [["The above methods generate schedules", "TREATMENT", 3, 39]]], ["3) Most of the above methods generated schedules for one day or less, but longterm activity schedules are required for our simulation.Problem StatementWe developed a motivation-driven method on the basis of that presented in the reviewed study [16] to build our activity schedule generator.", [["longterm activity schedules", "TREATMENT", 74, 101]]], ["An MV represent a resident's desire to perform an activity sequence (AS).", [["MV", "SPECIES", 3, 5], ["an activity sequence", "TEST", 47, 67]]], ["While performing the activity is dependent on its MV reaching its threshold in [16] , in our method, the MVs are used to determine the probability distribution (P) of sampling the next AS.", [["MVs", "CELL", 105, 108], ["MVs", "CELL_TYPE", 105, 108], ["the MVs", "TEST", 101, 108]]], ["The evolution of the MVs is adaptive to the input indoor spatial data and resident's profile.", [["MVs", "ANATOMY", 21, 24], ["MVs", "CELL", 21, 24], ["MVs", "OBSERVATION", 21, 24]]], ["We need to design an evolution mechanism and initialize the MVs carefully to generate stable, but not tedious, activity schedules in the long term that will address issue 3).", [["stable", "OBSERVATION_MODIFIER", 86, 92]]], ["The studies mentioned in Sect.", [["The studies", "TEST", 0, 11]]], ["2 took into account a limited number of activities, implying that these activities occupy the entire timeline, which is unrealistic.Model of AS, MV, Resident Profile, and PMapping the Relationship Between AS and MV.", [["MV", "SPECIES", 145, 147], ["MV", "SPECIES", 212, 214]]], ["A resident performs activities on the basis of motivation, in which MVs quantify the degree of motivation.", [["MVs", "CELL", 68, 71], ["MVs", "CELL_TYPE", 68, 71]]], ["When an MV is high, the resident may perform a sequence of activities to satisfy the motivation, e.g., if the value of hunger motivation is high, he/she will cook and eat.", [["MV", "SPECIES", 8, 10]]], ["We determined that a resident has 13 motivations at most, which correspond to 13 MV i -AS i pairs: MV 1 : wash and brush teeth => sleep (at night) => wash and brush teeth, MV 2 : sleep (at noon), MV 3 : take food => cook => take tableware => eat, MV 4 : take a bath => get dressed => put clothes in wash machine, MV 5 : get dressed => go out => get dressed, MV 6 : go to toilet (short duration), MV 7 : go to toilet (long duration), MV 8 : watch TV, MV 9 : read, MV 10 : clean, MV 11 : take clothes out of washing machine, MV 12 : wander, and MV 13 : relax.", [["teeth", "ANATOMY", 121, 126], ["teeth", "ANATOMY", 165, 170], ["teeth", "ORGAN", 121, 126], ["teeth", "ORGAN", 165, 170], ["MV", "SPECIES", 450, 452], ["MV", "SPECIES", 478, 480], ["MV", "SPECIES", 543, 545], ["brush teeth", "PROBLEM", 115, 126], ["a bath", "TREATMENT", 259, 265], ["MV", "TEST", 433, 435], ["MV", "TEST", 450, 452], ["MV", "TEST", 463, 465], ["MV", "TEST", 478, 480], ["MV", "TEST", 523, 525], ["MV", "TEST", 543, 545]]], ["An AS consists of one or more activities, and activities in the AS are performed in order without lag to satisfy the corresponding motivation and decrease the corresponding MV i .", [["MV", "SPECIES", 173, 175]]], ["MV i determines the possibility of performing ith AS, P i .Model of AS, MV, Resident Profile, and PAS and MV Are Adaptive to the Layout.", [["MV", "SPECIES", 0, 2], ["MV", "SPECIES", 72, 74], ["MV", "SPECIES", 106, 108]]], ["The actual composition of an AS is also adaptive to the layout like the evolution of MVs.", [["MVs", "ANATOMY", 85, 88], ["MVs", "CELL", 85, 88], ["MVs", "CELL_TYPE", 85, 88], ["MVs", "OBSERVATION", 85, 88]]], ["An activity in an AS will be omitted if its corresponding places are not in the layouts The mapping relationship of all activities and places is shown in Table 1 , e.g., if the kitchen stove, refrigerator, and cupboard are not in the house, AS 3 will omit the procedure take food => cook => take tableware, which implies the resident eats food prepared by someone out of the house in this case.", [["activity", "OBSERVATION_MODIFIER", 3, 11]]], ["If all activities of an AS can not be performed because of the layout, its MV i will always be 0.Model of AS, MV, Resident Profile, and PResident's Personal Profile.", [["MV", "SPECIES", 75, 77], ["MV", "SPECIES", 110, 112]]], ["To keep generated schedules diverse and reasonable, parameters corresponding to the evolution of MVs should depend on the resident's profile.", [["MVs", "CELL", 97, 100]]], ["T i and f i mean the period and frequency of performing the ith AS, respectively, e.g., T 12 means how many days between two instances of the resident's wandering and f 6 means how many times the resident performed the activity \"go to toilet (short duration)\" per day on average, where T i \u00c2 f i = 1.Model of AS, MV, Resident Profile, and Pif the resident is not sleeping.Model of AS, MV, Resident Profile, and Pif the resident is sleeping, and i \u00bc 3 or 6:Model of AS, MV, Resident Profile, and Pif the resident is sleeping, and i 6 \u00bc 3 and 6:Model of AS, MV, Resident Profile, and Pwhere x i is an increasing rate and \u025b is random noise.Model of AS, MV, Resident Profile, and PNote: When the resident is sleeping, the increasing rates of the MVs of \"eat\" and \"go to toilet (short duration)\" decrease to 10%, rates of other MVs decrease to 0.Rule 2.3)Following the principle that MV i should be generally unchanged after one period in an ideal case, x i can be determined by D, T, and f.Rule 2.3)Note: e.g., for the 8 th AS, watching TV, assuming that the resident watches TV for 4 h (D 8 ), and sleeps 8 h (D 1 + D 2 ) per day (T 8 = 24 h), x 8 is determined by Eq.", [["MV", "SPECIES", 313, 315], ["MV", "SPECIES", 385, 387], ["MV", "SPECIES", 650, 652], ["MV", "SPECIES", 879, 881], ["an increasing rate", "PROBLEM", 596, 614], ["increasing", "OBSERVATION_MODIFIER", 599, 609], ["random noise", "OBSERVATION", 624, 636], ["unchanged", "OBSERVATION_MODIFIER", 904, 913]]], ["(2),Rule 2.3)which means x 8 should increase by Norm_MV in the remaining 12 h, while it decreases by Norm_MV during the 4 h (D 8 ).Rule 2.3)7T i ] for i = 8 or 9, and from [0.95T i , 1.05T i ] for other cases.Rule 3.4)The resident may perform the activities \"eat\" and \"go to toilet\" outside.", [["i", "TEST", 151, 152], ["other cases", "TEST", 197, 208]]], ["When he/she is going out, if MV 3 , MV 6 or MV 7 reach Norm_MV, and there is sufficient time to perform the corresponding AS, this MV decreases as the AS is performed.Rule 3.4)Initialization of MVs.", [["MVs", "ANATOMY", 194, 197], ["MVs", "CELL", 194, 197], ["MVs", "CELL_TYPE", 194, 197], ["MV", "SPECIES", 29, 31], ["MV", "SPECIES", 36, 38], ["MV", "SPECIES", 44, 46], ["MV", "SPECIES", 131, 133], ["MV", "TEST", 29, 31], ["MV", "TEST", 36, 38], ["MV", "TEST", 44, 46], ["this MV", "TEST", 126, 133], ["MVs", "PROBLEM", 194, 197], ["MVs", "OBSERVATION", 194, 197]]], ["MVs should be initialized before evolution, which can be achieved by determining when each AS will be performed for first time.", [["MVs", "ANATOMY", 0, 3], ["MVs", "CELL", 0, 3], ["MVs", "CELL_TYPE", 0, 3], ["MVs", "PROBLEM", 0, 3]]], ["The time when the ith AS is first performed is approximately equal to the time when MV i first reaches Norm_MV.", [["MV", "SPECIES", 84, 86]]], ["MV 0 thus is Norm_MV, as D i and x i is known, other initial MVs can be calculated with Eq.", [["MVs", "CELL", 61, 64], ["MV", "SPECIES", 0, 2], ["MV", "TEST", 0, 2]]], ["(1), e.g., assuming that D 1 = 8 h, and the resident will eat breakfast 1 h after waking up, initial MV 3 is calculated by Eq.", [["MV", "SPECIES", 101, 103]]], ["(4).Rule 3.4)To keep the generated schedule stable in the long term, we need to avoid two MVs whose ASs require long durations to reach Norm_MV at the same time.Rule 3.4)Relationship Between MV and P. The possibility of performing the ith AS depends on the motivation value, MV i , as shown in Eq.", [["MVs", "ANATOMY", 90, 93], ["MVs", "CELL", 90, 93]]], ["(5)ImplementationWe wrote a Python3 program to achieve activity schedule generation.", [["a Python3 program", "TREATMENT", 26, 43], ["activity schedule generation", "TREATMENT", 55, 83]]], ["The original MV and the start time of the schedule generation are determined in Line 4.", [["MV", "SPECIES", 13, 15], ["the schedule generation", "TREATMENT", 38, 61]]], ["From Lines 7 to 15, the program determines the AT of performing each AS with Rule 3.3), updates MV using the other rules, samples the next performed AS with Eq.", [["MV", "SPECIES", 96, 98]]], ["The program converts these two lists into an activity schedule in Line 17.", [["an activity schedule in Line", "TREATMENT", 42, 70]]], ["The schedule indicates the start times of all activities performed.Performance of the GeneratorWe input indoor spatial data generated by the spatial attribute generator into the activity schedule generator, which then produces diverse activity schedule data.", [["the activity schedule generator", "TREATMENT", 174, 205]]], ["Figure 3a) shows a schedule for a resident who sleeps around noon, goes out, watches TV, and takes a bath every day, while Fig. 3b) shows a schedule for who does not sleep around noon, watches TV, and takes a bath every day, but only goes out every four days.Performance of the GeneratorWe also tested the performance of our generator on PC with an Intel (R) core (TM) i7-8550U CPU.", [["our generator on PC", "TREATMENT", 321, 340], ["an Intel (R) core (TM)", "TREATMENT", 346, 368]]], ["The generator ran 100 times in 3.987 s.Performance of the GeneratorAdditional generated schedules are available via this website [17] .Using Generated Activity Schedules for SimulationSmart house are often equipped with passive infrared (PIR) sensors.", [["the GeneratorAdditional generated schedules", "TREATMENT", 54, 97], ["passive infrared (PIR) sensors", "TREATMENT", 220, 250]]], ["Each PIR sensor has a unique ID number which can be recorded when the sensor turns on or off.", [["PIR", "PROTEIN", 5, 8]]], ["By placing several PIR sensors in the house and analyzing their records, a resident's movement trajectories can be acquired, which can be used to determine whether they contain wandering travel patterns associated with dementia [18].Using Generated Activity Schedules for SimulationIn the simulation, the PIR sensor records were generated from simulated real-time location data.", [["dementia", "DISEASE", 219, 227], ["dementia", "PROBLEM", 219, 227], ["the PIR sensor records", "TEST", 301, 323]]], ["We built a generator that could convert an activity schedule, a sample of indoor spatial data, and several samples of travel pattern data into a sample of real-time location data.", [["a generator", "TREATMENT", 9, 20], ["indoor spatial data", "TEST", 74, 93]]], ["We developed an interface to convert the real-time location data into virtual PIR sensor records, which can be used to optimize the placement of the PIR sensors in a smart house.Using Generated Activity Schedules for SimulationExamples of the performance of the real-time location data generator and the interface are shown in figures and tables.", [["the placement of the PIR sensors", "TREATMENT", 128, 160]]], ["Table 2 shows part of an activity schedule.", [["an activity schedule", "TREATMENT", 22, 42]]], ["Smart houses with a sensor network and domestic robots were built to take care elderly people living alone.", [["sensor network", "MULTI-TISSUE_STRUCTURE", 20, 34], ["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93], ["domestic robots", "TREATMENT", 39, 54]]], ["Many simulation tools have been proposed to help smart house developers test and verify their designs, but it takes time and effort to build a simulation scenario, and developers need to repeat scenario-generation procedures if they want to use multiple simulators.", [["repeat scenario-generation procedures", "TREATMENT", 187, 224], ["multiple simulators", "TREATMENT", 245, 264]]], ["To address these issues, we proposed a simulation tool that provides diverse simulation scenarios and enables developers to build scenarios automatically in multiple simulation platforms [11] .Using Generated Activity Schedules for SimulationIn this paper, we proposed an activity schedule generator that is an essential part of our simulator.", [["diverse simulation scenarios", "TREATMENT", 69, 97], ["an activity schedule generator", "TREATMENT", 269, 299]]], ["With an improved motivation-driven method, the generator produces diverse daily activity schedules to mimic the daily lives of residents living alone.", [["the generator", "TREATMENT", 43, 56], ["improved", "OBSERVATION_MODIFIER", 8, 16]]], ["Part of the activity schedule shown in Fig. 3 simulated smart house; 2) there is no unspecified time in the timeline of generated schedules; and 3) it generates stable, but not tedious schedules for a number of days.Using Generated Activity Schedules for SimulationA generated schedule includes a list of activities and their start time.", [["the activity schedule", "TREATMENT", 8, 29], ["SimulationA generated schedule", "TREATMENT", 255, 285], ["no", "UNCERTAINTY", 81, 83], ["stable", "OBSERVATION_MODIFIER", 161, 167]]], ["For example, we convert the real-time locations to records of virtual PIR sensors, and the records are useful for optimizing placement of these sensors.", [["virtual PIR sensors", "TEST", 62, 81], ["optimizing placement of these sensors", "TREATMENT", 114, 151]]]]}